,0,COI?
0,,No
1,"M.M. Brands reports research funding from Intrabio and serving as principal investigator at the Amsterdam site for the study: N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC). M. el Sayed is involved in a premarketing study with Indorses; all financial arrangements are made through AMC Research BV. CH.E. Hollak and M. Langeveld are involved in premarketing studies with Genzyme, Idorsia, and Protalix. S.J. van der Veen was involved in premarketing studies with Chiesi/Protalix; financial arrangements were made through AMC Research BV. A.B.P. van Kuilenburg reports research funding from Biosidus. L. Vogt reports consultancy for AstraZeneca Netherlands, Bayer BV Netherlands, and Vifor Pharma Netherlands; research funding from Dutch Kidney Foundation and Health Holland; and role as an Associate Editor of <i>BMC Nephrology</i>. All remaining authors have nothing to disclose.",
2,"Dr. Bhatt discloses the following relationships - Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald's Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda. P. Ho reports research funding: PMH had a research agreement with Bristol-Myers Squibb through the University of Colorado and advisory or leadership role: Deputy Editor for Circulation: Cardiovascular Quality and Outcomes. H. Hochheiser reports research funding: Philips Respironics. P. Palevsky reports consultancy: Janssen Research & Development, LLC and advisory or leadership role: National Kidney Foundation: Past President, Member, Scientific Advisory Board, Renal Physicians Association: Member, Quality, Safety and Accountability Committee, Quality Insights Renal Network 4: Chair, Medical Review Board, UpToDate: Section Editor, RAcute Kidney Injury, Journal of Intensive Care Medicine: Member, Editorial Board. S. Weisbord reports consultancy: Takeda. All remaining authors have nothing to disclose.",
3,Financial Disclosure: The authors declare that they have no relevant financial interests.,No
4,The authors declare no funding or conflict of interest.,No
5,R.J. Johnson reports having consultancy agreements with Horizon Pharmaceuticals; reports having ownership interest in Colorado Research Partners LLC (founder shares); reports receiving research funding from the National Institutes of Health and Veteran's Administration; reports receiving honoraria from Horizon Pharmaceutical and universities; reports having patents or patent applications on uric acid and fructose metabolism; reports receiving royalties from <i>Comprehensive Clinical Nephrology</i> (Elsevier) and <i>Nature Wants Us to Be Fat</i> (BenBella); and reports having stocks in XORTX Therapeutics. S.E. Young reports consultancy agreements with Horizon Therapeutics. The remaining author has nothing to disclose.,
6,"T. Greene reports grant support from Durect Corporation, Janssen Pharmaceuticals, NKF, and Pfizer; consultancy for AstraZeneca, Invokana, Janssen Pharmaceuticals, Novartis, and Pfizer Inc.; and research funding from AstraZeneca, Boehringer Ingelheim, CSL, and Vertex. A. Gucciardo is employed by the National Kidney Foundation. H.J.L. Heerspink received grant support from the NKF to his institute and is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Gilead, Janssen, Merck, Novartis, NovoNordisk, and Travere Therapeutics. L.A. Inker reports funding from Chinook, the National Institutes of Health (NIH), the National Kidney Foundation (NKF), Omeros, and Reata Pharmaceuticals for research and contracts to the Tufts Medical Center and consulting agreements with Diamerix. The remaining author has nothing to disclose.",
7,"J. Bitzel and D.M. Patel report employment with Johns Hopkins University. D.C. Crews reports employment with Johns Hopkins University; consultancy for Yale New Haven Health Services Corporation Center for Outcomes Research and Evaluation (CORE); research funding from Baxter International and Somatus, Inc.; honoraria from Maze Therapeutics; and other interests or relationships with Board of Directors of National Kidney Foundation of Maryland/Delaware, Council of Subspecialist Societies of the American College of Physicians, Executive Councilor of the American Society of Nephrology, and Nephrology Board of the American Board of Internal Medicine. D.C. Crews reports advisory or leadership roles for Advisory Group, Health Equity Collaborative, Partner Research for Equitable System Transformation after COVID-19 (PRESTAC); Associate Editor for <i>Kidney360</i>; Co-Chair of Bayer HealthCare Pharmaceuticals Inc. Patient and Physician Advisory Board Steering Committee for Disparities in Chronic Kidney Disease Project; Editorial Boards for <i>CJASN</i>, <i>JASN</i>, and the <i>Journal of Renal Nutrition</i>; and Optum Labs. D.M. Fine reports employment with Johns Hopkins University School of Medicine, consultancy for Fresenius Kidney Care Medical Advisory Board and GlaxoSmithKline DSMB, and advisory or leadership role for Medical Advisory Board—Fresenius Medical Corporation. T. Grader-Beck reports employment with Johns Hopkins, consultancy for IQVIA and Novartis, and advisory or leadership role for Novartis. M.E. Grams reports employment with New York University; advisory or leadership roles for the <i>American Journal of Kidney Diseases</i>, the American Society of Nephrology Publication Committee, <i>CJASN</i>, the <i>JASN</i> Editorial Fellowship Committee, the National Kidney Foundation Scientific Advisory Board, the Kidney Disease: Improving Global Outcomes Executive Committee (co-chair elect), and the United States Renal Data System Scientific Advisory Board; grant funding from NKF, which receives funding from multiple pharmaceutical companies; grant funding from NIH; payment from academic institutions for grand rounds; and payment from NephSAP. C.R. Parikh reports employment with Johns Hopkins University School of Medicine; consultancy for Genfit Biopharmaceutical Company; ownership interest in Renaltix AI; research funding from the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); and advisory or leadership roles for Genfit Biopharmaceutical Company and Renalytix. S. Thavarajah reports employment with Johns Hopkins University School of Medicine and other interests or relationships with the National Kidney Foundation as a National Board member and member of the national scientific advisory board and with the local NKF chapter medical advisory board and board of advisors. S. Thavarajah reports advisory or leadership roles as Medical Advisory Board NKF of Maryland immediate past chair and as previous vice chair of Maryland Kidney Commission 2021–2022, and now chair. S. Thavarajah reports honoraria as a speaker for a CME program conducted by the NKF in December 2020—the NKF had funding for the program and provided a speaker's honorarium to each of the faculty speakers. The original funding was from Bayer, but the honorarium came through the NKF.",
8,"A.G. Gharavi reports having consultancy agreements with Actio Biosciences, AstraZeneca Center for Genomics Research, Goldfinch Bio, Natera, Novartis, and Travere; reports having an ownership interest in Actio Biosciences; reports receiving research funding from Natera and the Renal Research Institute; reports receiving honoraria from Alnylam and Sanofi; and reports having an advisory or leadership role with the editorial boards of <i>JASN</i> and the <i>Journal of Nephrology</i>. A. Parsa reports having an advisory or leadership role with the National Institutes of Health (NIH). B. Levy reports having consultancy agreements with Igenomix, Myome, Myriad, and Natera; reports having an ownership interest in Natera; and reports having an advisory or leadership role with American College of Medical Genetics Foundation, College of American Pathologists Cytogenetics committee, Cancer Genomics Consortium, International Society for Prenatal Diagnosis, and Wiley Prenatal Diagnosis. B.A. Warady reports having consultancy agreements with Amgen, Bayer, Lightline Medical Reata, Relypsa, and UpToDate; reports receiving research funding from Baxter Healthcare; reports receiving honoraria from Amgen, Bayer, Reata, Relypsa, and UpToDate; and reports having an advisory or leadership role with Midwest Transplant Network Governing Board, National Kidney Foundation, North American Pediatric Renal Trials and Collaborative Studies, and NTDS Board of Directors. C.S. Wong reports having an advisory or leadership role with the Steering Committee for National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)–funded CKiD study, participated in the past year on the <i>ad hoc</i> advisory committee to the National Kidney Foundation, board of the New Mexico Pediatric Society in Albuquerque, NM; and reports having other interests or relationships with a contract with NephCure International as part of the CurGN study (participating site). D.R. Crosslin reports having consultancy agreements with UnitedHealth Group; reports having an ownership interest in SoundBiology LLC; reports receiving research funding from UnitedHealth Group; and reports having an advisory or leadership role with the UnitedHealth Group. A.Khan received funding from NIH National Center for Advancing Translational Sciences grant UL1TR001873 and NIH NIDDK grant K25DK128563. E.E. Kenny reports having consultancy agreements with and Forsite Labs Inc. and Galatea Inc.; reports having an ownership interest in Galatea Inc, and Forsite Labs Inc.; reports receiving honoraria from 23&Me, Illumina Inc., and Regeneron Pharmaceuticals; reports having an advisory or leadership role with the editorial boards of <i>American Journal of Human Genetics</i>, Cell Genomics, Frontiers in Ecology and Evolution, and G3; reports being on the Advisory Boards of the American Society of Human Genetics (un-paid), Forsite Labs Inc. (paid), and Galatea Inc., Chair of Science Foundation Ireland Center for Research Training in Genomics Data Science Board (un-paid); and reports receiving speakers bureau from 23&Me, Illumina Inc, and Regeneron, Inc. H.I. Feldman reports having consultancy agreements with Kyowa Hakko Kirin and the National Kidney Foundation; reports receiving honoraria from InMed Inc.; reports having an advisory or leadership role as the American Journal of Kidney Disease Editor in Chief, Member of Advisory Board of the National Kidney Foundation, and Steering Committee Chair of the CRIC Study; and reports receiving speakers bureau from InMed, Inc. K. Kiryluk reports having consultancy agreements with Calvariate, and HiBio; and reports receiving research funding from Aevi Genomics, AstraZeneca, Bioporto, Vanda, and Visterra. Mr. Pavan Khosla reports previous employment with Basepair Inc., and reports having an ownership interest in BioNano Genomics Inc., Canopy Growth Corp., GrowGeneration Corp., GSK PLC (formerly GlaxoSmithKline PLC), Pfizer Inc., Pacific Biosciences of California Inc., Nokia Oyj., and 10X Genomics Inc. R.J.F. Loos reports having consultancy agreements with Regeneron; and reports having an advisory or leadership role as Board member of the European Association of the Study of Diabetes. Dr. Simone Sanna-Cherchi reports receiving research funding from NIH/NIDDK, US Department of Defense; reports receiving honoraria from Travere Therapeutics; and reports having an advisory or leadership role with the editorial boards, with no royalties received, from <i>Acta Biomedica</i>, <i>Kidney International</i>, <i>Journal of Nephrology</i>, and Negative Results. Y. Shen reports having an advisory or leadership role with the Scientific Reports. All remaining authors have nothing to disclose. Funding for the CRIC study was obtained under a cooperative agreement from the NIDDK through grants U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990). The eMERGE Network was initiated and funded by National Human Genome Research Institute through grants: U01HG006828 (Cincinnati Children's Hospital Medical Center and Boston Children's Hospital), U01HG006830 (Children's Hospital of Philadelphia), U01HG006389 (Essentia Institute of Rural Health, Marshfield Clinic Research Foundation, and Pennsylvania State University), U01HG006382 (Geisinger Clinic), U01HG006375 (Group Health Cooperative and the University of Washington), U01HG006379 (Mayo Clinic), U01HG006380 (Icahn School of Medicine at Mount Sinai), U01HG006388 (Northwestern University), U01HG006378 (Vanderbilt University Medical Center), and U01HG006385 (Vanderbilt University Medical Center serving as the coordinating center). Participation of Columbia University in the eMERGE network was supported by National Human Genome Research Institute grant U01HG008680 (to C. Weng, A.G. Gharavi, and G. Hripcsak). The CKiD study was conducted by the CKiD Investigators and supported by the NIDDK, with additional funding from the National Institute of Child Health and Human Development, and the National Heart, Lung, and Blood Institute (U01-DK-66143, U01-DK-66174, U01DK-082194, U01-DK-66116). The data and biospecimens from the CKiD study reported here were supplied by the NIDDK Central Repository. The FIND study was supported by grants U01DK57292, U01DK57329, U01DK057300, U01DK057298, U01DK057249, U01DK57295, U01DK070657, U01DK057303, and U01DK57304 from the NIDDK and, in part, by the Intramural Research Program of the NIDDK; support was also received from the National Heart, Lung and Blood Institute grants U01HL065520, U01HL041654, and U01HL041652; this project has been funded in whole or in part with federal funds from the National Cancer Institute, NIH, under contract N01-CO-12400 and the Intramural Research Program of the National Cancer Institute, Center for Cancer Research; this work was also supported by the National Center for Research Resources for the General Clinical Research Center grants: Case Western Reserve University, M01-RR-000080, Wake Forest University, M01-RR-07122, Harbor-University of California, Los Angeles Medical Center, M01-RR-00425, College of Medicine, University of California, Irvine, M01-RR-00827–29, University of New Mexico, HSC M01-RR-00997, and Frederic C. Bartter, M01-RR-01346. Because A.G. Gharavi is an editor of the <i>Journal of the American Society of Nephrology</i>, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.",
9,"P. Wang reports research funding from the National Natural Science Foundation of China (81873612); advisory or leadership role as department director, Blood Purification Center, The First Affiliated Hospital of Zhengzhou University; and other interests or relationships as Youth Committee of Chinese Medical Association Nephrology Branch, vice chairman. All remaining authors have nothing to disclose.",
10,"G.M. Chertow reports consultancy: Akebia, Ardelyx, AstraZeneca, Calico, Gilead, Miromatrix, Reata, Sanifit, Unicycive, and Vertex; ownership interest: Ardelyx, CloudCath, Durect, DxNow, Eliaz Therapeutics, Outset, Physiowave, PuraCath, Renibus, and Unicycive; research funding: CSL Behring, NIAID, and NIDDK; advisory or leadership role: Board of Directors, Satellite Healthcare, Co-Editor, <i>Brenner & Rector's The Kidney</i> (Elsevier); and other interests or relationships: DSMB service—Bayer, Gilead, Mineralys, NIDDK, and ReCor. C. Delgado reports membership of the GUIDE-US Anemia Council Scientific; advisory board for Glaxo Smith Kline; and serves on the editorial board for the <i>American Journal of Kidney Disease</i>. B. Grimes reports ownership interest: Abbot and Amgen. K.L. Johansen reports membership of the Steering Committee for the GSK ASCEND studies; consultancy for Akebia and Vifor Pharma; and serves as an Associate Editor for the <i>JASN</i>. N.R. Powe reports honoraria from Hennepin Healthcare Research Institute, Patient Centered Outcomes Research Institute, Robert Wood Johnson Foundation, and Vanderbilt University and scientific advisor or membership with Hennepin Healthcare Research Institute, Patient Centered Outcomes Research Institute, Robert Wood Johnson Foundation, the <i>JASN</i> as an Associate Editor, and Vanderbilt University. Because K.L. Johansen and N.R. Powe are editors of the <i>JASN</i>, they were not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.",
11,"S.B. has received lecture fees from Astellas. L.E. has received fees from Astellas, Chiesi, Novartis, and Sanofi. The other authors declare no conflicts of interest.",
12,"The authors declare no conflicts of interest. The results presented in this article have not been previously published in whole, but data examples from a few individuals have been presented in a methodological article (Nielsen CM, Skov K, Buus NH, et al. Kidney structural characteristics based on a kidney biopsy and contrast-enhanced computed tomography in healthy living kidney donors. Anat Rec (Hoboken ). 2020;303:2693–2701).",No
13,"Dr. J.M. Bargman has served as a consultant and speaker for Amgen, Baxter, Bayer, DaVita Healthcare Partners, and GSK. J.M. Bargman also reports consultancy: Otsuka; honoraria: Baxter Healthcare, Davita Healthcare Partners, and Glaxo Smith Kline; advisory or leadership role: Editorial Boards of <i>Journal of the American Society of Nephrology</i>, <i>Peritoneal Dialysis International</i>, and <i>Clinical Journal of the American Society of Nephrology</i>; and speakers bureau: Baxter Canada, Baxter Global, DaVita Healthcare Partners, and Glaxo Smith Kline. Dr. T.W. Meyer has served as a consultant for Baxter. T.W. Meyer also reports research funding: Outset Medical; honoraria: Renal Research Institute; and advisory or leadership role: ASN editorial board and KI editorial board. Because Joanne Bargman is an editor of the <i>Journal of the American Society of Nephrology</i>, she was not involved in the peer review process for this manuscript. Another editor oversaw the peer review and decision-making process for this manuscript.",
14,"R. Knight reports employment with American Association of Kidney Patients; honoraria from American Kidney Fund, Johns Hopkins Center for Health Equity, Labcorp, Northwestern University, Novartis, Otsuka, and Personalized Medicine Coalition; advisory or leadership roles for NIDDK Advisory Council, Scientific Advisory Board for the “Rescuing Kidneys at Risk of Discard” project, and SRTR Review Committee; serving as AAKP President and a member of Quality Insights Patient Advisory Committee; and other interests or relationships with Bowie State University Board of Advisors and SRTR Review Committee. S. Menez reports consulting fees from the Dedham Group and research funding from RenalytixAI. C.R. Parikh reports consultancy agreements with Genfit Biopharmaceutical Company; ownership interest in RenalytixAI; research funding from National Heart, Lung and Blood Institute (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); advisory or leadership roles for Genfit Biopharmaceutical Company and RenalytixAI; and is a coinventor on a pending patent, “Methods and Systems for Diagnosis of Acute Interstitial Nephritis,” that is subject to an option for a license agreement with RenalytixAI, Inc. S.V. Parikh reports consultancy agreements with Alexion, Aurinia Pharmaceuticals, Bristol Myers Squibb, GlaxoSmithKline, and Kezar Life Sciences; research funding from Aurinia Pharmaceuticals, NIH-NIDDK, and Serono-EMD; grant support from Aurinia Pharmaceuticals and Biogen Idec; and royalties from UpToDate.com. A.Z. Rosenberg reports research funding from NIH and NKF; honoraria from Georgetown University, Ichilov Hospital (Tel Aviv, Israel), and Stony Brook University; and an advisory or leadership role for Escala. B. Rovin reports consultancy agreements with Alexion, AstraZeneca, Aurinia, Biocryst, Biogen, BMS, Bristol Myers Squibb, Calliditas, Chemocentryx, Corrona, EMD-Serono/Merck, Exagen, Galapagos, Genentech, Horizon, Human Genome Sciences (GSK), Idorsia, Janssen, Lupus Foundation of America, MedImmune, Morphosys, Novartis, Omeros, Otsuka, Resonance, Retrophin, RILITE Foundation, Roche, and Vistera; research funding from Biogen; honoraria from Alexion, AstraZeneca, Aurinia, Biocryst, Biogen, BMS, Calliditas, Chemocentryx, Corrona, EMD-Serono/Merck, Exagen, Galapagos, Genentech, Horizon, Human Genome Sciences (GSK), Idorsia, Janssen, MedImmune, Morphosys, Novartis, Omeros, Otsuka, Resonance, Retrophin, RILITE Foundation, Roche, and Vistera; advisory or leadership roles for ASN Kidney Week, CureGN, KDIGO, <i>Kidney International</i>, <i>Kidney International Reports</i>, Lupus Foundation of America, <i>Nephrology Dialysis and Transplantation</i>, and UpToDate; and a lot of work with the ASN—mostly educational courses, work with the ISN and NKF, and work with the LFA. The remaining authors have nothing to disclose.",
15,"A.M. Huml reports Advisory or Leadership Role: Cleveland Minority Organ and Tissue Transplant Education Program (MOTTEP) Advisory Board Co-Chair, Chairperson for IPRO ESKD Network of the Ohio River Valley Medical Review Board, Member of the Medical Director Advisory Council for The National Forum of ESKD Networks. S.A. Husain reports Research Funding: Nelson family foundation; and Honoraria: Fresenius. S. Mohan receives grant funding from Kidney Transplant Collaborative and the NIH, and personal fees from Kidney International Reports and Health Services Advisory Group outside of the submitted work. S. Mohan also reports Consultancy: eGenesis and HSAG; Patents or Royalties: Columbia University; Advisory or Leadership Role: Chair of UNOS Data advisory committee, Deputy Editor of <i>Kidney International Reports</i> (ISN), Member of ASN Quality committee, Member of SRTR Review Committee, and National Faculty Chair of ETCLC. R.E. Patzer reports Employer: Vital (spouse); Ownership Interest: Vital Software (spouse has ownership); Advisory or Leadership Role: Editorial board of <i>American Journal of Transplantation</i>, <i>CJASN</i> editorial board, Chair of United Network for Organ Sharing Data Advisory Board; and Other Interests or Relationships: Vital ER—husband is a chief medical officer. J.D. Schold reports Consultancy: eGenesis and Sanofi Corporation; Research Funding: One Legacy Foundation; Honoraria: eGenesis and Sanofi Inc.; Advisory or Leadership Role: Data Safety Monitoring Board Member—Bristol Myers Squibb and Vice Chair UNOS Data Advisory Committee; and Speakers Bureau: Sanofi. The remaining author has nothing to disclose.",
16,"L. Zhou reports Employer: Foundation Medicine, Inc. M.E. Grams reports Advisory or Leadership Role: <i>American Journal of Kidney Diseases</i>, <i>Clinical Journal of the American Society of Nephrology</i>, <i>Journal of the American Society of Nephrology</i> Editorial Board, NKF Scientific Advisory Board, KDIGO Executive Committee, USRDS Scientific Advisory Board; and Other Interests or Relationships: Grant funding from NKF—which receives funding from multiple pharmaceutical companies, grant funding from NIH, payment from academic institutions for grand rounds, and payment from NephSAP. B. Gwen Windham reports Advisory or Leadership Role: <i>Journal of Gerontology</i>: Medical Sciences Associate Editor. E. Selvin reports Research Funding: National Institutes of Health (NIH); Patents or Royalties: Royalties from UpToDate for sections on screening, diagnosis, and laboratory testing for diabetes; and Advisory or Leadership Role: Deputy Editor of Diabetes Care, and on the Editorial Board of <i>Diabetologia</i>. J. Coresh reports Consultancy: Healthy.io and SomaLogic; Ownership Interest: Healthy.io; Research Funding: National Institutes of Health (NIH), National Kidney Foundation (NKF, which receives industry support); and Advisory or Leadership Role: Healthy.io, and National Kidney Foundation. L.A. Inker reports Consultancy: Diamtrix; Research Funding: funding to institute for research and contracts with the National Institutes of Health, National Kidney Foundation, Chinnocks, Omeros and Reata Pharmaceuticals; consulting agreements with Tricida Inc.; Advisory or Leadership Role: Alport Foundation—Medical Advisory Council, NKF—Scientific Advisory Board; and Other Interests or Relationships: American Society of Nephrology member, and National Kidney Foundation member. A.S. Levey reports Research Funding: Grants and contracts paid to Tufts Medical Center from NIH, and NKF; Contracts to paid to A.S. Levey from AstraZeneca (DSMB for dapagliflozin trials); and Honoraria: Academic medical centers for visiting professorships. All remaining authors have nothing to disclose.",
17,Disclosure Statement. The authors of this manuscript have no conflicts of interest to disclose as described by the <i>American Journal of Transplantation</i>.,No
18,"D. Sawinski reports Ownership Interest: CareDx; Research Funding: National Institutes of Health; Advisory or Leadership Role: American <i>Journal of Kidney Diseases</i>, <i>Clinical Transplantation</i>, Councilor at Large for American Society of Transplantation Board of Directors; and Other Interests or Relationships: UNOS Kidney Committee member, and Expert witness testimony. S.V. Niederhaus reports Consultancy: Memo Therapeutics; Honoraria: ASN/CDC; and Advisory or Leadership Role: National Kidney Foundation of Maryland/Delaware Board Member. J.S. Gill reports Consultancy: Takeda; Veloxis; Research Funding: Astellas; Honoraria: Hansa, Takeda, Veloxis; and Advisory or Leadership Role: <i>American Society of Transplantation</i>, Canadian Blood Services, and <i>Journal of the American Society of Nephrology</i> Associate Editor. Because J.S. Gill is an Associate Editor of the <i>Journal of the American Society of Nephrology</i>, he was not involved in the peer review process for this manuscript. Another editor oversaw the peer review and decision-making process for this manuscript. All remaining authors have nothing to disclose.",
19,"Conflicts of interest Dr. Fishman serves on the scientific advisory boards of Jura Bio, Well Medical Inc. , Sfunga Inc. , and as a consultant to eGenesis Inc and Makana Inc. He receives royalties from UpToDate. Dr. Fishman holds Patents 6190861; 6699663; 7,465,573. Molecular sequence of swine retrovirus and methods of use (J.A. Fishman, sole inventor, filed November, 1995).",
20,"T. Akizawa reports consultancy for Astellas, Bayer, GlaxoSmithKline, JT, Kissei, Kyowa Kirin, Nipro, Sanwa Kagaku, and Torii; honoraria from Astellas, Bayer, Chugai, Fuso, Kissei, Kyowa Kirin, Mitsubishi-Tanabe, Ono, Sanwa Kagaku, and Torii; and speakers bureau for Astellas, Bayer, Chugai, Fuso, Kissei, Kyowa Kirin, Mitsubishi-Tanabe, Ono, Sanwa Kagaku, and Torii. M. Fukagawa reports consultancy for AstraZeneca Japan, Kissei, Kyowa Kirin, Ono, Sanwa, Sanwa Kagaku, and Torii; research funding from Kyowa Kirin; honoraria from AstraZeneca, Bayer Japan, Kissei, Kyowa Kirin, Ono, Sanofi, Sanwa Kagaku, and Torii; and speakers bureau for AstraZeneca, Bayer Japan, Kissei, Kyowa Kirin, Ono, Sanofi, Sanwa Kagaku, and Torii. K. Hagita, D. Honda, and Y.S. Watanabe are employees of Sanwa Kagaku Kenkyusho Co. Ltd. Y. Isaka reports consultancy for Kirin Co. Ltd. and Sanwa Kagaku Kenkyusyo Co. Ltd.; research funding from Kirin Co. Ltd.; advisory or leadership role for Kirin Co. Ltd. and Sanwa Kagaku Kenkyusyo Co. Ltd.; and speakers bureau for Astellas Pharma Inc., AstraZeneca plc, Kirin Co. Ltd., Kissei Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical Co. Ltd., and Sanwa Kagaku Kenkyusyo Co. Ltd. F. Koiwa reports consultancy for Kyowa Kirin Co. Ltd. and Sanwa Kagaku Kenkyusho Co., Ltd.; honoraria from Kissey Pharmaceutical CO, Ltd. and Kyowa Kirin CO, Ltd.; and speakers bureau for Bayer Yakuhin, Ltd., Kissey Pharmaceutical CO, Ltd., Kyowa-Hakko Kirin CO, Ltd., Ono Yakuhin Co. Ltd., and Sanwa Kagaku Kenkyusyo Co., Ltd. T. Shigematsu reports research funding from Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Ono Pharmaceutical Co. Ltd., and Sanwa Kagaku Kenkyusho Co., Ltd.; honoraria from Sanwa Kagaku Kenkyusho Co., Ltd.; advisory or leadership role for Sanwa Kagaku Kenkyusho Co., Ltd.; and speakers bureau for Bayer in Japan, Kissei Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Ono Pharmaceutical Co. Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., and Torii Pharmaceutical Co. Ltd.",
21,"D. Assimos reports serving on the Editorial Boards of the <i>Journal of Endourology</i> and the <i>Journal of Urology</i>. J. Calle reports employment with Benesch Friedlander Coplan & Aronoff LLP and Cleveland Clinic; honoraria from Travere Pharmaceuticals; advisory or leadership role for Precision BioSciences, Inc. Primary Hyperoxaluria type 1 Advisory board; and speakers bureau for Travere Pharmaceuticals. A. Grauer reports employment with Federation Bio; ownership interest in Federation Bio; and advisory or leadership role for Sirana Pharma, Scientific Advisory Board. A. Kausz reports consultancy for Allena Pharmaceuticals, Inc., Noveome Biotherapeutics, ProKidney, and Viridian and advisory or leadership role for Kidney Health Initiative Board of Directors and Noveome Biotherapeutics. F. Knauf reports consultancy for Allena Pharmaceuticals, United States; Alnylam Pharmaceutical, United States; Chinook Pharmaceuticals, United States; Oxthera Pharmaceuticals, Sweden; Zai Pharmaceuticals, China; and EcoR1, United States; research funding from Alnylam Pharmaceuticals, Deutsche Forschungsgemeinschaft, Dicerna Pharmaceuticals, and Else Kröner Fresenius Stiftung; honoraria from Advicenne, Alnylam, ECoR1, Medice, and Sanofi; royalties from PocketDoktor Medical Books; and advisory or leadership role for Oxalosis and Hyperoxaluria Foundation, NYC, Scientific Advisory Board. F. Knauf is an employee of the nonprofit institute Charité-Universitätsmedizin Berlin, which recently filed a patent application for oxalate-lowering agents in dialysis patients with F. Knauf as one of two inventors. There has been no decision yet. C.B. Langman reports consultancy for Alexion Pharmaceuticals, Allena Pharmaceuticals, and Dicerna Pharmaceuticals and honoraria from Alexion Pharmaceuticals and Horizon Pharmaceuticals. J.C. Lieske reports employment with Mayo Clinic; consultancy for Allena, Alnylam, the American Board of Internal Medicine, BioMarin, Chinook, Dicerna, Federation Bio, Intellia, Mirium, Novo Nordisk, Novobiome, Orfan, Oxidien, OxThera, Siemens, and Synlogic; research funding from Allena, Alnylam, Dicerna, Novobiome, OxThera, Retrophin, Siemens, and Synlogic; honoraria from the American Board of Internal Medicine and UpToDate; and advisory or leadership role for <i>Kidney International</i> and ABIM. M.A. Malley reports employment with Travere Therapeutics and ownership interest in Travere Therapeutics and Altimmune. D. Milliner reports employment with Mayo Clinic; consultancy for Alnylam, Dicerna, Mirum, Novo Nordisk, and OxThera pharmaceutical companies; research funding from Alnylam, Dicerna, Novo Nordisk, and OxThera pharmaceutical companies—all research funding is provided to Mayo Clinic and not to D. Milliner personally; advisory or leadership roles for <i>Urolithiasis</i> Editorial Board, Alnylam pharmaceuticals Humanitarian Program, Advisory committee for Alnylam pharmaceutical company, Data Safety Monitoring Board for clinical trials conducted by Dicerna pharmaceutical company, and ongoing work with the Oxalosis and Hyperoxaluria Foundation, a nonprofit, private foundation. This includes some research funding; there is no personal compensation. D. Milliner reports ongoing work with the OHF and KHI for a KHI-sponsored project. L. Nazzal reports consultancy for Allena, Dicerna, Federation Bio, Oxthera, Novome, and Synlogic; honoraria from Guidepoint, GLG consultancy, and Magnolia innovations; and advisory or leadership role for Scientific Advisory Board of the Oxalosis and Hyperoxaluria Foundation. G. Tasian reports consultancy for and research funding from Alnylam Pharmaceuticals and Novo Nordisk. A. Thompson reports employment with US Food and Drug Administration. K.D. Wood reports consultancy for Alnylam Pharmaceuticals, Biomarin, Chinook Therapeutics, Intellia Therapeutics, Novome Biotechnologies, Steris Corporation, and Synlogic Therapeutics; research funding from Arbor Biotechnology and Chinook Therapeutics; patents through University of Alabama; and advisory or leadership role for Scientific Advisory Board for the Oxalosis and Hyperoxaluria Foundation (not paid). E. Worcester reports patents or royalties from BMA Biomedical and advisory or leadership role for the Oxalosis and Hyperoxaluria Foundation. S. Yang reports employment with FDA and ownership interest in BABA, Facebook, FVRR, LPSN, Lyft, NVDA, OPEN, PINS, PLTR, RIVN, TWLO, UPWK, and Yelp. All remaining authors have nothing to disclose.",
22,"Z. Dong reports Consultancy: DILIsym/RenaSym and Mitobridge; Honoraria: DILIsym/RenaSym and Mitobridge; and Advisory or Leadership Role: Associate Editor for <i>American Journal of Physiology-Renal Physiology</i>, Associate Editor for <i>Kidney Diseases</i>, Board of Directors: Adjunct Professorship at The Second Xiangya Hospital of Central South University in China and Chinese American Society of Nephrology, and Editorial board member for <i>American Journal of Physiology-Cell Physiology</i>, <i>JASN</i>, and <i>Kidney International</i>. All remaining authors have nothing to disclose.",
23,The authors declare no funding or conflicts of interest,No
24,"S.D. Bieber reports employer: Kootenai Health. During manuscript content development and revision, Dr. Y. Brahmbhatt has been employed by AstraZeneca and holds AstraZeneca stocks. Voting and review of measures by Dr. Y. Brahmbhatt was completed while employed at the Division of Nephrology, Thomas Jefferson University, Philadelphia, USA. P.S. Garimella receives speaker fees from Otsuka Inc. and honoraria from Dialysis Clinic Inc. unrelated to the submitted work. E. Gould reports consultancy: Premier Inc.; ownership interest: Apple, Microsoft; research funding: Allena, AstraZeneca, Oxthera, Palladio; and advisory or leadership role: ASN Home Dialysis Steering Committee. Dr. N. Gupta serves on an advisory board of Fresenius Medical Care and received royalties from UpToDate. Dr. K.L. Lentine is a Senior Scientist of the SRTR, receives research funding from the National Institutes of Health (R01DK120551 | R01DK120518), and is supported by the Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation; Dr. K.L. Lentine is chair of the American Society of Transplantation Living Donor Community of Practice, a member of the ASN policy and Advocacy Committee, and a member of the NKF Transplant Advisory Committee; unrelated to this work, Dr. K.L. Lentine receives consulting fees from CareDx and speaker honoraria from Sanofi. S.Q. Lew receives consultation fee from Triomed. S.Q. Lew reports employer: George Washington University Medical Faculty Associates and Mitre; consultancy: Triomed; advisory or leadership role: Quality Insights: Medical Review Board, George Washington University: ACO Board of Director; and other interests or relationships: ASN: KHI member, ASN: Quality Committee member, ASN: KidneyX grant reviewer, ASN: COVID-19 home dialysis subcommittee, NIA: grant reviewer, NIH's Kidney Precision Medical Project: Data Safety Monitoring Board member, USFDA Gastroenterology and Urology Devices Panel of FDA's Medical Devices Advisory Committee. F. Liu reports consulting from Outset Medical, medical advisor to CVS/Accordant, and speakers bureau for AstraZeneca. F. Liu reports employer: the Rogosin Institute; consultancy: CVS/Accordant, Outset Medical; Speakers Bureau: AstraZeneca; and other interests or relationships: Outset Medical (PI for clinical study), CVS (PI for clinical study). M.L. Mendu reports advisory or leadership role: advisory board of New England Life Care. S. Mohan receives research funding from the NIH and the Kidney Transplant Collaborative, is a consultant for HSAG, chair of the CMS/HRSA ESRD Treatment Choices Collaborative, and Deputy Editor for Kidney International Reports. S. Mohan reports consultancy: eGenesis, HSAG; patents or royalties: Columbia University; advisory or leadership role: Deputy Editor of Kidney International Reports (ISN), Chair of UNOS, Data advisory committee, Member of SRTR Review Committee, Member of ASN Quality committee, National Faculty Chair ETCLC; and other interests or relationships: Research Funding from NIH (NIDDK, NIHMD, and NIBIB) and Kidney Transplant Collaborative. M. Somers reports consultancy: Alnylam, Dicerna, Horizon, Orfan Biotech, Precision Biosciences; research funding: BioPorto, Dicerna; and advisory or leadership role: NAPRTCS—Board of Directors and ASPN—President and Past President. S.L. Tummalapalli reports research funding: Scanwell Health and other interests or relationships: travel support through the Abbott Pharmaceuticals and International Society of Nephrology. D.E. Weiner reports research funding, all compensation paid to Tufts MC from Bayer (site PI), Cara (site PI), Vertex (site PI); advisory or leadership role: Co-Editor-in-Chief of NKF Primer on Kidney Diseases 8th Edition, Editor-in-Chief, Kidney Medicine, Medical Director of Clinical Research, Dialysis Clinic Inc., Member of ASN Quality and Policy Committees and ASN representative to KCP, Member of Scientific Advisory Board for National Kidney Foundation; and other interests or relationships: Member of Safety and Clinical Events Committee for “A Prospective, Multi-Center, Open-Label Assessment of Efficacy and Safety of Quanta SC+ for Home Hemodialysis” Trial (Avania CRO) and Member of Adjudications Committee of ProKidney REACT Trial (George Institute CRO). Mr. D.L. White is employed by the American Society of Nephrology. K. Erickson reports Consultancy: Acumen LLC, Boehringer Ingelheim; Honoraria: Dialysis Clinic, Inc., University of Missouri, Satellite Healthcare, Boehringer Ingelheim, UC Irvine, Columbia University; Advisory or Leadership Role: AJKD - associate editor, CJASN - associate editor, American Society of Nephrology Public Policy Board's Quality Committee (member), Seminars in Dialysis - associate editor; and Other Interests or Relationships: research funding from Health Care Service Corporation's Affordability Cures grant, and travel funds from KDIGO. N. Gupta reports Consultancy: Fresenius Medical Care advisory board; Research Funding: Quanta; Patents or Royalties: UpToDate; Speakers Bureau: Baxters Speaker Bureau; and Other Interests or Relationships: Member of the ASN Quality Committee, and Member of ASN EPC, TDAT. K. Lentine reports Consultancy: CareDx, Inc.; Ownership Interest: CareDx, Inc.; and Speakers Bureau: Sanofi. E. Gould reports Consultancy: Premier Inc.; Ownership Interest: Apple, Microsoft; Research Funding: Oxthera, Astra Zeneca, Allena; Palladio; and Advisory or Leadership Role: ASN Home Dialysis Steering Committee. M. Somers reports Consultancy: Horizon, Alnylam, Dicerna, Orfan Biotech, Precision Biosciences; Research Funding: BioPorto, Dicerna; and Advisory or Leadership Role: NAPRTCS Board of Directors, ASPN President and Past President. S. Mohan reports Consultancy: eGenesis, HSAG; Patents or Royalties: Columbia University; Advisory or Leadership Role: Deputy Editor of Kidney International Reports (ISN), Chair of UNOS Data advisory committee, Member of SRTR Review Committee, Member of ASN Quality committee, National Faculty Chair of ETCLC; and Other Interests and Relationships: Research Funding from NIH (NIDDK, NIHMD and NIBIB), and Kidney Transplant Collaborative. Y. Brahmbhatt reports Employer: Astrazeneca, Chinook Therapeutics; Ownership Interest: Astrazeneca, Chinook Therapeutics; and Advisory or Leadership Role: Served on advisory boards as part of job function at Astrazeneca (not paid additionally for this). Y. Brahmbhatt reports Employer: Astrazeneca, Chinook Therapeutics; Ownership Interest: Astrazeneca, Chinook Therapeutics; and Advisory or Leadership Role: Served on advisory boards at Astrazeneca (unpaid). S. Mohan reports Consultancy: eGenesis, HSAG; Patents or Royalties: Columbia University; Advisory or Leadership Role: Deputy Editor Kidney International Reports (ISN), Chair UNOS, Data advisory committee, Member of SRTR Review Committee, Member of ASN Quality committee, National Faculty Chair ETCLC; and Other Interests or Relationships: Research Funding from NIH (NIDDK, NIHMD and NIBIB) and Kidney Transplant Collaborative. E. Gould reports Consultancy: Premier Inc.; Ownership Interest: Apple, Microsoft; Research Funding: Oxthera, Astra Zeneca, Allena, Palladio; and Advisory or Leadership Role: ASN Home Dialysis Steering Committee. K. Lentine reports Consultancy: CareDx, Inc.; Ownership Interest: CareDx, Inc.; and Speakers Bureau: Sanofi. K. Erickson reports Consultancy: Acumen LLC; Boehringer Ingelheim; Honoraria: Dialysis Clinic, Inc.; University of Missouri; Satellite Healthcare; Boehringer Ingelheim; UC Irvine; Columbia University; Advisory or Leadership Role: AJKD - associate editor; CJASN - associate editor; American Society of Nephrology, Public Policy Board's Quality Committee (member); Seminars in Dialysis - associate editor.; and Other Interests or Relationships: Receive research funding from Health Care Service Corporation's Affordability Cures grant, Received travel funds from KDIGO. N. Gupta reports Consultancy: Fresenius Medical Care advisory board; Research Funding: Quanta; Patents or Royalties: UpToDate; Speakers Bureau: Baxters Speaker Bureau; and Other Interests or Relationships: Member, ASN Quality Committee, Member ASN EPC, TDAT. All remaining authors have nothing to disclose.",
25,"E. Boerwinkle reports ownership interest in Codified Genomics and honoraria from The University of Washington, honoraria for participating in the PRIDE program. N. Franceschini reports advisory or leadership roles for the Women's Health Initiative Publication and Presentation Committee and the Women's Health Initiative Ancillary Study Committee. R. Kaplan reports employment with Albert Einstein College of Medicine. J.P. Lash reports serving an advisory or leadership role for <i>Kidney360</i>. B.M. Lin reports ownership interest in ARWR, CNK, and EDIT. D. Muoio reports research funding from Eli Lilly and Co. and honoraria from Eli Lilly and Co. B. Thygarajan reports consultancy agreements with Diversigen Inc. and research funding from Peak Diagnostics. The remaining authors have nothing to disclose.",
26,"Y. Becker's spouse reports employment with Village MD. R. Formica reports consultancy for Sanofi Pharmaceuticals and Veloxis Pharmaceuticals, nonbranded educational lectures for Sanofi, role as an Associate Editor of <i>CJASN</i>, and other interests or relationships as Vice President of the OPTN Board of Directors. J. Friedewald reports consultancy for egenesis, Eurofins—Transplant Genomics, Inc., and Veloxis; research funding from CSL Behring, Eurofins—Viracor, Inc., Hansa BioPharma, NIH, Regeneron, and Veloxis; honoraria from Sanofi and UpToDate; patents or royalties from Northwestern University/Scripps Research Institute; and speakers bureau for Sanofi. J.M. Gonzalez Sepulveda reports consultancy for Biomarin, IQVIA, Merck, and Vertex; research funding from Amgen, Astellas, Grifols, GSK, and Janssen; honoraria from RAND Corporation; and advisory or leadership roles for International Academy of Health Preference Research and ISPOR. D. Kaufman reports research funding from NIH and advisory or leadership roles for Blue Rock, eGenesis, Eledon, and Vertex. D.P. Ladner reports research funding from Viracore as PI of grant until December 2022. S. Mehrotra reports ownership interest in Geeta Services, Inc. K.J. Schantz reports employment with Vector Psychometric Group. J.-C. Yang reports employment with and ownership interest in Pacific Economic Research, LLC.",
27,"S.S. Farouk reports serving on the Editorial Boards of <i>American Journal of Kidney Diseases</i>, ASN <i>Kidney News</i>, and <i>Clinical Transplantation</i>. M.A. Sparks reports employment with Durham VA Health Care System; research funding from Renal Research Institute; honoraria from Elsevier—<i>Nephrology Secrets</i> and National Kidney Foundation—NephMadness; and other interests or relationships with Alnylam Pharmaceutical as a consultant (no payment). M.A. Sparks reports serving on the Editorial Boards of <i>American Journal of Kidney Diseases</i>, ASN <i>Kidney News</i>, <i>Kidney360</i>, and <i>Kidney Medicine</i> and reports advisory or leadership roles for American Board of Internal Medicine, KCVD Membership and Communications Committee—AHA, KCVD Scientific and Clinical Education Lifelong Learning Committee (SCILL)—AHA, and NKF North Carolina—Medical Advisory Board, and Nephrology Board, Board of Director, NephJC. All remaining authors have nothing to disclose.",
28,"S. Berger reports consultancy for Chiesi and Novartis; research funding from Chiesi and Novartis; honoraria from Astellas and Novartis; and advisory or leadership roles for Advisory Board for Novartis and Supervisory Board for Dutch Transplant Foundation. R.T. Gansevoort reports consultancy for AstraZeneca, Bayer, Galapagos, Mironid, and Sanofi-Genzyme; research funding from Abbvie, AstraZeneca, Bayer, Galapagos, Otsuka Pharmaceuticals, Roche, and Sanofi-Genzyme; role on the Editorial Boards of <i>American Journal of Kidney Diseases</i>, <i>CJASN</i>, <i>Journal of Nephrology</i>, <i>Kidney360</i>, and <i>Nephron Clinical Practice</i>; and role as Editor of <i>Nephrology Dialysis Transplantation</i> and member of the Council of the European Renal Association. H.J.L. Heerspink reports ongoing consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli-Lilly, Gilead, Janssen, Merck, Novartis, Novo Nordisk, and Travere Pharmaceuticals; research funding from AstraZeneca, Boehringer Ingelheim, Janssen research support (grant funding directed to employer), and Novo Nordisk; lecture fees from AstraZeneca and Novo Nordisk; and speakers bureau for AstraZeneca.",
29,"A.Y.-M. Wang reports current advisory or leadership roles as ISN Councilor, Chair of ISN North and East Asia Regional Board, Chair of ISN Education working group, Council member of ISPD, Immediate Past President of International Society of Renal Nutrition and Metabolism, Committee member of ISN-Advancing Clinical Trial, Executive committee member of SONG Initiative; Associate Editor of <i>Nephron Clinical Practice</i>; Editorial Board member for <i>CJASN</i>, <i>JASN</i>, <i>Journal of Diabetes</i>, <i>Journal of Renal Nutrition</i>, <i>Kidney International</i>, <i>Kidney Medicine,</i> and <i>Nephrology Dialysis Transplantation</i>; and Editor-in-chief of <i>European Medical Journal Nephrology</i> H.H.L. Wu. reports other interests or relationships as a Member of the CardioRenal Toolkit Workgroup for International Society of Nephrology, Associate Editor of <i>Nutrition and Health</i>, Editorial Board Member of <i>BMC Nephrology</i>, Editorial Board Member of <i>PLOS One</i>, and Review Editor (Nephrology Section) of <i>Frontiers</i><i>in Medicine</i>.",
30,"Disclosure. The authors of this manuscript have conflicts of interest to disclose as described by the <i>American Journal of Transplantation</i>. D. Ayares is an employee of revivicor, blacksburg, va. All other authors have no conflicts of interest to declare.",
31,"I. Ay reports employer: Takeda Pharmaceuticals (spouse). P. Caravan has equity in and is a consultant to Collagen Medical LLC, has equity in Reveal Pharmaceuticals Inc., and has research support from Indalo Therapeutics, Pfizer, Janssen, Pliant Therapeutics, Takeda, and Transcode Therapeutics. P. Caravan also reports research funding: Mariana Oncology; patents or royalties: Factor 1A LLC and Reveal Pharmaceuticals; and advisory or leadership role: Board member Reveal Pharmaceuticals, unpaid. R.B. Colvin reports consultancy: eGenesism Sangamo and NephoSant; research funding: Egenesis; and advisory or leadership role: NephroSant. B.C. Fuchs was a consultant for Gilead and had research support from Blade Therapeutics, Collagen Medical, and Enanta. B.C. Fuchs also reports employer: Ferring Pharmaceuticals and advisory or leadership role: Mediar Therapeutics. R.V.P. Martinez is employee of Pfizer. R.V.P. Martinez also reports ownership interest: Pfizer and research funding: Pfizer. I.A. Rosales reports advisory or leadership role: <i>Frontiers in Transplantation</i> (Associate Editor, unpaid) and <i>Philippine Journal of Pathology</i> (associate editor, unpaid). F.J. Schlerman is employee of Pfizer. F.J. Schlerman also reports ownership interest: Pfizer. J. Wellen reports employer: Bristol Myers Squibb, Janssen Research and Development, and Pfizer Global Research and Development and ownership interest: Bristol Myers Squibb, Johnson & Johnson, and Pfizer. All remaining authors have nothing to disclose.",
32,"D.L.S. receives honoraria for AstraZeneca, CareDx, Houston Methodist, Northwell Health, Optum Health Education, Sanofi, and WebMd, as well as consulting fees from AstraZeneca, CareDx, Moderna Therapeutics, Novavax, Regeneron, and Springer Publishing. C.M.D. received honoraria from Gilead Sciences for serving on a grant review committee. V.S. received research grant support from Eli Lilly and Company and consulting fees from DiaSorin SpA. M.P. received grant support from Merck, Hologic, Moderna, Shire/Takeda, and Pfizer, as well as provided consultation to/serves on the advisory board for Rebiotix, Takeda, and Union Therapeutics. C.B.S. has received grants paid to her institution from GlaxoSmithKline, ViiV, Abbott, Merck, Gilead, Chimerix, Shire/Takeda, Schering-Plough, Ablynx, Janssen, Ansun Biopharma, and Karyopharm Therapeutics. G.H. is a recipient of research grants from Allovir, Karius, and AstraZeneca. G.H. serves on the scientific advisory boards of Karius and AstraZeneca and has received honoraria from MDOutlook and MAD-ID/ID Connect. J.H. is a recipient of grants paid to his institution from Pfizer, Janssen, and Scynexis. The other authors declare no conflicts of interest.",
33,"L.M.P. Palma reports the following: Employer: State University of Campinas (UNICAMP); Consultancy: OrphanDC/Apellis Brazil; Honoraria: Speaker for Alexion Pharma Brazil; Speaker for Apellis; Advisory or Leadership Role: Committee of Pediatric Nephrology of the Brazilian Society of Nephrology and Committee of Pediatric Transplantation of the Brazilian Association of Organ Transplantation; and Speakers Bureau: Speaker for Alexion Pharma Brazil; Speaker for Apellis. S. Sethi reports Consultancy: Novartis; Honoraria: Honorarium for Teaching, Grand Rounds, Lectures, Up to date, reviewing slides for a study for Novartis; Patents or Royalties: Patents for membranous nephropathy antigens; and Speakers Bureau: Reach MD, MJH videos. All remaining authors have nothing to disclose.",
34,"J.J. Carrero reports research funding from Astellas, Amgen, MSD, Novo Nordisk, Swedish Heart and Lung Foundation, Swedish Research Council, and Vifor Pharma; advisory or leadership roles for Advisory Committee: AstraZeneca and GSK, Editorial Boards: <i>American Journal of Kidney Diseases</i>, <i>European Heart Journal</i>, <i>Journal of Nephrology</i>, and <i>Nephrology Dialysis and Transplantation</i>; speakers bureau for Abbott Laboratories, AstraZeneca, Baxter, Fresenius Kabi, and GSK; and other interests or relationships with the European Renal Nutrition working group at the ERA-EDTA and the International Society of Renal Nutrition and Metabolism. M. Hecking reports research funding from Astellas Pharma, Boehringer Ingelheim, Eli Lilly, and Siemens Healthcare and other interests or relationships with Bayer AG. N. Scholes-Robertson reports advisory or leadership roles for Rural Kidney Association Inc. (NSW, Australia) and as Patient Editor for <i>Cochrane Kidney and Transplant</i> and reports other interests or relationships with BEAT-CKD Consumer Advisory Board (Australia) and Rural Kidney Association Inc. (NSW, Australia). All remaining authors have nothing to disclose.",
35,"M.A. Josephson reports consultancy agreements with Exosome Diagnostics, IMMUCOR, Labcorp, Otsuka, UBC Pharmaceutical Support services for the mycophenolate pregnancy registry, and Vera Therapeutics; ownership interest in Seagen; research funding from Bucksbaum Institute and Gift of Hope; honoraria from ASN Board Review Course and ASN for Highlights; and is President-Elect for American Society of Nephrology. A.S. Kliger reports employment with Metabolism Associates, New Haven; consultancy agreements with ASN; multiple equity positions managed by UBS; advisory or leadership roles as American Society of Nephrology Chair of NTDS; Chair of EPC Advisory Committee and Co-Chair of COVID-19 Response Team; and other interests or relationships with American Society of Nephrology and Renal Physicians Association. V. Kumar reports research funding from NIH CTOT studies as sub investigator and United Therapeutics/Revivicor—XenoTransplantation as sub investigator, starting Jan 2022; honoraria from American Society of Nephrology/American Society of Transplantation for combined TNCC invited video lecture, American Society of Nephrology for the early course for ASN Kidney Week invited lecture, AREP for an educational webinar, ASN COVID 19 effort, Elsevier for a book chapter, and Medscape for a podcast, and NKF talks (travel and hotel, no honoraria); advisory or leadership roles as American Society of Transplantation - Elected Councilor American Society of Transplantation BOARD (no payment), exam item writer for ABIM (no honorarium), Member of DSMB for KIRA study (no honorarium), Region 3 UNOS living donor physician representation (no honorarium), and Veloxis Member of Delpi group examining the effectiveness of Envarsus in Kidney Transplant Recipients in an evidence based fashion with the ultimate goal of publication (honorarium deferred); and other interests or relationships with American Society of Transplantation (AST): Board Liaison to the Living Donor Community of Practice; AST Transplant Community and Community Education Committee; AST Cutting Edge in Transplantation Planning Committee (CeOT) 2022, Incoming Chair of Planning Committee; Member, AST Community Education Committee; UNOS Region 3 Representative to OPTN Living Donor Community; and Schwartz Center Rounds for compassionate Rounds - Facilitator. N. Leca reports consultancy agreements with CareDx, Veloxis, and Transplant Genomics and research funding from Angion, CareDx, CSL Behring, Natera, Novartis, Transplant Genomics, and Verici. K.A. Leigh reports employment with American Society of Nephrology. K.L. Lentine reports consultancy agreements with CareDx, Inc.; ownership interest in CareDx, Inc.; speakers bureau for Sanofi; and is a volunteer member of the ASN Policy and Advocacy Committee. R.B. Mannon reports consultancy agreements with Chinook Therapeutics and Olaris Inc.; research funding from Transplant Genomics, Inc. and Verici DX; honoraria from CSL Behring; patents or royalties from Eurofins; advisory or leadership roles for Steering Committee Verici Dx and Steering Committee of Vitaerris VKTX01 IMAGINE Trial; and other interests or relationships as Chair of ASN Policy and Advocacy Committee, Chair of Scientific Registry of Transplant Recipients (SRTR) Review Committee, Immediate Past-Chair of Women in Transplantation, member of ASN Grants Committee, Deputy Editor of <i>American Journal of Transplantation</i>, and member of DSMB for NIDDK/NIH. S. Mohan reports consultancy agreements with Angion Biomedica, eGenesis, and HSAG; advisory or leadership roles as Deputy Editor of <i>Kidney International Reports</i> (ISN), member of ASN Quality committee, member of SRTR Review Committee, National Faculty Chair of ETCLC, and Vice Chair of UNOS Data advisory committee; and research funding from Kidney Transplant Collaborative and NIH (NIDDK, NIHMD, and NIBIB). G. Roberts reports employment with Kidney Research Institute; ownership interest in Options Unlimited International (50%); speakers bureau for American Association of Kidney Patients; and other interests or relationships with American Association of Kidney Patients, APOLLO, APOLLO CAB, ASN COVID-19 Response Team and Transplant Subcommittee, ASN NTSD QAIE WG, Can-SOLVE CIRAC, CPATH BmDR Charter/Governance WG, HDU Advisory Committee, International Nephrology Society (ISN) Patient Group, KDIGO CKD & Complications in Dialysis WGs, KHI APOL1 Steering Committee, KHI PFPC, NKF Ambassador of KAC Diversity WG & Patient Education Series, and NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. G. Roberts reports advisory or leadership roles for Center for Innovations in Cancer & Transplants, chair of Community Engagement (Eng.) Committee (Comm.), and Steering Comm.; KRI Patient Advisory Comm.; CDI Patient Advisory Board; Kidney Precision Medicine Project Community Engagement Committee; C-Path Patient Eng. Comm. & DIKI Project; CRIC study and Expert Patient Panel; and University of Minnesota's Office of Discovery and Translation: Reduce Medication-Related Disparities in African American Patients with Chronic Kidney Disease. G. Roberts's spouse reports consultancy agreements with Vortex. D.L. Sawinski reports ownership interest in CareDx; research funding from National Institutes of Health; advisory or leadership roles for <i>American Journal of Kidney Diseases</i>, <i>Clinical Transplantation</i>, and Councilor at Large of American Society of Transplantation Board of Directors; and other interests or relationships as UNOS Kidney Committee member and expert witness testimony. All remaining authors have nothing to disclose. The authors are volunteer members of the ASN COVID-19 Transplant Response Team.",
36,"J.V.G. consults for and received grants from Organ Recovery Systems (Itasca, IL) and consults for GATT Technologies. The other authors declare no conflicts of interest.",
37,"The authors report funding from the JLH Foundation. G.L. consults for TransMedics, Inc. and Abiomed and receives grant support at Baylor College of Medicine from TransMedics, Inc., Abiomed, AtriCure, and Abbott. The authors report no other conflicts of interest.",
38,"V.A. Assimon reports Employer: Cartography Biosciences, Maze Therapeutics, and Soteria Biotherapeutics; Consultancy: Capstan Therapeutics and Soteria Biotherapeutics; Ownership Interest: Cartography Biosciences, Cleave Therapeutics, Denali Therapeutics, Maze Therapeutics, and Soteria Biotherapeutics; Research Funding: Cartography Biosciences, Maze Therapeutics, and Soteria Biotherapeutics; and Patents or Royalties: Maze Therapeutics, Soteria Biotherapeutics, and University of California San Francisco. A.G. Bick reports Ownership Interest: TenSixteen Bio. H. Chan reports Employer: Maze Therapeutics; and Ownership Interest: Cytokinetics, Gilead, Illumina, Nektar, and Vertex.S. Chandrasekar reports Employer: Apple Inc., Arcus Biosciences, and Maze Therapeutics; and Ownership Interest: Apple Inc., Arcus Biosciences, and Maze Therapeutics. C.P. Chung reports Advisory or Leadership Role: Journals: <i>Arthritis Care & Research</i>, <i>Clinical Pharmacology & Therapeutics</i>, and <i>Clinical Rheumatology</i>. K. Estrada reports Employer: Maze TX; and Ownership Interest: BioMarin, Maze TX, and Regeneron. R.R. Graham reports Employer: Maze Therapeutics; Ownership Interest: Maze Therapeutics; and Patents or Royalties: Maze Therapeutics. E.M. Green reports Employer: Maze Therapeutics; Ownership Interest: Maze Therapeutics; Patents or Royalties: Maze Therapeutics; and Advisory or Leadership Role: Maze Therapeutics. M. Hoek reports Employer: Maze Therapeutics; Ownership Interest: Maze Therapeutics and Merck & Co.; Research Funding: Maze Therapeutics and Merck & Co.; and Patents or Royalties: Maze Therapeutics and Merck & Co. A.M. Hung reports Consultancy: NHLBI consultant for Gene and life interaction grant; Research Funding: Vertex Grant to VUMC and VHA CSR&D Merit “Genetics of Kidney Disease and Hypertension, Risk Prediction and Drug Response”; and Advisory or Leadership Role: Ad-hoc Scientific Review Committee CSR&D, Ad-Scientific Review Committee KNOD, Ad-hoc SRC NHLBI, Co-Chair Million Veteran Program Publications and Presentation committee, Co-Chair Pharmacogenomics for COVID-19 Million Veteran Program, Section Editor, <i>Clinical Nephrology</i>; Standing member SRC HSR&D bioinformatics, and Veterans Affairs. M.E. Matheny reports Consultancy: Food and Drug Administration (FDA) and NIH-VA-DoD Pain Management Grant Consortium (PMC3); and Advisory or Leadership Role: SMRB Study Section, Steering Committee—Indianapolis VA HSR&D COIN Center, Steering Committee—VA HSR&D VIREC, Steering Committee—Salt Lake City VA HSR&D COIN Center, VA HSR&D, Informatics & Methods Section, and VA ORD Million Veterans Program Executive Steering Committee. S.V. Mozaffari reports Employer: Maze Therapeutics; and Ownership Interest: Maze Therapeutics; 23andMe. C. Robinson-Cohen reports Advisory or Leadership Role: <i>BMC Nephrology</i> Editorial Board Member, <i>CJASN</i> Editorial Board Member, and <i>Clinical Nephrology</i>, Genetics Section Editor. S.C. Shah reports Consultancy: Medscape, Phathom Pharmaceuticals, and RedHill Biopharma; and Research Funding: American Gastroenterological Association, National Institute of Health, US Department of Veterans Affairs. E.D. Siew reports Ownership Interest: Amazon stock and Apple stock; Patents or Royalties: Author for UptoDate (royalties); Advisory or Leadership Role: Editorial board of <i>CJASN</i>. Personal fees; and Other Interests or Relationships: Consultancy Agreement with Novartis (no fees received during past 24 months). K. Susztak reports Consultancy: Astra Zeneca, GSK, Novo Nordisk, and Pfizer; Ownership Interest: Jnana; Research Funding: Astra Zeneca, Bayer, Boehringer Ingelheim, Calico, Gilead, GSK, Jnana, Kyowa Kirin Genentech, Maze, Novartis, Novo Nordisk, ONO Pharma, Regeneron, and Variant Bio; Honoraria: AstraZeneca, Bayer, Jnana, Maze, and Pfizer; and Advisory or Leadership Role: Editorial board; <i>Cell Metabolism</i>, <i>EBioMedicine</i>, <i>JASN</i>, Jnana, <i>Journal of Clinical Investigation</i>, <i>Kidney International</i>, <i>Med</i>, and Pfizer. T. Thompson reports the following: Ownership Interest: Tenacious Products, LLC. L. Wheless reports Research Funding: Dermatology Foundation and VA ClinicalSciences R&D; and Advisory or Leadership Role: Board of Directors, International Immunosuppression and Transplant Skin Cancer Collaborative. R. Tao reports Employer: Vanderbilt University Medical Center, and Genentech. All remaining authors have nothing to disclose. Because Katalin Susztak is an editor of the <i>Journal of the American Society of Nephrology</i>, she was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.",
39,"M.E. Grams reports Advisory or Leadership Role: <i>American Journal of Kidney Diseases</i>, <i>Clinical Journal of the American Society of Nephrology</i>, <i>Journal of the American Society of Nephrology</i> Editorial Board, NKF Scientific Advisory Board, KDIGO Executive Committee, USRDS Scientific Advisory Board and Other Interests or Relationships: Grant funding from NKF, which receives funding from multiple pharmaceutical companies, grant funding from NIH, payment from academic institutions for grand rounds, and payment from NephSAP. J. Coresh reports Consultancy: Healthy.io; Ownership Interest: Healthy.io; Research Funding: National Institutes of Health (NIH), National Kidney Foundation (NKF, which receives industry support); and Advisory or Leadership Role: Healthy.io, and National Kidney Foundation. K. Matsushita reports Consultancy: Akebia and Kyowa Hakko Kirin; Honoraria: Fukuda Denshi, Kowa Company Ltd.; and Advisory or Leadership Role: <i>Kidney International</i>, <i>American Journal of Kidney Disease</i>, <i>Circulation Reports</i>. S. Bell reports Consultancy: AstraZeneca; and Honoraria: AstraZeneca. J.J. Carrero reports Consultancy: AstraZeneca, Bayer, Nestle; Research Funding: Amgen, Astellas, AstraZeneca, Swedish Heart and Lung Foundation, Swedish Research Council, and ViforPharma; Advisory or Leadership Role: Advisory Committee: AstraZeneca, Fresenius, Nestle, Editorial board: <i>Journal of Nephrology, Nephrology, Dialysis and Transplantation</i>, <i>American Journal of Kidney Disease</i>, <i>European Heart Journal</i>; Speakers Bureau: Abbott Laboratories, AstraZeneca, Baxter, Fresenius, and Viforpharma; and Other Interests or Relationships: European Renal Nutrition working group at the ERA-EDTA, and Ïnternational Society of Renal Nutrition and Metabolism. G. Chodick reports Institutional research funding from Merck & Co., Inc. M. Evans reports Consultancy: AstraZeneca, Vifor Pharma; Research Funding: Astellas pharma, institutional grant; Honoraria: Payment for lectures by Astellas, AstraZeneca, Baxter healthcare, Fresenius Medical Care, and Vifor Pharma; Advisory or Leadership Role: Astellas, AstraZeneca and Vifor Pharma Advisory board; and Other Interests or Relationships: Member of Steering committee in the Swedish Renal Registry and the ERA-EDTA Registry Committee. H.J.L. Heerspink reports Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Chinook, Dimerix, Eli-Lilly, Gilead, GoldFinch, Janssen, Merck, NovoNordisk, and Travere Pharmaceuticals; Research Funding: AstraZeneca, NovoNordisk and Janssen research support (grant funding directed to employer); Honoraria: Lecture fees from AstraZeneca; and Speakers Bureau: AstraZeneca. L.A. Inker reports Consultancy: Diamtrix; Research Funding: L.A. Inker—funding to institute for research and contracts with the Chinnocks, National Institutes of Health, National Kidney Foundation, Omeros, and Reata Pharmaceuticals; and consulting agreements with Tricida Inc.; Advisory or Leadership Role: Alport Foundation—Medical Advisory Council, NKF—Scientific Advisory Board; and Other Interests or Relationships: American Society of Nephrology member, National Kidney Foundation member. K. Iseki reports Consultancy: Kyowa Hakko Kirin, MedyGate, Inc; and Honoraria: Bayer, Chugai, Daiichi Sankyo, Genzyme Japan, Kyowa Hakko Kirin, Otsuka, and Teijin. P.A. Kalra reports Consultancy: Astellas, Novartis, Otsuka, Unicyte, and Vifor; Research Funding: Astellas, BergenBio, Evotec, GSK, and Vifor; Honoraria: AstraZeneca, Bayer, Fresenius, GSK, MundiPharma, Napp, Novartis, Otsuka, Pharmacosmos, UCB, Unicyte, and Vifor; Advisory or Leadership Role: AstraZeneca, GSK, Pharmacosmos, and Vifor; and Speakers Bureau: AstraZeneca, Bayer, Napp, Pharmacosmos, and Vifor. H.L. Kirchner reports Employer: Geisinger; and Consultancy: Baylor College of Medicine. B.J. Lee reports Employer: Hawaii Permanente Medical Group A. Levin reports Consultancy: AstraZeneca, Bayer, Boeingher Ingleheim, Chinook Therapeutics, GSK, Janssen, Kidney Foundation of Canada, NIH, and REATA; Research Funding: AstraZeneca, Boehringer Ingelheim, Canadian Institute of Health Research (CIHR), CITF (Canadian Immunology Task Force), GSK, Health Research BC, Kidney Foundation of Canada, MOH BC, and Shared Care BC; Honoraria: AstraZeneca, Bayer, GSK, Janssen, and NIH; Advisory or Leadership Role: AstraZeneca, Boehringer Ingelheim, and NIDDK, DSMB for NIDDK, Kidney Precision Medicine, U Washington Kidney Research Institute Scientific Advisory Committee; International Society of Nephrology Research Committee, KRESCENT (Kidney Scientist Education Research National Training Program), GSK, Chinook Therapeutics, REATA BC Renal (Exec Director), Steering Committee Chair CURE Consortium, CADTH, CITF; and Other Interests or Relationships: CREDENCE National Coordinator from Janssen, directed to academic team, NIDDK CURE Chair Steering Committee, International Society of Nephrology, Canadian Society of Nephrology, Kidney Foundation of Canada, Steering Committee ALIGN trial, DSMB Chair RESOLVE Trial (Australian Clinical Trial Network). R.W. Major reports Research Funding: AstraZeneca UK; and Speakers Bureau: AstraZeneca UK. G.N. Nadkarni reports Consultancy: Daiichi Sankyo, GLG consulting, Qiming Capital, Reata, Renalytix, Siemens Healthineers, and Variant Bio; Ownership Interest: Data2Wisdom LLC, Doximity, Nexus iConnect, Pensieve Health, Renalytix, and Verici; Research Funding: Renalytix; Honoraria: Daiichi Sankyo; Patents or Royalties: Renalytix; Advisory or Leadership Role: Renalytix; and Speakers Bureau: Daiichi Sankyo. M.M. Sood reports Consultancy: Astrazeneca; Honoraria: Astrazeneca; and Advisory or Leadership Role: GlaxoSmithkline, Otsuka, and Servier. N. Staplin reports Research Funding: Boehringer Ingelheim, and Novo Nordisk N. Stempniewicz reports Employer: GSK; and Research Funding: GSK. B. Stengel reports Research Funding: AstraZeneca, Fresenius Medical Care, GSK, Vifor Fresenius. K. Sumida reports Honoraria: Siemens Healthineers. M. Woodward reports Consultancy: Amgen, Freeline; and Ownership Interest: MIS Statistical Consultants LLC. A.Y.-M. Wang reports Advisory or Leadership Role: Editorial Board: <i>Journal of the American Society of Nephrology</i>, <i>Kidney International</i>, <i>Clinical Journal of the American Society of Nephrology</i>, <i>Nephrology Dialysis Transplantation</i>, <i>Nephron Clinical Practice</i> (Associate Editor), <i>American Journal of Nephrology</i>, <i>Journal of Nephrology</i>, <i>Journal of Diabetes</i>, <i>Journal of Renal Nutrition</i>, <i>Journal of Geriatric Cardiology</i>, <i>Blood Purification</i>, <i>Biomedicine Hub</i>, <i>EMJ</i>; President of International Society of Renal Nutrition and Metabolism; Council member of ISPD; Executive committee member of SONG Initiatives; Committee member of ISN-ACT, Deputy Chair of ISN North and East Asia Regional Board, Deputy Chair of ISN Education working group; and Other Interests or Relationships: President of International Society of Renal Nutrition and Metabolism, Councilor of ISN, Council member of ISPD, Deputy Chair of ISN Regional Board, Deputy Chair of ISN Education working group, Committee member of ISN-ACT, Member of SONG-HD CVD Outcome Measures Working Group, Member of SONG-PD Working Group, Executive committee member of SONG Initiatives. N. Tangri reports Consultancy: Tricida Inc., PulseData Inc, Mesentech Inc., Renibus, Marizyme; Ownership Interest: Tricida Inc., PulseData Inc, Mesentech Inc., Clinpredict Ltd, Renibus, Marizyme, Klinrisk, Quanta; Research Funding: Astra Zeneca Inc., Tricida Inc, Janssen, Otsuka, BI-Lilly, Bayer; Honoraria: Otsuka Pharmaceuticals, Astra Zeneca Inc., BI-Lilly, Janssen, Pfizer, Bayer; Patents or Royalties: Marizyme, Klinrisk; Advisory or Leadership Role: Tricida Inc., Clinpredict, Klinrisk; and Other Interests or Relationships: National Kidney Foundation; Founder—Klinrisk, Clinpredict.",
40,"L. Cervantes reports receiving research funding from Retrophin and reports having an advisory or leadership role with Retrophin/Travere. L. Cervantes also reports other interests or relationships: Center for Health Progress Board of Directors, Denver Health Board of Directors, and National Kidney Foundation. L. Cervantes is funded by NIH Grant K23DK117018 and Robert Wood Johnson Foundation Clinical Scholars Program 7787, outside the scope of this work. K. Rizzolo reports other interests or relationships: Health Care Justice Committee. J.I. Shen reports having an advisory or leadership role as the <i>Kidney Medicine</i> Associate Editor, Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) Steering Committee, Peritoneal Dialysis International Editorial Board North American Council of the International Society of Peritoneal Dialysis and reports having other interests or relationships as a member of the ASN and National Kidney Foundation. J.I. Shen reports consulting fees from Dialco Medical, Healthmap Solutions, Outset Medical, and Spectral Medical. J.I. Shen was funded by NIH Grant K23DK103972 and the Canadian Institutes of Health Research outside the scope of this work. All remaining authors have nothing to disclose.",
41,"C. Beguin reports employment with Cliniques Universitaires Saint Luc—Université catholique de Louvain. J. Bernards reports employment with ZNA Middelheim, Antwerpen, Belgium. J.-F. Cambier reports consultancy for Vifor and honoraria from AstraZeneca and Boehringer Ingelheim. K.J. Claes reports consultancy for Alexion Pharmaceuticals, Astellas, Fresenius Kabi, GSK, and Sanofi; advisory or leadership roles for Alexion, Astellas, and Fresenius Kabi; and speaker's fee for AstraZeneca and Vifor Pharma. K. Dahan reports employment with Institut de Pathologie et de Génétique de Gosselies and Universite Catholique de Louvain; consultancy for AstraZeneca and CHIESI; and advisory or leadership roles as President and a member of advisory committees for three nonprofit patient organizations: AIRG, FAPA, and Retina, and an advisory or leadership role for the Board of Directors of IPG. D. Dierickx reports employment with University Hospitals Leuven, consultancy for Sanofi Genzyme, and honoraria from Sanofi Genzyme. C. Lambert reports employment with Cliniques universitaires Saint-Luc. E. Levtchenko reports consultancy for Chiesi, KKI, and Recordati and advisory or leadership roles for Chesi, Advicenne, KKI, and Recordati. T. Meyskens reports employment with AZ Klina/AZ Voorkempen. J. Morelle reports employment with Cliniques universitaires Saint-Luc, Brussels, Belgium, and UCLouvain, Brussels, Belgium; consultancy for Alexion Pharmaceuticals, AstraZeneca, Bayer, GlaxoSmithKline, and Sanofi-Genzyme; research funding from Alexion Pharmaceuticals, AstraZeneca, and Baxter Healthcare; advisory or leadership roles for Alexion Pharmaceuticals, AstraZeneca, Bayer, Sanofi-Genzyme, and Versantis; speaker honoraria for AstraZeneca, Baxter Healthcare, and Fresenius Medical Care; funding from the National Fund for Scientific Research (FRS-FNRS, Brussels, Belgium), the Association pour l’Information et la Recherche sur les Maladies Rénales Génétiques (AIRG, Brussels, Belgium), and the Saint-Luc Foundation (Brussels, Belgium); and travel grants from Sanofi-Genzyme and Vifor Pharma. X. Poiré reports employment with Cliniques Universitaires St-Luc and consultancy for MSD and Novartis. P. Storms's spouse reports employment (currently and during the past 24 months) with Puilaetco, a Quintet Private Bank (Europe) SA Branch. Y. Zizi reports employment with Cliniques universitaires Saint-Luc. All remaining authors have nothing to disclose.",
42,"P. Chen, Y. Kang, Y. Leng, Y. Li, L. Liu, J. Lv, B. Xu, X. Zhou, and L. Zhu report employment with Peking University First Hospital. H. Zhang reports employment with Peking University First Hospital and consultancy for Alebund, Calliditas, Chinook, Novartis, OMEROS, and Ostuka. The remaining author has nothing to disclose.",
43,"T. Benzing reports Consultancy: Advisory activity for Otsuka in the field of cystic kidney disease and hyponatremia; Honoraria: Speaker honoraria and travel support from Amgen, Hexal, Novartis, Otsuka, Roche, and Sanofi-Genzyme; and Speakers Bureau: Speaker honoraria and travel support from Amgen, Hexal, Novartis, Otsuka, Roche, and Sanofi-Genzyme. V. Burst reports Research Funding: Fresenius Kabi. M. Johnsen reports Honoraria: Heel. F.C. Koehler reports Consultancy: Atriva Therapeutics GmbH; and Research Funding: Else Kröner-Fresenius-Stiftung, German Research Foundation under Germany's Excellence Strategy—EXC 2030: CECAD–Excellent in Aging Research and Koeln Fortune program/Faculty of Medicine, University of Cologne, Germany. C. Lucas reports Employer: Merck Healthcare KgAA and Syft GmbH. R. Mueller reports Consultancy: Alnylam and Sanofi; Ownership Interest: Bayer, Chemocentryx, Novartis, Pfizer, Roche, and Santa Barbara Nutrients; Research Funding: Otsuka Pharmaceuticals and Thermo Fisher Scientific; all research funding was paid to the employer (Department II of Internal Medicine); Honoraria: Alnylam and Sanofi (consultancy agreements see above); and Advisory or Leadership Role: Board member of the WGIKD (ERA-EDTA); Editorial Board “<i>Kidney and Dialysis</i>,” and Scientific Advisory Board Santa Barbara Nutrients. M.R. Späth reports Honoraria: BAYER AG. The Department II of Internal Medicine received research funding from Fresenius Kabi. The remaining authors have nothing to disclose.",
44,Declaration of interests. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.,No
45,"M.D. Griffin reports honoraria from the American Society of Nephrology, Hebei Medical University, China, National Institutes of Health (NIDDK), Novo Nordisk, and Théa Pharma Ltd., Ireland; Research Funding: Orbsen Therapeutics Ltd.; and advisory roles as an Associate Editor for <i>Mayo Clinic Proceedings</i> and an Editorial Board member for the journals <i>Frontiers in Pharmacology</i> and <i>Transplantation</i>. G. Remuzzi reports Consultancy: Consulting fees: Alexion Pharmaceuticals, AstraZeneca Pharmaceuticals, Otsuka, and Silence Therapeutics; and Advisory or Leadership Role: member of numerous Editorial Boards of Scientific Medical Journals. All remaining authors have nothing to disclose.",
46,"C.J. Gimblet reports research funding from the American Heart Association. D.I. Jalal reports research funding from AstraZeneca and Corvidia; honoraria from K-INBRE, Reata, PER (Physicians Education Resource), and Sullivan conference-University of Kansas; and an advisory or leadership role for Reata. G.L. Pierce reports research funding from Microvascular Health Solutions (free supplement for clinical study) and an advisory or leadership role for North American Artery, treasurer (unpaid). All remaining authors have nothing to disclose.",
47,"I. Alquisiras-Burgos reports receiving research funding <i>via</i> a postdoctoral fellowship from the Cognitive Neuroscience Laboratory, Department of Neurosciences in the Institute of Cellular Physiology, National Autonomous University of Mexico (UNAM), Mexico City, Mexico (March 2022 to present). D.H. Ellison reports serving on the editorial board of <i>American Journal of Physiology-Renal Physiology</i>, as a consulting editor for <i>Hypertension</i>, and on the editorial board of <i>JASN</i>; receiving honoraria from Boston University School of Medicine and Renaissance School of Medicine; and having patents with or receiving royalties from UpToDate (as an author). M. Madero reports serving in an advisory or leadership role for Abbvie, <i>American Journal of Kidney Disease</i>, AstraZeneca, Bayer, International Society of Nephrology, Kidney Disease Improving Global Outcomes Executive Committee; receiving research funding from Abbvie, AstraZeneca, Boehringer Ingelheim, and Bayer; serving on a speakers bureau for AstraZeneca; and receiving honoraria from AstraZeneca, Baxter, Boehringer Ingelheim, and Fresenius Medical Center. All remaining authors have nothing to disclose.",
48,"E.W. Chan reports consultancy for AstraZeneca, Novartis, and Pfizer; research funding from AstraZeneca, Novartis, Pfizer, and RGA Reinsurance Company; honoraria from The Hospital Authority, Hong Kong SAR; and speakers bureau for AstraZeneca, Novartis, and Pfizer. C.S.L. Chui reports consultancy for Primevigilance and research funding from Amgen, Food and Health Bureau of the Hong Kong Government, Hong Kong Innovation and Technology Commission, Hong Kong Research Grant Council, IQVIA, MSD, and Pfizer. F.T.T. Lai reports research grants from Research Grants Council and Health Bureau of the Hong Kong SAR Government. X. Li reports consultancy fee from Merck Sharp & Dohme, unrelated to this work; research grants from Research Fund Secretariat of the Health Bureau, Health and Medical Research Fund (HMRF, HKSAR), Research Grants Council Early Career Scheme (RGC/ECS, HKSAR), Research Grants Council Research Impact Fund (RGC/RIF, HKSAR), educational and investigator initiate research fund from Janssen and Pfizer; and internal funding from the University of Hong Kong, unrelated to this work. S.C.W. Tang reports consultancy for Eledon Pharmaceuticals and Travere Therapeutics, Inc.; honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Novartis; role on the Editorial Boards of <i>American Journal of Nephrology</i>, <i>CJASN</i>, <i>Journal of Nephrology and Kidney Diseases</i>, and <i>Kidney International</i>; advisory or leadership role as Associate Editor of <i>Glomerular Diseases</i> and Theme and Subspecialties Editor of <i>Nephrology Dialysis Transplantation</i>; advisory or leadership role on KDIGO Executive Committee; speakers bureau for AstraZeneca; and other interests or relationships as President of Asian Pacific Society of Nephrology. E.Y.F. Wan reports research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region and the Hong Kong Research Grants Council, outside the submitted work. C.K.H. Wong reports research funding from AstraZeneca, Boehringer Ingelheim, and EuroQol Research Foundation. I.C.K. Wong reports research funding outside the submitted work from Amgen, Bayer, Bristol-Myers Squibb, European Commission, GSK, Janssen, Novartis, Pfizer, National Health and Medical Research Council in Australia, National Institute for Health Research in England, and the Hong Kong RGC; speaker fees from Janssen and Medice in the previous 3 years; and advisory or leadership role as an independent non-executive director of Jacobson Medical in Hong Kong. All remaining authors have nothing to disclose.",
49,"Y. Cao reports employment with the American Society of Nephrology. M. Gong reports employment with DHC Technologies. F.F. Hou reports consultancy for and honoraria from AstraZeneca. H. Liu reports employment with Affiliated Hospital of Guangdong Medical University and research funding from the National Natural Science Foundation of China. X. Xu reports employment with Fujun Genetics, Shanghai, China, and ownership interest in Apple Inc. All remaining authors have nothing to disclose.",
50,"A.J. Fowler reports research funding from Barts Charity and National Institutes of Health Research. R.M. Pearse reports employment with Bart Health NHS Trust; research funding from Edwards Life Sciences, GlaxoSmithKline, and Intersurgical; and honoraria from Edwards Life Sciences, GlaxoSmithKline, and Intersurgical. J.R. Prowle reports employment with Barts Health NHS Trust; consultancy for Baxter, Nikkiso Europe, Jafron Biomedical Co Ltd, Mission Therapeutics Ltd, Cambridge UK, Nephrolytx GmbH, and Paion Ltd; research funding from Barts and the London Charity, bioMérieux SA, Jafron Biomedical Ltd, National Institue of Health Research, and Rosetrees Trust; honoraria from Baxter Inc, BBraun, Fresenius Kabi, and Nikkiso Europe GmbH; a US patent application “Markers of Acute Kidney Injury” in conjunction with Dr M. Westerman, Intrinsic LifeSciences LLC, La Jolla, CA, USA; and other interests or relationships as UK Kidney Research Consortium (UKKRC) Acute Kidney Injury Clinical Specialties Group colead and European Society of Intensive Care Medicine Acute Kidney Injury Speciality Section Chair Elect. Z. Puthucheary reports employment with Puthucheary Medical Consultancy Ltd; consultancy for Bioage, Faraday Pharmaceuticals, Fresenius Kabi, Nestle, and Nutricia; ownership interest in Puthucheary Medical Consultancy Ltd; research funding from Baxter, Fresenius Kabi, and Vitaflo (Nestle); and honoraria from Baxter, Sedana, Fresenius Kabi, Nestle, and Nutricia. All remaining authors have nothing to disclose.",
51,The authors declare no conflicts of interest.,No
52,"R.T. Gansevoort reports Consultancy: AstraZeneca, Bayer, Galapagos, Mironid, and Sanofi-Genzyme; Research Funding: AstraZeneca, Abbvie, Bayer, Galapagos, Otsuka Pharmaceuticals, Roche, and Sanofi-Genzyme; Honoraria: Galapagos, Mironid, and Otsuka Pharmaceuticals; and Advisory or Leadership Role: Editor of <i>American Journal of Kidney Diseases</i>, <i>CJASN</i>, <i>Journal of Nephrology</i>, <i>Kidney360</i> Member of the Council of the European Renal Association, <i>Nephron Clinical Practice</i>, and <i>Nephrology Dialysis Transplantation</i>. S. Hayat reports Consultancy: Sequantrix GmbH; Ownership Interest: Sequantrix GmbH; and Research Funding: Askbio GmbH and Novo Nordisk. E.J. Hoorn reports Research Funding: Aurinia; Honoraria: UpToDate; and Advisory or Leadership Role: Editorial Boards: <i>American Journal of Physiology-Renal Physiology</i>, <i>JASN</i>, and <i>Journal of Nephrology</i>; Other committees: Board Member, Dutch Federation of Nephrology and ERA Working Group Genes and Kidney. R. Kramann reports Consultancy: Bayer Healthcare, Gruenenthal, Novo Nordisk, and Pfizer; Research Funding: Chugai, Galapagos, Novo Nordisk, and Travere Therapeutics; Honoraria: Sequantrix; Patents or Royalties: Gli1 cells in fibrosis (method of use); and Advisory or Leadership Role: Board Member and Co-Founder Sequantrix and Scientific Advisory Board Hybridize Therapeutics. E. Meijer reports Research Funding: Dutch Kidney Foundation, Ipsen, Otsuka Pharmaceuticals, Sanofi; all money was paid directly to the institution; and Other Interests or Relationships: Dutch Kidney Foundation, Health Holland, Nieren.nl, NvN, and werkgroep erfelijke nierziekten. R.-U. Müller reports Consultancy: Alnylam and Vifor; Ownership Interest: Bayer and Santa Barbara Nutrients; Research Funding: Otsuka Pharmaceuticals and Thermo Fisher Scientific. All research funding was paid to the employer (Department II of Internal Medicine); Honoraria: Alnylam; Patents or Royalties: Detechgene; and Advisory or Leadership Role: Editorial Board “<i>Kidney and Dialysis</i>,” Chair of the Board of the Working Group “Genes and Kidney” (ERA), and Scientific Advisory Board Santa Barbara Nutrients. M. Salih reports Advisory or Leadership Role: NedMed.nl Scientific advisory board. M.H. van Heugten reports Research Funding: Aurinia Pharmaceuticals has in part supported our research on lupus nephritis between 2022 and 2023. H. van Willigenburg reports Employer: Antea; and Ownership Interest: funds. All remaining authors have nothing to disclose.",
53,"Declaration of Competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Lisa Potter reports a relationship with Takeda Pharmaceuticals USA Inc that includes: board membership. Lisa Potter reports a relationship with Veloxis Pharmaceuticals Inc that includes: funding grants and speaking and lecture fees. David Taber reports a relationship with Veloxis Pharmaceuticals Inc that includes: board membership and funding grants. David Taber reports a relationship with Takeda Pharmaceuticals USA Inc that includes: funding grants. David Taber reports a relationship with Merk that includes: funding grants. David Taber reports a relationship with CareDx Inc that includes: funding grants. Rita Alloway reports a relationship with Bristol Myers Squibb Co that includes: funding grants. Rita Alloway reports a relationship with Nobelpharma Co Ltd that includes: funding grants. Rita Alloway reports a relationship with National Institutes of Health that includes: funding grants. Rita Alloway reports a relationship with Veloxis Pharmaceuticals Inc that includes: board membership and speaking and lecture fees. Rita Alloway reports a relationship with Sanofi that includes: speaking and lecture fees. The authors A. B. Lichvar, M. M. Chandran, B. R. Crowther, C. T. Doligalski, and A. J. C. Martinez of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. The following authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. L. M. M. Potter reported serving as an advisory board member for Takeda in Dec 2021. E. A. Cohen reported serving for the speaker bureau of Veloxis that ended in Dec 2021 and receiving an investigator-initiated research grant from Veloxis Pharmaceuticals. D. J. Taber reported serving as a board member of the Veloxis grant and advisory board, Takeda grant, Merck grant, and CareDx grant. R. R. Alloway reported BMS, Nobelpharma, Thinker NEXT grant, Veloxis advisory board, Veloxis, and Sanofi speaker bureau.",
54,"Dr. L. Cervantes was supported by NIDDK K23DK117018, RWJF 77887, and NHLBI G08LMO13186. L. Cervantes also reports Research Funding: Retrophin; and Other Interests or Relationships: Center for Health Progress Board of Directors, Denver Health Board of Directors, and National Kidney Foundation. Dr. L. Golestaneh was supported by NIDDK R18DK118471 and serves on the Clinical Events Committee for the Axon Therapeutics and Cardiovascular Research Institute; she also receives consulting fees from Horizon Therapeutics. L. Golestaneh also reports Honoraria: Horizon Pharmaceuticals: $4000, WebMD $2500; Advisory or Leadership Role: Advances in Chronic Kidney Disease; and Other Interests or Relationships: compensation from the Cardiovascular Research Foundation for fulfillment of duties as a member of the Clinical Events Committee for the Spyral Hypertension trials, sponsored by Medtronic. Dr. T.K. Novick was supported by the National Institute of Diabetes and Digestive and Kidney (NIDDK) Diseases grant K23DK127153. The CHW intervention in Austin was funded and supported by a National Kidney Foundation Young Investigator Research Grant. F. Reyna reports Other Interests or Relationships: National Kidney Foundation (employer). Dr. S.E. Rosas is supported by NIDDK U01DK133092 and U01DK116102. Dr. S.E. Rosas reports receiving grant support, paid to Joslin Diabetes Center, from AstraZeneca. Dr. S.E. Rosas has received advisory board fees from AstraZeneca and Bayer. S.E. Rosas reports Consultancy: AstraZeneca, Bayer-honorarium; Research Funding: AstraZeneca; Bayer; NIH-NIDDK; Honoraria: AstraZeneca, Bayer-honorarium; and Advisory or Leadership Role: <i>CJASN</i>, AKHD, AJKD Editorial Board; NKF-NE Medical Adivisory Board; NKF Scientific Advisory Board, NKF President; all positions are voluntary and without payment. A. Sandoval reports Other Interests or Relationships: employed by the National Kidney Foundation. Dr. J. Shen was supported by a National Center for Advancing Translational Sciences UCLA CTSI Grant UL1TR001881, the National Kidney Foundation, and serves on the medical advisory board for Healthmap Solutions. J. Shen also reports Consultancy: Healthmap, Outset Medical, Spectral Medical; and Other Interests or Relationships: American Society of Nephrology, International Society of Peritoneal Dialysis, National Kidney Foundation, and PDOPPS.",
55,S.K. has received funding for clinical study design and evidence reviews from OrganOx Ltd. T.Z. was supported by the Royal Academy of Engineering under the Research Fellowship scheme. This article presents independent research funded by the National Institute for Health and Care Research under its Artificial Intelligence Program (grant AI_AWARD02316). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The other authors declare no conflicts of interest.,
56,Disclosure. The authors declare no competing interests or conflicts of interest.,No
57,"<b>Financial Disclosure:</b> Dr. Harhay discloses a consultancy agreement with Nephria Bio, unrelated to the study. The other authors declare that they have no relevant financial interests.",
58,"Y. Isaka reports consultancy for Kirin Co., Ltd. and Sanwa Kagaku Kenkyusyo Co., Ltd.; research funding from Kirin Co., Ltd.; advisory or leadership role for Kirin Co., Ltd. and Sanwa Kagaku Kenkyusyo Co., Ltd.; and speakers bureau for Astellas Pharma Inc., AstraZeneca plc, Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical Co., Ltd., and Sanwa Kagaku Kenkyusyo Co., Ltd. I. Matsui reports consultancy for Kyowa Hakko Kirin. Y. Sakaguchi reports research funding from Chugai pharmaceutical Co., Ltd., FUSO Pharmaceutical Industries, Ltd., Kissei pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Terumo Co., Ltd., and Torii pharmaceutical Co., Ltd., and speakers bureau for AstraZeneca plc, Fuso Pharmaceutical Industries, Ltd., Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., Ono Pharma Healthcare Co., Ltd., and Torii Pharmaceutical Co., Ltd. All remaining authors have nothing to disclose.",
59,"W.J.W. Bos reports research funding from Dutch Kidney Foundation, Leading the Change, Zilveren Kruis Insurance, and ZonMW and advisory or leadership roles for ICHOM working group CKD (chair), various committees on Value Based Healthcare of the Association of Dutch University Hospitals (NFU), and various committees of the Dutch Nephrology Quality Initiative “Nefrovisie.” R. Coppo reports consultancy for Amgen, Anylam, Argenx, Bayer, Calliditas, Chinook, Menarini, Novartis, Otsuka-Visterra, Purespring, Reata, and Stadapharm; honoraria from Amgen, Bayer, Chinook, Menarini, Novartis, Purespring, Stadapharm, and Travere; royalties from UpToDate; advisory or leadership roles for <i>Nephrology Dialysis Transplantation</i> Editorial Board and as an Associate Editor for <i>Pediatric Nephrology</i>; and speakers bureau for Stadpharm and Travere. E. Damato reports employment with and consultancy for Charles River Associates. F. Fakhouri reports consultancy for, honoraria from, and advisory or leadership roles for Alexion, Alnylam, Apellis, Novartis, and Roche. I. Nistor reports speaker fee for AstraZeneca, Boeringer Ingelheim, and Zentiva. A. Ortiz reports consultancy for Fresenius Medical Care, Genzyme Sanofi, and Travere; research funding from AstraZeneca, Mundipharma, and Sanofi Genzyme; honoraria from Advicciene, Alexion, Amgen, Amicus, Astellas, AstraZeneca, Bayer, Chiesi, Freeline, Fresenius Medical Care, Idorsia, Kyowa Kirin, Menarini, Otsuka, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma; advisory or leadership roles for Board of Directors IIS-Fundacion Jimenez Diaz UAM, Dutch Kidney Foundation scientific advisory board, SOMANE and ERA Councils, and Spanish Society of Nephrology (member); roles on the Editorial Boards of <i>Journal of Nephrology</i>, <i>JASN</i> and <i>Peritoneal Dialysis International</i>; and honoraria for speaker engagements for Advicciene, Alexion, Amgen, Amicus, Astellas, AstraZeneca, Bayer, Chiesi, Fresenius Medical Care, Idorsia, Kyowa Kirin, Menarini, Otsuka, Sanofi-Genzyme, and Vifor Fresenius Medical Care Renal Pharma. M. Pistollato reports employment with, consultancy for, and research funding from Charles River Associates. F. Schaefer reports consultancy for Alexion, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius Medical Care, GSK, Otsuka, Purespring, and Roche; research funding from Fresenius Medical Care, Novartis, and Roche; honoraria from Amgen, Otsuka, and Roche; textbook royalties from Springer; and Scientific Advisory Board activities for Alexion and Otsuka. F. Schaefer is a member of the European Reference Network for Rare Kidney Diseases (ERKNet). R. Vanholder reports consultancy for AstraZeneca, Baxter, Fresenius Kabi, Fresenius Medical Care, GlaxoSmithKline, Kibow, Nipro, Nextkidney, and Novartis; honoraria from Baxter Healthcare and Fresenius Medical Care; royalties from UpToDate; and speakers bureau for Fresenius Medical Care, Baxter Healthcare, and Nipro. All remaining authors have nothing to disclose.",
60,"J.J. Carrero reports research funding from Amgen, Astellas, MSD, Novo Nordisk, Swedish Heart and Lung Foundation, Swedish Research Council, and Vifor Pharma; advisory or leadership role on Advisory Committees for AstraZeneca and GSK; role on Editorial Boards for <i>American Journal of Kidney Diseases</i>, <i>European Heart Journal</i>, <i>Journal of Nephrology</i>, and <i>Nephrology Dialysis Transplantation</i>; speakers bureau for Abbott Laboratories, AstraZeneca, Baxter, Fresenius Kabi, and GSK; and other interests or relationships with European Renal Nutrition working group at the ERA-EDTA and the International Society of Renal Nutrition and Metabolism. J.J. Carrero has been a consultant, speaker, or grant recipient for Abbott, Amgen, AstraZeneca, Bayer, Fresenius, Fresenius Kabi, MSD, Nestle, and Vifor Pharma, for topics unrelated to this work. All remaining authors have nothing to disclose.",
61,"G.E. Abra was an employee of Satellite Healthcare; consultancy from Baxter; and advisory or leadership roles as Co-Chair of ASN HDU Virtual Education Program Workgroup (unpaid), <i>Nephrology News & Issues</i> Associate Editor (unpaid), and PDOPPS US Advisory Group member (unpaid). W.F. Hussein reports employment with Satellite Healthcare and advisory or leadership role for GSK. E.D. Weinhandl was an employee of Satellite Healthcare and is now an employee of DaVita Clinical Research; research funding from Dialyze Direct and Outset Medical; and advisory or leadership role for Home Dialyzors United Board of Directors and Medical Education Institute Board of Directors.",
62,"D. Barwinska reports other interests or relationships with Kidney Precision Medicine Project. J.M. Henderson reports consultancy for Novartis and Pfizer and research funding from Pfizer, Q32 Bio, and Visterra. C.L. Phillips reports ownership interest in Alphabet, Berkshire Hathaway, and Disney. P.S. Silva reports consulting and speaker fees from Bayer, Novartis, and Roche and research funding from Kubota Vision, Optomed, and Optos. D.W. Steenkamp reports consultancy for Abbott Diabete Care and grant funding to institution from Abbott Diabetes Care, Novo Nordisk, and Tandem Diabetes Care. A. Verma reports advisory or leadership roles for Editorial Boards for <i>BMC Medicine</i>, <i>BMC Nephrology</i>, <i>Therapeutic Advances in Chronic Disease</i>, and <i>Therapeutic Advances in Endocrinology and Metabolism</i>. A. Verma is a contributor to BMJ Best Practices. S.S. Waikar reports consultancy for Bain, BioMarin, CANbridge, Goldfinch, Google, GSK, Ikena, Novo Nordisk, PepGen, Sironax, Strataca, and Wolters Kluewer; research funding from JNJ, Natera, Pfizer, and Vertex; and serving as an expert witness for litigation related to dialysis lab testing (DaVita), PPIs (Pfizer), PFAO exposure (Dechert), and voclosporin patent (Aurinia). S.S. Waikar's spouse reports employment with Advanced Clinical. All remaining authors have nothing to disclose.",
63,"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: P F Halloran reports financial support was provided by Thermo Fisher Scientific. P F Halloran reports financial support was provided by Natera Inc. P F Halloran reports a relationship with Natera, Inc. that includes: consulting or advisory. Disclosure P F Halloran holds shares in Transcriptome Sciences Inc (TSI), a University of Alberta research company dedicated to developing molecular diagnostics, supported in part by a licensing agreement between TSI and Thermo Fisher Scientific, and by a research grant from Natera Inc. P.F. Halloran is a consultant to Natera Inc. The other authors have nothing to disclose.",
64,"D.G. Manuel reports serving on advisory boards and committees related to coronavirus disease 2019 (no for-profit boards) and serving as a public health consultant for the World Bank and the European Commission. G.A. Knoll reports serving on the editorial board of <i>Canadian Journal of Kidney Health and Disease</i>. M.M. Sood reports having consultancy agreements with, and receiving honoraria and a speaker fee from, AstraZeneca; serving on the editorial boards of <i>American Journal of Kidney Disease</i>, <i>Canadian Journal of Cardiology</i>, and <i>CJASN</i>; serving as an editor for <i>Canadian Journal of Kidney Disease and Health</i>; and serving as a member of the ASN Highlights ESRD Team. N. Tangri reports having consultancy agreements with Marizyme Tricida Inc., Mesentech Inc., PulseData Inc., and Renibus; having an ownership interest in Clinpredict Ltd., Klinrisk, Marizyme, Mesentech Inc., PulseData Inc., Quanta Tricida Inc., and Renibus; receiving research funding from AstraZeneca Inc., Bayer, BI-Lilly, Janssen, Otsuka, and Tricida Inc.; receiving honoraria from AstraZeneca Inc., Bayer, BI-Lilly, Janssen, Otsuka Pharmaceuticals, and Pfizer; having patents or royalties from Klinrisk and Marizyme; having advisory or leadership roles for Clinpredict, Klinrisk, and Tricida Inc.; having other interests or relationships with National Kidney Foundation; and being the founder of Clinpredict and Klinrisk. All remaining authors have nothing to disclose.",
65,"K.L. Cavanaugh reports serving on the editorial boards for <i>American Journal of Kidney Diseases</i>, <i>CJASN</i>, and <i>Medical Decision Making</i>; having ownership interest in HCA Healthcare; having consultancy agreements with Kidney Health Initiative, Reata Pharmaceuticals, and Responsum Health; serving as associate editor for <i>Kidney360</i>; and serving in an advisory or leadership role for the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative education committee. S. Crowley reports serving in an advisory or leadership role for Veterans Health Administration (VHA). L. Fried reports having consultancy agreements with Akebia, Fibrogen, Bayer, and 3D Communications; having ownership interest <i>via</i> stock in Archer Daniels Midland, ATT, Kroger, Procter & Gamble, and Walmart; receiving research funding from AstraZeneca; and serving on data safety monitoring boards for CSL Behring and Novo Nordisk. A.M. Shukla reports ongoing research support from the Department of Veterans Affairs, Office of Rural Health, Health Service Research and Development award I01HX002639, and Clinical Science Research and Development award I01CX001661; consultancy agreements with Chemocentryx and serving in an advisory or leadership role for the VHA National Peritoneal Dialysis Workgroup. A. Wadhwa reports serving on the medical advisory board of ESRD Network 10, and in an advisory or leadership role for Illinois NKF.",
66,<i>Financial Disclosure:</i> All authors declare that they have no relevant financial interests.,No
67,"D. Lysak reports Consultancy: AbbVie, AstraZeneca, Janssen, and Novartis. J. Machová reports Other Interests or Relationships: Member of the Czech Society of Nephrology and Member of the Czech Transplant Society. All remaining authors have nothing to disclose.",
68,"A. Vijayan reports having consultancy agreements with Astute Inc. and NxStage; having stock in Outset; receiving research funding from Astellas and Spectral; receiving honoraria from ASN, Baxter, Medscape, and NxStage; having an advisory or leadership role for NxStage; and other interests or relationships as a member of the National Kidney Foundation. The remaining author has nothing to disclose.",
69,"A.M.J.S. is supported through a Canada Research Chair (Tier 1) in Regenerative Medicine and Transplant Surgery and through grant support from the Juvenile Diabetes Research Foundation, Diabetes Canada, The Canadian Donation and Transplant Research Project, the Diabetes Research Institute Foundation of Canada, the Alberta Diabetes Foundation, and the Canadian Stem Cell Network. A.M.J.S. serves as a consultant to ViaCyte Inc, Aspect Biosystems Inc, and ProtoKinetix Inc. B.A.M.-G. is currently supported by the Patronage of the National Institute of Medical Sciences and Nutrition Salvador Zubirán by the Foundation for Health and Education Dr Salvador Zubirán (FunSaEd) and the CHRISTUS-LatAm Hub—Excellence and Innovation Center. P.A.S. holds the Charles A. Allard Chair in Diabetes Research. P.A.S. and A.L. are supported by Alberta Health through the Academic Medicine and Health Services Program. The other authors declare no conflicts of interest.",
70,This work was supported in part by grants from the National Institutes of Health (AI142747 and AI148705) to A.S.C. The other author declares no conflicts of interest.,
71,M.C.C.v.G. has Astellas project funding paid to the Erasmus MC. J.U.B. is advisor for Sanofi. The other authors declare no conflicts of interest.,
72,"A. Azhar reports research funding from Eurofins Viracor. V. Balaraman reports research funding from Caredx and Natera and speakers bureau for Veloxis. A. Bhalla reports consultancy for CareDx, Natera, and Visterra. G. Gupta reports consultancy for CareDx; research funding from Merck Pharmaceuticals; honoraria from Alexion, CareDx, Mallinckrodt, Natera, and Veloxis; advisory or leadership role for Frontiers of Medicine; speakers bureau for Alexion, CareDx, Mallinckrodt, and Veloxis; and other interests or relationships with AST KPOP Executive Committee, AST Transplant Nephrology Fellowship Accreditation Committee, and National Kidney Foundation Virginia. I.E. Hall reports advisory or leadership roles as a UNOS Donor Management Goals Advisory Board member (unpaid), Donor Connect Organ Procurement Research Oversight Committee member (unpaid), and National Kidney Foundation member of the Transplant Advisory Committee and the Scientific Advisory Board (both unpaid). M.Z. Molnar reports consultancy for CareDx; honoraria from CareDx; and role on the Editorial Boards of the <i>Clinical Kidney Journal</i>, <i>Frontiers in Medicine</i>, the <i>Journal of Renal Nutrition</i>, <i>International Urology and Nephrology</i>, <i>ISRN Nephrology</i>, and <i>Renal Failure</i>. All remaining authors have to disclose.",
73,"L. Blackwell reports honoraria from Otsuka Canada Pharmaceutical Inc. for participating in a Renal Pharmacist Regional Advisory Board Meeting. P.G. Blake is a contracted Medical Lead at Ontario Renal Network, Ontario Health. P.G. Blake reports honoraria from Baxter Global and Otsuka Australia; an advisory or leadership role as the Medical Director of Ontario Renal Network—this is a paid role; and serving on the Editorial Board of the <i>American Journal of Nephrology</i>. P.A. Brown reports consultancy with Amgen Canada, AstraZeneca Canada, and Otsuka Canada; research funding from Otsuka Canada; and honoraria from AstraZeneca Canada and Otsuka Canada. Z. Chagla reports consultancy agreements with Pfizer; research funding from Gilead, Pfizer, and Roche; and speakers bureau from Gilead and Pfizer. R. Cooper, J. Ip, D. Thomas, and A. Yeung are salaried employees of Ontario Renal Network, Ontario Health. S. Hiremath reports research salary support from the Department of Medicine, University of Ottawa; serving on the Editorial Boards of the <i>American Journal of Kidney Disease</i>, the <i>American Journal of Hypertension</i>, and the <i>Canadian Journal of Cardiology</i>; and serving on the Board of Directors for NephJC (not-for-profit educational entity; unpaid volunteer position). A.K. Jain is a contracted Medical Lead at Ontario Renal Network, Ontario Health. A.K. Jain reports consultancy agreements with AWAK Technologies; research funding from Baxter Healthcare; honoraria from Baxter Healthcare; and an advisory or leadership role for Ontario Renal Network. M. McGuinty reports research funding from VBI. M. Oliver is a contracted Medical Lead at Ontario Renal Network and Ontario Health. He is the owner of Oliver Medical Management, Inc., which is a private corporation that licenses Dialysis Management Analysis and Reporting System software. Oliver Medical Management Inc. is the co-owner of a Canadian patent for DMAR systems. M. Oliver has received honoraria from Baxter Healthcare. M. Pandes reports honoraria from, an advisory or leadership role with, and speakers bureau for AstraZeneca. All remaining authors have nothing to disclose.",
74,"H.-J. Anders received consultancy fees from Aptarion, AstraZeneca, Bayer, Boehringer-Ingelheim, GSK, Janssen, Kezar, Lilly, Novartis, Sanofi, and Vifor; research funding: Boehringer-Ingelheim; and advisory or leadership role: <i>JASN</i>, NDT. N. Bouteldja reports employer: Ocumeda GmbH. O. Gross received consultancy fees from AstraZeneca, Bayer, Boehringer-Ingelheim, Novartis, and Sanofi. O. Gross also reports consultancy: Codon-X Therapeutics Inc., Galapagos, Genzyme/Regulus Therapeutics, ONO-Pharmaceutical Co. Ltd., Reata Pharmaceuticals, Roche; research funding: Bayer AG; and advisory or leadership role: advisory committees for AstraZeneca, Boehringer-Ingelheim, Reata Pharmaceuticals, Roche, and Sanofi US Services Inc./Genzyme/Regulus Therapeutics. P. Romagnani reports research funding: AstraZeneca. All remaining authors have nothing to disclose.",
75,"M.D. Breyer reports Employer: JNJ pharma; Ownership Interest: Eli Lilly and company; Johnson and Johnson; Other Interests or Relationships: University of Michigan Frankel translational research initiative scientific board member. C.-M. Hao reports Consultancy: AstraZeneca; Bayer; Fibrogen; Nicoya Therapeutics (Shanghai) Co., Ltd; Research Funding: Fibrogen; Honoraria: AstraZeneca; Bayer; Eli Lilly; Fibrogen; Novartis; Advisory or Leadership Role: Editorial Board: AJP-renal; Associate Editor: Kidney Disease; and Other Interests or Relationships: Member: ASN; Member: ISN; Standing Committee Member: Chinese Society of Nephrology; President: Chinese Society of Physiology—Renal Physiology. R.C. Harris reports Ownership Interest: Apple; Research Funding: Bayer; and Patents or Royalties: eNOS db/db mouse.",
76,"G.B. Appel reports consultancy agreements with Achillion, Alexion, Apellis, Aurinia, Bristol Myers Squibb, Calliditas, Chemocentryx, E. Lilly, EMD Serono, Genzyme-Sanofi, GlaxoSmithKline, Mallinkrodt, Merck, Novartis, Omeros, Pfizer, Reata, Roche—Genentech, Travere Therapeutics, and Vera Therapeutics; research funding from Achillion-Alexion, Apellis, Calliditas, Chemocentryx, Columbia U, Equillium, Genentech-Roche, Goldfinch, Mallinkrodt, Nephronet, Novartis, Reata, Sanofi-Genzyme, Travere, and Vertex; honoraria from Aurinia and GlaxoSmithKline; royalties from UpToDate; serving on the UpToDate Editorial Board and Med Advisory board for Alexion-Achillion, Alexion, Apellis, Aurinia, BM Squib, Genentech, GlaxoSmithKline, Lilly, Reata, Roche, and Sanofi; and speakers bureau for Aurinia and GSK on lectures on lupus nephritis. S.V. Badve reports in kind support from Bayer AG; funding from the National Health and Medical Research Council of Australia; speakers honorarium from Amgen, AstraZeneca, Bayer, Pfizer, and Vifor Pharma, with fees paid to S.V. Badve's institution; and advisory or leadership roles for advisory boards for Bayer, AstraZeneca, and Vifor Pharma, with fees paid to S.V. Badve's institution. F. Caravaca-Fontán reports consultancy agreements with Apellis and Novartis, research funding from Novartis Pharmaceuticals, and speakers bureau for Apellis and Novartis. J. Chalmers reports research funding from National Health and Medical Research Council (NHMRC) of Australia and from Servier. W.H. Collier reports funding from the NKF to his institute for his graduate research assistantship. J. Floege reports consultancy agreements with Amgen, AstraZeneca, Bayer, Boehringer, Calliditas, Chinook, Novo Nordisk, Novartis, Omeros, Travere, Vifor, and Visterra; honoraria from Amgen, AstraZeneca, Bayer, Boehringer, Calliditas, Chinook, Novo Nordisk, Novartis, Omeros, Travere, Vifor, and Visterra; lecture and consulting honoraria from Alynlam, Amgen, AstraZeneca, Bayer, Boehringer, Calliditas, Fresenius, Novartis, Omeros, Travere, and Vifor; advisory or leadership roles for Calliditas, Omeros, and Travere; speakers bureau for Amgen, AstraZeneca, Novartis, and Vifor; and serving as a member of the data safety monitoring board in trials of Novo Nordisk and Visterra. T. Greene reports research funding from NIH, Janssen Pharmaceuticals, Durect Corporation, and Pfizer and consultancy agreements with AstraZeneca, CSL, and Boehringer-Ingleheim. B. Haaland reports consultancy agreements with Ally Bridge, AstraZeneca, Avidity Partners Management, Guidepoint Global, National Kidney Foundation, Prometic Life Sciences, Proxima Clinical Research, and Value Analytics Labs and ownership interest in Haaland Consulting, LLC, BHP, IBM, RIO, ENB, AQN, GOOD, SQM, WBA, SBRA, BCS, UTG, GSK, WPC, VOD, VICI, AGNC, OHI, MPW, KMI, EPD, PBR, VALE, VZ, IEP, ZIM, ABBV, and ABT. H.J.L. Heerspink reports ongoing consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Chinook, Dimerix, Eli-Lilly, Gilead, GoldFinch, Janssen, Merck, Novo Nordisk, and Travere Pharmaceuticals; research funding from AstraZeneca, Novo Nordisk and Janssen research support (grant funding directed to employer); lecture fees from AstraZeneca; and speakers bureau for AstraZeneca. E. Imai reports research funding from AstraZeneca, Boehringer Ingelheim, and Tanabe Mitsubishi; honoraria from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli-Lilly, and Ono; and research funding and honorarium for lectures from AstraZeneca, Tanabe Mitsubishi, Boehringer Ingelheim, Daiich Sankyo, Kyowa Kirin, and Novo Nordisk. L.A. Inker reports consultancy agreements with Diamtrix; funding from National Institutes of Health, National Kidney Foundation, Chinnocks, Omeros, Dialysis Clinics, Inc., and Reata Pharmaceuticals for research and contracts to Tufts Medical Center; consulting agreements to Tufts Medical Center with Tricida and HealthLogistics Interactive; advisory or leadership role for Alport Foundation Medical Advisory Council and NKF Scientific Advisory Board; and membership with American Society of Nephrology and National Kidney Foundation. J.B. Lewis reports consultancy agreements with CSL Behring, Biovie, and Veno Stent; ownership interest in circle medical management, a dialysis company; honoraria from CSL Bering and BIOVIE; and advisory or leadership role as treasurer and board member of the CSG, collaborative study group a not for profit academic research organization—not paid; and role as chair of cardio renal advisory committee for the FDA—paid for time. P.K.T. Li reports speaker honoraria from AstraZeneca, Baxter, and FibroGen; honoraria from AstraZeneca for moderator for a symposium during Asian Pacific Congress of Nephrology Oct 2020; speaker honoraria for Baxter on Modern PD Symposium May 2021 and speaker honoraria for Kyowa Kirin; advisory or leadership role for <i>Kidney International</i> and <i>Peritoneal Dialysis International</i>; and other interests or relationships as President, International Association of Chinese Nephrologists. F. Locatelli reports consultancy agreements with Amgen and Baxter; honoraria from Amgen, Astellas, Baxter, and Roche Vifor-Pharma as speaker at sponsored meetings; advisory or leadership roles for Accelsior, Amgen, Astellas, AstraZeneca, Baxter, GSK, Norgine, Otsuca Roche, PT Kalbe Genexine Biologics, Otsuka, Travere, and Vifor Pharma; speakers bureau for Amgen, Astellas, and Roche; speaker at meetings supported with unrestricted grant by Amgen, Astellas, and Vifor; and other interests or relationships with ERA, IN, DOPPS, and Kidney Disease Improving Global Outcomes. B.D. Maes is the National Leader in the ASCEND-D and ND-trial of GSK, the PROTECT and DUPLEX of TRAVERE, and steering committee member in the Novartis APPLAUSE trial and ATACICEPT trial of Vera Therapeutics. B.D. Maes reports employment with AZ Delta Roeselare, Deltalaan 1, 8800 Roeselare, Belgium; consultancy agreements with Novartis, Travere, AstraZeneca, GSK, and VeraTherapeutics; and advisory or leadership role for Novartis and GSK. B.L. Neuen reports consultancy agreements with AstraZeneca, Bayer, Cambridge Healthcare Research, Boehringer and Ingelheim, and Janssen; research funding from Bayer; honoraria from AstraZeneca, Bayer, Boehringer and Ingelheim, Janssen, and Medscape; advisory or leadership role with AstraZeneca, Bayer, and Boehringer and Ingelheim; and speakers bureau for AstraZeneca. B.L. Neuen reports fees for advisory boards, scientific presentations, continuing education, steering committee roles, and travel for AstraZeneca, Bayer, Boehringer and Ingelheim, Cambridge Healthcare, Janssen, and Medscape, with all honoraria paid to his institution. R.D. Perrone reports consultancy agreements with Caraway, Janssen, Navitor, Otsuka, Palladiobio, Reata, and Sanofi-Genzyme; research funding from Kadmon, Otsuka, Palladiobio, Reata, Sanofi, and the US Department of Defense (TAME PKD); honoraria from Otsuka, Reata, and Sanofi-Genzyme; advisory or leadership roles for Otsuka, Palladio Bio, and Sanofi-Genzyme; and other interests or relationships with Critical Path Institute, PKD Foundation, and UpToDate. R.D. Perrone has been a member of steering committees for Otsuka, Sanofi Genzyme, and TAME PKD, with fees paid to employing institutions. G. Remuzzi reports consulting fees from Akebia Pharmaceuticals, Alexion Pharmaceutical, AstraZeneca, BioCryst Pharmaceuticals, Janssen Research & Development, Menarini Ricerche Spa, Otsuka, and Silence Therapeutics and is a member of numerous editorial boards of scientific medical journals. G. Remuzzi has had consultancy agreements with Akebia Therapeutics, Alexion Pharmaceuticals Inc, AstraZeneca, Biocryst Pharmaceuticals, Janssen Pharmaceutical, and Menarini Ricerche SpA and speaker honoraria/travel reimbursement from Boehringer Ingelheim and Novartis. F.P. Schena reports research funding from Puglia Region, Italy; Ministry of University, Rome, Italy; and Ministry of Health, Rome, Italy. C. Wanner reports consultancy agreements with Akebia, Bayer, Boehringer-Ingelheim, Gilead, GSK, MSD, Sanofi, Triceda, and Vifor; Idorsia grant to institution and Sanofi grant to institution; honoraria from Amgen, Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Chiesi, FMC, Eli-Lilly, Sanofi, and Takeda; advisory or leadership role as President European Renal Association (ERA); and other interests or relationships with European Renal Association (ERA). The remaining authors have nothing to disclose.",
77,"A.S. Bomback reports consultancy for Amgen, Apellis, Catalyst, Genentech, Kezar, Novartis, Q32, Silence Therapeutics, and Visterra and honoraria from Alexion, ANI, Aurinia, Calliditas, GlaxoSmithKline, Principio, Travere, and UpToDate. P.A. Canetta reports consultancy for Chinook, Novartis, Otsuka, and Travere and research funding from Calliditas, Novartis, and Travere. D. Fermin reports employment with University of Michigan and ownership interest in 10X Genomics, AstraZeneca, Moderna, and Thermo-Fisher Scientific. D.S. Gipson reports employment with NIH/NIDDK/KUH; consultancy between AstraZeneca, Boehringer-Ingelheim, Genentech (no individual consultancy agreements), Goldfinch Bio, Roche, University of Michigan, and Vertex; research funding to University of Michigan from Boehringer-Ingelheim, Genentech/Roche, Goldfinch Bio, Novartis, Reata, and Travere; role on advisory boards/steering committees for AstraZeneca, Goldfinch Bio, Roche/Genentech, and Vertex; member of the Kidney Health Initiative focal segmental glomerulosclerosis and Pediatric IgA Nephropathy projects; Editorial Board member of <i>JASN</i>; collaboration with NephCure Kidney International in efforts to promote pediatric participation in clinical trials for glomerular diseases (PIONEER); and other interests or relationships with Nephrotic Syndrome Patient-Reported Outcome Consortium (public-private partnership, with Goldfinch Bio, GSK, NephCure Kidney International, and Pfizer) and as the Co-chair for National Kidney Foundation Improving Vaccinations in Kidney Disease Workshop. M. Helmuth reports employment with Arbor Research Collaborative for Health, Red Viking, and the University of Michigan. R.A. Lafayette reports consultancy for Alexion, Inc., Aurinia, Calliditas, Inc., Chemocentryx, Chinook, Inc., Novartis, Omeros, Inc., Otsuka, Inc., Travere, Inc., Vera, Inc., and Visterra, Inc. and research funding from Apellis, Calliditas, Inc., Chemocentryx, Chinook, Inc., NIH, Omeros, Inc., Otsuka, Inc., Pfizer, Roche, Travere, Inc., and Vera, Inc. M. Larkina and J.Y. Lai Yee report employment with University of Michigan. D. Marchel reports employment with Centers for Medicare & Medicaid Services. L.H. Mariani reports employment with University of Michigan; consultancy for Calliditas Therapeutics Advisory Board, Chinook Therapeutics Advisory Board, Reata Pharmaceuticals CKD Advisory Committee, and Travere Therapeutics Advisory Board; research funding from Boehringer-Ingelheim and Travere Therapeutics; honoraria from Calliditas Therapeutics Advisory Board, Chinook Therapeutics Advisory Board, Reata Pharmaceuticals CKD Advisory Committee, and Travere Therapeutics Advisory Board; and advisory or leadership roles for Calliditas Therapeutics, Chinook Therapeutics, Reata Pharmaceuticals, and Travere Therapeutics. A.K. Mottl reports consultancy for Bayer, Chinook, and ProKidney; research funding from Alexion, Bayer, Calliditas, Duke Clinical Research Institute, Pfizer, and University of Pennsylvania; honoraria from UpToDate; and advisory or leadership roles for Bayer and Chinook. R.S. Parekh reports consultancy for Vertx as part of the clinical trial support; ownership interest in Coramed-stock, SpineFx, and Synaptive-stock; research funding from the Canadian Institute of Health Research (CIHR), NIH, and Ontario Ministry; patents or royalties from IZI and SpineFx; serving as an Associate Editor of <i>CJASN</i>, a Board Member of Bishop Strachan School, a Board Member of Conference of Independent Schools of Ontario, a Board Member of Baycrest Academy, and a Board Member of Baycrest Hospital; and an advisory or leadership role for ISN Council. R.S. Parekh’s spouse reports patents or royalties from Coramed and serves as an officer of Coramed and SpineFx. M.K. Saha reports consultancy for Calliditas; ownership interest in AMZN, CMG, Novavax, and NVDA; and honoraria from Calliditas, Chemocentryx, Elseiver, and Travere Therapeutics. M.G. Sampson reports an advisory or leadership role for Natera. H. Trachtman reports consultancy for Maze Therapeutics Inc; employment with RenalStrategies LLC and University of Michigan; consultancy for Aclipse, Akebia, Alexion (inactive), Angion, Astellas (inactive), Boehringer-Ingelheim, Bristol Meyers Squibb (inactive), Chemocentryx (DMSB), Complexa (inactive), Goldfinch Bio, Kaneka (inactive), Natera (RenaSight), Otsuka (DSMB Chair for Pediatric Trials), PhaseV, Travere Therapeutics, and Walden; ownership interest in Aclipse and PhaseV; research funding for support for trial design from Goldfinch, Travere Therapeutics, and Walden; honoraria for attendance at glomerular disease panels organized by Astellas and Reata; patents or royalties for design of the EPPIK trial conducted by Travere Therapeutics, planned submission; advisory or leadership roles for Chair of DSMB Otsuka trials of tolvaptan in children, DSMB for ANCA vasculitis for Chemocentryx (completed), DSMB bumetanide-seizure trial (completed), DSMB RIVUR Trial (completed), MEDCAC committee member, Steering Committee for Abatacept Trial for BMS (completed), Steering Committee for DUPRO (DUPLEX and PROTECT trials) for Travere Therapeutics, Steering Committee for Goldfinch Bio (Steering Committee), and Kidney Health Initiative Board of Directors; role on Editorial Boards for <i>Kidney360</i>, <i>Glomerular Disease</i>, and <i>Pediatric Nephrology</i>; and serves as a partner with NephCure Kidney International in efforts to promote pediatric participation in clinical trials for glomerular diseases (PIONEER).",
78,"S. Kalim reports serving on the speakers bureau for Fresenius Kabi. T. Shafi reports consultancy agreements with Cara Therapeutics and Siemens; research funding from Baxter (clinical trial site investigator), Bayer (clinical trial site investigator), CVS (clinical trial site investigator), Goldfinch (clinical trial site investigator), Natera (clinical trial site investigator), and Vertex (clinical trial site investigator); grants from the NIH during the conduct of the study; honoraria from Cara Therapeutics and Siemens; and advisory or leadership roles for <i>American Journal of Kidney Diseases</i>, <i>American Journal of Medicine</i>, <i>CJASN</i>, and <i>Kidney360</i>. All remaining authors have nothing to disclose.",
79,"B.A. Kerlin reports employment with The Abigail Wexner Research Institute at Nationwide Children's Hospital and the Pediatric Academic Association, research funding from Aurinia Pharmaceuticals Inc., and patents or royalties with Nationwide Children's Hospital. S.V. Parikh reports consultancy agreements with Alexion, Aurinia Pharmaceuticals, and Kezar Life Sciences; research funding from Aurinia Pharmaceuticals, NIH-NIDDK, and Serono-EMD; and royalties from UpToDate.com. B.H. Rovin reports consultancy agreements with Alexion, AstraZeneca, Aurinia, Biocryst, Biogen, BMS, Calliditas, Chemocentryx, Corrona, EMD-Serono/Merck, Exagen, Galapagos, Genentech, Horizon, Human Genome Sciences (GSK), Idorsia, Janssen, MedImmune, Morphosys, Novartis, Omeros, Otsuka, Resonance, Retrophin, RILITE Foundation, Roche, and Vistera; research funding from Biogen; honoraria from Alexion, AstraZeneca, Aurinia, Biocryst, Biogen, BMS, Calliditas, Chemocentryx, Corrona, EMD-Serono/Merck, Exagen, Galapagos, Genentech, Horizon, Human Genome Sciences (GSK), Idorsia, Janssen, MedImmune, Morphosys, Novartis, Omeros, Otsuka, Resonance, Retrophin, RILITE Foundation, Roche, and Vistera; advisory or leadership role for ASN Kidney Week, CureGN, KDIGO, <i>Kidney International</i>, <i>Kidney International Reports</i>, Lupus Foundation of America, <i>Nephrology Dialysis and Transplantation</i>, and UpToDate; a lot of work with the ASN, mostly educational courses, work with the NKF and the ISN, and work with the LFA. W.E. Smoyer reports consultancy agreements with Otsuka, Vertex, and Visterra; ownership interest in NephKey Therapeutics; research funding from Aurinia; honoraria from USC for CTSA External Advisory Committee and from UCLA for CTSA External Advisory Committee; royalties from UpToDate; and advisory or leadership roles as a member of the Board of Directors for PNRC, a member of the Board of Directors of NephCure Kidney International (NKI), and a member of the Coordinating Committee of Institute for the Advancement of Clinical Trials in Children (I-ACT). J.R. Stanek reports employment with Nationwide Children's Hospital. A.P. Waller reports employment with The Research Institute at Nationwide Children's Hospital. The remaining authors have nothing to disclose.",
80,"J. Coresh reports consultancy from Healthy.io and SomaLogic; ownership interest in Healthy.io; research funding from National Institute of Health and National Kidney Foundation; and an advisory or leadership role for SomaLogic. D.C. Crews reports consultancy for Yale New Haven Health Services Corporation Center for Outcomes Research and Evaluation (CORE); research funding from Baxter International and Somatus, Inc.; an investigator-initiated grant from Baxter; honoraria from Maze Therapeutics; role on the Editorial Boards of <i>CJASN</i>, <i>JASN</i>, and <i>Journal of Renal Nutrition</i>; role as Associate Editor of <i>Kidney360</i>; role on Advisory Group, Health Equity Collaborative, Partner Research for Equitable System Transformation after COVID-19 (PRESTAC), Optum Labs; role on Board of Directors of National Kidney Foundation of Maryland/Delaware, Nephrology Board of American Board of Internal Medicine, and Council of Subspecialist Societies for American College of Physicians; and role as Executive Councilor of American Society of Nephrology. M.M. Estrella reports employment with San Francisco VA Health Care System; consultancy for AstraZeneca, Inc. and Boehringer-Ingelheim, Inc.; research funding from Bayer, Inc.; honoraria from AstraZeneca and Boehringer Ingelheim; and other interests or relationships with <i>American Journal of Kidney Diseases</i>, <i>CJASN</i>, and National Kidney Foundation. M.M. Estrella's spouse reports consultancy for Castle Biosciences, Isothrive, Medtronic, Phathom Pharmaceuticals, and Sanofi. J.L. Januzzi reports consultancy for Abbott, Jana Care, Janssen, Novartis, Prevencio, and Roche Diagnostics; research funding from Abbott Diagnostics, Applied Therapeutics, HeartFlow, Innolife, Novartis Pharmaceuticals, and Roche Diagnostics; advisory or leadership roles as a Trustee of the American College of Cardiology, a Board member of Imbria Pharmaceuticals, and a Director at Jana Care; and role on clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, Bayer, CVRx, Janssen, MyoKardia, Takeda, and Vifor. A.S. Levey reports grants and contracts paid to Tufts Medical Center from NIH and NKF, contracts paid to A.S. Levey from AstraZeneca (DSMB for dapagliflozin trials), and honoraria to A.S. Levey from academic medical centers for visiting professorships. K. Matsushita reports consultancy for AMGA; honoraria from Fukuda Denshi and Kowa Company Ltd.; and advisory or leadership roles for <i>American Journal of Kidney Disease</i>, <i>Circulation Reports</i>, and <i>Kidney International</i>. M.G. Shlipak reports research funding from Bayer Pharmaceuticals; honoraria from AstraZeneca, Bayer, and Boeringer Ingelheim; patents or royalties from Kidney Health Monitoring in Hypertension Patients; advisory or leadership roles for <i>American Journal of Kidney Disease</i>, <i>Circulation</i>, and <i>JASN</i>; role as Board Member of Northern California Institute for Research and Education; role as Committee Member of KDIGO Guidelines Committee; and previously served as a consultant to Cricket Health and Intercept Pharmaceuticals. All remaining authors have nothing to disclose.",
81,"L.P. Gregg reports employment with Michael E. DeBakey VA Medical Center, Houston, TX, and VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX. L.P. Gregg currently serves as an Editorial Fellow for <i>JASN</i>. M.E. Matheny reports employment with Department of Veterans Affairs; consultancy for Food and Drug Administration (FDA) and NIH-VA-DoD Pain Management Grant Consortium (PMC3); and advisory or leadership roles for SMRB Study Section for VA HSR&D Informatics and Methods Section, Steering Committee—Indianapolis VA HSR&D COIN Center, Steering Committee—VA HSR&D VIREC, Steering Committee—Salt Lake City VA HSR&D COIN Center, and VA ORD Million Veterans Program Executive Steering Committee. S.D. Navaneethan reports employment with Michael E. DeBakey VA Medical Center; consultancy for ACI Clinical, AstraZeneca (Data safety monitoring board), Bayer, Boehringer-Ingelheim/Lilly, GSK, Intercept (event adjudication committee), Vertex (event adjudication committee), and Vifor; honoraria for ACI Clinical, AstraZeneca, Bayer, Boehringer-Ingelheim/Lilly, GSK, Intercept, Vertex, and Vifor; research funding from the Department of Veterans Affairs Health Services Research and Development and NIH; and advisory or leadership roles for <i>American Journal of Kidney Diseases</i>, <i>American Journal of Nephrology</i>, <i>Cardiorenal Medicine</i>, <i>CJASN</i>, and <i>Current Opinion in Nephrology and Hypertension</i>; and role as a KDIGO: Guideline writing committee member. M.W. Segar reports consultancy for ParaDocs Health, research funding from American Heart Association, and speakers bureau for Merck & Co. S.S. Virani reports honoraria from American College of Cardiology as Associate Editor for Innovations, ACC.ORG, advisory or leadership role for Southwest Chapter of the National Lipid Association, and grant support from Department of Veterans Affairs, NIH, and Tahir and Jooma Family. All remaining authors have nothing to disclose.",
82,"A.K. Agarwal reports employment with VA Central California Health Care System; consultancy from Akebia; honoraria from Amgen; advisory or leadership role for ASDIN, <i>Clinical Nephrology</i>, <i>Frontiers in Nephrology</i>, <i>International Journal of Nephrology</i>, ISN, <i>Journal of Vascular Access</i>, KSAP, NKF, and <i>The Open Urology & Nephrology Journal</i>—all unpaid; and other interests or relationships with ASDIN, ASN, ISN, and NKF. C.D. Chu reports research support from Bayer Healthcare. M. Dobre reports employment with Case Western Reserve University, NIH grant funding (NHLBI HL141846), and consultancy for CareDx, Inc. (<$3,000). J.P. Dwyer reports employment with University of Utah Health; consultancy for Acuta Capital, Akebia, Applied Therapeutics, Ardelyx, AstraZeneca, Aurinia, Bayer, BI, BioRasi, BioVie, Botanix, Caladrius, Cincor, Eli Lilly, ES Therapeutics, Fibrogen, Genentech, GSK, Icon, Inversago, Ionis, Keros Therapeutics, Medpace, MicuRx, Novo Nordisk, ProKidney, PSI CRO, Rarestone, Reata, RenalytixAI, Sanofi, Tricida, ValenzaBio, and Worldwide clinical trials; ownership interest in Acelyrin, BioRasi, Inc., Innovative Renal Care, LLC, PathEx, Inc., and Venostent, Inc.; research funding from AstraZeneca and CinCor; and advisory or leadership roles for Collaborative Study Group (Board of Directors and President) and The Bolles School (Board of Trustees). E. Horwitz reports other interests or relationships as medical director for in-patient dialysis services at MetroHealth Medical Center contracted with Fresenius Kidney Care, a member of American Society of Nephrology, and a member of the International Society for Peritoneal Dialysis. J.H. Ix reports consultancy for Akebia, AstraZeneca, Bayer, Cincor, and Sanifit; research funding from Baxter International and Juvenile Diabetes Research Foundation; honoraria from Akebia, AstraZeneca, Bayer, Cincor, and Sanifit; advisory or leadership role for AlphaYoung; and other interests or relationships with Executive Board for Kidney Disease: Improving Global Outcomes. J.P. Lash reports employment with University of Illinois at Chicago and advisory or leadership role for <i>Kidney360</i>. A. McWilliams reports employment with Atrium Health and ownership interest in iEnroll, LLC. S. Oparil reports ownership interest in CinCor Pharma Inc.; research funding from CinCor Pharma Inc. (site PI-primary aldosterone study), George Clinical Pty (site PI-GMRx2 treatment of hypertension), Higi (site PI-BP validation study), and Mineralys (site PI-uncontrolled hypertension); patents or royalties from Elsevier; and other interests or relationships as Editor-in-Chief of <i>Current Hypertension Reports</i> (Springer Science Business Media LLC) until December 2023 with annual stipend of $5,000 (Springer). N.M. Pajewski reports ownership interest in Eyenovia, Longeveron, and Ocuphire Pharma. P. Pemu reports research funding from Amgen and Janssen; patents or royalties for a system and method for chronic illness care; and advisory or leadership role for American Heart Association Southeast Board (not paid). J. Powell reports employment with ECU Physicians and research funding from Idorsia as a site PI for a study done by Idorsia. J. Powell was not compensated directly. F.F. Rahbari-Oskoui reports consultancy for Otsuka and UpToDate; research funding from Duke University, Kadmon, NIH, Reata, and Sanofi/Genzyme; honoraria from Otsuka; author royalties from UpToDate; advisory or leadership roles for <i>BMC Nephrology</i> (Associate Editor), <i>Journal of Cardiology and Vascular Medicine</i> (Editorial Board member), and PKD Foundation Scientific Advisory Board Panel member; and unbranded speaker bureau for Otsuka (only raising disease awareness in ADPKD without any reference to commercial products). M. Rahman reports employment with Case Western Reserve University; research funding from Bayer Pharmaceuticals and Duke Clinical Research Institute; honoraria from Barologics for consulting for a one-time discussion and from AstraZeneca for consultant meeting; and advisory or leadership roles as an Associate Editor of <i>CJASN</i> and an Editorial Board member of <i>American Journal of Nephrology</i>. D.S. Raj reports employment with The George Washington University School of Medicine; consultancy for Novo Nordisk; research funding from NIH; honoraria from Novo Nordisk; advisory or leadership roles for NHLBI, NIDDK, and Novo Nordisk; and other interests or relationships with American Association of Kidney Patients. A. Rastogi reports consultancy for Akebia, Amicus, Ardelyx, AstraZeneca, Aurinia, Chiesi Global Inc., Chinook Therapeutics, Fresenius Medical Care-Vifor, GlaxoSmithKline, Novartis, Otsuka, Sanofi S. A., Travere Therapeutics, and Vifor Pharma Inc.; research funding from Alnylam Pharmaceuticals, AstraZeneca, Bayer, GlaxoSmithKline, Idorsia Pharmaceuticals, Ltd., Kadmon Corporation, LLC, NIH, Novo Nordisk, Omeros Inc., Palladio Biosciences, Pfizer, Protalix Biotherapeutics Ltd., Reata Pharmaceuticals, Inc., Regulus Therapeutics, Summit Therapeutics, and Sanofi; honoraria from Amgen, AstraZeneca, Aurinia, Baxter, Bayer, Fresenius Medical Care, Genzyme/Sanofi, Janssen, Natera, and Vifor Pharma Inc.; research grants and consulting fees from Amgen, AstraZeneca, Bayer, CSL Vifor, Gilead, GlaxoSmithKline, Janssen, Otsuka, Pfizer, and Sanofi; advisory or leadership roles for Akebia, Amicus, Ardelyx, AstraZeneca, Aurinia, Chiesi Global Inc., Chinook Therapeutics, Fresenius Medical Care-Vifor, GlaxoSmithKline, Novartis, Otsuka, Sanofi S. A., Travere Therapeutics, and Vifor Pharma Inc.; and speakers bureau for Amgen, AstraZeneca, Aurinia, Baxter, Bayer, Fresenius Medical Care, Genzyme/Sanofi, Natera, and Vifor Pharma Inc. M.V. Rocco reports consultancy for Bayer and George Clinical, research funding from Bayer and Boehringer Ingelheim, advisory or leadership role for National Kidney Foundation, and other interests or relationships as co-chair of International Society of Nephrology Kidney Care Network Project and as NKF KDOQI chair. S. Soman reports ownership interest in Nephroceuticals and Pfizer; advisory or leadership roles for American Medical Informatics Association, National Kidney Foundation, and National Kidney Foundation, MI; and other interests or relationships with American Medical Informatics Association, National Kidney Foundation Education Committee, and National Kidney Foundation Michigan Scientific Advisory Board. G. Thomas reports research funding from Boehringer Ingelheim and honoraria from UpToDate. R.R. Townsend reports employment with University of Pennsylvania School of Medicine; consultancy for BARD, BD, Cytel, IONIS, Janssen, Medtronic, Orchestra, and Regeneron; DSMB for Cytel and Novartis; research funding from NIH; and royalties from UpToDate. D.S. Tuot reports honoraria from Projects in Knowledge and advisory or leadership roles for BluePath Health eConsult Workgroup and National Kidney Foundation Bay Area Medical Advisory Board. P.K. Whelton reports employment with Tulane University School of Public Health and Tropical Medicine. All remaining authors have nothing to disclose.",
83,"T.V.G., G.A.B., R.B.M., D.K., S.C., P.N., and A.D. are members of the steering committee for the IMAGINE study and receive consulting fees from CSL Behring. M.Be. received consulting fees from CSL Behring and is a shareholder. L.A.L. is employed by CSL Behring and is a shareholder. The other author declares no conflicts of interest",
84,"A. Levin reports Consultancy: Astra Zeneca, Bayer, Boeingher Ingleheim; Chinook Therapeutics; GSK; Janssen, Kidney Foundation of Canada; NIH, Novo Nordisk; Occuryx/Certa, Otsuka, REATA; Research Funding: Astra Zeneca; Boehringer Ingelheim; Canadian Institute of Health Research (CIHR); CITF (Canadian Immunology Task Force), GSK, Health Research BC, Kidney Foundation of Canada; MOH BC, Shared Care BC; Honoraria: AstraZeneca; Bayer; GSK; Janssen; NIH; Advisory or Leadership Role: AstraZeneca, Boehringer Ingelheim, and NIDDK, DSMB for NIDDK, Kidney Precision Medicine, U Washington Kidney Research Institute Scientific Advisory Committee; International Society of Nephrology Research Committee; KRESCENT (Kidney Scientist Education Research National Training Program); GSK, Chinook Therapeutics, BC Renal (Exec Director), Steering Committee Chair CURE Consortium, CADTH, CITF, Co Lead Long Covid Web Grant; PI CanSOLVE CKD; and Other Interests or Relationships: CREDENCE National Coordinator from Janssen, directed to her academic team; NIDDK CURE Chair Steering Committee; International Society of Nephrology; Canadian Society of Nephrology; Kidney Foundation of Canada, Steering Committee ALIGN trial, DSMB Chair RESOLVE Trial (Australian Clinical Trial Network)l ASPIRE Trial (ACTN), Executive Steering Committee AstraZeneca Clinical Trial.",
85,"M.S. Balzer reports consultancy: Boehringer-Ingelheim; ownership interest: Arcturus Therapeutics, AstraZeneca, Bayer, BioNTech, CureVac, Linde, Moderna, Pfizer; honoraria: Boehringer-Ingelheim; and advisory or leadership role: Boehringer-Ingelheim, <i>Journal of the American Society of Nephrology</i>. K. Susztak reports consultancy: AstraZeneca, GSK, Novo Nordisk, Pfizer; ownership interest: Jnana; research funding: AstraZeneca, Bayer; Boehringer Ingelheim; Calico, Gilead; GSK, Jnana, Kyowa Kirin Genentech, Maze, Novartis, Novo Nordisk, ONO Pharma, Regeneron; Variant Bio; Honoraria: AstraZeneca, Bayer, Jnana, Maze, Pfizer; and advisory or leadership role: Editorial board; <i>Cell Metabolism</i>, <i>eBioMedicine</i>, Jnana, <i>Journal of American Society of Nephrology</i>, <i>Journal of Clinical Investigation</i>, <i>Kidney International</i>, Med, Pfizer. All remaining authors have nothing to disclose. Because Katalin Susztak is an editor of the <i>Journal of the American Society of Nephrology</i>, she was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.",
86,"B. Canaud reports Employer: Scientific consultant for Fresenius Medical Care, Germany up to December 2022—Retired from December 2022; and Consultancy: Senior scientist consultant for Fresenius Medical Care up to December 2022. B. Genser received a consulting fee from FMC for conducting the statistical analysis. M. Jardine reports Research Funding: Baxter, CSL, Dimerix with all payments to my institution; Honoraria: AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, MSD, Occuryx and Vifor, and directs honoraria to clinical research programs; Advisory or Leadership Role: Chinook, CSL, Janssen. All honoraria directed to clinical research programs; and Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Janssen, and directs speaker fees to clinical research programs. M.R. Marshall reports Ownership Interest: Microsoft Corporation. J. Pinter received a grant from Fresenius Medical Care for authorship related expenses regarding journal publication, abstract submission, organization, management and travel costs for conference presentations. P. Rossignol reports Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, CinCor, Idorsia, KBP, NovoNordisk, Sanofi, Servier, Sequana medical, Vifor; Ownership Interest: Cardiorenal cofounder (stocks); G3P (stock options); Research Funding: Relypsa Inc. and Vifor Fresenius Medical Care Renal Pharma, and a Vifor Pharma Group Company; Honoraria: Dr. Rossignol reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, CinCor, Idorsia, KBP, NovoNordisk, Sanofi, Sequana medical, Servier, Vifor; Patents or Royalties: CardioRenal cofounder (a company developing a home potassium self-monitoring device); Advisory or Leadership Role: ESH: “hypertension and the kidney” working group board member since 2016; WG board member HFA, Cardio renal (2016–) and translational 2016–2020; WG board member Eurecam ERA-EDTA 2021–2023; WG on biomarkers board member HFA, 2020–2022; KDIDO executive committee member since 2023; and Speakers Bureau. B. Smyth reports Research Funding: In-kind support provided by iX Biopharma (Singapore) for investigator-initiated research; Honoraria: Research Review Australia; CSL-Vifor (funds to institution); and Advisory or Leadership Role: Unpaid committee positions for not-for-profit organisations/clinical trials (ANZSN Research Advisory Committee, INCH-HD study SC, RESOLVE trial SC); Paid position with CSL-Vifor (funds to institution). S. Stuard is an employee of Fresenius Medical Care; Ownership Interest: Fresenius Medical Care; and Patents or Royalties: Fresenius Medical Care. C. Wanner has received honoraria for advisory or educational activities from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, CSL-Vifor, Fresenius Medical Care, Gilead, GSK, MSD, NovoNordisk and grants from Boehringer Ingelheim and Sanofi to the institution. C. Wanner also reports Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, CSL-Vifor, GSK, MSD, NovoNordisk; Honoraria: Amicus, Chiesi, Eli-Lilly, FMC, Novartis, Sanofi, Stadapharm, Takeda; and Other Interests or Relationships: European Renal Association (ERA). D.C. Wheeler has an ongoing consultancy contract with AstraZeneca. In the last 2 years he has received honoraria/consultancy fees from Astellas, Bayer, Boehringer Ingelheim, Eledon, Galderma, Gilead, GlaxoSmithKline, Janssen, Prokidney, Tricida, Vifor and Zydus for clinical trial related, Advisory or Educational activities. D.C. Wheeler also reports Consultancy: George Clinical, Merck Sharp and Dohme, Pfizer, ProKidney; Advisory Boards, Trial Committees and Consultancy; Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelhiem, GalaxoSmithKline, Janssen, Napp, Merck Sharp and Dohme, Napp, Pharmacosmos, Reata, Vifor Fresenius; Advisory or Leadership Role: AstraZeneca; and Speakers Bureau: Amgen, Astellas, AstraZeneca, Janssen, Merck Sharp and Dohme, Mundipharma, Napp, Vifor Fresenius.",
87,"D. Wesson reports Consultancy: Tricida, Inc. until January 31, 2023; Research Funding: Tricida, Inc. (South San Francisco, CA); Honoraria: Brigham and Women's Hospital, Medscape, The Methodist Hospital (Houston), UCLA Medical Center, University of Buffalo Medical School, University of Rochester School of Medicine, and U of Southern California Medical Center; Advisory or Leadership Role: <i>American Journal of Nephrology</i> Editorial Board; <i>CJASN</i> Editorial Board, <i>JASN</i>, Deputy Clinical Editor, <i>Journal of Renal Nutrition</i> Editorial Board, <i>Kidney International</i> Editorial Board, and Tricida Scientific Steering Committee (ending January 31, 2023); and Other Interests or Relationships: Paid consultant of the Texas Kidney Foundation.",
88,"G.A.B. is a member of the steering committee for an ongoing pivotal phase 3 trial evaluating clazakizumab in chronic active antibody-mediated rejection ( ClinicalTrials.gov number, NCT03744910; sponsored by CSL Behring). E.C. was formerly an employee of Vitaeris Inc, a manufacturer of clazakizumab. The other authors have no conflicts of interest to declare.",
89,The authors declare no conflicts of interest.This research was supported by the National Institute for Health Research Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge in collaboration with Newcastle University and in partnership with National Health Service Blood and Transplant.,No
90,The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Daniel Saleh reports a relationship with Stryker UK Ltd that includes: speaking and lecture fees. Daniel Saleh reports a relationship with Sanofi Genzyme that includes: speaking and lecture fees. Romain Bosc reports a relationship with Alexion Pharma France SAS that includes: consulting or advisory. Romain Bosc reports a relationship with AstraZeneca SAS that includes: consulting or advisory. Sheila Jowsey-Gregoire reports a relationship with US Department of Defense that includes: funding grants. Sheila Jowsey-Gregoire reports a relationship with Mayo Clinic that includes: travel reimbursement.,
91,"S.J.L. Bakker reports employment with University Medical Center Groningen; research funding from Astellas Pharma and Chiesi; and advisory or leadership roles for Dutch Health Council and Scientific Board of the Dutch Kidney Foundation. M.H. de Borst reports employment with University Medical Center Groningen, The Netherlands; consultancy agreements with Astellas, AstraZeneca, Kyowa Kirin, Pharmacosmos, Sanofi Genzyme, and Vifor Pharma; research funding from Sanofi Genzyme and Vifor Pharma; and serving as an Associate Editor of <i>Nephrology Dialysis Transplantation</i>. M. Gritter reports employment with Erasmus MC Rotterdam. E.J. Hoorn reports employment with Erasmus Medical Center; research funding from Aurinia; honoraria from UpToDate; serving on the Editorial Boards of <i>American Journal of Physiology—Renal Physiology</i>, <i>Journal of Nephrology</i>, and <i>Journal of the American Society of Nephrology</i>; and serving as a Board Member of ERA Working Group on Inherited Kidney Diseases and a Board Member of Dutch Federation of Nephrology. J.I. Rotmans reports employment with LUMC; research funding from Dutch Kidney Foundation and Dutch Ministry of Science; advisory or leadership role for Advisory Board Neokidney; and serving as Chair of Thematic Working Group Vascular Tissue Engineering at TERMIS, president-elect of Vascular Access Society, and a member of the guideline committee Dutch Society of Nephrology. J.J. van Zanden reports employment with Certe. L. Vogt reports employment with Amsterdam University Medical Centers; consultancy agreements with AstraZeneca, Bayer BV Netherlands, Carlsbad, CA, ISIS Pharmaceuticals, Inc, and Vifor Pharma; research funding from Dutch Kidney Foundation and Health Holland; and serving as an Associate Editor of <i>BMC Nephrology</i>. R.D. Wouda reports employment with Amsterdam University Medical Centers, location AMC. S.M.H. Yeung reports employment with University Medical Center Groningen.",
92,"IM has received research funding from Regeneron and Genentech, and a member of Garuda Therapeutics’s scientific advisory board. B.R.B. receives remuneration as an advisor to Magenta Therapeutics and BlueRock Therapeutics; research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre biopharmaceuticals, and Carisma Therapeutics, Inc.; and is a cofounder of Tmunity Therapeutics.",
93,The remaining authors declare that they have no relevant financial interests.,No
94,"V.K. Derebail reports consultancy for Amgen, Bayer, Forma Therapeutics, Merck, Novartis, and Travere; research funding as site PI for clinical trials (Boehringer Ingelheim, Chemocentryx, Gilead, Hansa, Infla-RX, Merck, Travere, and Vertex); and honoraria from UpToDate. P.H. Nachman reports consultancy from GSK and Q32 and in the past: Hansa Biopharma; research funding as site PI for clinical trials: current: Hansa Biopharma, NIH, and Omeros and past: Aurinia, ChemoCentryx, FDA, and Goldfinch-Bio; honoraria from ASN, FDA, NIH, and UpToDate; royalties from UpToDate; and advisory or leadership role with ASN past: Kidney Health Initiative.",
95,"I.H. de Boer reports Consultancy: Alnylam, Astra Zeneca, Bayer, Boehringer-Ingelheim, Boehringer-Ingelheim/Lilly, George Clinical, Gilead, Medscape, Otsuka; Research Funding: Dexcom, Novo Nordisk; Honoraria: National Institutes of Health; and Advisory or Leadership Role: Deputy Editor of Clinical <i>Journal of the American Society of Nephrology</i>, Clinical Practice Guideline Co-Chair of Kidney Disease Improving Global Outcomes, and Chair of the American Heart Association Kidney in Heart Disease Science Committee. G.M. Chertow reports Consultancy: Akebia, Ardelyx, AstraZeneca, Calico, Gilead, Miromatrix, Reata, Sanifit, Unicycive, Vertex; Ownership Interest: Ardelyx, CloudCath, Durect, DxNow, Eliaz Therapeutics, Outset, Physiowave, PuraCath, Renibus, Unicycive; Research Funding: CSL Behring, NIAID, NIDDK; Advisory or Leadership Role: Board of Directors, Satellite Healthcare, Co-Editor, Brenner & Rector's The Kidney (Elsevier); and Other Interests or Relationships: DSMB service: Bayer, Gilead, Mineralys, NIDDK, ReCor. P. Geldsetzer reports Advisory or Leadership Role: GSK plc. M.K. Tamura reports Ownership Interest: Recursion; Honoraria: American Federation for Aging Research (nonprofit); and Advisory or Leadership Role: Beeson External Advisory Committee; <i>CJASN</i> Editorial Board; Clin-Star Advisory Board. L. Tian reports Employer: Gilead Inc.; Consultancy: Athersys Inc.; Biogen Inc., Ownership Interest: Gilead Inc.; and Research Funding: Consulting service with Athersys Inc., Biogen Inc., and Eisai Inc. All remaining authors have nothing to disclose.",
96,Declaration of competing interest. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.,No
97,"A.G. Abraham reports consultancy for Implementation Group, Inc.; research funding from NIH; honoraria from Elsevier; and advisory or leadership role as an Associate Editor of <i>American Journal of Epidemiology</i> and an Associate Editor of <i>Population Health Metrics</i>. J. Coresh reports employment with The Johns Hopkins University, Welch Center for Prevention, Epidemiology, and Clinical Research and research funding from the National Institutes of Health. M.R. Denburg reports research funding from Mallinckrodt; patents or royalties from InBore LLC; advisory or leadership role on the Editorial Board of <i>Kidney International Reports</i> and on KDIGO Executive Committee; and other interests or relationships with American Society of Pediatric Nephrology Research and Program Committees. M.R. Denburg's spouse reports consultancy for TriSalus Life Sciences; ownership interest in InBore LLC, Instylla, and Precision Guided Interventions LLC; and an advisory or leadership role for TriSalus Life Sciences Scientific Advisory Board. S.L. Furth reports consultancy for Genentech. E.A. Hartung reports advisory or leadership role for Polycystic Kidney Disease Foundation—Scientific Advisory Committee and PKD in Children Council/ARPKD Task Force (volunteer) and other interests or relationships as American Society of Pediatric Nephrology member and American Board of Pediatrics—Nephrology Subboard Member. P.L. Kimmel reports employment with National Institute of Diabetes and Digestive Kidney Diseases (NIDDK); royalties for co-editing <i>Chronic Renal Disease and Psychosocial Aspects of Chronic Kidney Disease</i> and royalties from Mayo Clinic Press for <i>The Body's Keepers</i>; patents or royalties from Elsevier; advisory or leadership role as an unpaid member of Board of Directors of Academy of Medicine of Washington, DC; and other interests or relationships as Co-Editor of <i>Chronic Renal Disease </i>(Academic Press) and Co-Editor of <i>Psychosocial Aspects of Chronic Kidney Disease</i>. As a Federal Employee at NIDDK, P.L. Kimmel's holdings are reviewed each year for potential conflicts of interest. At this time, P.L. Kimmel's only stock holding related in any fashion to health care is CVS and GE Healthcare. M.B. Matheson reports employment with Johns Hopkins Bloomberg School of Public Health and research funding from Toshiba Corporation. R.S. Vasan reports consultancy for NIDDK. B.A. Warady reports consultancy for Amgen, Bayer, GlaxoSmithKline, Light Line Medical, and UpToDate; research funding from Baxter Healthcare; honoraria from Amgen, Bayer, GlaxoSmithKline, and UpToDate; advisory or leadership role as Vice President of North American Pediatric Renal Trials and Collaborative Studies; and advisory or leadership roles on National Kidney Foundation Board of Directors, NTDS Board of Directors, and Midwest Transplant Network Governing Board. Y. Xu reports employment with Johns Hopkins School of Public Health. All remaining authors have nothing to disclose.",
98,"A. Dorison reports having an advisory or leadership role as a member of the Medical Research Future Fund 2021 Stem Cell Therapies Grant Assessment Committee for the National Health and Medical Research Council. C. Quinlan reports having employment with a partner MYOB (Australian software company); and reports having an advisory or leadership role on the Blue Ribbon Panel of Nephmadness, as an executive member of Nephrology Social Media Collective, faculty member of NephSim, and on the Education and Training committee of Australian and New Zealand Society of Nephrology. M.H. Little reports receiving research funding from Novo Nordisk; reports having patents or royalties with Murdoch Children’s Research Institute and Uniquest; reports having advisory or leadership role as a Board Member of Research Australia, CEO of Novo Nordisk Foundation Center for Stem Cell Medicine, and President of International Society for Stem Cell Research; reports being a member of the editorial board of <i>Cell Stem Cell, Development</i>, <i>Journal of the American Society for Nephrology</i>, <i>Kidney International</i>; and reports being a Member of the Advisory Board for Nature Reviews Nephrology; reports speakers bureau through presenting a seminar for Roche and was paid an honorarium; and reports having other interests or relationships as Chief Scientist and Group Leader of Murdoch Children’s Research Institute, Co-Chair of Advisory Committee for the Medical Research Future Fund Stem Cell Therapies Mission Australia, Past President of International Society for Stem Cell Research, Professor of University of Copenhagen, Professor of University of Melbourne, and Reviewer for National Health and Medical Research Council Australia; and reports holding an National Health and Medical Research Council Senior Principal Research Fellowship (GNT1136085). M. Ramialison reports having an advisory or leadership role as Treasurer of the Australian Bioinformatics and Computational Biology Society (not paid). M.A. Saleem reports having consultancy agreements with Confo Therapeutics, Mission Therapeutics, Pfizer, and Retrophin; reports having an ownership interest in Purespring Therapeutics; reports receiving research funding from Evotec, Retrophin, and UCB (global biopharmaceutical company); reports receiving honoraria from Purespring Therapeutics Director and Chief Scientific Officer; reports having patents or royalties from Purespring Therapeutics and the University of Bristol; and reports having an advisory or leadership role as a Director of Purespring Therapeutics. M. See reports having employment with Telstra Australia; reports having an ownership interest in AGL Energy, Austal, Coles Group, Commonwealth Bank of Australia, Medibank Private, Origin Energy, and Woolworths. S.E. Howden reports having consultancy agreements with Ovid Research; and reports having an advisory or leadership role with Scientific Reports. The Murdoch Children's Research Institute Gene Editing Facility is supported by the Stafford Fox Medical Research Foundation, the Novo Nordisk Foundation (NNF21CC0073729) and Phenomics Australia (National Collaborative Research Infrastructure Strategy, NCRIS). T.A. Forbes reports having an ownership interest in their partner owning stocks in Avita Medical, Cochlear, and other Australian Stock Exchange–listed companies without medical or biotechnology affiliations; reports receiving honoraria from Otsuka; reports receiving speakers honorarium from a nondirected donation to research; and reports having other interests or relationships as site principal investigator for Phase 2 and 3 clinical trials for nedosiran with Dicerna/Novo Nordisc; and reports being a Clinician Scientist Fellow supported by the Royal Children’s Hospital Foundation. The research conducted at the Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program. All remaining authors have nothing to disclose.",
99,A.R.C. is an Oxford-BMS Fellow. F.I. is a Wellcome Trust CRCD Fellow (211122/Z/18/Z). The other authors declare no conflicts of interest.,
100,"<b>Financial Disclosure:</b> Dr Johansen reports research support from NIDDK; personal fees from and advisory board participation for GSK and Vifor; also reports participation in an NIAID OSMB and a NIDDK DSMB as well as serving as an Associate Editor for JASN. Dr Chertow reports receiving fees from AstraZeneca for the DAPA-CKD trial steering committee, research grants from NIDDK and Amgen; board of directors for Satellite Healthcare; receiving fees for advisory boards from Baxter, Cricket, DiaMedica and Reata; receiving fees from Akebia, Sanifit and Vertex for trial steering committees, and receiving fees for data and safety monitoring board service from Angion, Bayer, and ReCor. Dr Israni reports receiving research funds/grants awarded to Hennepin Healthcare Research Institute from Gilead, Health Resources and Services Administration, NIH and AHRQ. He has served on an Advisory Board for CSL Behring; receives consulting fees from Medical Review Institute of America; and discloses family members that are employees of Vera and GSK pharmaceutical companies. Dr Ku reports grant support from Care DX, NIDDK, and Natera; received honorarium from New York Academy of Medicine; reports stock ownership in Edison company; received gifts made to UCSF to support research; and is a member of the AKF Kidney Health Equity Coalition as well as an Associate Editor for <i>AJKD</i>. Dr Obrador reports grant funding from Fundación Río Arronte, AstraZeneca, and Secretaría de Tecnología, Educación e Innovación de la CDMX; royalties from Elsevier Barcelona and UpTo Date/Wolters Kluwer; honoraria received from GlaxoSmithKline and AbbVie; travel support from GlaxoSmithKline, AstraZeneca, and KDIGO; advisory board participation for GlaxoSmithKline; receiving discounted medications from Novartis for SIPASA clinics; and serving on boards SIPASA (Pan American Health Care System), Fundación Mexicana del Rin~ón and Consejo Mexicano para la Acreditación de la Educación Médica in unpaid roles. Dr O’Hare reports institutional funding from VA HSR&D; honoraria and travel support from UCSF Division of Nephrology; advisory board for Murea; and travel fees from NKF Northern California and JAMA. Dr Roetker reports institutional research grants from Merck & Co. and NIH. Dr Scherer reports royalties from UpToDate; consulting fees from Vifor/Cara Pharmaceuticals; and member of the clinical advisory board for Monogram Health. Dr St. Peter reports grant support from NIH and the University of Minnesota Office of Discovery and Translation; serving as Director for Advancing Kidney Health through Optimal Medication Management Initiative, personal fees from Total Renal Care, Inc; and medical writing from Bayer. Dr Snyder reports research funding from Health Resources and Services Administration, US Department of Health and Human Services; honorarium from Houston Methodist and American Foundation for Donation and Transplantation; participation in DSMB for A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible BD Organ Donors; editor for AJT and Transplantation journals; and membership in the Board of Directors for Donate Life America, LifeSource, and Organ Donation and Transplantation Alliance. Dr Winkelmayer reports grants/contracts from NIH and Health Care Service Corporation; honoraria from Pharmacosmos; consulting fees from Relypsa and Unicycive; serving on advisory boards for Akebia, Ardelyx, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Merck & Co., Otsuka, Reata, Zydus; and travel support and co-chair for KDIGO committee. Dr Wong reports research funding from Doris Duke Charitable Foundation, NIH and National Palliative Care Research Center; and meeting/travel support from the National Kidney Foundation. Dr Wetmore reports institutional support from Amgen, BMS-Pfizer, GSK, Merck & Co, Genentech, OPKO, Relypsa, AstraZeneca, Acadia, and NIDDK; Dr Wetmore also reports payments from Vifor for presentations; participation in DSMB for CARSK and Vifor and advisory board for Aurinia and BMS-Pfizer Alliance. The remaining authors declare that they have no relevant financial interests.",
101,"C.F. and A.J.H. have received research funding and consultancy fees from Guanguong Shunde Innovative Design Institute, Guangdong, China. The other authors declare no conflicts of interest.",
102,"S.M. Bagshaw is supported by a Canada Research Chair in Critical Care Outcomes and Systems Evaluation; reports consultancy agreements with Baxter, BioPorto, and Novartis; reports research funding from Baxter; reports honoraria from Baxter; reports fees from Baxter for scientific advisory and speaking; reports fees from BioPorto for scientific advisory and clinical adjudication; reports fees from Novartis for scientific advisory; serves as an associate editor for <i>Critical Care</i> and a Data and Safety Monitoring Board (DSMB) member for the The Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis in COVID (I-SPY-COVID) trial; and serves on a speakers bureau for Baxter. M. Ostermann reports consultancy agreements with Biomerieux and NxStage; reports research funding from Baxter, Biomerieux, Fresenius Medical Care, and La Jolla Pharma; reports speaker honoraria from Baxter, Biomerieux, and Fresenius Medical; serves on the editorial boards of <i>Blood Purification</i>, <i>Critical Care</i>, <i>Intensive Care Medicine</i>, and <i>Nephrology Dialysis Transplantation</i>; and serves as a member of the Executive Committee of the European Society of Intensive Care Medicine and a member of the Executive Committee of the Intensive Care Society UK. R. Wald reports unrestricted research funding from Baxter and consulting fees from Lilly; serves on the editorial boards of <i>CJASN</i>, <i>Kidney360</i>, and <i>Kidney Medicine</i>; and is a contributor to UpToDate. All remaining authors have nothing to disclose.",
103,Disclosure. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.,No
104,"J. Coresh consultancy for Healthy.io and SomaLogic, ownership interest in Healthy.io, research funding from the National Institute of Health and National Kidney Foundation, and an advisory or leadership role for SomaLogic. M.W. Foster reports research funding from Biomilq, Circumvent Pharmaceuticals, and Oerth Bio. N. Franceschini reports advisory or leadership roles for Women's Health Initiative Chair of Ancillary Committee and Women's Health Initiative Publication and Presentation Committee. M.E. Grams reports advisory or leadership roles for the <i>American Journal of Kidney Diseases</i>, ASN Publication Committee, <i>CJASN</i>, <i>JASN</i> Editorial Fellowship Committee, KDIGO Executive Committee (co-chair elect), NKF Scientific Advisory Board, and USRDS Scientific Advisory Board; grant funding from NKF, which receives funding from multiple pharmaceutical companies; grant funding from NIH; payment from academic institutions for grand rounds; and payment from NephSAP. S. Liu reports consultancy for Novo Nordisk and TwinHealth. J.E. Manson reports research funding from Mars Edge. L.M. Raffield reports consultancy for TOPMed Administrative Coordinating Center (through Westat). M.J. Telen reports consultancy from Novartis and Pfizer, Inc.; research funding from BioMedomics, CSL Behring, NIH, Novartis, Novo Nordisk, and Pfizer; and honoraria from Novartis and Pfizer. All remaining authors have nothing to disclose.",
105,"G.J. Beck and M.K. Radeva report employment with Cleveland Clinic. S.A. Berceli reports research funding from Alucent Biomedical. A.K. Cheung reports employment with Veterans Affairs Salt Lake City Healthcare System; consultancy agreements with Boehringer-Ingelheim, Calliditas, and UptoDate; ownership interest in Merck; honoraria from Boehringer-Ingelheim and Calliditas; and royalties from UpToDate. J.J. Gassman reports employment with Cleveland Clinic, consultancy agreements with Baim Institute (formerly Harvard Clinical Research, Inc.), and honoraria from Baim Institute (Harvard Clinical Research Institute). Y. He reports research funding from Alucent Biomedical. P.B. Imrey reports employment with Cleveland Clinic Foundation; consultancy agreements with Colgate Palmolive; ownership interest in AT&T, American Electric Power, Avista, Chevron, Comcast, Constellation Energy, Duke Energy, Entergy, Exelon, Exxon Mobil, Idacorp, IBM, Kyndryl Holdings, Martin Marietta Materials, Northwest National Holding Company, Occidental Petroleum, Pacific Gas and Electric, Sempra, Southwest Gas Holdings, Teradata, Vulcan Materials, Warner Brothers Discovery, Wells Fargo, and Weyerhaeuser; and serving on the <i>American Journal of Nephrology</i> Editorial Board. P. Roy-Chaudhury reports employment with VAMC Salisbury, NC; consultancy agreements with Akebia, Bayer, BD-Bard, Cormedix, Humacyte, InRegen, Medtronic/Covidien, Reata, Vifor-Relypsa, and WL Gore; ownership interest as Chief Scientific Officer and Founder of Inovasc LLC; NIH small business grants as MPI or site PI with Adgero, Cylerus, Eko, and Inovasc; honoraria from Akebia, Bayer, BD-Bard, Chugai Pharmaceuticals, Cormedix, Humacyte, InRegen, Medtronic/Covidien, Reata, Vifor-Relypsa, and WL Gore; advisory or leadership roles for Akebia, ASN, Bayer, BD-Bard, Cardiorenal Society, Cormedix, Humacyte, InRegen, Medtronic/Covidien, Reata, Vascular Access Society of the America's, Vifor-Relypsa, and WL Gore; serving on the <i>Journal of Vascular Access</i> Editorial Board; discussions with Elucid Bio, Outset Medical, and Vasbio; and research contract while at University of Arizona with Kidney Research Institute, Seattle. Y. Shiu reports employment with VA Salt Lake City Health Care System. The remaining author has nothing to disclose.",
106,"J.B. Byrd reports consultancy for Nonin and PhaseBio; patents US15/611,427 Filing date: 2017-06-01—Legal status Pending; serving as an editorial board member of the <i>Journal of Clinical and Translational Endocrinology</i> (Elsevier) and an Associate Editor of the <i>Journal of Human Hypertension</i> (Springer-Nature) and an Associate Editor of <i>Hypertension Research</i> (Springer-Nature). J.B. Byrd has served on an advisory board for PhaseBio and is funded by the NIH and PCORI. D.H. Ellison reports employment with Portland VA Medical Center; honoraria from Renaissance School of Medicine, Boston University School of Medicine; royalties as an author for UpToDate; serving as Consulting Editor for <i>Hypertension</i>; and serving on the Editorial Boards of <i>American Journal of Physiology-Renal Physiology</i> and <i>JASN</i>. Y. He reports ownership interest in Ontmed, Inc.; serving as an advisory committee member of China Biomedical Ontology Consortium (<i>i.e.</i>, OntoChina) 2017–present, host and co-chair for ICBO 2022: International Conference on Biomedical Ontology, and 2020–2022 President elect of Overseas Chinese Society for Microbiology (Sino-Micro); and serving as an Associate Editor for <i>Frontier in Cellular and Infection Microbiology</i> and on the Editorial Board of <i>Scientific Data</i> (a Nature journal). S.S. Hong's spouse is a founder of ProtonBio, Inc.; spouse holds patents and have pending patents on chemical compounds that have potential to cure diseases and has received royalties from Partners Health, MGH, for licensed assets to Keros Therapeutics; spouse is a board member of American Heart Association of Greater Maryland and Baltimore, board of directors of Sarnoff Cardiovascular Research Foundation, and editorial board member of <i>Frontiers in Drug Discovery Journal</i>—he is not paid for these roles. S.L. Kane-Gill reports advisory or leadership roles for Executive Committee of Society of Critical Care Medicine and on the Editorial Board of <i>Annals of Pharmacotherapy</i> and <i>Critical Care Medicine</i> and grant funding from NIDDK. F. Liu reports ownership interest in Alibaba, Amazon, Apple, Costco, Palantir Technologies, and Robinhood. S.K. Mallipattu reports consultancy for L.E.K and Wildwood Therapeutics, Inc. Consulting; research funding from Dialysis Clinic Inc. and Spectral Medical Inc.; patents Krüppel-like factor 15 (KLF15) Small Molecule Agonists in Kidney Disease. US 63/018.247. April 30, 2021; and advisory or leadership role for Clinically Integrated Network, Board Member (Accountable Care Organization, LLC Stony Brook Medicine). R.A. Moffitt reports employment with Cold Spring Harbor Laboratories; consultancy for Data Driven Biosciences and Stottler Henke Associates; ownership interest in Aflac, Global Payments Inc; and patents or royalties from GeneCentric. C.R. Parikh reports consultancy for Genfit Biopharmaceutical Company and Novartis; is a member of the advisory board of and owns equity in RenalytixAI; reports research funding from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Heart, Lung and Blood Institute (NHLBI); and serves advisory or leadership roles for Genfit Biopharmaceutical Company and Renalytix. A. Sakhuja reports advisory or leadership role for Carolinas/Virginia's chapter of SCCM—unpaid and current funding from NIH/NIDDK 1K08DK131286-01A1 (PI: Ankit Sakhuja) and past funding from NIH/NIGMS 5U54GM104942 (PI: Sally Hodder). J.H. Saltz reports honoraria from Mark Foundation and Memorial Sloan Kettering and advisory or leadership roles for Morehouse School of Medicine and Mark Foundation—both are academic, neither are companies. R. Saran reports serving as an American Nephrologists of Indian Origin (ANIO) Steering Committee Member and World Federation of Non Communicable Diseases International Advisory Council member. R. Saran is PI on subcontract on a grant awarded to the National Kidney Foundation of Michigan (NKFM). S. Setoguchi reports consultancy for BMS, Medtronic, Merck Inc., Pfizer Inc., and Pfizer Japan; research funding from BMS, Daiichi Sankyo, Pfizer Inc., and Pfizer Japan; and serving on the Editorial Board for <i>Pharmacoepidemiology and Drug Safety</i>. L.A. Torre-Healy reports an advisory or leadership role for Latino Medical Student Association (unpaid). K.J. Wilkins reports employment with National Institute of Diabetes & Digestive & Kidney Diseases; advisory or leadership role for <i>International Journal of Obesity</i> editorial board (unpaid); and previously made commitments to involve members of kidney patient/advocacy organizations in kidney research conferences or technical expert panels: American Association of Kidney Patients (through Board member Jenny Kitsen), Renal Support Network (through President and Founder Lori Hartwell), and only correspondence with similar organizations or advocates within last 24 months for Voice of the Patient (through Kevin Fowler) and Hassanah Consulting (through Janice Tufte). Y.J. Yoo reports research funding from NIH. All remaining authors have nothing to disclose.",
107,"V. Audard reports consultancy for, honoraria from, and advisory or leadership roles on Advisory boards for Addmedica, Alnylam, AstraZeneca, Bayer, and Vifor pharma. J.J. Boffa reports consultancy for AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka, Travere, and Vifor pharma; honoraria from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Otsuka, and Vifor pharma; and advisory or leadership roles for AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka, Travere, and Vifor pharma. J. Chemouny reports consultancy for AstraZeneca. A. Devresse reports consultancy for and advisory or leadership roles for Alnylam Pharmaceuticals and Merck. S. Duquennoy reports employment with Fondation AUB SANTE. J.M. Halimi reports consultancy for Alexion, AstraZeneca, Bayer, Boehringer Ingelheim France, Servier, and Vifor Fresenius; research funding from AstraZeneca; and honoraria from Alexion, AstraZeneca, Bayer, Boehringer Ingelheim France, MSD, Sanofi, Servier, and Vifor. D. Joly reports honoraria from AstraZeneca and Bayer. A. Karras reports consultancy for Alnylam, GlaxoSmithKline, Novartis, Otsuka, Vifor; honoraria from AstraZeneca, Bohringer-Ingelheim, GlaxoSmithKline, Novartis, Otsuka, Pfizer, and Vifor; advisory or leadership roles for Novartis, Otsuka, and Vifor; and speakers bureau for AstraZeneca, Boehringer-Ingelheim, Otsuka, Pfizer, and Vifor. A. Mathian reports consultancy for AstraZeneca, GlaxoSmithKline, Novartis, and Otsuka; honoraria from AstraZeneca, GlaxoSmithKline, Novartis, and Otsuka; advisory or leadership role for AstraZeneca; and speakers bureau for AstraZeneca, GlaxoSmithKline, and Otsuka. L. Mercadal reports honoraria for Congress travel and hotel in France and reports advisory or leadership roles for nephrologie thérapeutique review board and Société francophone de néphrologie dialyse transplantation. J. Olagne reports serving on speakers bureau for GlaxoSmithKline. S. Palat reports employment with and advisory or leadership role for Janssen Cilag. E. Plaisier reports employment with AURA PARIS. O. Thaunat reports consultancy for AstraZeneca, Biotest, and Novartis; research funding from bioMérieux, BMS, and Immucor; honoraria from Astellas, Biotest, and Novartis; and advisory or leadership role for ESOT. E. Vilaine reports consultancy for and honoraria from AstraZeneca. All remaining authors have nothing to disclose.",
108,"Disclosure. The authors of this manuscript have conflicts of interest to disclose as described by the <i>American Journal of Transplantation</i>. MLF has received speaking honoraria from Veloxis Pharmaceuticals, Inc. The other authors have nothing to disclose.",
109,"P.P. Reese reports consultancy: VALHealth-identification of patients with CKD and behavior change strategies; ownership interest: various equities, but none specifically health-focused and none directly related to author's research; research funding: co-principal investigator for investigator-initiated and collaborative trials with funding and/or antiviral medication supplied by AbbVie, Gilead, and Merck paid to the University of Pennsylvania to support research on transplantation of HCV-infected organs into uninfected recipients, followed by antiviral treatment; honoraria: salary from the National Kidney Foundation for work as Associate Editor of the <i>American Journal of Kidney Diseases</i>; advisory or leadership role: unpaid ethics consultation to eGenesis, related to patient selection and education, unpaid DSMB service in two trials; and other interests or relationships: legal consultation for private defendants, in a setting where the plaintiffs requiring kidney disease care. D. Sawinski reports ownership interest: CareDx; research funding: National Institutes of Health; advisory or leadership role: <i>American Journal of Kidney Diseases</i>, <i>American Society of Transplantation Board of Directors</i>, <i>Clinical Transplantation</i>, Councilor at Large; and other interests or relationships: UNOS Kidney Committee member and Expert witness testimony. All remaining authors have nothing to disclose.",
110,"T. Lee reports consultancy: BD Bard Consultant, Boston Scientific, Venostent, Xeltis and advisory or leadership role: Associate Editor, <i>Kidney360</i>. G.R. Cutter reports consultancy: AI thera, AMO, Astra-Zeneca, Avexis, BMS/Celgene, CSL Behring, DSMB ApplThera, Horizon, Immunic, Karunar, Kezar, Mapi, Merck, Mitsubishi Tanabe, Novartis, Opko Biologics, Prothena, Reata, Regeneron, Sanofi-Aventis, Teva, University of Texas Southwestern, University of Pennsylvania, Visioneering Technologies, Inc.; ownership interest: Pythagoras, Inc. a private consulting company; advisory or leadership role: <i>JASN</i> Statistical editor, Multiple Sclerosis Journal Editorial board, Multiple Sclerosis and Related Diseases Editorial Board, Neurology Clinical Practice Contributing Statistical Editor; and other interests or relationships: Consulting or Advisory Boards: Alexion, Antisense Therapeutics, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Entelexo Biotherapeutics, Inc., Genentech, Genzyme, GW Pharmaceuticals, Hoya Corporation, Immunic, Immunosis Pty Ltd, Klein-Buendel Incorporated, Linical, Merck/Serono, Novartis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Roche, SAB Biotherapeutics. M. Allon is Editor-in-Chief, <i>Kidney360</i>. All remaining authors have nothing to disclose.",
111,"R. De Caterina reports fees, honoraria, and research funding from Amarin, Amgen, AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Guidotti, Menarini, Merck, Milestone, Novartis, Noventure, Portola, Roche, and Sanofi-Aventis; research funding from Amarin, Amgen, AstraZeneca, Bayer, BMS/Pfizer, Daiichi-Sankyo, Guidotti, Menarini, Merck, Milestone, Novartis, Noventure, Portola, Roche, and Sanofi-Aventis; fees and honoraria from Amarin, Amgen, AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Guidotti, Menarini, Merck, Milestone, Novartis, Noventure, Portola, Roche, and Sanofi-Aventis; and speaker fees from Amarin, Amgen, AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Guidotti, Menarini, Merck, Milestone, Novartis, Noventure, Portola, Roche, and Sanofi-Aventis. R. Giugliano reports consultancy for Artivion, Inc., Beckman Coulter, Daiichi Sankyo, Gilead, Inari, Inventiva, PhaseBio Pharmaceuticals, Samsung, and Sanofi Aventis; research funding from Amgen, Anthos Therapeutics, Daiichi Sankyo, and Ionis; and honoraria from Amgen, Daiichi Sankyo, Dr. Reddy's Laboratories, Medical Education Resources (MER), Menarini, SAJA Pharmaceuticals, Servier, and SUMMEET. J.-M. Halimi reports consultancy for Alexion, AstraZeneca, Bayer, Boehringer Ingelheim France, Servier, and Vifor Fresenius; research funding from AstraZeneca; and honoraria from Alexion, AstraZeneca, Bayer, Boehringer Ingelheim France, MSD, Sanofi, Servier, and Vifor. F. Mallamaci reports consultancy for Fresenius; honoraria from Fresenius; and advisory or leadership roles as Associate Editor <i>Clinical Kidney Journal</i>, Member of the Editorial Board of the <i>International Journal of Nephrology</i>, Member of the Editorial Board of <i>Turk Nefroloji</i>, the Official Journal of the Turkish Society of Nephrology, Past Editor-in-Chief of the <i>Journal of Nephrology</i>, and Theme Editor of <i>Nephrology Dialysis and Transplantation</i>. Because F. Mallamaci is an editor of the <i>Clinical Journal of the American Society of Nephrology</i>, she was not involved in the peer review process for this manuscript. Another editor oversaw the peer review and decision-making process for this manuscript. P. Rossignol reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, CinCor, Idorsia, KBP, Novo Nordisk, Sanofi, Sequana Medical, Servier, and Vifor; ownership interest in CardioRenal (stocks as a cofounder) and G3P (stock options); research funding from Relypsa Inc., a Vifor Pharma Group Company, and Vifor Fresenius Medical Care Renal Pharma; and patents or royalties as a CardioRenal cofounder, a company developing a home potassium self-monitoring device. P. Rossignol reports advisory or leadership role for ESH: “hypertension and the kidney” working group board member since 2016; KDIDO executive committee member since 2023; WG board member HFA, Cardio renal (2016–) and translational 2016–2020; WG board member Eurecam ERA-EDTA 2021–2023; and WG on biomarkers board member HFA, 2020–2022. P. Sarafidis reports consultancy for AstraZeneca, Bayer, Healthink, Innovis Pharma, Menarini, Primeview, and Recor Medical; research funding from AstraZeneca, Boehringer, Elpen Pharmaceuticals, and Servier; honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Genesis Pharma, Menarini, Peervoice, Sanofi, Springer, and Winmedica; advisory or leadership role as a Council Member of European Renal Association; and role on Editorial Boards for <i>American Journal of Nephrology</i>, <i>Hellenic Nephrology</i>, <i>Journal of Human Hypertension</i>, and <i>Nephrology Dialysis Transplantation</i>. F. Zannad reports consultancy for 89Bio, Applied Therapeutics, Bayer, BMS, Boehringer, Cardior, Cellprothera, Cereno pharmaceutical, CEVA, CVRx, KBP, Merck, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, Roche Diagnostics, Servier, and US2.AI; ownership interest in CardioRenal, Cereno, CVCT, and Eshmoun; honoraria from Applied Therapeutics, Bayer, BMS, Boehringer, Cardior, Cellprothera, Cereno pharmaceutical, CEVA, CVRx, KPB, Merck, Novartis, Novo Nordisk, Roche Diagnostics, and Servier; advisory or leadership roles for 89Bio, Applied Therapeutics, Bayer, BMS, Boehringer, Cardior, Cellprothera, Cereno pharmaceutical, CEVA, CVRx, KPB, Merck, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, Roche Diagnostics, Servier, and US2.AI; and speakers bureau for Bayer and Boehringer Ingelheim. C. Zoccali reports a consultancy agreement with Fresenius Medical Care, Europe.",
112,"J.S.M. has honoraria from One Lambda, Inc, and has a family member who is employed by and has an equity interest in Genentech/Roche. J.S.M. is also a member of the scientific advisory board for Qihan. J.C.T. has a family member who is employed by and has an equity interest in Genentech/Roche. The other author declares no conflicts of interest.",
113,"P.J.K. reports having received payments from CareDx and Natera for consulting and working at an institution that received research payments from CareDx and Natera. Neither CareDx nor Natera were involved in the conceptualization of the study, data collection and analysis, manuscript preparation, and editing of the final article.",
114,"C.T. Chan reports consultancy for Dialco, Medtronic, and Quanta; research funding from Medtronic through their external grant program; advisory or leadership roles for DaVita, Medtronic, and Quanta; and role as an Associate Editor of <i>CJASN</i>. K. Colwill reports an advisory or leadership role for Canadian National Proteomics Network—Board of Directors and VP of Communications (unpaid). K. Colwill's spouse reports employment with CI Investments. A.-C. Gingras reports consultancy for 908Devices—instrumentation for mass spectrometry/ paid; research funds from a research contract with Providence Therapeutics Holdings, Inc. (vaccine company) for other projects; no honorarium from companies, but honoraria from public organizations, including granting agencies (compensation for grant reviews), the American Society for Biochemistry and Molecular Biology, and the European Research Council; advisory or leadership roles as an advisor for the journals <i>Molecular Cell</i> and <i>Molecular Systems Biology</i> and Deputy Editor for <i>Molecular & Cellular Proteomics</i>, role on the COVID-19 Immunity Task Force Immune Science and Testing working party, and role on the SABs of several international large grants (NIH P41, Horizon 2020). A.-C. Gingras chaired the Canadian Institutes of Health Research (CIHR) Institute of Genetics Advisory Board (to 2022), chairs the SAB of the National Research Council of Canada (NRC) Human Health Therapeutics Board, and is also the lead for the Functional Genomics pillar of CoVaRR-Net. M.A. Hladunewich reports research funding from Calliditas Therapeutics, Chinook Pharmaceuticals for studies in immunoglobulin A nephropathy, Ionis, Pfizer for a study in focal segmental glomerulosclerosis, and Roche for a preeclampsia study; honoraria from UpToDate; and other interests or relationships as Medical Lead for Glomerular Disease Ontario Renal Network. J.A. Leis has received payment for expert testimony upon request of hospitals of Ontario Hospital Association, the Ministry of Attorney General of Ontario, and Seneca College. A. Levin reports employment with BC Provincial Renal Agency and Providence Health Care; consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, Chinook Therapeutics, GSK, Janssen, Kidney Foundation of Canada, NIH, Occuryx/Certa, Otsuka, and Reata; research funding from AstraZeneca, Boehringer Ingelheim, Canadian Institute of Health Research (CIHR), CITF (Canadian Immunology Task Force), GSK, Health Research BC, Kidney Foundation of Canada, MOH BC, and Shared Care BC; honoraria from AstraZeneca, Bayer, GSK, Janssen, and NIH; advisory or leadership roles for AstraZeneca, Boehringer Ingelheim, CADTH, Chinook Therapeutics, CITF, GSK, KRESCENT (Kidney Research Scientist Core Education and National Training Program), NIDDK, Reata BC Renal (Exec Director), and Steering Committee Chair CURE Consortium; DSMB for NIDDK, Kidney Precision Medicine, U Washington Kidney Research Institute Scientific Advisory Committee; co-lead of Long Covid Web Grant; International Society of Nephrology Research Committee; and PI of CanSOLVE CKD; and other interests or relationships as CREDENCE National Coordinator from Janssen—directed to her academic team, Executive Steering Committee AstraZeneca Clinical Trial, the Canadian Society of Nephrology, the DSMB Chair RESOLVE Trial (Australian Clinical Trial Network) ASPIRE Trial (ACTN), the International Society of Nephrology, the Kidney Foundation of Canada Steering Committee ALIGN trial, and the NIDDK CURE Chair Steering Committee. M.J. Oliver reports reports ownership interest in and is the sole owner of Oliver Medical Management Inc., which is a private corporation that licenses the Dialysis Measurement Analysis and Reporting (DMAR) software system. Oliver Medical Management Inc. is co-owner of a Canadian Patent for DMAR systems. M.J. Oliver reports honoraria from Baxter Healthcare and other interests or relationships with Ontario Health and as contracted Medical Lead at Ontario Renal Network. All remaining authors have nothing to disclose.",
115,"B.D. Humphreys reports Consultancy: Chinook Therapeutics, Janssen, Pfizer; Ownership Interest: Chinook Therapeutics; Research Funding: Janssen, Pfizer; Honoraria: Novartis; Patents or Royalties: AG, Evotec; and Advisory or Leadership Role: <i>Seminars in Nephrology</i>: Editorial Board, <i>Kidney International</i>: Editorial Board, <i>JCI Insight</i>: Editorial Board, <i>American Journal of Physiology Renal Physiology</i>, Editorial Board, RegMed XB, Regenerative Medicine Crossing Borders: SAB, ASCI: President, Chinook Therapeutics, SAB, Member of Board of Scientific Advisors of NIDDK. J.H. Miner reports Consultancy: Bayer, Guidepoint; Research Funding: Chinook Therapeutics, Keros Therapeutics, Lung Therapeutics Inc, Myonid Therapeutics; Honoraria: AstraZeneca, Axiom Healthcare Strategies, Pfizer, Visterra; Patents or Royalties: Elsevier; Kerafast; Maze Therapeutics; Advisory or Leadership Role: American Society for Matrix Biology, President; <i>Journal of Clinical Investigation</i>, Consulting Editor; <i>Kidney International</i>, Editorial Board; Matrix Biology, Editorial Board; Matrix Biology Plus, Editorial Board; and Other Interests or Relationships: Alport Syndrome Foundation (Scientific Advisory Research Network). All remaining authors have nothing to disclose.",
116,"R.R. Quinn is coinventor and coowner of intellectual property associate with the Dialysis Measurement Analysis and Reporting (DMAR) System and reports consultancy for Baxter Corporation, research funding from ISPD PD Catheter Registry (Baxter partially funding project), honoraria from Baxter (PD University) and Baxter Advisory Board, speaker fees from Baxter Corporation, and Canadian patent for Dialysis Measurement, Analysis, and Reporting (DMAR) System. The remaining author has nothing to disclose.",
117,"C. Colón-Emeric reports consultancy for Amgen and Novartis, research funding from UCB, co-inventor 2 use patents for bisphonate indication in cardiovascular diseases, and advisory or leadership roles for Amgen and Novartis. L.J. Fish reports advisory or leadership role as Board President of Be the Village. R.K. Hall reports consultancy for Bayer, Chinook, Goldfinch, Inside Edge, Otsuka, Reata Pharmaceuticals, Third Bridge, Travere Pharmaceuticals, and United Health Group; ownership interest in Pfizer and Vertez; advisory or leadership role for the <i>CJASN</i> Editorial Board, <i>Journal of American Geriatrics Society</i> Editorial Board, <i>Kidney360</i>, and <i>Pediatric Nephrology;</i> speakers bureau for Inside Edge and Otsuka; and other interests or relationships as owner of Internal Shifts Coaching LLC. A. Lucas reports an advisory or leadership role for American Kidney Fund Medical Advisory Committee. W. St. Peter reports the consultancy for CSL-Vifor Pharma, GSK, and Total Renal Care, Inc.; honoraria from American Nephrology Nursing Association, Integritas Group, Letters and Sciences, and OptumLabs; advisory or leadership role as Scientific Advisory Board Member for National Kidney Foundation; and other interests or relationships with Centers for Medicare and Medicaid Services Technical Expert Panel on Development of a Quality Measure Assessing Delay in Progression of Chronic Kidney Disease (CKD), NKF and ASN Task Force on eGFR and Race, and Technical Expert Panel for Quality Insights Kidney Care Pilot project. J. St. Clair Russell reports consultancy for AdheaRx and Renalytix. J. Rutledge reports research funding from NephroNet, Inc. and Vifor Pharma, Inc. The remaining author has nothing to disclose.",
118,"E.F. Barreto reports employment with Mayo Clinic, research funding from AHRQ and NIAID, honoraria from Vifor Pharma, and advisory or leadership roles for FAST Biomedical advisory board (paid as needed for consulting services) and Wolters Kluwer (paid as needed for consulting services). A.H. Flannery reports consultancy agreements with and research funding from La Jolla Pharmaceutical Company. The remaining author has nothing to disclose.",
119,J.B.W. is a noninventive contributor to the development and validation of a diagnostic method for quantification of donor-derived cell-free DNA (WO/2013/049892). The other authors declare no conflicts of interest.,
120,"S.M. Boyle serves as a training program director. A.M. Burgner serves as a nephrology training program director. S.M. Halbach reports consultancy for Worldwide Clinical Trials and other interests or relationships with UpToDate. K. Jain serves as a nephrology training program director, serves as principal site investigator for the FSGSALLAGE (NCT04065438) and FSGS Pediatric (NCT02235857) clinical trials, and reports research funding from Visterra as PI for IgA trial (past) and from Kaneka as PI for liposorber study. K.A. Pivert is an employee of the American Society of Nephrology. D.K. Weidemann serves as an associate training program director and reports consultancy for UpToDate and role as an American Board of Pediatrics Pediatric Nephrology Sub-Board member (paid an annual honorarium of $3000 for volunteering to serve on the board and write/edit questions).",
121,"D.E. Wesson is Clinical Deputy Editor of <i>JASN</i> and is a paid consultant of the not-for-profit Texas Kidney Foundation. D.E. Wesson also reports Consultancy: Tricida, Inc., until January 31, 2023; Research Funding: Tricida, Inc., (South San Francisco, CA); Honoraria: Brigham and Women's Hospital, Medscape, The Methodist Hospital (Houston), UCLA Medical Center, University of Buffalo Medical School, University of Rochester School of Medicine, and University of Southern California Medical Center; Advisory or Leadership Role: <i>American Journal of Nephrology</i> Editorial Board, <i>CJASN</i> Editorial Board, <i>JASN</i>, <i>Journal of Renal Nutrition</i> Editorial Board, <i>Kidney International</i> Editorial Board, and Tricida Scientific Steering Committee (ending 01-31-23).",
122,"G.B. Appel reports Consultancy: Achillion, Alexion, Apellis, Arrowhead, Aurinia, Bristol Myers Squibb, Chemocentryx, Chinook, EMD Serono, Genentech, Genzyme-Sanofi, Glaxo-Smith-Kline, E. Lilly, Merck, Mallinkrodt, Novartis, Omeros, Pfizer, Reata, Travere therapeutics, and Vertex therapeutics; Research Funding: achillion-alexion, Apellis, Chemocentryx, Equillium, Genentech-Roche, Goldfinch, Mallinkrodt, Novartis, Reata, and Sanofi-Genzyme; Honoraria: Aurinia and Glaxo Smith Kline; Patents or Royalties: UpToDate; Advisory or Leadership Role: UpToDate—Editorial Board, Med Advisory board for Alexion, Alexion-Achillion, Apellis, Arrowhead, Aurinia, BM Squib, Chinook, Genentech, Glaxo-Smith-Kline, Lilly, Reata, Roche, and Sanofi; and Speakers Bureau: Aurinia—lectures on Lupus Nephritis and GSK—lectures on Lupus Nephritis. T.M. Chan reports Consultancy: GSK and Novartis; Research Funding: Astellas Pharma Inc, Baxter; and Honoraria: Visterra. F. Fervenza reports Consultancy: Alexion Pharmaceuticals, ByoCrystal, Galapagos, GSK, Novartis, Otsuka, and Takeda; Research Funding: Chemocentryx, Genentech, Hoffman La Roche, Janssen Pharmaceutical, Morphosys, and Retrophin; Honoraria: UpToDate; and Advisory or Leadership Role: Kidney International, Nephrology, UpToDate; Nephrology Dialysis and Transplantation, Journal of the American Society of Nephrology. J. Floege received lecture and consultancy honoraria from Alnylam, Amgen, Astellas, AstraZeneca, Bayer, Boehringer, Calliditas, Novartis, Omeros, and Travere and is a member of data safety monitoring board for Novo Nordisk and Visterra. J. Floege reports Consultancy: Amgen, AstraZeneca, Bayer, Boehringer, Calliditas, Chinook, Novo Nordisk, Novartis, Omeros, Travere, Vifor, and Visterra; Honoraria: Amgen, AstraZeneca, Bayer, Boehringer, Calliditas, Chinook, Novo Nordisk, Novartis, Omeros, Travere, Vifor, and Visterra; Advisory or Leadership Role: Calliditas, Omeros, and Travere; and Speakers Bureau: Amgen, AstraZeneca, Novartis, and Vifor. T. Greene reports grant support from Durect Corporation, Janssen Pharmaceuticals, Pfizer statistical consulting AstraZeneca, Boehringer-Ingleheim, and CSL. T. Greene reports Consultancy: AstraZeneca, Invokana, Janssen Pharmaceuticals, Novartis, and Pfizer Inc; and Research Funding: AstraZeneca, Boehringer-Ingleheim, CSL, and Vertex. B. Haaland reports Consultancy: AstraZeneca, Guidepoint Global, National Kidney Foundation, Prometic Life Sciences, and Value Analytics Labs; and Ownership Interest: ABR, AGNC, AQN, ARLP, BCS, BHP, DOW, DVN, ENB, EPD, ET, GOOD, GSK, Haaland Consulting, IBM, IEP, KMI, LLC, MMP, MPLX, MPW, NLY, OCSL, OHI, PBR, PFE, PFLT, RIO, SBRA, SQM, T, TD, UTG, VALE, VICI, VOD, VZ, WBA, WPC, and ZIM. H.J.L. Heerspink is consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli-Lilly, Gilead, GoldFinch, Janssen, Merck, Novo Nordisk, and Travere Pharmaceuticals. H.J.L. Heerspink also reports Research Funding: AstraZeneca, Novo Nordisk, and Janssen research support (grant funding directed to employer); Honoraria: Lecture fees from AstraZeneca; and Speakers Bureau: AstraZeneca. E. Imai received research funding and honorarium for lecture from AstraZeneca, Boehringer Ingelheim, Daiich Sankyo, Kyowa Kirin, Novo, and Tanabe Mitsubishi. E. Imai also reports Honoraria: Eli-Lilly and Ono. L.A. Inker reports Consultancy: Diamtrix; Research Funding: funding to institute for research and contracts with the Chinnocks, National Institutes of Health, National Kidney Foundation, and Omeros and Reata Pharmaceuticals; consulting agreements with Tricida Inc.; Advisory or Leadership Role: Alport Foundation—Medical Advisory Council, NKF—Scientific Advisory Board; and Other Interests or Relationships: American Society of Nephrology member and National Kidney Foundation member. J.B. Lewis is consultant for BIOVIE, CSL, NIH Nations Study, REPRIEVE, TEUCER, treasurer and board member of the CSG, and Chair of FDA Cardiorenal Advisory Committee. J.B. Lewis also reports Consultancy: Veno Stent; Ownership Interest: circle medical management a dialysis company; and Honoraria: CSL bering, BIOVIE. P.K.T. Li received speaker honorarium from AstraZeneca, Baxter, and FibroGen. P.K.T. Li also reports Speaker Honoraria for Kyowa—Kirin; Advisory or Leadership Role: KI and PDI; and Other Interests or Relationships: President of International Association of Chinese Nephrologists. F. Locatelli is/was a member of an advisory board of Akebia, Amgen, Astellas, AstraZeneca, Baxter, GSK, Otsuka, Roche, Travere Pharmaceuticals, and Vifor Pharma and was a speaker at meetings supported by unrestricted grants from Amgen, Astellas, Roche, and Vifor Pharma. F. Locatelli reports Consultancy: Amgen, Asyellas, Baxter, GSK, Travere, and Vifor; Advisory or Leadership Role: Accelsior, Amgen, Astellas, AstraZeneca, GSK, Norgine, Otsuca Roche, Travere, and Vifor Pharma; Speakers Bureau: Amgen and Astellas; and Other Interests or Relationships: DOPPS, ERA, KDIGO, and SIN. B.D. Maes reports Consultancy: AstraZeneca, GSK, Novartis, Travere, Vera Therapeutics and Advisory or Leadership Role: GSK and Novartis. R.D. Perrone received research support from Kadmon, Otsuka, Reata, Sanofi Genzyme, and the US Department of Defense (TAME PKD); has been a member of steering committees for Otsuka, Sanofi Genzyme, and TAME PKD with fees paid to employing institutions; and has provided consultancy for Navitor, Otsuka, Palladiobio, and Reata. R.D. Perrone also reports Consultancy: Caraway, Janssen, and Sanofi-Genzyme; Research Funding: Palladiobio and Reata; Honoraria: Otsuka, Reata, and Sanofi-Genzyme; Advisory or Leadership Role: PalladioBio; and Other Interests or Relationships: UpToDate; PKD Foundation, Critical Path Institute. M. Praga is consultant for Alexion, Apellis, Aurinia, GlaxoSmithKline, Novartis, Otsuka, Roche-Genetech, Silence, and Travere. M. Praga also reports Consultancy: AstraZeneca, Silence, and Vifor; and Honoraria: Alexion, GSK, Novartis, Otsuka, Travere, Vand ifor. F.P. Schena reports grants from Puglia Region and from the Italian Ministry of University. F.P. Schena reports Research Funding: Puglia Region in Italy, Ministry of University in Rome Italy, and Ministry of Health in Rome Italy. C. Wanner received speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Ely-Lilly, and FMC and was a member of an advisory board of Bayer, Boehringer Ingelheim, Gilead, GSK, MSD, and Sanofi Genzyme. C. Wanner also reports Consultancy: Akebia, Bayer, Boehringer-Ingelheim, Gilead, GSK, MSD, Sanofi, Triceda, and Vifor; Research Funding: Sanofi grant to institution and Idorsia grant to institution; Honoraria: Amgen, Astellas, Chiesi, Sanofi, and Takeda; Advisory or Leadership Role: President European Renal Association (ERA); and Other Interests or Relationships: European Renal Association (ERA). D. Xie reports Other Interests or Relationships: ISN member. All remaining authors have nothing to disclose.",
123,"V. Gunabushanam reports that his spouse is employed by Fitch Ratings. S. Hariharan reports being the owner of Transplant Interface, LLC. C. Puttarajappa reports research funding from NIH (NIDDK) and that his spouse is a site Primary Investigator for contracted clinical research with Abeona/Ultragenyx, Denali, Regenxbio, and Shire. S. Mohan reports consultancy for Angion Biomedica, eGenesis, and HSAG; an advisory or leadership role for ASN Quality Committee (member), ETCLC (National Faculty Chair), Kidney International Reports (ISN; deputy editor), SRTR Review Committee (member), and UNOS data advisory committee (vice chair); and research funding from NIH (NIDDK, NIHMD and NIBIB) and the Kidney Transplant Collaborative. All remaining authors have nothing to disclose.",
124,"F.T. has served as a consultant for Bayer, Ipsen, and Eisai and an advisory board member for Laforce. M.I.: speaking/teaching, consultant, and the advisory board for Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, Guerbet, and EISAI. M.D.G. received honoraria for serving on advisory boards for Eisai and Bayer. F.T. is an advisor and a consultant for Bayer and an advisory board member for Sirtex, Alfasigma, and Bristol-Myers Squibb. F.P. is a consultant for AstraZeneca, Bayer AG, EISAI, GE, and Tiziana Life Sciences; Speaker bureau honoraria: Bayer AG, Bracco, EISAI, and Laforce; research contract with Esaote. A.G. has served as a consultant for Bayer. The other authors declare no conflicts of interest.",
125,The authors declare no competing interests.,No
126,"P.F.H. has shares in Transcriptome Sciences Inc (TSI), a University of Alberta research company with an interest in molecular diagnostics. The other authors declare no conflicts of interest.",
127,"S.N. Babayev reports ownership interest in McKesson, honoraria from Medscape, and advisory or leadership role for Flo Health, Inc. E.M. Bendel-Stenzel reports research funding from Aerogen Pharma Corporation. F.T. Chebib reports research funding from research grant Otsuka pharmaceuticals, patents or royalties from Patent no US20200368191A1, and advisory or leadership role for PKD foundation Chair of Education Advisory Panel. N.K. Dahl reports consultancy agreements with Otsuka Pharmaceuticals; research funding as a PI for clinical trials sponsored by Janssen, Reata, and Vertex; honoraria from Natera and Otsuka Pharmaceutical; advisory or leadership role for Natera Scientific Advisory Board and PKD Foundation; speakers bureau for Otsuka until December 2022; and other interests or relationships include Medical Advisory Board NKF NE Chapter. P.C. Harris reports consultancy agreements with CorrectorBio, Janssen, Maze Therapeutics, Mitobridge, Otsuka, Regulus, Sen Therapeutics, and Vertex; research funding from Acceleron, Espervita, Jemincare, and Navitor; and patents or royalties from Bayer, Calico Life Sciences, Maze Therapeutics, Mitobridge, Sanofi, and Vertex. V.E. Torres reports consultancy agreement with Blueprint Medicines, Crinetics, Johnson & Johnson, Mironid, Otsuka Pharmaceuticals, Palladio, Reata, Regulus, Sanofi, Sanofi Genzyme, and Tribune Therapeutics (all payments to the Mayo Foundation); and research funding from Mironid, Otsuka Pharmaceuticals, Palladio Biosciences, Reata, Regulus, Sanofi Genzyme, and Tribune Therapeutics (all payments to the Mayo Foundation). M.J. Wick reports advisory or leadership role on Board of Directors American Board of Medical Genetics and Genomics. All remaining authors have nothing to disclose.",
128,"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Michael Green Consultant ITB-MED : DSMB member for siplizumab for induction in adult KTx Consultant for BMS: DSMB member for belatacept as rescue therapy in adolescent KTx recipients Member Adjudication committee for Allovir: assessment of response to CTL therapy for Adenovirus infection in pediatric stem cell transplant recipients. Masayoshi Shinjoh Outside this study, M.S. has received speaking honoraria from Meiji Seika Pharma Co., Ltd., Shionogi & Co., Ltd., MSD KK, FUJIREBIO Inc., Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd., The Mainichi Newspapers Co., Ltd., Maruho Co., Ltd., Astellas Pharma Inc., Sumitomo Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., and Japan Vaccine, and grant support from JSPS KAKENHI, Japan (Grant Number JP20K10546, 2020-2022), none of which was in connection with the work presented here. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.",
129,"The Susztak lab is supported by Bayer, Boehringer Ingelheim, Gilead, GSK, Jnana, Maze, Novartis, Novo Nordisk, and Regeneron for work that is unrelated to the current manuscript. K. Susztak reports Consultancy: AstraZeneca, Bayer, GSK, Jnana, Maze, Novo Nordisk, Pfizer, and Ventus; Ownership Interest: Jnana; Research Funding: Bayer, Boehringer Ingelheim, Calico, Gilead, GSK, Jnana, Lilly, Maze, Merck, Novartis, Novo Nordisk, and Regeneron; Honoraria: AstraZeneca, Bayer, Jnana, Maze, and Pfizer; and Advisory or Leadership Role: Editorial boards of <i>Kidney International</i>, <i>Journal of Clinical Investigation</i>, <i>Cell Metabolism</i>, <i>Medicine</i>, <i>eBioMedicine</i>, <i>Journal of the American Society of Nephrology</i>, and Jnana. Because K. Susztak is an Associate Editor of the <i>Journal of the American Society of Nephrology</i>; she was not involved in the peer review process for this manuscript. Another editor oversaw the peer review and decision-making process for this manuscript. All remaining authors have nothing to disclose.",
130,P. Xu reports Patents or Royalties: Beijing Proteome Research Center. All remaining authors have nothing to disclose.,
131,"A.S. De Vriese is scientific advisor/consultancy for Bluestar Bioadvisors, Confo Therapeutics, Goldfinch Bio, Liberum, Nipro Digital Technologies, Novartis, Pfizer, Vifor Pharma, and Xeltis; Research Funding: Amgen, Kaydence Pharma, and Nattopharma; and Speakers Bureau: Vifor Pharma. K. El Karoui is scientific advisor for Vifor Pharma and has received consulting fees from Alexion, Astra Zeneca, and Vifor Pharma; and Honoraria: Alexion, AstraZeneca, Otsuka, and Vifor Pharma. F.C. Fervenza has received unrestricted research grants from Genentech/Roche, Janssen Pharmaceuticals, and Travere, Morphosys AG; consulting fees from Alexion Pharmaceuticals, BioCryst, ChemoCentryx, Galapagos, GSK, Morphosys AG, Novartis, Otsuka Pharmaceuticals, Takeda, Travere, and Zyversa Therapeutics; Research Funding: Chemocentryx, Genentech/Roche, and Retrophin, Honoraria: UpToDate; and Advisory or Leadership Role: <i>JASN</i>, <i>Kidney International</i>, <i>Nephrology</i>, <i>Nephrology Dialysis Transplantation</i>, and UpToDate.",
132,"G.P. Hess reports employment with SomaLogic; consultancy agreements with Flexion Therapeutics; ownership interest in SomaLogic; research funding from Vertex, Inc.; serving as an American Society of Clinical Oncology Physician Advisory Board Member and Chair of Precision Medicine Advisory Council SomaLogic; and serving in advisory or leadership role for Millennium Health Clinical Excellence Committee and Neogenomics Scientific Advisory Board. C. Joseph reports consultancy agreements with and ownership interest in Takeda Pharmaceuticals. K.L. Lentine reports consultancy agreements with CareDx, Inc., ownership interest in CareDx, Inc., and speaker honoraria from Sanofi. B.E. Lonze reports research funding from AbbVie, CareDx, and Hansa; honoraria from Physicians' Education Resource, LLC (PER); and advisory or leadership roles for AlloVir, Argenx, and Hansa. M. McAdams-DeMarco reports honoraria from UpToDate. M. Schnitzler reports consultancy agreements with CareDx and honoraria from OPTUM. D.L. Segev reports consultancy agreements with AstraZeneca, Bridge to Life, CareDx, CSL Behring, Jazz Pharmaceuticals, Kamada, Mallinckrodt, MediGO, Novartis, Novavax, Regeneron, Sanofi, Takeda, Thermo Fisher Scientific, Transmedics, and Veloxis; honoraria from AstraZeneca, CareDx, and Sanofi; speaking honoraria from CSL Behring, Novartis, and Sanofi; and serving as Editor-in-Chief of <i>Current Transplant Reports</i>. The remaining authors have nothing to disclose.",
133,Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.,No
134,"During the past 3 years, L.M. Dember has received compensation from the National Kidney Foundation for her role as Deputy Editor of the <i>American Journal of Kidney Diseases</i>; compensation for serving on Data and Safety Monitoring Boards for the National Institute of Diabetes and Digestive and Kidney Diseases, CSL Behring, and Vertex Pharmaceuticals; consultancy for AstraZeneca, Cara Therapeutics, CSL Behring, Merck, and Vertex; and research funding from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Kyowa Kirin, Novo Nordisk, and Regeneron. L.M. Dember's spouse reports consultancy for Actelion, Alexion, Bristol Myers Squibb, ChemCentryx, Genentech/Roche, Genzyme/Sanofi, and GlaxoSmithKline; stock options from Kyverna; research funding from Actelion, Bristol Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, and GlaxoSmithKline; and compensation as author and section editor for UpToDate. J.H. Ng reports employment with Northwell Health; consultancy for Vifor Pharmaceuticals; ownership interest in PublishedMD Consulting LLC; research funding from NIH/NIDDK (award number: 1K23DK132459-01); roles as Editorial Board Member of ASN Kidney News (unpaid) and Editorial Board Member of <i>Advances in Chronic Kidney Disease</i> (unpaid); and other interests or relationships as founder of PublishedMD Consulting LLC. W. Yang reports currently serving as a statistical editor for the <i>American Journal of Kidney Diseases</i>.",
135,"G.B. Appel reports consultancy for Achillion, Alexion, Apellis, Arrowhead, Aurinia, Bristol Myers Squibb, Chemocentryx, Chinook, EMD Serono, Genentech, Genzyme-Sanofi, GlaxoSmithKline, E. Lilly, Mallinkrodt, Merck, Novartis, Omeros, Pfizer, Reata, Travere Therapeutics, and Vertex Therapeutics; research funding from Achillion-Alexion, Apellis, Calliditas, Chemocentryx, Equillium, Genentech-Roche, Goldfinch, Mallinkrodt, Novartis, Reata, Sanofi-Genzyme, and Vertex—all through Columbia University; honoraria from Aurinia, Calliditas, and GlaxoSmithKline; royalties from UpToDate; advisory or leadership roles for UpToDate Editorial Board and Med Advisory board for Alexion, Alexion-Achillion, Apellis, Arrowhead, Aurinia, BM Squib, Chinook, Genentech, GlaxoSmithKline, Lilly, Reata, Roche, and Sanofi—no role as officer or board member of any pharmaceutical or other; and speakers bureau for Aurinia lectures on lupus nephritis, for GSK for lectures on lupus nephritis, and Calliditas for lecture on the gut and IgAN. N. Aslam reports ownership interest in Doximity; research funding from AstraZeneca, Baxter, Idorsia, Novartis, and Otsuka; and advisory or leadership roles for Chinook Advisory Board, Florida Society of Nephrology Board of Directors, and Travere Therapeutics Advisory Board. S.J. Barbour reports consultancy for Achillion, Alexion, Eledon, HIBio, Inception Sciences, Novartis, Pfizer, Vera, and Visterra; research funding from Alexion, Novartis, and Roche; and honoraria from Alexion and Roche. D.C. Cattran reports consultancy for Alexi, Alnylam, Aurinia, Calliditis, Chemocentrx, Chinook Therapeutics, Forsee, Horizon, Reistone, Vera Therapeutics, and Zyversa Therapeutics; research funding from Alnylam; honoraria from Alexion, Calliditis, and Kyowa Hakko Kirin Co; advisory or leadership roles for Alnylam, Calliditis, NephCure, SONG-GD, UpToDate, and Vera; and other interests or relationships with Aurinea, Dimerix, Novartis, and Vera Therapeutics. F.C. Fervenza reports employment with Mayo Clinic; consultancy for Alexion Pharmaceuticals, ByoCrystal, Galapagos, GSK, Novartis, Otsuka, and Takeda; research funding from Chemocentryx, Genentech, Hoffman La Roche, Janssen Pharmaceutical, Morphosys, and Retrophin; honoraria from UpToDate; and advisory or leadership roles for <i>JASN</i>, <i>Kidney International</i>, <i>Nephrology</i>, <i>Nephrology Dialysis and Transplantation</i>, and UpToDate. M.A. Hladunewich reports research funding from Calliditas Therapeutics, Chemocentryx, Chinook, Ionis, Pfizer, and Roche; honoraria from UpToDate; and other interests or relationships as medical lead for the Glomerular Disease Ontario Renal Network. D. Induruwage reports employment with the BC Provincial Renal Agency. K. Kiryluk reports consultancy for Calvariate and HiBio and research funding from Aevi Genomics, AstraZeneca, Bioporto, Vanda, and Visterra. R. Lafayette reports consultancy for Alexion, Inc., Aurinia, Calliditas, Inc., Chinook, Inc., Novartis, Omeros, Inc., Otsuka, Inc., Travere, Inc., Vera, Inc., and Visterra, Inc. and research funding from Apellis, Calliditas, Chemocentryx, Chinook, NIH, Omeros, Otsuka, Pfizer, Roche, Travere, and Vera. H.N. Reich reports consultancy for Calliditas, Chinook, Novartis, Omeros, Pfizer, and Retrophin (Travere); research funding from clinical trial recruitment: Alnylam, Calliditas, Chemocentryx, Omeros, and Pfizer and national coordinating investigator: Calliditas and Chinook; advisory or leadership roles for Academic advisory—Omeros, Academic leadership committee—Calliditas, Calliditas, Chinook, and <i>Kidney International</i> Editorial Board, and Steering Committee—Eledon; peer-reviewed funding from the Kidney Foundation of Canada; other interests or relationships with Canadian Institutes for Health Research and Pearson Foundation; fellowship support from the Fast Foundation; and consultation for the Canadian Agency for Drugs and Technologies in Health. B. Rovin reports consultancy for Alexion, AstraZeneca, Aurinia, Biocryst, Biogen, BMS, Calliditas, Chemocentryx, Corrona, EMD-Serono/Merck, Exagen, Galapagos, Genentech, Horizon, Human Genome Sciences (GSK), Idorsia, Janssen, Morphosys, MedImmune, Novartis, Omeros, Otsuka, Resonance, Retrophin, RILITE Foundation, Roche, and Vistera; research funding from Biogen; honoraria from Alexion, AstraZeneca, Aurinia, Biocryst, Biogen, BMS, Calliditas, Chemocentryx, Corrona, EMD-Serono/Merck, Exagen, Galapagos, Genentech, Horizon, Human Genome Sciences (GSK), Idorsia, Janssen, MedImmune, Morphosys, Novartis, Omeros, Otsuka, Resonance, Retrophin, RILITE Foundation, Roche, and Vistera; advisory or leadership roles for ASN Kidney Week, CureGN, KDIGO, <i>Kidney International</i>, <i>Kidney International Reports</i>, Lupus Foundation of America, <i>Nephrology Dialysis and Transplantation</i>, and UpToDate; a lot of work with the ASN, mostly educational courses; work with the NKF and the ISN; and work with the LFA. L. Zand reports employment with Mayo Clinic, Rochester, MN, and research funding from Genentech, Janssen Pharmaceuticals, and Mallinckrodt. All remaining authors have nothing to disclose.",
136,"R. Wald reports Research Funding: Baxter; Advisory or Leadership Role: Editorial Board, <i>Clinical Journal of the American Society of Nephrology</i>, <i>Kidney Medicine</i>, <i>Kidney360</i>; and Other Interests or Relationships: Contributor, UpToDate. A. Akbari reports Consultancy: AstraZeneca and Otsuka; Research Funding: AstraZeneca and Otsuka; Honoraria: AstraZeneca; Advisory or Leadership Role: AstraZeneca and Otsuka; and Speakers Bureau: AstraZeneca. S. Huang reports Advisory or Leadership Role: Sanofi; and Speakers Bureau: Norvartis. A.X. Garg reports Research Funding: Astellas, Baxter; Advisory or Leadership Role: Currently on the Editorial Boards of <i>American Journal of Kidney Diseases</i> and <i>Kidney International</i>; and Other Interests or Relationships: Serve on the Data Safety and Monitoring Board for an Anemia Trial Program Funded by Glaxo Smith Kline (activity now complete), Medical Lead Role to Improve Access to Kidney Transplantation and Living Kidney Donation for the Ontario Renal Network (government funded agency located within Ontario Health). M. Hladunewich reports Consultancy: Alnylam Pharmaceuticals; Research Funding: Calliditas Therapeutics, Chemocentryx, Ionis, Pfizer, and Roche; Advisory or Leadership Role: Kidney International, UpToDate; and Other Interests or Relationships: Medical Lead for Glomerular Disease Ontario Renal Network.",
137,Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Yan He reports financial support was provided by National Natural Science Foundation of China. Yan He reports financial support was provided by Natural Science Foundation of Hunan Province. Xiaonan Dong reports financial support was provided by R&D Program of Guangzhou Laboratory. Xiaonan Dong reports financial support was provided by National Natural Science Foundation of China. Bing Jiang reports financial support was provided by Key Research and Development (R&D) Plan of Hunan Province. Jing Tian reports administrative support was provided by Hunan Provincial Health Commission General Guidance Project. Yan He has patent licensed to Yan He.,
138,Declaration of interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: none.,No
139,All authors have nothing to disclose.,No
140,"I.H. de Boer reports consulting for AstraZeneca, Bayer, Boehringer-Ingelheim, Boehringer-Ingelheim/Lilly, Cyclerion Therapeutics, Ironwood Pharmaceuticals, George Clinical, Gilead, Goldfinch Bio, Medscape, and Otsuka; support for research (equipment and supplies) provided to his institution by DexCom; honoraria from the National Institutes of Health; and advisory or leadership roles as Deputy Editor of <i>CJASN</i>, Clinical Practice Guideline Co-Chair for Kidney Disease Improving Global Outcomes, Chair of the American Heart Association Kidney in Heart Disease Science Committee, and Associate Editor for <i>Contemporary Clinical Trials</i>. I.B. Hirsch reports consulting for Abbott Diabetes Care, Hagar, embecta, and Lifescan; receives research support to his institution from Dexcom and Insulet; reports honoraria from Abbott Diabetes Care; and serves as a Board Member of Juvenile Diabetes Foundation Western Washington Chapter Board of Directors.",
141,"J. Coresh reports grants from National Institute of Health and National Kidney Foundation and consulting fees from Healthy.io. J. Coresh also reports consultancy: Soma Logic; ownership interest: Healthy.io. A. Doria reports receiving grants from the JDRF and Novo Nordisk Foundation. A. Doria also reports speakers bureau: Novo Nordisk though Aristea “D-zOne Project: Global perspectives for diabetes and obesity management: getting out of the comfort zone?—November, 26th 2021.” M.M. Estrella reports grant to institution from Bayer Inc.; scientific meeting co-chair for National Kidney Foundation; and Editorial board member for <i>American Journal of Kidney Diseases</i> and <i>CJASN</i>. M.M. Estrella reports consultancy: Boehringer-Ingelheim, Inc.; spouse: Castle Biosciences: Isothrive, Medtronic, Phathom Pharmaceuticals, and Sanofi; research funding: Bayer, Inc.; and other interests or relationships: <i>American Journal of Kidney Diseases</i>, <i>CJASN</i>, and National Kidney Foundation. M. Froissart reports consultancy: CSL Vifor. V. Gudnason reports research funding: Novartis. L. Inker reports research grant from Chinook Therapeutics, National Kidney Foundation, NIH/NIDDK, Omeros, and Reata Pharmaceuticals and consulting agreements with Tricida Inc.; advisory role for Alport Foundation—Medical Advisory Council and NKF—Scientific Advisory Board; consultancy to Diamtrix; and other interests or relationships: <i>American Society of Nephrology</i> member, National Kidney Foundation member. R. Kalil reports research grant from Eurofins. R. Kalil reports research funding: Eurofins/Viracor. A.S. Levey reports research from the NIH and NKF to Tufts Medical Center, honoraria for lectures at academic medical centers, advisory board participation for clinical trials of dapagliflozin at AstraZeneca, and royalties from Up-To-Date. M. Mauer reports receiving grant (1R01DK129318) for a pilot study of fenofibrate to prevent kidney function loss in type 1 diabetes. M. Mauer also reports consultancy: Acelink, Acelink Theraputics, Amicus, Avrobio, Chiesi, Freeline Theraputics, Sangano, and Sanofi/Genzyme; research funding: Amicus, Freeline Theraputics, and Sanofi/Genzyme; honoraria: Acelink Theraputics, Amicus, Freeline Therapeutics, and Sanofi/Genzyme; and advisory or leadership role: North American Fabry Registry Board and International Fabry Registry Board. P. Rossing reports receiving honoraria to his institution from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Novo Nordisk, and Sanofi. P. Rossing also reports research funding: AstraZeneca, Bayer, and Novo Nordisk and advisory or leadership role: Astra Zeneca, Bayer, Gilead, Novo Nordisk, all honoraria to institution. J. Seegmiller reports subcontracts from CDC and NIH and participation on data and safety monitoring board for HIV in Nigeria (H3). M.G. Shlipak reports research grant from Bayer Pharmaceuticals, NIA, NIDDK, and NIH-NHLBI; consultancy fees from Cricket Health and Intercept Pharmaceuticals; and honorarium from AstraZeneca, Bayer Pharmaceuticals, and Boehringer Ingelheim. M.G. Shlipak reports research funding: Bayer Pharmaceuticals; honoraria: AstraZeneca, Bayer, and Boeringer Ingelheim; patents or royalties: Kidney Health Monitoring in Hypertension Patients; advisory or leadership role: <i>American Journal of Kidney Disease</i>, <i>Circulation</i>, <i>JASN</i>, and Board Member, Northern California Institute for Research and Education; and other interests or relationships: Committee Member—KDIGO Guidelines Committee. H. Tighiouart reports ownership interest: Bank of America, Cheniere Energy, Citi, Exxon Mobile, Ford, Merck, Oracle, Organon, and TJ Maxx. All remaining authors have nothing to disclose.",
142,"K.-H. Lee reports employment with and research funding from Taipei Veterans General Hospital. S.-y. Li and S.-M. Ou report employment with Taipei Veterans General Hospital. C.-C. Lin reports employment with Taipei Veterans General Hospital, consultancy from WS Far Infrared Company, and honoraria from AstraZeneca, Baxter, and Boehringer Ingelheim. M.-T. Tsai reports employment with Taipei Veterans General Hospital, Taipei, Taiwan; was invited by the Genomics company to deliver a speech on Olink PEA technology in September 2023; and currently serves as the Deputy Chairperson of the Academy and Research Committee for the Taiwan Society of Nephrology.",
143,"L.O. Lerman reports Consultancy: AstraZeneca, Beren Therapeutics, Butterfly Biosciences, and CureSpec; Research Funding: AstraZeneca; Honoraria: AstraZeneca, Butterfly Biosciences, and CureSpec; Patents or Royalties: Cohbar; Stealth Biopharmaceuticals; Advisory or Leadership Role: AstraZeneca, CureSpec; and Other Interests or Relationships: AHA, and NIH. L. Barisoni reports Consultancy: Protalix, Sangamo, Vertex; Honoraria: Protalix, Sangamo, Vertex; Advisory or Leadership Role: Nephcure scientific advisory Board, Nature Review Nephrology, <i>Glomerular Disease Journal</i>; and Other Interests or Relationships: Nephcure. L. Barisoni reports Consultancy: Protalix, Sangamo, Vertex; Honoraria: Protalix, Sangamo, Vertex; Advisory or Leadership Role: Nephcure scientific advisory Board, Nature Review Nephrology, <i>Glomerular Disease Journal</i>; and Other Interests or Relationships: Nephcure. All remaining authors have nothing to disclose.",
144,"R.J.M. Bindels reports Advisory or Leadership Role: REGMED XB Regenerative Medicine Crossing Borders; and Other Interests or Relationships: Scientific Board of the Dutch Kidney Foundation. J.H.F. de Baaij reports Other Interests or Relationships: Research funding from the Dutch Diabetes Research Foundation, the Dutch Kidney Foundation, the Dutch Organization of Scientific Research, and the European Union. J. Deinum reports Speakers Bureau: Health Investment and Prevents. L. Vermeltfoort reports Employer: House of Smart and Jeroen Bosch Ziekenhuis (boyfriend). The remaining author has nothing to disclose.",
145,"C. Baigent reports employment with the University of Oxford, research funding from Boehringer Ingelheim, has served as Chair of the European Society of Cardiology Clinical Practice Guidelines Committee 2020–22, and is a trustee of the UK charity Alport-UK, which supports patients and families with Alport Syndrome. A.S. Butterworth reports research funding from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Merck, Novartis, and Sanofi and honoraria from Novartis. L. Folkersen reports employment with Nucleus Genomics. S. Gustafsson reports employment with Sence Research AB. R. Haynes reports employment with the University of Oxford and research funding from Boehringer-Ingelheim and Novartis. W.G. Herrington reports employment with the University of Oxford; research funding from Boehringer Ingelheim & Lilly; serving as <i>Nephrology Dialysis Transplantation</i> and <i>Clinical Kidney Journal</i> subject editor; and advisory or leadership roles with European Society of Cardiology, KDIGO guideline committee, and UK Kidney Association. M.V. Holmes reports employment with, ownership interest in, and research funding from 23andMe. M.V. Holmes has consulted for Boehringer Ingelheim while he was in role at the University of Oxford. In compliance with the University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit (CSTU) staff policy, he did not accept personal honoraria or other payments from pharmaceutical companies. CTSU has a staff policy of not accepting honoraria or other payments from the pharmaceutical industry, except for the reimbursement of costs to participate in scientific meetings. A. Malarstig reports employment with Pfizer Worldwide Research and Development, ownership interest in Pfizer Inc., and research funding from Olink Proteomics. G. Pare reports employment with Hamilton Health Sciences; consultancy agreements with Amgen and Bayer; research funding from Bayer; honoraria from Amgen, Bayer, and Sanofi; and advisory or leadership roles for Amgen, Bayer, and Sanofi. R. Sardell's spouse reports employment with, consultancy agreements with, ownership interest in, and research funding from Precision Life. N. Staplin reports research funding from Boehringer Ingelheim and Novo Nordisk. Q. Wang reports employment with GSK. The remaining authors have nothing to disclose.",
146,"P. Gao reports employment with Population Health Research Institute and institutional grants from the AstraZeneca, Cadila Pharmaceuticals, Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, and Wellcome Trust related to the TIPS-3 or HOPE-3 studies (or both). P. Joseph reports institutional grants from the AstraZeneca, Cadila Pharmaceuticals, Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, and Wellcome Trust related to the TIPS-3 or HOPE-3 studies (or both). R. Malekzadeh reports institutional grant funding from Alborz Darou, Barakat Foundation, and Tehran University of Medical Sciences related to the PolyIran study. J.F.E. Mann reports employment with KfH Nierenzentrum; consultancy for AstraZeneca, Bayer, Boehringer, Novo Nordisk, and UpToDate; research funding from AstraZeneca, Bayer, European Union, Idorsia, Novo Nordisk, and Sanofi; and speakers bureau for AstraZeneca, Bayer, Novartis, and Novo Nordisk. P. Pais reports research funding from Cadila Pharma India Ltd and speakers bureau for Eli Lilly. G. Roshandel reports institutional grant funding from Alborz Darou, Barakat Foundation, and Tehran University of Medical Sciences related to the PolyIran study. S. Yusuf reports research funding from AstraZeneca, Bayer, Boehringer Ingelheim, and Cadila; grants from the AstraZeneca, Cadila Pharmaceuticals, Canadian Institutes of Health Research, and Wellcome Trust related to conducting the HOPE-3 or TIPS-3 studies; and honoraria and reimbursement for travel expenses from AstraZeneca, Bayer, Boehringer Ingelheim, and Ferrer. All remaining authors have nothing to disclose.",
147,"<b>Financial Disclosure:</b> MK reports grants from the National Institute of Diabetes and Digestive and Kidney Diseases in support of this manuscript. Grants and contracts outside the submitted work through the University of Michigan with National Institutes of Health, JDRF, Chan Zuckerberg Initiative, AstraZeneca, NovoNordisk, Eli Lilly, Gilead, Goldfinch Bio, Janssen, Boehringer-Ingelheim, Moderna, European Union Innovative Medicine Initiative, Certa, Chinook, amfAR, Angion, RenalytixAI, Travere, Regeneron and IONIS. MK reports consulting fees through the University of Michigan from Astellas, Poxel, Janssen and UCB. In addition, MK has a patent PCT/EP2014/073413 “Biomarkers and methods for progression prediction for chronic kidney disease” licensed. The other authors declare that they have no relevant financial interests.",
148,"A.D. Rule reports Patents or Royalties: UpToDate; and Advisory or Leadership Role: <i>JASN</i>—Associate Editor, Mayo Clinic Proceedings—Section Editor, NIDDK—Urological Diseases of America Contract Management Board. All remaining authors have nothing to disclose. Because Andrew Rule is an editor of the <i>Journal of the American Society of Nephrology</i>, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.",
149,"J.-X. Bei reports Ownership Interest: Junshi Ltd.; and Patents or Royalties: Sun Yat-sen University Cancer Center. G.-R. Jiang reports Research Funding: Fibrogen. J. Lee reports Consultancy: Boehringer Ingelheim; and Advisory or Leadership Role: ThoughtFull World Pte. Ltd. E.S. Tai reports Consultancy: Farma Mondo S.A., Novartis Singapore Pte. Ltd., and Kowa Pharmaceutical Asia Pte. Ltd.; Ownership Interest: Abbott, Abbvie, and Novavax; Honoraria: As listed under consultancy agreements; and Speakers Bureau: as listed under consultancy agreements. E.-K. Tan reports Research Funding: YiQi Company; and Honoraria: Academic activities (Esai) and Editorial duties (Elsevier). H. Zhang reports Consultancy: Calliditas, Chinook, Novartis, OMEROS, and Ostuka; and Advisory or Leadership Role: Ostuka. All remaining authors have nothing to disclose.",
150,"V. Audard reports consultancy for Advisory boards of Addmledica, Alnylam, AstraZeneca, Bayer, and Vifor pharma; honoraria for Advisory boards for Addmledica, Alnylam, AstraZeneca, Bayer, and Vifor pharma; and advisory or leadership roles on Advisory boards for Addmledica, Alnylam, AstraZeneca, Bayer, and Vifor pharma. F. Bridoux reports research funding from Baxter and Janssen; honoraria from AstraZeneca, Janssen, and Sanofi; advisory or leadership roles for AstraZeneca, Attralus, Janssen, Novartis, and Prothena; and speakers bureau for AstraZeneca, Janssen, and Sanofi. V. Esnault reports consultancy from Alexion, AstraZeneca, Bayer, BMS-Pfizer, Boehringer-Ingelheim, and Novartis; research funding from AstraZeneca, BMS-Pfizer, Boehringer-Ingelheim, Hemotech, and Novartis; honoraria from Alexion, Amgen, Bayer, BMS-Pfizer, Boehringer-Ingelheim, Fresenius, Lilly, and Novartis; and advisory or leadership roles for AstraZeneca, Bayer, and Boehringer-Ingelheim. V. Frémeaux-Bacchi served as consultant for Alexion Pharmaceuticals, Apellis, BioCryps, Novartis, Roche, Sobi, and UCB; reports research funding from Alexion Pharmaceuticals; honoraria from Alexion Pharmaceuticals, Apellis, BioCryps, Novartis, Roche, Sobi, and UCB; and advisory or leadership roles for Alexion Pharmaceuticals, Apellis, BioCryps, Novartis, and Sobi. N. Jourde-Chiche reports consultancy for Alexion, GSK, Otsuka, and Vifor and role as a Otsuka advisory board member (paid) and Vifor advisory board member (paid). A. Karras reports consultancy for Alnylam, GSK, Novartis, Otsuka, and Vifor; honoraria from AstraZeneca, Bohringer-Ingelheim, GSK, Novartis, Otsuka, Pfizer, and Vifor; advisory or leadership role for Novartis, Otsuka, and Vifor; and speakers bureau for AstraZeneca, Boehringer-Ingelheim, Otsuka, Pfizer, and Vifor. M. Le Quintrec reports consultancy for Alexion, GSK, Novartis, and Sanofi; research funding from Alexion and Sanofi; honoraria from Alexion, Astellas, GSK, Novartis, and Sanofi; and advisory or leadership role for Novartis French board. F. Provot reports consultancy from Alexion, Astellas, and Sanofi and advisory or leadership roles for Novartis, Sanofi, and Takeda. P. Remy reports honoraria from Biogen and BMS. A. Servais reports consultancy for Chiesi; honoraria from Alexion, Chiesi, Recordati, and Vertex; and advisory or leadership role for Novartis. E. Thervet reports consultancy for Pfizer and Vifor; research funding from Alexion and GSK; and honoraria from Pfizer and Vifor. J. Zuber reports consultancy for Alexion Pharma and honoraria from Alexion Pharmaceuticals and BMS Pharmaceuticals. All remaining authors have nothing to disclose.",
151,"G. Chodick reports employment with Maccabi Healthcare Services. A. Karasik reports consultancy for, research funding from, and honoraria from AstraZeneca, Boheringer Ingelheim, and Novo Nordisk, and speakers bureau for Abbott, AstraZeneca, Boheringer Ingelheim, and Novo Nordisk. C. Melzer Cohen reports employment with Maccai Healthcare Services and research funding from Boehringer Ingelheim. O. Mosenzon reports employment with Regeneron Pharmaceuticals, NY, since May 1, 2023; consultancy for AstraZeneca, Bayer, Boehringer Ingelheim, BOL Pharma, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi; research funding through Hadassah Hebrew University Hospital from AstraZeneca and Novo Nordisk; honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi; role on Advisory Boards for AstraZeneca, Bayer, Boehringer Ingelheim, BOL Pharma, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, and Sanofi; and speakers bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, and Sanofi. D. Rosenzweig is an employee of Boehringer Ingelheim RCV GmbH & Co KG. Boehringer Ingelheim RCV GmbH & Co KG funded the study, which was managed independently, as disclosed by the named investigator. A. Rozenberg reports hourly payment from AstraZeneca through Hadassah Medical Center and from Novo Nordisk. M. Schechter reports honoraria from AstraZeneca and support to participate in a conference from AstraZeneca and Novo Nordisk through Hadassah Medical Center. I. Yanuv reports hourly payment from AstraZeneca through Hadassah Medical Center and from Novo Nordisk. All remaining authors have nothing to disclose.",
152,"D.R. Cheng reports an advisory or leadership role for Adventist Healthcare Limited. J. Kausman reports ownership interest in CBA, Chorus group, Telstra, and Worley and research funding from Alexion. C. Quinlan reports serving as a faculty member of NephSim; executive member of Nephrology Social Media Collective; advisory or leadership roles for Blue Ribbon Panel of NephMadness and Education and Training committee of ANZSN; and her partner reports employment with MYOB (Australian software company). The remaining authors have nothing to disclose.",
153,The authors declare no funding or conflicts of interest.,No
154,"A.A. Alexander reports an advisory or leadership role for Boston Children's Hospital. B.I. Freedman reports employment with Wake Forest University School of Medicine and Health Systems Management, Inc.; consultancy for AstraZeneca Pharmaceuticals, RenalytixAI, and Xinthera; research funding from AstraZeneca Pharmaceuticals and RenalytixAI; advisory or leadership roles on Editorial Boards of <i>American Journal of Nephrology</i>, <i>JASN</i>, and <i>Kidney International</i>; and other interests or relationships as Chief Medical Officer of Health Systems Management, Inc., Wake Forest University Health Sciences. B.I. Freedman has rights to a US patent related to APOL1 genetic testing. M.H. Spainhour reports employment with and research funding from Atrium Health Wake Forest Baptist. All remaining authors have nothing to disclose.",
155,"M.C. Hogan reports employment with Mayo Clinic; consultancy agreements with Otsuka Pharmaceuticals; research funding from Camurus, Palladio, Reata, and Regulus Pharmaceuticals; honoraria from American Society of Nephrology; advisory or leadership role for Camurus Pharmaceuticals (no payment), <i>Mayo Clinic Proceedings Quality & Outcomes Journal</i> (no payment), and Sail Bio (no payment); and other interests or relationships with American Society of Nephrology, PKD Disease Outcomes Consortium, and PKD Foundation. T.V. Masyuk reports employment with Mayo Clinic and is an inventor on US Patent 8,232,241 B2 for treating liver diseases.",
156,"A. Caroli reports research funding from Alexion Pharmaceuticals, Brembo, and Laminate Medical Technologies and speakers bureau for Fresenius Medical Care. F. Carrara, D. Cugini, D. Martinetti, T. Peracchi, A. Perna, N. Rubis, M. Trillini, and G. Villa report employment with Istituto di Ricerche Farmacologiche Mario Negri IRCCS. P. Ruggenenti and M. Caruso report employment with ASST Papa Giovanni XXIII. V.F. Leone reports employment with ASST Papa Giovanni XXIII; research funding from Achillion Pharmaceuticals, Alexion Pharmaceuticals, and Novartis Pharmaceutical company; and other interests or relationships with ERK Net. N. Perico reports research funding from Bayer AG and honoraria from Bayer S.p.A. G. Remuzzi reports consulting fees from Akebia Pharmaceuticals, Alexion Pharmaceutical, AstraZeneca, BioCryst Pharmaceuticals, Janssen Research & Development, Menarini Ricerche Spa, Otsuka, and Silence Therapeutics and serving as a member of numerous editorial boards of scientific medical journals. All remaining authors have nothing to disclose.",
157,"Y. Isaka reports research funding from Chugai Pharma Co., Ltd., Kirin Co., Ltd., Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical Co., Ltd.; advisory or leadership roles for Chugai Pharma Co., Ltd. and Kirin Co., Ltd.; and speakers bureau for Astellas Pharma, Inc., AstraZeneca plc, Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical Co., Ltd. N. Kashihara reports consultancy agreements with AstraZeneca, Kyowa Kirin, and Novartis; research funding from Astellas, Daiichi-Sankyo, Otsuka, and Takeda; honoraria from Astellas, Daiichi-Sankyo, Otsuka, and Takeda; advisory or leadership roles for AstraZeneca, Kyowa Kirin, and Novartis; and other interests or relationships with Japan Kidney Association and Japanese Society of Nephrology. Y. Sakaguchi reports research funding from Chugai Pharmaceutical Co., Ltd., FUSO Pharmaceutical Industries, Ltd., Kissei Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Terumo Co., Ltd., and Torii Pharmaceutical Co., Ltd. and honoraria from AstraZeneca, Bayer Yakuhin, Ltd., Chugai Pharmaceutical, Co., Ltd., Fuso, Kyowa Kirin Co., Ltd., and Torii Pharmaceutical, Co., Ltd. The remaining authors have nothing to disclose.",
158,"A. Bihorac, T. Ozrazgat-Baslanti, and P. Rashidi report research funding from National Institute of Health (NIH). P. Rashidi also reports ownership interest in Simour.ai and research funding from National Science Foundation (NSF). A. Bihorac, T. Ozrazgat-Baslanti, and P. Rashidi report Method and Apparatus for Prediction of Complications after Surgery, US Patent Application Number 20200161000, filed June 1, 2018; A. Bihorac, T. Ozrazgat-Baslanti, P. Rashidi, and B. Shickel report Systems and Methods for Using Deep Learning to Generate Acuity Scores for Critically Ill or Injured Patients, US patent 20220044809, filed February 21, 2020; and A. Bihorac and P. Rashidi report Method and Apparatus for Pervasive Patient Monitoring, US Patent Number 11424028, patent date Aug. 23, 2022. All remaining authors have nothing to disclose.",
159,"L. Chan reports consultancy for CSL Vifor Pharma, Inc. and research funding from NIH. R. Hilburg's spouse reports employment with and ownership interest in Lockheed Martin. A.S. Parsons reports consultancy for National Board of Medical Examiners and NEJM Education Group. L.D. Stern reports advisory or leadership role for Lightline Medical—Medical Advisory Board, speakers bureau for Baxter Inc., and other interests or relationships with Home Dialysis University. All remaining authors have nothing to disclose.",
160,"J.G. Bhat reports employment with and ownership interest in Atlantic Dialysis Management Services, LLC. S.R. Blue reports employment with Saint Alphonsus Health System, Sawtooth Epidemiology and Infectious Diseases, and St. Lukes Health System. M. Dittrich reports employment with US Renal Care; ownership interest in multiple dialysis units, Signify Health, and US Renal Care; and advisory or leadership role as US Renal Care Chief Medical Officer. R. Durvasula reports employment with Puget Sound Kidney Centers. B.I. Freedman reports employment with Health Systems Management, Inc.; consultancy for AstraZeneca Pharmaceuticals and RenalytixAI; research funding from AstraZeneca Pharmaceuticals and RenalytixAI; role on the Editorial Boards of <i>American Journal of Nephrology</i>, <i>JASN</i>, and <i>Kidney International</i>; and other interests or relationships as Chief Medical Officer, Health Systems Management, Inc. and Wake Forest University Health Sciences, and B.I. Freedman has rights to a US patent related to APOL1 genetic testing. J. Giullian reports employment with and ownership interest in DaVita, Inc. G. Green reports current employment with Satellite Healthcare and former employment with Nephrology Associates Medical Group of Santa Rosa (through September 30, 2021); ownership interest in Doximity and MedWave Software Solutions; advisory or leadership role for Akebia Therapeutics Advisory Board (paid at hourly fair market value rate), American Society of Nephrology Emergency Partnership Initiative (steering committee membership, workgroup co-chair, unpaid), and National Kidney Foundation serving Northern California Medical Symposium Program Planning Committee; and other interests or relationships with Kidney Care Council (member). G. Green’s spouse reports current employment with The Permanente Medical Group, ownership interest in MedWave Software Solutions and The Permanente Medical Group; and other interests or relationships with Society for Vascular Surgery (member). J.L. Hymes reports employment with Fresenius Medical Care North America; ownership interest in DaVita, Fresenius Medical Care, and Nephroceuticals; advisory or leadership role for Fresenius Medical Care; and other interests or relationships with KCP. J. Silberzweig reports employment with The Rogosin Institute; consultancy work for Alkahest, Bayer, Honeywell, Kaneka, and St. Gobain; stock in American Express, AT&T, IBM, and Wells Fargo; research funding as the national principal investigator for two clinical trials sponsored by Kaneka: one is using their Lixelle device for treatment of beta-2-microglobulin amyloidosis in patients with ESKD, and the other is using lipid apheresis for the treatment of focal glomerulosclerosis; and advisory or leadership roles for American Society of Nephrology: Nephrologists Transforming Dialysis Safety COVID-19 and Other Current and Emerging Threats workgroup, COVID-19 Response team, and Emergency Partnership Initiative. J. Silberzweig’s wife is an employee of Elevance Health and holds stock in American Express, AT&T, Elevance Health, IBM, and Wells Fargo. R. Spech reports employment with Centers for Dialysis Care and Nephrology and Hypertension Associates, Inc.; ownership interest in Bank of America, Microsoft, Moderna, Nutrien, and Range Resources; advisory or leadership role for Centers for Dialysis Care; and other interests or relationships with Centers for Dialysis Care and Nephrology Associates of Cleveland. L. Spry reports the employment with Lincoln Nephrology & Hypertension; consultancy for Guidepoint Network for Nephrology; shares with Home Dialysis of Lincoln, a for-profit home dialysis provider in Lincoln, Nebraska; research funding as a primary investigator for Nebraska Nephrology Research, a CRO based in Lincoln, Nebraska; research funding from Outset as the primary investigator at the Dialysis Center of Lincoln, Lincoln, Nebraska; research funding from Baxter International as the primary investigator at the Dialysis Center of Lincoln, Lincoln, Nebraska; research funding as a primary investigator for Somnos, is a CRO in Lincoln, Nebraska; honoraria from the Southeast Nebraska Rural Physician Association (SERPA) related to a presentation on Kidney Disease in September 2021; role on the Board of Directors for the Bryan Health Connect, a physician hospital organization in Lincoln, Nebraska; and other interests or relationships as the Chief Medical Officer for the Dialysis Center of Lincoln, a non-profit Dialysis Provider. R. Taylor reports employment with REACH/DCi incorporated and advisory or leadership role for Alive Hospice. L.P. Wong reports employment with Intermountain Healthcare; consultancy for Baxter and Fresenius Medical Care; honoraria from Baxter; advisory or leadership role for Nephrologists Transforming Dialysis Safety Board of Directors, role on <i>BMC Nephrology</i> Editorial Board, and role as a Member-at-Large for ASN Excellence in Patient Care Committee.",
161,"M.-h. Zhao reports consultancy for AstraZeneca, GSK, INFLARX, Kira, Novartis, and Roche. All remaining authors have nothing to disclose.",
162,"E. Cavalier reports consultancy for bioMerieux, DiaSorin, Fujirebio, IDS, Nittobo, Orifarm, Snibe, and Werfen. K. Claes reports consultancy for Astellas, Fresenius Kabi, GSK, and Sanofi; support from Alexion, Astellas, and AstraZeneca; advisory or leadership role for Alexion, Astellas, and Fresenius Kabi; and speaker's fee from AstraZeneca and Vifor Pharma. P. Evenepoel reports consultancy for Vifor CSL; research funding from Amgen, Sanofi, and Vifor CSL; and honoraria from Vifor CSL. H.S. Jørgensen reports other interests or relationships as a Steering Committee member of the European Renal Osteodystrophy initiative, under the CKD-MBD working group of the European Renal Association (ERA). D. Kuypers reports consultancy for Astellas Company, AZ, GSK, Hansa, Sangamo-Tx, and Takeda; honoraria from Astellas, AZ, GSK, Hansa, and Takeda; speakers bureau for Astellas and HIKMA; and advisory or leadership role as an Associate Editor for <i>Transplantation</i> and as an Editorial Board member of <i>Current Clinical Pharmacology</i>, <i>Therapeutic Drug Monitoring</i>, and <i>Transplantation Reviews</i>. M. Naesens reports consultancy for Agomab, Aiosyn, Argenx, and Hansa; research funding from CareDx; and honoraria from Argenx and Hansa. M. Naesens is inventor of two patents related to the FWO-SBO application: EP19152365.3: mRNA-based biomarkers for antibody-mediated transplant rejection. This biomarker was licensed in September 2020 to CareDx, a precision medicine solutions company focused on solutions for transplant patients; PCT/EP2018/097044: Biomarkers for typing allograft recipients (patent application submitted December 2018). All remaining authors have nothing to disclose.",
163,"O. Aubert reports Honoraria: CareDX and Novartis. É. Bailly reports Ownership Interest: Gilead, Johnson & Johnson, Merck, Novartis, and Pfizer. O. Bestard reports Patents or Royalties: Oxford Immunotec. A. Del Bello reports Speakers Bureau: Hansa Pharma and Neovii. J.J. Friedewald reports Consultancy: egenesis, Eurofins—Transplant Genomics, Inc., and Veloxis; Research Funding: CSL Behring, Eurofins—Viracor, Inc., Hansa BioPharma, NIH, Regeneron, and Veloxis; Honoraria: Sanofi and Up to Date; Patents or Royalties: Northwestern University/Scripps Research Institute; and Speakers Bureau: Sanofi. C. Lefaucheur reports Consultancy: Hansa Biopharm; Research Funding: EU Train/H2020 and KTD-Innov/ANR France; Advisory or Leadership Role: Chiesi; and Speakers Bureau: Astellas and Hansa Biopharma for ESOT Symposium 2023. M. Naesens reports Consultancy: Agomab, Aiosyn, Argenx, and Hansa; Research Funding: CareDx; Honoraria: Argenx and Hansa; and Patents or Royalties: inventor of two patents related to the FWO-SBO application; EP19152365.3: mRNA-based biomarkers for antibody-mediated transplant rejection. This biomarker was licensed in September 2020 to CareDx, a precision medicine solutions company focused on solutions for transplant patients; PCT/EP2018/097044: Biomarkers for typing allograft recipients (patent application submitted December 2018). L. Riella reports Consultancy: Caredx; Research Funding: Brystol-Meyers Squibb, Caredx, Natera, Sanofi, and Visterra; Honoraria: Caredx; and Advisory or Leadership Role: CareDx. C. Wang reports Research Funding: Astellas Pharma Inc. All remaining authors have nothing to disclose.",
164,"A.K. Cheung reports Consultancy: 3D Communications, Boehringer-Ingelheim, and CSL Behring; Ownership Interest: Merck; and Patents or Royalties: UpToDate. L.F. Fried reports Consultancy: CSL Behring, Data Safety Monitoring boards, and Novo Nordisk; Ownership Interest: Stock ownership: Amgen, Archer Daniels Midland, ATT, Dow, Kroger, Procter & Gamble; and Research Funding: AstraZeneca. A. Hoofnagle reports Consultancy: Kilpatrick Townsend & Stockton LLP; Ownership Interest: Seattle Genetics; Research Funding: Waters; Patents or Royalties: SISCAPA Assay Technologies; Advisory or Leadership Role: <i>Clinical Chemistry</i> (Associate Editor); and Other Interests or Relationships: Expert witness for Kilpatrick, Townsend, and Stockton, LLC. T. Isakova reports Consultancy: Blueprint Partnership Manchester Ltd.; and Advisory or Leadership Role: Associate Editor, <i>American Journal of Kidney Diseases</i>. J.H. Ix reports Consultancy: Akebia, AstraZeneca, Bayer, Cincor, and Sanifit; Research Funding: Baxter International and Juvenile Diabetes Research Foundation; Honoraria: Akebia, AstraZeneca, Bayer, Cincor, and Sanifit; Advisory or Leadership Role: AlphaYoung; and Other Interests or Relationships: Executive Board for Kidney Disease: Improving Global Outcomes (KDIGO). R. Katz reports Consultancy: UCSD and UPenn; and Advisory or Leadership Role: <i>CJASN</i> Editorial Board. D.S. Raj reports Consultancy: Novo Nordics; Research Funding: NIH; Honoraria: Novo Nordics; Advisory or Leadership Role: NHLBI, NIDDK, and Novo Nordics; and Other Interests or Relationships: American Association of Kidney Patients. S. Sprague reports Consultancy: Amgen, Ardelyx, Bayer, Fresenius, Horizon, Litholink Corp, OPKO, Shire, and Vifor; Ownership Interest: Individually owned stocks; Apple, Baxter, Bristol Myers, Coca Cola, First Australia Fund, lBM, and Walgreens; Research Funding: Amgen, Amylot, Ardelyx, OPKO, Reata, and Takeda; Honoraria: Amgen, Ardelyx, Bayer, Fresenius, OPKO, and Vifor; Advisory or Leadership Role: American Association of Endocrine Surgeons, American Journal of Nephrology, International Federation of Clinical Chemistry and Laboratory Medicine-Work Group for Parathyroid Hormone, and National Kidney Foundation of Illinois; and Speakers Bureau: Amgen, Bayer, Fresenius, and OPKO. M. Wolf reports Consultancy: Akebia, Alexion, Amgen, Bayer, Enyo, Jnana, Pfizer, Pharmacosmos, Reata, and Torii; Ownership Interest: Akebia, Unicycive, and Walden; Research Funding: CSL Behring; Honoraria: Akebia, Alexion, Amgen, Bayer, Enyo, Jnana, Pfizer, Pharmacosmos, Reata, and Torii; and Advisory or Leadership Role: Akebia, Unicycive, and Walden. All remaining authors have nothing to disclose.",
165,"Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: David Berglund reports financial support was provided by ITB-MED. David Berglund reports a relationship with ITB-MED that includes: employment, equity or stocks, and funding grants. David Berglund has patent pending to ITB-MED.Erik Berglund reports financial support was provided by ITB-MED. Erik Berglund reports a relationship with ITB-MED that includes: employment and equity or stocks. Erik Berglund has patent pending to ITB-MED. Filip Cvetkovski reports financial support was provided by ITB-MED. Filip Cvetkovski reports a relationship with ITB-MED that includes: employment. Filip Cvetkovski has patent pending to ITB-MED. The other authors have nothing to declare. The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. F. Cvetkovski, R. Razavi, E. Berglund, and D. Berglund are employees of ITB-MED. E. Berglund and D. Berglund own shares in ITB-MED. F. Sellberg is a former employee of ITB-MED. The ITB-MED Group has applied for patent protection for the use of siplizumab in combination with CTLA4-Ig treatment.",
166,"D. Concepcion reports employment with St. Joseph Hospital; consultancy agreements with Antelope Valley Kidney Institute and Care Dialysis Center; ownership interest in Outset Medical; advisory or leadership roles for <i>Nephrology News & Issues</i> Editorial Advisory Board and Nephrology Nursing Certification Commission; and other interests or relationships with ESRD Network 18, National Kidney Foundation, Nephrology Nursing Certification Committee, and Renal Health Associates. D. Cukor reports research funding from NIH research funding and royalties from Elsevier—Academic Press. B. Schiller reports employment with Satellite Healthcare; consultancy agreements with Akebia, CVS, Quanta, and Rockwell Medical; ownership interest in Unicycive Therapeutics Inc.; an advisory or leadership role for Board of Directors at Unicycive; and speakers bureau for AstraZeneca. J. Silberzweig reports employment with The Rogosin Institute; consultancy work for Alkahest, Bayer, Honeywell, Kaneka, and St. Gobain; research funding from Kaneka Pharma America; and advisory or leadership roles for American Society of Nephrology: COVID-19 Response team, Emergency Partnership Initiative, and Nephrologists Transforming Dialysis Safety Current and Emerging Threats workgroup. J. Silberzweig is the National Principal Investigator for two clinical trials sponsored by Kaneka. One is using their Lixelle device for treatment of Beta-2-microglobulin amyloidosis in patients with ESKD; the other is using lipid apheresis for the treatment of focal glomerulosclerosis. J. Silberzweig and his spouse hold stock in American Express, AT&T, IBM, and Wells Fargo. J. Silberzweig's spouse is an employee of Anthem and holds stock in the company. M. Sinclair reports advisory or leadership roles for ASN COVID-19 Response Team (unpaid position) and ASN NTDS CET Workgroup (unpaid position). F. Speed reports employment with Fresenius Kidney Care. T. Watson reports employment with Nephrology Associates, PC; consultancy agreements with Fresenius Kidney Care; and ownership interest in Alabama Kidney Ventures, Clutch Health, DaVita Kidney Care, Evergreen Nephrology, Fresenius Kidney Care, Interwell Health, and Nephrology Associates, PC; and an advisory or leadership role for Fresenius Kidney Care. T. Watson's practice has joint venture partnerships with Azura Vascular Care, DaVita, Evergreen Nephrology, Fresenius, and Interwell Health. D. Weiner reports employment with Tufts Medical Center Physicians Organization; research funding from the following, with all compensation paid to Tufts MC: Bayer (site PI), Cara (site PI, pending start-up), CSL Behring (site PI, completed), Goldfinch Bio (site PI, completed), and Vertex (site PI, pending startup); and advisory or leadership roles as Co Editor-in-Chief of <i>NKF Primer on Kidney Diseases, 8th Edition</i>, Editor-in-Chief of <i>Kidney Medicine</i>, Medical Director of Clinical Research for Dialysis Clinic Inc., member of ASN Quality and Policy Committees and ASN representative to KCP, and member of Scientific Advisory Board of National Kidney Foundation. D. Weiner reports other interests or relationships as adjudications committee, Chair, and VALOR Trial (George Institute, CRO, sponsored by Tricida, completed); member of Data Monitoring Committee, Feasibility of Hemodialysis with GARNET in Chronic Hemodialysis Patients with a Bloodstream Infection Trial (Avania CRO); and member of Safety and Clinical Events Committee for A Prospective, Multi-Center, Open-Label Assessment of Efficacy and Safety of Quanta SC+ for Home Hemodialysis Trial (Avania CRO). N. Welder reports employment with and ownership interest in DaVita Inc. S. Wu reports employment with CapitalRx.",
167,"R.J. Johnson has equity with XORT Therapeutics, which is developing novel xanthine oxidase inhibitors, is an inventor on several patents on the role of uric acid in hypertension, metabolic syndrome, and diabetic nephropathy that resulted from research (US Patent Nos. 7,799,794; 8,236,488; 8,557,831; 9,155,740 B), and has consulted for AstraZeneca, Danone Research Foundation, and Horizon Pharmaceuticals. R.J. Johnson also reports Ownership Interest: Colorado Research Partners LLC (founder shares); Research Funding: NIH, Veteran's Administration; Honoraria: Horizon Pharmaceutical, Universities; Patents or Royalties: Comprehensive Clinical Nephrology (Elsevier) and Nature Wants Us to Be Fat (BenBella). T. Beaver reports Consultancy: Jace orthopedics; Ownership Interest: Rivian, Lucid, Shockwave, Exxon, Carnival, Norwegian, Disney, Genuine Parts, Amazon; Research Funding: Surgical Site PI for valve trials, Edwards, Medtronic, Abbot; and Advisory or Leadership Role: Atricure Inc Scientific Advisory for IST trial. All remaining authors have nothing to disclose.",
168,"E.A.B. receives research support from Merck, Takeda, and Hologic; is a member of a Data and Safety Monitoring Board (DSMB) for Amplyx; and is a member of Scientific Advisory Committees for Merck and Takeda. E.L. is a member of a DSMB for Merck and is a member of a scientific advisory committee for Paratek and Shionogi. K.A. serves on a scientific advisory board for Becton Dickinson. J.H.H. was affiliated with the University of Pennsylvania during the conduct of this research and is now employed by, and holds shares in, the GlaxoSmithKline group of companies. None of these conflicts are relevant to this article. The other authors declare no conflicts of interest.",
169,"C.N.K. has received consulting fees and participated in adjudication committees and advisory boards for Biotest, Merck & Co Inc, Takeda, QIAGEN, and Roche Diagnostics. A.G.S. declare no conflicts of interest.",
170,"A.X. Garg reports Research Funding: Astellas and Baxter; Advisory or Leadership Role: Currently on the Editorial Boards of <i>American Journal of Kidney Diseases</i> and <i>Kidney International</i>; and Other Interests or Relationships: Served as the Medical Lead Role to Improve Access to Kidney Transplantation and Living Kidney Donation for the Ontario Renal Network (government funded agency located within Ontario Health). This position ended October 2022. S.A. Silver has received consulting fees from AstraZeneca, speaking fees from Baxter Canada and honorarium from Novo Nordisk and Otsuka. S.A. Silver reports Advisory or Leadership Role: Canadian Society of Nephrology Board Member. M.M. Sood reports Consultancy: Astrazeneca; and Advisory or Leadership Role: Bayer, GlaxoSmithKline, and Otsuka. M.M. Sood has received speaker fees from AstraZeneca. A. Thomas reports Honoraria: Astra-Zeneca Pharmaceuticals Canada, GSK Canada, and Otsuka Canada; and Speakers Bureau: GSK Canada and Otsuka Canada. A. Thomas has received speaker fees from AstraZeneca and Otsuka. R. Wald reports Consultancy: Lilly and Otsuka; Research Funding: Baxter; Honoraria: Baxter; Advisory or Leadership Role: Editorial Boards of <i>CJASN</i>, <i>Kidney Medicine</i>, and <i>Kidney360</i>; and Other Interests or Relationships: Contributor for UpToDate. R. Wald has received unrestricted grant support and speaking fees from Baxter. Data Access/Access to Data Analysis Protocol: The analysis was conducted by members of the ICES Kidney Dialysis & Transplantation (KDT) team at the ICES Western facility (London, ON). Y. Kang was responsible for the data analysis. The protocol can be obtained by emailing S.A. Silver at samuel.silver@queensu.ca. All remaining authors have nothing to disclose.",
171,"A. Agarwal reports employment with VA Medical Center, Wright State University, and an advisory or leadership role for the American College of Cardiology Board of Trustees—Ohio Chapter (an unpaid position). S.A. Athar reports employment with Loma Linda VA Medical Center. E. Carpenter-Song served as a consultant for Westat during 2022 to support the use of qualitative methods in two studies: (<i>1</i>) a study examining an employment program for Veterans transitioning to civilian life and (<i>2</i>) a study examining evidence-based supported employment for young adults with serious mental illnesses. E. Carpenter-Song was part of a research team that received funding in 2020 from the Bristol Meyers Squibb Foundation to conduct research examining the impact of COVID-19 on rural health systems and communities. S. Girotra reports research funding from National Heart, Lung, and Blood Institute (R01HL160734 and R56HL158803). T.J. Helton reports employment with James H. Quillen VA Medical Center and ownership interest in Apple, AirBNB, ASML holding, Confluent, Crowdstrike, Microsoft, Shopify, and Upstart. C. Leung reports employment with Orlando Veterans Affairs Medical Center. M.E. Matheny reports employment with Department of Veterans Affairs and consultancy agreements with NIH-VA-DoD Pain Management Grant Consortium (PMC3). M. Matheny reports advisory or leadership roles for Informatics & Methods Section, SMRB Study Section, VA HSR&D; Steering Committee—Indianapolis VA HSR&D COIN Center; and Steering Committee—VA HSR&D VIREC. A.J. O'Malley reports consultancy agreements with JB Associates and an advisory or leadership role for Statistics in Medicine and Observational Studies. M.E. Plomondon reports employment with Veterans Health Administration, Washington, DC. R. Solomon reports consultancy agreements with MediBeacon, Inc., PLC Inc., and Sonogenix, Inc.; research funding from REATA and Vera Pharmaceuticals; and advisory or leadership roles for MediBeacon, PLC Med, Inc., and Sonogenix. M.I. Vidovich reports consultancy agreements with Boston Scientific, research funding from Boston Scientific, patents or royalties from Merit Medical, and an advisory or leadership role for Intersocietal Accreditation Commission. S.W. Waldo reports employment with Rocky Mountain Regional VA Medical Center and research funding from Cardiovascular Systems Incorporated and Janssen Pharmaceuticals. L. Zubkoff reports employment with Birmingham VA Healthcare System. All remaining authors have nothing to disclose.",
172,"M.R.M. reports payment made to institution from Abbott for consulting, consulting fees from Mesoblast, Janssen, Moderna, Paragonix, and Baim Institute for Clinical Research, and advisory board member for Transmedics, NuPulseCV, Leviticus, and FineHeart. The other authors declare no conflicts of interest.",
173,"Conflict of intrest. The other author of this manuscript has no conflicts of interest to
disclose as described by the American Journal of Transplantation.",No
174,"S. Bhorade reports Employer: Natera and Veracyte; Ownership Interest: Natera and Veracyte; and Patents or Royalties: Veracyte. S. Bhorade, M.S. Bloom, D. Clark, Z.P. Demko, S. Jandeska, K. Marshall, S. Punj, H. Tabriziani, M. Westemeyer, and Z. Zhang are employees of Natera, Inc. and own or have the option to own stock. V. Broumand reports Consultancy: Bayer, Outset Medical, and Vifor Pharma; Ownership Interest: ADR, Ardelyx, Outset Medical, Precigen, Renalytx, and US Renal Care; Research Funding: AMAG Pharmaceuticals, Astra Zenca, Fibrogen, Kind Pharmaceuticals, and Pathalys Pharma; Honoraria: Bayer, Outset Medical, and Vifor Pharma; Advisory or Leadership Role: Chief Medical Officer, Christus Santa Rosa Westover Hills Hospital, and Health System Dialysis Medical Director; and Speakers Bureau: Bayer, Outset Medical, Natera, and Vifor Pharma. F.T. Chebib has received research and educational fellowship grant funding from Otsuka Pharmaceuticals. F.T. Chebib also reports Patents or Royalties: Patent no US20200368191A1; and Advisory or Leadership Role: PKD Foundation—Chair of Education Advisory Panel. N.K. Dahl reports Consultancy: Otsuka Pharmaceuticals; Research Funding: PI for clinical trials sponsored by Reata, and Vertex; Honoraria: Natera and Otsuka Pharmaceuticals; Advisory or Leadership Role: Natera Scientific Advisory Board and PKD Foundation; Speakers Bureau: on the unbranded speakers bureau for Otsuka until December 2022; and Other Interests or Relationships: Medical Advisory Board and NKF NE Chapter. R.A. Fatica reports Research Funding: Natera and Reata. A.G. Gharavi receives a research grant from Natera and has served on advisory boards for Natera through a service agreement with Columbia University. A.G. Gharavi has served on advisory boards for Actio Biosciences, Alnylam, Novartis, and Travere and has stock options for Actio Biosciences. A.G. Gharavi also reports Consultancy: Actio Biosciences, Alnylam, Novartis, and Travere; Research Funding: Renal Research Institute; Honoraria: Alnylam and Sanofi; and Advisory or Leadership Role: Editorial board: <i>JASN</i>, <i>Journal of Nephrology</i>, and <i>Science Advances</i>. S. Jandeska reports Employer: BioCryst Pharmaceuticals, Inc., Blue Comet Medical Solutions, LLC, Natera, Inc., and University Anesthesiologists, SC; and Ownership Interest: BioCryst Pharmaceuticals, Inc. and Natera, Inc. S. Punj reports Employer: LabCorp, Myriad Genetics, and Natera Inc.; and Ownership Interest: LabCorp, Myriad Genetics, and Natera Inc. D.S. Raj reports Consultancy: Novo Nordics; Research Funding: NIH; Honoraria: Novo Nordics; Advisory or Leadership Role: NIDDK, NHLBI, and Novo Nordics; and Other Interests or Relationships: American Association of Kidney Patients. H.M. Rasouly reports Research Funding: Natera. H. Tabriziani reports Consultancy: Natera; Patents or Royalties: Natera; Advisory or Leadership Role: Natera; Speakers Bureau: Natera; and Other Interests or Relationships: HossMed, Inc. Because A.G. Gharavi is an editor of the <i>JASN</i>, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript. All remaining authors have nothing to disclose.",
175,"Y. Cho reports research funding from Baxter Healthcare and Fresenius Medical Care; honoraria from Baxter Healthcare, Fresenius Medical Care, and Genzyme; research grants and speaker’s honoraria from Baxter Healthcare and Fresenius Medical Care; and other interests or relationships as Clinical Trialist and immediate past Chair of Peritoneal Dialysis Working Group for Australasian Kidney Trials Network, member of Coordinating Committee for Standardized Outcomes in Nephrology (SONG), and Chair of Australia and New Zealand Peritoneal Dialysis Academy (sponsored by Baxter Healthcare). She is a current recipient of the Australian Government National Health and Medical Research Council Emerging Leadership Investigator Grant and Queensland Health Advanced Clinical Fellowship (mid-career). M.B. Rivara reports serving on the Editorial Board of <i>CJASN</i>, on the Medical Executive Committee for Northwest Kidney Centers, and as an At-Large member of the North American Chapter Council for the International Society of Peritoneal Dialysis and reports other interests or relationships with National Kidney Foundation Project ECHO.",
176,"J. Hu reports employment with, ownership interest in, and patents or royalties from IBM. Y. Park reports employment with and ownership interest in Moderna.",
177,"P. Cockwell reports Advisory or Leadership Role: UK Kidney Association (President and Trustee); Speakers Bureau: Amgen; and Other Interests or Relationships: Boehringer Ingleheim—non-remunerated research collaboration, AstraZeneca—non-remunerated clinical development program, and Glaxo Smith Kline—non-remunerated sponsored session chair at ISN 2020. S.J. Elliman is an employee of and equity holder in Orbsen Therapeutics. He was not involved in recruitment or follow-up of participants enrolled in the trial, nor was involved in the collection, analysis, and interpretation of the data presented herein. S.J. Elliman also reports Research Funding: Orbsen Therapeutics; Patents or Royalties: Orbsen Therapeutics; and Speakers Bureau: Orbsen Therapeutics. W.E. Fibbe reports Consultancy: Boost Pharma, Glycostem Therapeutics (iDMC), and Starfish Innovations; and Advisory or Leadership Role: Starfish Innovations. M.D. Griffin reports honoraria from the American Society of Nephrology, Hebei Medical University in China, Novo Nordisk, and Théa Pharma Ltd. in Ireland, as well as advisory roles as an Editorial Board member for the journals <i>Frontiers in Pharmacology</i> and <i>Transplantation</i> and an Associate Editor for <i>JASN</i> and <i>Mayo Clinic Proceedings</i>. M.D. Griffin also reports Research Funding: Orbsen Therapeutics Ltd.; Honoraria: American Society of Nephrology and National Institutes of Health (NIDDK). T.P. Griffin reports Consultancy: Abbvie, AztraZeneca, Dexcom, Eli Lilly, and Novo Nordisk; Research Funding: Hardiman Scholarship from the College of Medicine, Nursing and Health Science at the National University of Ireland in Galway, a bursary from the Irish Endocrine Society/Royal College of Physicians of Ireland, and a grant from the European Commission Horizon 2020 Collaborative Health Project NEPHSTROM (grant number 634086); Honoraria: Abbvie, AztraZeneca, Dexcom, Eli Lilly, and Novonordisk; Advisory or Leadership Role: Irish Diabetes Technology Network—no fee, Diabetes Ireland Research Alliance—no fee; Speakers Bureau: Dexcom, Eli Lilly, and Novonordisk; and Other Interests or Relationships: Member of Diabetes UK, Irish Endocrine Society, ADA, EASD, TG and spouse have pensions that are invested by pension providers. TG and spouse not aware of the stocks purchased by these pension providers but could include pharmaceutical company stocks. TG collaborated with RANDOX Teronta and was a subinvestigator for studies conducted by Medtronic and Abbot. M. Introna reports Research Funding: Associazione Italiana Ricerca sul Cancro (AIRC), Fondazione Regionale per la Ricerca Biomedica Regione Lombardia (FRBB), and European Horizion 2017. T. O’Brien is a Director and Equity holder in Orbsen Therapeutics. He was not involved in recruitment or follow-up of participants enrolled in the trial, nor was involved in the collection, analysis, and interpretation of the data presented herein. T. O’Brien also reports Employer: University of Galway; Consultancy: AstraZeneca and Novo Nordisk; and Advisory or Leadership Role: Board member of Orbsen Therapeutics. G. Remuzzi reports Consultancy: Consulting fees: Alexion Pharmaceuticals, AstraZeneca Pharmaceuticals, Otsuka, and Silence Therapeutics; and Advisory or Leadership Role: member of numerous Editorial Boards of Scientific Medical Journals. J. Smythe reports Other Interests or Relationships: JACIE Inspector. M. Todeschini reports Employer: Recordati S.p.A. (spouse). All remaining authors have nothing to disclose. Because Matthew Griffin is an editor of the <i>Journal of the American Society of Nephrology</i>, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.",
178,"The authors of this article have a conflict of interest to disclose. A.P. is currently employed by and has an ownership interest in Natera, Inc. The remaining authors have nothing to disclose.",
179,"C. Arnott is supported by an NHMRC/MRFF Priority Fellowship and a NSW Health EMC Grant. G.M. Chertow has received fees from AstraZeneca for the DAPA-CKD trial steering committee, research grants from CSL Behring, NIAID, and NIDDK; he is on the board of directors for Satellite Healthcare, has received fees for advisory boards for Cricket, DiaMedica, and Reata. He holds stock options for Ardelyx, CloudCath, Durect, DxNow, Outset, Renibus, and Unicycive; has received fees from Akebia, Gilead, Sanifit, and Vertex for trial steering committees; and has received fees for DSMB service from Bayer, Gilead, Mineralys, Palladio and ReCor. G.M. Chertow also reports Consultancy: Akebia, Ardelyx, AstraZeneca, Calico, Gilead, Miromatrix, Reata, Sanifit, Unicycive, and Vertex; Ownership Interest: Eliaz Therapeutics, Physiowave, and PuraCath; Advisory or Leadership Role: Co-Editor, <i>Brenner and Rector's The Kidney</i> (Elsevier). R. Correa-Rotter has received consulting and/or speaker and/or advisory board fees from Amgen, AstraZeneca, Bayer, Boehringer, Chinook Therapeutics, GSK, Janssen, Novo Nordisk, and Sanofi. R. Correa-Rotter also reports Consultancy: Dimerix; Research Funding: Astra Zeneca, Baxter, GSK, and Novo Nordisk; Honoraria: Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Janssen, and Sanofi; Advisory or Leadership Role: Astra Zeneca, Bayer, GSK, Membership Steering Committee of DAPA-CKD, Membership Steering Committee FINEREAL, National Leader ASCEND study, National Leader FLOW study, Novo Nordisk, Editorial Board <i>Nefrologia Latinoamericana</i>, <i>Revista de Investigación Clinica</i>, <i>American Journal of Kidney Diseases</i>, <i>Frontiers in Nephrology</i> Associate Editor: <i>Blood Purification</i> Associate Editor; Speakers Bureau: Abbvie; and Other Interests or Relationships: Member of ASN, Member EDTA/ERA, Member of International Society of Nephrology, Member Latin American Society of Nephrology and Hypertension, Member Mexican Institute for Research in Nephrology, and Member of National Kidney Foundation. R.A. Fletcher is supported by a PhD studentship from the Health Data Research UK-The Alan Turing Institute Wellcome Trust Program in Health Data Science. This funding had no role in the production of this manuscript. R.A. Fletcher reports the following: Employer: The George Institute for Global Health and Sensyne Health PLC (employment ended August 2021). H.J.L. Heerspink is consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Gilead, Janssen, Merck, Novo Nordisk, ProKidney, Travere Therapeutics, and Vifor Fresenius. He has received research support from AstraZeneca, Boehringer Ingelheim, Janssen, and Novo Nordisk. H.J.L. Heerspink also reports Consultancy: Novartis; Honoraria: Lecture fees from AstraZeneca and Novo Nordisk; and Speakers Bureau: AstraZeneca. M.J. Jardine is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship; is responsible for research projects that have received unrestricted funding from Amgen, Baxter, Eli Lilly, and Merck Sharpe Dohme; serves on a Steering Committee sponsored by CSL; has served on advisory boards sponsored by Akebia, Baxter, Boehringer Ingelheim, and Vifor; and has spoken at scientific meetings sponsored by Janssen; with any consultancy, honoraria, or travel support paid to her institution. M.J. Jardine also reports the following: Research Funding: CSL and Dimerix with all payments to institution; Honoraria: AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, MSD, Occuryx, and Vifor, and directs honoraria to clinical research programs; Advisory or Leadership Role: Chinook and Janssen, All honoraria directed to clinical research programs; and Speakers Bureau: Astra Zeneca, Boehringer Ingelheim, Janssen, and directs speaker fees to clinical research programs. N. Jongs reports travel grants from AstraZeneca. K.W. Mahaffey has received research support from Afferent, Amgen, Apple Inc., AstraZeneca, Cardiva Medical Inc., Daiichi, Ferring, Google (Verily), Johnson & Johnson, Luitpold, Medtronic, Merck, National Institutes of Health, Novartis, Sanofi, St. Jude, and Tenax and has served as a consultant (speaker fees for continuing medical education events only) for Abbott, Ablynx, AstraZeneca, Baim Institute, Boehringer Ingelheim, Bristol-Myers Squibb, Elsevier, GlaxoSmithKline, Johnson & Johnson, MedErgy, Medscape, Mitsubishi Tanabe, Myokardia, NIH, Novartis, Novo Nordisk, Portola, Radiometer, Regeneron, Springer Publishing, and University of California, San Francisco. J.J.V. McMurray has received funding to his institution from Amgen and Cytokinetics for his participation in the Steering Committee for the ATOMIC-HF, COSMIC-HF, and GALACTIC-HF trials and meetings and other activities related to these trials; has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardurion, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; has received personal lecture fees from the Abbott, Corpus, Global Clinical Trial Partners (GCTP), Hikma, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director, and Sun Pharmaceuticals. B.L. Neuen has received fees for advisory boards, steering committee roles, scientific presentations, and travel support from AstraZeneca, Bayer, Boehringer Ingelheim, Cambridge Healthcare Research, Cornerstone Medical Education, Janssen, the Limbic, and Medscape, with all honoraria paid to his institution. B.L. Neuen also reports Consultancy: AstraZeneca, Bayer, Boehringer and Ingelheim, Cambridge Healthcare Research, and Janssen; Research Funding: Bayer; Honoraria: AstraZeneca, Bayer, Boehringer and Ingelheim, Cornerstone Medical Education, Janssen, the Limbic, and Medscape; Advisory or Leadership Role: AstraZeneca, Bayer, and Boehringer and Ingelheim; and Speakers Bureau: AstraZeneca and Boehringer and Ingelheim. V. Perkovic serves as a Board Director for St. Vincent's Health Australia, George Clinical and several Medical Research Institutes. He has received honoraria for Steering Committee roles, scientific presentations and/or advisory board attendance from Abbvie, Amgen, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, Chinook, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, Pharmalink, Reata, Relypsa, Roche, Sanofi, Servier, Travere, and Tricida. V. Perkovic also reports Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Travere, Tricida, and UptoDate; Ownership Interest: George Clinical; Research Funding: AstraZeneca, Bayer, Chinook, Gilead, GlaxoSmithKline, Janssen, Novartis, Novo Nordisk, Otsuka, Travere, and Tricida; Honoraria: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Travere, Tricida, and UptoDate. P. Rockenschaub is supported by the Alexander von Humboldt Foundation. P. Rossing declares receiving consultancy and/or speaking fees (to his institution) from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Novo Nordisk, Sanofi, and Vifor Pharma, and research grants from AstraZeneca, Bayer, and Novo Nordisk. P. Rossing also reports Honoraria: Abbott, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk, all honoraria to institution; and Advisory or Leadership Role: AstraZeneca, Bayer, Gilead, and Novo Nordisk, all honoraria to institution. R.D. Toto reports grant support from NIH and is a consultant to and has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Otsuka, Reata, and Relypsa. M. Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, speaker engagements with AstraZeneca, Novartis, and Roche Diagnostics, and participates on clinical trial committees for studies sponsored by Bayer AG, Galmed, Impulse Dynamics, Novartis, and Occlutech. M. Vaduganathan also reports Consultancy: American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; Research Funding: Galmed, Impulse Dynamics, and Occlutech; and Speakers Bureau: AstraZeneca, Cytokinetics, Lexicon Pharmaceuticals, Novartis, and Roche Diagnostics. D.C. Wheeler has received honoraria and/or consultancy fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Medscape, Merck Sharp and Dohme, Mundipharma, Napp, Reata, Takeda, Tricida, Vifor Fresenius, and Zydus. D.C. Wheeler also reports Consultancy: Astellas, Eledon, Galderma, George Clinical, Pfizer, and ProKidney; Advisory Boards, Trial Committees and Consultancy; Honoraria: Astellas and Pharmacosmos; Advisory or Leadership Role: AstraZeneca; and Speakers Bureau: Amgen, Astellas, AstraZeneca, Janssen, Merck Sharp and Dohme, Mundipharma, Napp, and Vifor Fresenius. K. Mahaffey reports Consultancy: Amgen, Applied Therapeutics, Bayer, BMS, BridgeBio, CSL Behring, Elsevier, Fibrogen, Fosun Pharma, Johnson & Johnson, Lexicon, Moderna, Myokardia, Novartis, Novo Nordisk, Otsuka, Phasebio, Portola, Quidel, Sanofi, Theravance; Research Funding: AHA, Apple Inc, Bayer, California Institute Regenerative Medicine, Eidos, Ferring, Gilead, Google (Verily), Idorsia, Johnson & Johnson, Luitpold, Novartis, PAC-12, Precordior, Sanifit; and Honoraria: Inova, Intermountain Health, Medscape, Mount Sinai, CSL. J. McMurray reports Consultancy: Personal Consultancy fees: Alynylam Pharmaceuticals, Bayer, BMS, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, River 2 Renal Corp.; Data Safety Monitoring Board: George Clinical PTY Ltd.; Honoraria: Personal lecture fees: Abbott, Alkem Metabolics, AZ, Blue Ocean Scientific Solutions Ltd., BI, Canadian Medical and Surgical Knowledge, Emcure Pharma., Eris Lifesciences, European Academy of CME, Hikma Pharma., Imagica Health, Intas Pharma., J.B. Chemicals & Pharma.., Lupin Pharma., Medscape/Heart.Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharma., The Corpus, Translation Research Group, Translational Medicine Academy.; Advisory or Leadership Role: employer, Glasgow University, has been paid for my participation in advisory boards organized by Novartis and AstraZeneca; and Other Interests or Relationships: Payments to my employer, Glasgow University, for my work on clinical trials, consulting and other activities: Amgen, AstraZeneca, Bayer, Cardurion, Cytokinetics, GSK, KBP Biosciences, Novartis; Director: Global Clinical Trial Partners Ltd (GCTP). C. Arnott reports Research Funding: Abbott Vascular; Honoraria: Amgen; Astra Zeneca, Novo Nordisk; and Advisory or Leadership Role: Novo Nordisk. R. Toto reports Consultancy: Amgen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Novartis, Novo Nordisk, CinCor, Calliditas, Otsuka, Medscape; Research Funding: NIH; Honoraria: Amgen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Novartis, Novo Nordisk, CinCor, Calliditas, Otsuka, Medscape; and Advisory or Leadership Role: Amgen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Novartis, Novo Nordisk, CinCor, Calliditas, Otsuka, Medscape.",
180,"J. Butler reports consulting fees from 3ivelabs, Abbott, American Regent, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element, Faraday, G3 Pharmaceutical, Imbria, Impulse Dynamics, Innolife, Inventiva, Ionis, Janssen, LivaNova, Lexicon, Medtronic, Merck, Novartis, Novo Nordisk, Otsuka, Occlutech, PharmaCosmos, Roche, Sanofi, Secretome, Sequana, Tricog, and Vifor and speakers bureau for AstraZeneca, Boehringer Ingelheim-Lilly, Impulse Dynamics, and Novartis. M.K. Hansen reports employment with Janssen Research & Development and ownership interest in Johnson & Johnson. H.J.L. Heerspink reports ongoing consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Gilead, Janssen, Merck, Novartis, Novo Nordisk, and Travere Pharmaceuticals; research funding from AstraZeneca, Boehringer Ingelheim, Janssen research support (grant funding directed to employer), and Novo Nordisk; lecture fees from AstraZeneca and NovoNordisk; and speakers bureau for AstraZeneca. J.L. Januzzi is supported by the Hutter Family Professorship, is a Trustee of the American College of Cardiology, and is a board member of Imbria Pharmaceuticals. J.L. Januzzi reports consultancy for Abbott Diagnostics, AstraZeneca, Bayer, Beckman-Coulter, Jana Care, Janssen, Novartis, Prevencio, Quidel, Roche Diagnostics, and Siemens; research funding from Abbott Diagnostics, Applied Therapeutics, AstraZeneca, Bayer, HeartFlow, Innolife, Novartis Pharmaceuticals, and Roche Diagnostics; clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, CVRx, Pfizer, and Takeda; and advisory or leadership roles for American College of Cardiology, Imbria, and Jana Care. M. Jardine reports employment with NHMRC Clinical Trials Centre; research funding from Baxter, CSL, and Dimerix with all payments to institution; honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, MSD, OccuRx, and Vifor, with honoraria directed to clinical research programs; advisory or leadership roles for AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Chinook, CSL, Janssen, OccuRx, and Vifor, with all honoraria directed to clinical research programs; and speakers bureau for AstraZeneca, Boehringer Ingelheim, Janssen, with speaker fees directed to clinical research programs. S. Masson reports employment with and patents or royalties from Roche Diagnostics International Ltd. C.A. Pollock reports consultancy for AstraZeneca and Vifor CSL; honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lily, GlaxoSmithKline, Novartis, Otsuka, and Vifor CSL; advisory or leadership roles for AstraZeneca, Boehringer Ingelheim, Janssen Cilag, Novartis, Otsuka, Pharmaxis, and Vifor CSL (all paid); advisory or leadership roles for Certa Therapeutics and Photobionic Research Institute (Unpaid); speakers bureau for Astellas, AstraZeneca, Boehringher Ingelheim/Eli Lily, and Otsuka; and other interests or relationships as Chair of Kidney Health Australia, Chair of the NSW Bureau of Health Information, Deputy Chair of Australian Organ Tissue and Transplant Authority, Director of Certa Therapeutics, and Director of Photobiomic Research Institute. N. Sattar reports consultancy for Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; research funding from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics; honoraria from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, and Novo Nordisk; and advisory or leadership roles as an Associate Editor of <i>Diabetes Care</i> and Editorial Board Member of <i>BMC Medicine</i> and <i>Diabetes & Metabolic Syndrome: Clinical Research & Reviews</i>. Y. Yavin reports employment with Janssen Research & Development and ownership interest in Bristol-Myers Squibb and Johnson & Johnson. All remaining authors have nothing to disclose.",
181,"A. Bick reports Ownership Interest: TenSixteen Bio. C.P. Chung reports Advisory or Leadership Role: Clinical Pharmacology and Therapeutics, Arthritis Care and Research, and Clinical Rheumatology. A.M. Hung reports Consultancy: NHLBI consultant for Gene and life interaction grant; Research Funding: VHA CSR&D Merit “Genetics of Kidney Disease & Hypertension, Risk Prediction and Drug Response,” Vertex Grant to VUMC; and Advisory or Leadership Role: Co-Chair Million Veteran Program Publications & Presentation committee for Veterans Affairs, Co-chair Pharmacogenomics for COVID-19 Million Veteran Program, Journal of renal nutrition, Section Editor Clinical Nephrology, Standing member SRC HSR&D bioinformatics, Ad-hoc SRC NHLBI, Ad-hoc Scientific Review Committee CSR&D, Ad-Scientific Review Committee KNOD. T.A. Ikizler reports Consultancy: Abbott Renal Care, Fresenius–Kabi, La Renon, Nestle; Honoraria: Fresenius–Kabi, Abbott Renal Care, La Renon, Nestle; Patents or Royalties: Vanderbilt University Medical Center; and Advisory or Leadership Role: Kidney International. L. Lipworth reports Research Funding: EpidStrategies. M.E. Matheny reports Consultancy: NIH-VA-DoD Pain Management Grant Consortium (PMC3); and Advisory or Leadership Role: SMRB Study Section, VA HSR&D, Informatics & Methods Section, Steering Committee—Indianapolis VA HSR&D COIN Center, Steering Committee—VA HSR&D VIREC, Steering Committee—Salt Lake City VA HSR&D COIN Center, and VA ORD Million Veterans Program Executive Steering Committee. C. Robinson-Cohen reports Advisory or Leadership Role: <i>Clinical Journal of the American Society of Nephrology</i> Editorial Board Member, and Clinical Nephrology Genetics Section Editor. E.D. Siew reports Ownership Interest: Amazon stock, Apple stock; Patents or Royalties: Author for UptoDate (royalties); and Advisory or Leadership Role: Editorial board of <i>CJASN</i>. All remaining authors have nothing to disclose.",
182,"Disclosure. The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Research funding was provided by Tonix Pharmaceuticals. Tonix Pharma has filed patent applications on the genetic modification of crystallizable fragment portion of 5c8 described in this article. B.D., S.F., and S.L. are employees of Tonix Pharmaceuticals.",
183,"M. Davidson is former CEO and CMO of Corvidia Therapeutics, which was the sponsor of the RESCUE trial prior to acquisition by Novo Nordisk. C. Jensen reports Ownership Interest: Novo Nordisk A/S. M. Davidson reports: Employer: Chief Executive Officer of New Amsterdam Pharma, Professor of Medicine and Director of the Lipid Clinic at the University of Chicago; Consultancy: Novo Nordisk; Advisory or Leadership Role: Caladrius BioScience, Tenax Therapeutics; and Speakers Bureau: Esperion, Astra Zeneca, AMGEN, and Regeneron. C. Jensen, A.A. Mohseni Zonoozi, and P. Andreas Schytz are employees of Novo Nordisk A/S. P. Andreas Schytz also reports Ownership Interest: Novo Nordisk; and Research Funding: Novo Nordisk. P.E. Pergola was an investigator in the RESCUE trial and is a consultant for GSK and Novo Nordisk. P.E. Pergola also reports Employer: Renal Associates, P.A.; Consultancy: Ardelyx, AstraZeneca, Bayer, Renibus, Unicycive; Ownership Interest: Unicycive Therapeutics; Research Funding: Principal or subinvestigator on multiple clinical trials (contracts are with practice, not individual); and Advisory or Leadership Role: Ardelyx, Unicycive. V. Perkovic is employed by University of New South Wales Sydney and the Royal North Shore Hospital; and serves as a board director for St Vincent's Health Australia, George Clinical, and several medical research institutes. He has received honoraria for steering committee roles, scientific presentations, and/or advisory board attendance from AbbVie, Amgen, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Chinook, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe Pharma Corporation, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, PharmaLink, Reata, Relypsa, Roche, Sanofi, Servier, Travere, and Tricida. V. Perkovic also reports Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Travere, Tricida, UptoDate; Ownership Interest: George Clinical; Research Funding: AstraZeneca, Bayer, Chinook, Gilead, GlaxoSmithKline, Janssen, Novartis, Novo Nordisk, Otsuka, Travere, Tricida; and Honoraria: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Travere, Tricida, UptoDate. D.S. Raj is supported by funding from the National Institutes of Health through 1 R01DK125256, R01 DK073665‐01A1, 1U01DK099924‐01, and 1U01DK099914‐01. He has received research funding from Relypsa and serves on the advisory board for Corvidia Therapeutics and Novo Nordisk. D.S. Raj also reports Consultancy: Novo Nordisk; Honoraria: Novo Nordisk; Advisory or Leadership Role: NHLBI; NIDDK; Novo Nordisk; and Other Interests or Relationships: American Association of Kidney Patients. K.R. Tuttle reports grants/contracts from the NIDDK/NIH, the NHLBI/NIH, the National Center for Advancing Translational Sciences (NCATS)/NIH, the Centers for Disease Control and Prevention (CDC) and Travere, and consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Goldfinch Bio, Novo Nordisk, and Travere. She has also received honoraria from AstraZeneca, Bayer, Eli Lilly, Gilead, and Goldfinch Bio, and support for travel and meetings from Eli Lilly and Novo Nordisk. K.R. Tuttle is Chair of a data safety monitoring board for the NIDDK/NIH and the George Clinical Institute and is also Chair of the Diabetic Kidney Disease Collaborative Task Force of the American Society of Nephrology. She was on the Board of Directors for the Kidney Health Initiative of the US Food and Drug Administration and American Society of Nephrology. K.R. Tuttle also reports Research Funding: Bayer; and Honoraria: Boehringer Ingelheim, and Novo Nordisk.",
184,"M.R.M. reports payments made to his institution from Abbott for consulting and consulting fees from Janssen, Mesoblast, Broadview Ventures, Natera, Paragonix, Moderna, and Baim Institute for Clinical Research; he is an advisory board member for NuPulseCV, Leviticus, and FineHeart. The other authors declare no conflicts of interest.",
185,"S. Bate reports Employer: Manchester University NHS Foundation Trust, and IQVIA. N. Brown reports Honoraria: Vifor. A. Dhaygude reports Honoraria: Astra Zeneca; and Advisory or Leadership Role: Vifor Pharma. V. Tesar reports Consultancy: Alexion, AstraZeneca, Baxter, Bayer, Boehringer- Ingelheim, Calliditas, Fresenius Medical Care, Eli Lilly, Novartis, Omeros, Otsuka, Pfizer, Sanofi, Swixx BioPharma, and Travere; Honoraria: For consultancy as follows: Alexion, AstraZeneca, Bayer, Boehringer-Ingelheim, Calliditas, Fresenius Medical Care, Eli Lilly, Novartis, Omeros, Pfizer, Swixx Biopharma, and Travere; and Advisory or Leadership Role: member of the B. Braun, Calliditas, Fresenius Medical Care, Novartis, Omeros, and Travere. S. McAdoo reports Consultancy: GSK, and Vifor; Research Funding: Therini Bio; Honoraria: Celltrion, Rigel Pharmaceuticals, and ThermoFisher Scientific; and Advisory or Leadership Role: Cochair United Kingdom & Ireland Vasculitis Society (unpaid). M.A. Little reports Consultancy: AnaptysBio, and LightStone; Research Funding: Vifor pharma; and Patents or Royalties: Euroimmun. D. Geetha reports Consultancy: ChemoCentryx as consultant and as an adjudicator for BVAS/VDI, Consultant Aurinia, and Consultant GSK. S.R. Brix reports consultancy: Vifor. C. Pusey reports Consultancy: Vifor, Alentis; Honoraria: Med Update Europe, Amgen; and Advisory or Leadership Role: <i>CJASN</i>. All remaining authors have nothing to disclose.",
186,"E.A. Brown reports consultancy agreements with AWAK, Baxter Healthcare, and LiberDi; speaker fees from Baxter Healthcare, Fresenius Medical Care, and Vifor; and advisory or leadership roles for AWAK, Baxter Healthcare, and LiberDi. R.W. Corbett reports serving as Chair of the Home Dialysis Workstream of the London Kidney Network. R.W. Corbett's spouse reports employing a research student funded by Astra Zeneca. All remaining authors have nothing to disclose.",
187,"L. Benning reports research funding from CareDx to the Department of Nephrology in the receipt of kits and supplies for donor-derived cell-free DNA testing; and reports honoraria from CareDx to the Department of Nephrology for panel discussions. G.A. Böhmig reports consultancy fees from Vitaeris Inc.; reports research funding from CareDx, MorphoSys, and Vitaeris Inc.; reports honoraria from Astellas, Fresenius Medical Care, Hansa Biopharma, One Lambda, and Sandoz; and reports advisory or leadership role with CSL Behring and Vitaeris Inc. D. Czock reports consultancy fees from Chiesi; and reports research funding from Chiesi and Daiichi-Sankyo. V. Daniel reports a patent on regulatory B cell development during MIC treatment. C. Kleist reports two patents on MIC treatment; and consultancy fees and honoraria from and ownership interest with TolerogenixX; and reports research funding from Heidelberg University Hospital. U. Merle reports honoraria from Falk. C. Morath reports a patent on MIC treatment; and employment and ownership interest with TolerogenixX; and reports research funding from Federal Ministry for Economic Affairs and Technology, Federal Ministry of Education and Research, and TolerogenixX. C. Müller-Tidow reports consultancy fees from Exeter Pharma Consultancy, MorphoSys, Takeda Pharma, The Kay Kendall Leukemia Fund, and Wilhelm Sander Stiftung; reports research funding from the German Cancer Research Center (DKFZ), The Kay Kendall Leukemia Fund, and Wilhelm Sander Stiftung; reports honoraria from DKFZ, Exeter Pharma Consultancy, MorphoSys, RG Gesellschaft für Information und Organisation mbH, The Kay Kendall Leukemia Fund, and Wilhelm Sander Stiftung; and reports advisory or leadership role with Janssen-Cilag. C. Nusshag reports research funding from Physician Scientist Programme of Heidelberg Faculty of Medicine; and reports research support from Sphingotec. G. Opelz reports two patents on MIC treatment; and advisory or leadership role with TolerogenixX. G. Ponath reports employment with TolerogenixX. J. Reiser is co-founder and shareholder of Trisaq, a biopharmaceutical company that develops novel therapy for kidney diseases; reports consultancy fees from Aclipse Therapeutics, GLG, Guidepoint, Mantra Bio, Merck, Novateur, Reata, Visterra, and Walden Biosciences; reports ownership interest with and research funding from Walden Biosciences; reports honoraria from Aclipse Therapeutics, GLG, Guidepoint, Mantra Bio, Merck, Novateur, Reata, and Visterra; reports patents or royalties: inventor on issued and pending patents pertinent to novel methods and treatments for proteinuric kidney diseases and stands to gain royalties from future commercialization; is scientific co-founder of Walden Biosciences, a biotechnology company (parts of his intellectual property have been outlicensed to Miltenyi Biotech); reports an advisory or leadership role with Walden Biosciences (co-chair of Scientific Advisory Board); and reports other interests or relationships with Nephcure Kidney International. M. Schaier reports a patent on MIC treatment; and employment and ownership interest with and research funding from TolerogenixX. A. Schmitt reports employment with University Hospital Heidelberg and TolerogenixX; reports consultancy fees from Bristol-Myers Squibb and Janssen-Cilag; reports ownership interest with TolerogenixX; reports research funding and honoraria from Mallinckrodt; reports patents or royalties from TolerogenixX; reports advisory or leadership role with Merck Sharp and Dohme; and reports other interests or relationships: co-founder and part-time employee of TolerogenixX. M. Schmitt reports consultancy fees from Hexal/Novartis; reports ownership interest as co-founder of TolerogenixX; reports research funding from Apogenix, Hexal/Novartis, and Mallinckrodt; reports honoraria from Amgen, Hexal/Novartis, and Teva; reports patents or royalties from TolerogenixX; and reports advisory or leadership role with Merck Sharp and Dohme, and acted as co-principal investigator of clinical trials for Merck Sharp and Dohme, GlaxoSmithKline, Kite, and Bristol-Myers Squibb. C. Süsal reports honoraria from CareDx; and reports patents or royalties from TolerogenixX. P. Terness reports two patents on MIC treatment; and consultancy fees and honoraria from TolerogenixX. L. Wang reports employment with TolerogenixX. M. Zeier reports ownership interest as co-founder of TolerogenixX; and reports patents or royalties: patent for MIC treatment. All remaining authors have nothing to disclose.",
188,"Models were fit using Cox proportional hazards regression with kidney failure as the event of interest and death treated as a competing risk. CCI, Charlson Comorbidity Index; CI, confidence interval; HR, hazard ratio; MGRS, monoclonal gammopathy of renal significance; MGUS, monoclonal gammopathy of undetermined significance. F.C. Fervenza reports employment with Mayo Clinic; consultancy for Alexion Pharmaceuticals, Amgen, ByoCryst Pharmaceuticals, Galapagos, GSK, Morphosys AG, Novartis, Otsuka, Takeda, Travere, and Zyversa Therapeutics; research funding from Chemocentryx, Genentech, Hoffman La Roche, Janssen Pharmaceutical, Morphosys, Retrophin, and Travere; unrestricted research grants from Genetech and Janssen pharmaceutical paid to Mayo Clinic; honoraria from UpToDate; and advisory or leadership roles for <i>JASN</i>, <i>Kidney International</i>, <i>Nephrology</i>, <i>Nephrology Dialysis and Transplantation</i>, and UpToDate. S. Moubarak and L. Vaughan report employment with Mayo Clinic. J.P.T. Sy-Go reports employment with Mayo Clinic Rochester (fellowship training) and Renal Physicians Hawaii, LLC (current employer). J.P.T. Sy-Go's spouse reports employment with Hawaii Infectious Disease Associates (current employer). J.K. Viehman reports employment with Mayo Clinic and NAMSA. L. Zand reports employment with Mayo Clinic, Rochester, MN; unrestricted research grants from Genetech and Janssen pharmaceutical paid to Mayo Clinic; and advisory or leadership roles for Calliditas Therapeutics and Travere Pharmaceuticals. The remaining author has nothing to disclose.",
189,"T. Alhamad reports consultancy for CareDx, Mallinckrod, and Veloxis; research funding from Angion, CareDx, Europhines, and Natera; honoraria from CareDx, Sanofi, and Veloxis; an advisory or leadership role for CareDx, Europhines, and QSANT; and participation in a speakers’ bureau for CareDx, Sanofi, and Veloxis. D.C. Brennan reports consultancy for CareDx, Hansa, Medeor Therapeutics, Sanofi, and Vera Therapeutics; research funding from Amplyx (Vera Therapeutics), Allovir, CareDx, and Natera; honoraria from CareDx and Sanofi; and an advisory or leadership role for Transplantation and UpToDate (on editorial boards). J.S. Bromberg reports consultancy for Eurofins and Pfizer; research funding from Angion, Astellas, CareDx, Natera, Novartis, and Quark; and an advisory or leadership role for the National Institutes of Health and <i>Transplantation</i>. S. Bunnapradist reports consultancy for CareDx, Natera, Nephrosant, Takeda, Transplant Genomics, and Veloxis; research funding from Allovir, Astellas, CareDx, Merck, Natera, and Transplant Genomics; honoraria from Astellas, Allovir, CareDx, Merck, Natera, Nephrosant, Sanofi, Takeda, Transplant Genomics, and Veloxis; and participation in a speakers’ bureau for CareDx, Natera, Nephrosant, Sanofi, Takeda, Transplant Genomics, and Veloxis. S. Chandran reports consultancy for Bridge Bio Gene Therapy and Everest Clinical Research. R.L. Fairchild reports consultancy for Eurofins/Viracor; royalties from Eurofins/Viracor for a license monitoring urine RNA from kidney transplant patients for gene expression signature indicating T cell–mediated rejection; and an advisory or leadership role for Eurofins/Viracor (scientific advisory board). R. Formica reports consultancy for Mallinckrodt Pharmaceuticals, Sanofi, and Veloxis Pharmaceuticals; participation in a speakers’ bureau for Sanofi (nonbranded educational lectures); and other interests or relationships with OPTN (member of the board of directors). K. Kesler reports being an employee of Rho, Inc. S.J. Kim reports an advisory or leadership role for the Canadian Blood Services, Canadian Organ Replacement Register, Canadian Society of Transplantation, Eledon Pharmaceuticals (Data Monitoring Committee member for phase 1b trial; paid), and Health Canada. R.B. Mannon reports research funding from Transplant Genomics, Inc., Verici DX; honoraria from CSL Behring, Olaris Inc., and Vitaerris; patents or royalties for Eurofins; an advisory or leadership role for Verici Dx (steering committee) and the Vitaerris VKTX01 IMAGINE Trial (steering committee); and other interests or relationships with the American Society of Nephrology (grants committee, chair of the policy and advocacy committee), the Data and Safety Monitoring Board, the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health, the Scientific Registry of Transplant Recipients Review Committee (co-chair), TTS 2020 and 2022 (program committee), and Women in Transplantation (chair). M.C. Menon reports ownership interest in Renalytix AI; research funding from Natera Pharmaceuticals and the National Institute of Diabetes and Digestive and Kidney Diseases; and an advisory or leadership role for the American Society of Transplantation (scientific review committee), <i>Clinical Transplantation</i> (associate editor), <i>JASN</i> (editorial fellow of the transplantation section 2020), and the <i>Journal of Clinical Medicine</i> (editorial board). K.A. Newell reports consultancy for Care Dx, CSL Behring, Hansa, Immucor, Sangamo, Takeda, and Talaris Therapeutics. P. Nickerson reports consultancy for CSL Behring and Paladin Labs; research funding from the National Institutes of Health; and honoraria from Astellas and One Lambda. E.D. Poggio reports consultancy for CareDx, Transplant Genomics, and Verici; and honoraria from CareDx, Gador, Natera, Sanofi, and Scienzia. R. Sung reports research funding from Talaris Therapeutics and other interests or relationships with the American Society of Transplant Surgeons, Gift of Life Michigan, National Kidney Foundation of Michigan, and Organ Donation and Transplantation Alliance. R. Shapiro reports other interests or relationships with <i>Clinical Transplantation</i> (editor in chief). F. Vincenti reports research funding from Angion, Astellas, CSL Behring, Merck, Novartis, Pfizer, and Viela Bio; and honoraria from Veloxis. P.S. Heeger reports consultancy for Mallinckrodt Pharmaceuticals and Vertex; honoraria from Mallinckrodt Pharmaceuticals and Vertex; and an advisory or leadership role for Mallinckrodt Pharmaceuticals (paid scientific consultant) and Vertex (paid scientific consultant). All remaining authors have nothing to disclose.",
190,"D.T. Gilbertson reports employment with Chronic Disease Research Group; consultancy for Amgen; and research funding from Amgen, DaVita, GSK, HRSA, Merck, and NIH. K.L. Johansen reports employment with Hennepin Healthcare; consultancy for Akebia, CSL Vifor, and GSK; and an advisory or leadership role for GSK and as an Associate Editor of <i>JASN</i>. N.S. Roetker reports employment with Hennepin Healthcare Research Institute and research funding from Amgen, CDC, Merck, and NIH. J.B. Wetmore reports employment with Hennepin Healthcare; consultancy for BMS-Pfizer Alliance; research funding from Amgen, AstraZeneca, Bristol-Myers Squibb-Pfizer alliance (ARISTA investigator-initiated research program), Genentech, GlaxoSmithKline, Merck, NIH (NIDDK and NHLBI), and OPKO Health; honoraria from BMS-Pfizer Alliance and Vifor; fees from Vifor for CME-eligible activities; and honoraria for educational activities (CME-eligible) for NephSAP (ASN) and Healio.",
191,The other authors declare that they have no relevant financial interests.,No
192,"A.S. Levey reports receiving research funding from grants and contracts paid to Tufts Medical Center from NIH and NKF; reports contracts to paid from AstraZeneca (Data and Safety Monitoring Board (DSMB) for dapagliflozin trials); and reports receiving honoraria from academic medical centers for visiting professorships. H.A. Taylor reports having consultancy agreements with Pfizer, Novartis, and United Health Group (UHG); reports receiving research funding from 23andMe and UHG; and reports receiving honoraria from Pfizer, Novartis, and UHG. I.S. Kohane reports having consultancy agreements with Danaher; reports having an ownership interest in Activate Care, Canary Medical, and Inovalon; reports receiving honoraria from Janssen; and reports having an advisory or leadership role with Activate Care, Canary Medical, and Inovalon. J.K. Wang reports employment with PathAI; and having consultancy agreements with Prometheus Biosciences. L.A. Inker reports having consultancy agreements with Diamtrix; receiving research funding from to institute for research and contracts with the Chinnocks, NIH, NKF, Omeros, and Reata Pharmaceuticals; reports having consulting agreements with Tricida Inc.; reports having an advisory or leadership role with the Alport Foundation Medical Advisory Council and the NKF Scientific Advisory Board; and reports having other interests or relationships as an American Society of Nephrology member and an NKF member. N.R. Powe reports having an advisory or leadership role with Hennepin Health Care Research Institute, Patient Centered Outcomes Research Institute, Portland VA Research Foundation, Robert Wood Johnson Foundation, University of Washington, and Vanderbilt University. Because N.R. Powe is an associate editor of the <i>Journal of the American Society of Nephrology</i>, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript. All remaining authors have nothing to disclose.",
193,<b>Financial Disclosure</b>: The authors declare that they have no relevant financial interests.,No
194,"A.K. Bello reports consultancy for Amgen Incorporated, Bayer, GSK, and Otsuka; honoraria from Amgen and Otsuka; and advisory or leadership roles as Associate Editor for <i>Canadian Journal of Kidney Health and Disease</i> and Co-chair of ISN-Global Kidney Health Atlas. A.K. Bello received a Care Improvement Grant for early CKD management from Amgen Canada Incorporated and a Canadian Institutes of Health Research Strategy for Patient Oriented Research Grant for CKD management in primary care, not related to this work. All remaining authors have nothing to disclose.",
195,"S.W. Chen reports employment with Brigham and Women's Hospital and Joslin Diabetes Center. C.P. Corona-Villalobos reports employment with Johns Hopkins University. I.H. de Boer reports consultancy for Alnylam, AstraZeneca, Bayer, Boehringer-Ingelheim, Boehringer-Ingelheim/Lilly, George Clinical, Gilead, Medscape, and Otsuka; research funding from DexCom and Novo Nordisk; honoraria from National Intitutes of Health; and advisory or leadership roles as a Deputy Editor of <i>CJASN</i>, Chair of American Heart Association Kidney in Heart Disease Science Committee, and Clinical Practice Guideline Co-Chair of Kidney Disease Improving Global Outcomes. A.L. Dighe reports ownership interest in Electronic Arts and Microsoft. J. Himmelfarb reports consultancy for Maze Therapeutics; ownership interest in Kuleana Technology, Inc.; research funding from Aurinia Pharmaceuticals; honoraria from various academic institutions for invited lectures; patents held and patents pending owned by the University of Washington; and advisory or leadership roles for <i>BMC Medicine</i> Editorial Board, <i>CJASN</i> Editorial Board, and <i>Nature Reviews Nephrology</i> Advisory Board; research grant support from Northwest Kidney Centers; and other interests or relationships as CEO, Founder, President, and equity holder of Kuleana Technology, Inc. G.V. Roberts is the Director of External Relations and Patient Engagement at the Kidney Research Institute and Center for Dialysis Innovation in the Division of Nephrology at the University of WA and reports ownership interest in Options Unlimited International (50%), honoraria from ProKidney, and University of Washington patent titled “Water-Conserving Kidney Dialysis System Incorporating Urea Phot-Oxidation”; advisory or leadership roles for Center for Innovations in Cancer and Transplants chair of Community Engagement (Eng.) Committee (Comm.) (CEC), CDI Patient Advisory Board, C-Path Patient Eng. Committee and DIKI Project, KHI Board of Directors, Kidney Precision Medicine Project CEC, KRI Patient Advisory Committee, LifeCenter NW Advisory Board, Expert Patient Panel for CRIC Study, and University of Minnesota’s Office of Discovery and Translation: Reduce Medication-Related Disparities in African American Patients with CKD; speakers bureau for the American Association of Kidney Patients; and other interests or relationships with American Association of Kidney Patients, APOLLO, APOLLO CAB, ASN COVID-19 Response Team and Transplant Subcommittee, ASN NTSD QAIE WG, Can-SOLVE CIRAC, CPATH BmDR Charter/Governance BioMarkers WG, HDU Advisory Committee, International Nephrology Society (ISN) Patient Group, KAC Diversity WG and Patient Education Series, KDIGO CKD and Complications in Dialysis WGs, KHI APOL1 Steering Committee, NKF Ambassador, and NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. G.V. Roberts receives honoraria from the NIH-NIDDK APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) study and the Kidney Precision Medicine Project and is supported by 2U24DK114886-06 NIH/NIDDK, R01 DK126373 NIH/NIDDK, Northwest Kidney Centers—Center for Dialysis Innovation, STUDY00014861: MRD-AA-CKD University of Minnesota. G.V. Roberts’s spouse reports consultancy for Vorsitz. K.R. Tuttle reports consultancy for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Travere and research funding from Bayer and Travere; support by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, and UM1AI109568 and CDC contract 75D301-21-P-12254; consultancy and speaker for Novo Nordisk; and honoraria from Bayer, Boehringer Ingelheim, and Novo Nordisk. All remaining authors have nothing to disclose.",
196,<b>Financial Disclosure:</b> CJD reports consultancy with UnitedHealth Group. MLM reports ownership of Amgen stock due to his spouse’s employment. The remaining authors declare that they have no relevant financial interests.,
197,"S.O. Pastan reports advisory or leadership roles for BOD ESRD Network 6, BOD of the National Forum of Networks, and the Advisory Board for the nonprofit Kidney Transplant Collaborative and serving as an Associate Editor of <i>Kidney International Reports</i>. S.O. Pastan’s spouse owns Johnson & Johnson stock. R.E. Patzer reports serving on the Editorial Board of <i>American Journal of Transplantation</i> and <i>CJASN</i> and serving as Chair of United Network for Organ Sharing Data Advisory Board. R.E. Patzer’s spouse is a chief medical officer at Vital ER and has ownership interest in Vital Software. S. Paul reports ownership interest in Amazon, Visa, and Zoom. M. Urbanski reports serving on the Editorial Board of <i>Journal of Nephrology Social Work</i> (unpaid) and as Region 3 Representative on the UNOS Ethics Committee (unpaid). A. Wilk reports ownership interest in UnitedHealth Group. All remaining authors have nothing to disclose.",
198,"T. Fairhead reports honoraria from Alexion and Astellas; advisory or leadership roles for Alexion, Astellas, and AstraZeneca; and speakers bureau for Alexion. P. Giguère reports consultancy for Gilead Sciences and Merck. S. Hiremath reports research salary support from the Department of Medicine, University of Ottawa; serving on the Editorial Boards of <i>American Journal of Hypertension</i>, <i>American Journal of Kidney Disease</i>, and <i>Canadian Journal of Cardiology</i>; and serving on the Board of Directors of NephJC (not-for-profit educational entity; unpaid volunteer position). G. Knoll reports serving on the Editorial Board of <i>Canadian Journal of Kidney Health and Disease</i>. M. McGuinty reports research funding from VBI. All remaining authors have nothing to disclose.",
199,"L. Barisoni reports Consultancy: Protalix, Sangamo, and Vertex; Honoraria: Protalix, Sangamo, and Vertex; Advisory or Leadership Role: <i>Glomerular Disease Journal</i>, <i>Nature Review Nephrology</i>, and Nephcure Scientific Advisory Board; and Other Interests or Relationships: Nephcure. B.C. Leibovich reports Ownership Interest: Pathright Medical; and Advisory or Leadership Role: Kidney Cancer Association. A.D. Rule reports Patents or Royalties: UpToDate; and Advisory or Leadership Role: <i>JASN</i>—Associate Editor, <i>Mayo Clinic Proceedings</i>—Section Editor, and NIDDK—Urological Diseases of America Contract Management Board. M.D. Stegall reports Consultancy: Aiosyn, eGenesis, Hansa, and Novartis; Research Funding: Janssen, Talaris, and Veloxis; and Advisory or Leadership Role: Aisosyn and eGenesis. All remaining authors have nothing to disclose.",
200,"M.E.T. and F.P.V. received support from the Robert W. Faulk Career Development Award, and M.E.T. received support from the Mayo Clinic Transplant Center Scholarly Award. M.C.H. received funding from the Center for Individualized Medicine Research Award. The authors declare no conflicts of interest.",No
201,A.C. is supported by a grant from NIAID (K08AI166021-01). The other author declares no conflicts of interest.,
202,<b>Financial Disclosure:</b>The authors declare that they have no relevant financial interests.,
203,"R.J. Galindo reports consultancy agreements with Eli Lilly, Sanofi, Pfizer, Boehringer-Ingelheim, Merck, and Weight Watchers and research support to Emory University for studies from Dexcom, Eli Lilly, and Novo Nordisk. I.H. de Boer reports consultancy agreements with AstraZeneca, Bayer, Boehringer-Ingelheim, Boehringer-Ingelheim/Lilly, Cyclerion Therapeutics, George Clinical, Gilead, Goldfinch Bio, Ironwood Pharmaceuticals, Medscape, and Otsuka; research funding from DexCom; honoraria from the National Institutes of Health; and serving as a deputy editor of <i>CJASN</i>, an associate editor of <i>Contemporary Clinical Trials</i>, and a Clinical Practice Guideline Cochair of Kidney Disease Improving Global Outcomes. J.J. Neumiller reports consultancy agreements with Bayer, Novo Nordisk, and Sanofi; honoraria from the American Diabetes Association for serving on the editorial board; an advisory or leadership role with the American Diabetes Association; and speakers bureau for Dexcom. K.R. Tuttle reports consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, Goldfinch Bio, Janssen, Novo Nordisk, and Travere; research funding from Bayer, Goldfinch Bio, and Travere; honoraria from Bayer, Boehringer Ingelheim, Gilead, and Novo Nordisk; other support from Gilead and Eli Lilly; personal fees and other support from AstraZeneca and Boehringer Ingelheim; grants, personal fees, and other support from Bayer AG and Novo Nordisk; grants and other support from Goldfinch Bio; and grants from Travere and is supported by National Institutes of Health research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, and UM1AI109568 and Centers for Disease Control and Prevent project 75D301-21-P-1225.",
204,"I.H. de Boer reports consultancy for Alnylam, AstraZeneca, Bayer, Boehringer-Ingelheim, Boehringer-Ingelheim/Lilly, Cyclerion Therapeutics, George Clinical, Gilead, Goldfinch Bio, Ironwood, Lilly, Medscape, and Otsuka; research funding from DexCom and Novo Nordisk; research equipment and supplies from DexCom; honoraria from National Institutes of Health; and advisory or leadership roles as a Deputy Editor of <i>CJASN</i>, Chair of the American Heart Association Kidney in Heart Disease Science Committee, and Kidney Disease Improving Global Outcomes Clinical Practice Guideline Co-Chair. A. Doria reports speakers bureau for Novo Nordisk though Aristea “D-zOne Project: Global perspectives for diabetes and obesity management: getting out of the comfort zone”—November 26, 2021. A. Galecki reports research funding from JDRF and NIH, patents or royalties from Springer and Taylor Francis, and an advisory or leadership role for <i>Journal of Applied Statistics</i>. I.B. Hirsch reports consultancy for Abbott, embecta, Hagar, and LifeScan; research funding from Dexcom, Insulet, and Mannkind; and honoraria from UpToDate. A.N. Hoofnagle reports consultancy for Kilpatrick Townsend & Stockton LLP, ownership interest in Seattle Genetics, grant and equipment support from Waters, Inc., patents or royalties from SISCAPA Assay Technologies, an advisory or leadership role for <i>Clinical Chemistry</i> (Associate Editor), and other interests or relationships as an expert witness for Kilpatrick, Stockton, LLC, and Townsend. B.R. Kestenbaum reports consultancy for Launch Therapeutics. H.C. Looker and R.G. Nelson report employment with National Institutes of Health. M. Mauer reports consultancy for Acelink, Acelink Therapeutics, Amicus, Avrobio, Chiesi, Freeline Therapeutics, Sangano, Sanofi/Genzyme, and uniQure; research funding from Amicus, Freeline Therapeutics, Janssen Research and Development, and Sanofi/Genzyme; honoraria from Acelink Therapeutics, Amicus, Freeline Therapeutics, Sanofi/Genzyme, and uniQure; and advisory or leadership role for International Fabry Registry Board and North American Fabry Registry Board. S.S. Waikar reports consultancy for Bain, BioMarin, CANbridge, Goldfinch, Google, GSK, Ikena, Mineralys, Novo Nordisk, Ono, PepGen, Sironax, Strataca, Vertex, and Wolters Kluwer; research funding from JNJ, Natera, Pfizer, and Vertex; and other interests or relationships as an expert witness for litigation related to dialysis laboratory testing (DaVita), PPIs (Pfizer), PFAO exposure (Dechert), and voclosporin patent (Aurinia). S.S. Waikar's spouse reports employment with Advanced Clinical. All remaining authors have nothing to disclose.",
205,"J.A. Neyra reports consultancy for AcelRx, Baxter, Leadiant Biosciences, Outset Medical, and Vifor Pharma; advisory or leadership roles as a Guest Editor for Critical Care Nephrology in <i>Advances in Chronic Kidney Disease</i> and a Section Editor for <i>Clinical Nephrology</i>; roles on the Editorial Boards of <i>Advances in Chronic Kidney Disease</i>, <i>American Journal of Kidney Diseases</i>, and <i>Kidney360</i>. The remaining author has nothing to disclose.",
206,DISCLOSURE. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. Declaration of interests. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.,No
207,"J.C. Craig reports serving as Vice President of Flinders University and Coordinating Editor of <i>Cochrane Kidney and Transplant</i> and serving on the Editorial Boards of <i>Clinical Epidemiology</i> and <i>Prognosis and Diagnosis Research</i>. S. Kim reports serving as IPNA Juniors Committee ANZPNA Representative and TSANZ SPEC Committee Member. W. Lim reports research funding from AstraZeneca (education grant), honoraria from Alexion and Astellas, and advisory or leadership roles for Alexion and Astellas. H. McCarthy reports ownership interest in Australian Foundation Investment Company Limited, BHP Group Limited, Sonic Healthcare Limited, and Woodside Energy Group Limited. All remaining authors have nothing to disclose.",
208,"P. Cockwell reports advisory or leadership role for UK Kidney Association (President and Trustee); speakers bureau for Amgen; participation in an education forum, the myeloma knowledge exchange, funded by Amgen; and other interests or relationships with AstraZeneca—nonremunerated clinical development programme, Boehringer Ingleheim—nonremunerated research collaboration, and GlaxoSmithKline—nonremunerated sponsored session chair at ISN 2020. J.H. Pinney reports employment with University Hospitals Birmingham NHS Foundation Trust. G. Pratt reports employment with University Hospitals Birmingham NHS Foundation Trust; consultancy for Amgen, Beigene, Binding Site, BMS, Janssen, Prothena, Sanofi, and Takeda; research funding from Binding Site; honoraria from Amgen, Beigene, Binding Site, BMS, Janssen, Prothena, Sanofi, and Takeda; and speakers bureau for Beigene, BMS, Janssen, Sanofi, and Takeda.",
209,"J.A. Neyra reports serving on the editorial boards of <i>Advances in Chronic Kidney Disease</i>, <i>American Journal of Kidney Diseases</i>, and <i>Kidney360</i>; serving as a guest editor for critical care nephrology in <i>Advances in Chronic Kidney Disease</i> and a section editor for <i>Clinical Nephrology</i>; and having consultancy agreements with Baxter Healthcare Inc., Biomedical Insights, and Leadiant Biosciences. J.P. Teixeira reports receiving research funding from Astute Medical/bioMérieux, La Jolla Pharmaceutical Company, Pfizer, Rediscovery Life Sciences LLC, and Sentien Biotechnologies Inc.; having ownership interest <i>via</i> current or previous stocks and/or options (in the last 24 months) in Clever Leaves Holdings, Flora Growth Corp., Green Thumb Industries Inc., Juva Life Inc., NeoGenomics Inc., Novocure Ltd., and Novo Nordisk A/S; and having consultancy agreements with, and serving on a speakers bureau for, Outset Medical. J.P. Teixeira's spouse reports honoraria from Cara Therapeutics. A. Tolwani reports serving on a speakers bureau for Baxter; having a patent on 0.5% trisodium citrate solution for CRRT anticoagulation (the license has been bought by Baxter); having consultancy agreements with Baxter Healthcare; serving on the editorial boards of <i>CJASN</i> and <i>Kidney International</i>; and receiving honoraria from UpToDate.",
210,"R. Borg reports Consultancy: AstraZeneca, Bayer, and Boehringer Ingelheim; Research Funding: AstraZeneca, Boehringer Ingelheim, and NovoNordic Foundation; Honoraria: AstraZeneca, Bayer, and Boehringer Ingelheim; and Advisory or Leadership Role: AstraZeneca, Bayer, and Boehringer Ingelheim. L. Brandi reports Honoraria: Astellas. I. Bressendorff reports Research Funding: Novo Nordisk Foundation. N. Carlson reports Speakers Bureau: AstraZeneca—Lecture fees and Bristol Myers Squibb—Lecture fees. D. Hansen reports Research Funding: AstraZeneca A/S, Bayer A/S, Boehringer Ingelheim, Gedeon Richter, Kappa Bioscience AS, and Vifor Pharma; Advisory or Leadership Role: Pharmacosmos; and Speakers Bureau: AstraZeneca A/S and UCB Nordic. C.H. Kristiansen reports Employers: Akershus University Hospital, Oslo Metropolitan University, and Philips Healthcare. A. Pasch is a founder, stockholder, and employee of Calciscon AG, Bern, Switzerland, which commercializes the T<sub>50</sub> test. A. Pasch also reports the following: Employer: Biel, Switzerland; Ownership Interest: Biel, Switzerland; and Patents or Royalties: Calciscon AG, Biel, Switzerland. M. Schou reports Honoraria: AstraZeneca, Boehringer Ingelheim, Novartis, and Novo Nordisk; and Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Novartis, and Novo Nordisk. The remaining authors have nothing to disclose.",
211,"T. Wiech reports honoraria: Alexion, Bayer, GlaxoSmithKline GmbH, Novartis and advisory or leadership role: Novartis and Retrophin. M. Machalitza reports other interests or relationships: Stipend of the Else Kröner-Promotionskolleg Hamburg, translationale Euroimmun. S. Peine reports consultancy: Cerus Cooperation. R. Stahl reports patents or royalties: EUROIMMUN, Germany. E. Hoxha reports consultancy: Morphosys AG, Novartis and research funding: Deutsche Forschungsgemeinschaft. M. Rinschen reports honoraria: JASN, Physiological Genomics and advisory or leadership role: Editorial board American Physiology—Renal Physiology, Editorial board JASN, and Editorial board Physiological Genomics. Because M. Rinschen is an editor of the Journal of the American Society of Nephrology, he was not involved in the peer review process for this manuscript. Another editor oversaw the peer review and decision-making process for this manuscript. All remaining authors have nothing to disclose.",
212,"N.L. De La Mata reports Honoraria: Research square. J. Hedley reports Employer: Spouse employed by Carbon Revolution; and Ownership Interest: Carbon Revolution. S. Kim reports Other Interests or Relationships: IPNA Juniors Committee ANZPNA Representative and TSANZ SPEC Committee Member. A.C. Webster reports Advisory or Leadership Role: various editorial roles all unpaid and various data-related roles (clinical quality registry, trial registry) all unpaid. M.L. Wyld reports Advisory or Leadership Role: CMV Advisory Board, Takeda Pharmaceuticals (Declined payment offer). The remaining author has nothing to disclose.",
213,"P.G. Blake reports honoraria from Baxter Global and Otsuka Australia; advisory or leadership role as a contracted Medical Lead of Ontario Renal Network, Ontario Health—this is a paid role; and serving on the Editorial Board of <i>American Journal of Nephrology</i>. K.S. Brimble reports serving as a contracted medical lead of Ontario Renal Network, Ontario Health. R. Cooper, J. Ip, Y. Tang, D. Thomas, and A. Yeung are salaried employees of Ontario Renal Network, Ontario Health. M.A. Hladunewich reports consultancy agreements with Alnylam Pharmaceuticals; research funding from Calliditas Therapeutics, Chemocentryx, Ionis, Pfizer, and Roche; advisory or leadership roles for <i>Kidney International</i> and UpToDate; and other interests or relationships as medical lead for Glomerular Disease Ontario Renal Network. A. Levin reports employment with BC Provincial Renal Agency and Providence health Care; consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, Chinook Therapeutics, GSK, Janssen, Kidney Foundation of Canada, NIH, Otsuka, and REATA; research funding from AstraZeneca, Boehringer Ingelheim, Canadian Institute of Health Research (CIHR), CITF (Canadian Immunology Task Force), GSK, Health Research BC, Kidney Foundation of Canada, MOH BC, and Shared Care BC; honoraria from AstraZeneca, Bayer, GSK, Janssen, and NIH; advisory or leadership roles for AstraZeneca, Boehringer Ingelheim, CADTH, Chinook Therapeutics, CITF, GSK, KRESCENT (Kidney Scientist Education Research National Training Program), NIDDK, REATA BC Renal (Exec Director), and Steering Committee Chair CURE Consortium; DSMB for NIDDK, Kidney Precision Medicine, U Washington Kidney Research Institute Scientific Advisory Committee; International Society of Nephrology Research Committee; and other interests or relationships as CREDENCE National Coordinator from Janssen - directed to her academic team, NIDDK CURE Chair Steering Committee, International Society of Nephrology, Canadian Society of Nephrology, Kidney Foundation of Canada Steering Committee ALIGN trial, and DSMB Chair RESOLVE Trial (Australian Clinical Trial Network). M.J. Oliver is the sole owner of Oliver Medical Management Inc., which is a private corporation that licenses the Dialysis Measurement Analysis and Reporting (DMAR) software system. Oliver Medical Management Inc. is co-owner of a Canadian Patent for DMAR systems. M.J. Oliver is a contracted medical lead at Ontario Renal Network Ontario Health, reports honoraria from Baxter Healthcare, participated in advisory boards for Amgen and Janssen, and reports other interests or relationships with Ontario Health. All remaining authors have nothing to disclose.",
214,E.G. Clark and M. Canney report serving on the editorial board of <i>Canadian Journal of Kidney Health and Disease</i> and being employed by Nephrology Partners of Ottawa. All remaining authors have nothing to disclose.,
215,"L.P. Gregg is supported by a Veterans Affairs Clinical Sciences Research and Development Career Development Award (IK2CX002368) and serves as a <i>JASN</i> Editorial Fellow. A. Kronbichler reports consultancy for Catalyst Biosciences, CSL Vifor, Delta4, GSK, Otsuka, and Walden Biosciences; research funding for CSL Vifor and Otsuka; honoraria from CSL Vifor and Otsuka; an advisory or leadership role for the European Renal Association (Immunonephrology Working Group and Electronic Communication Committee); and serves as a <i>JASN</i> Editorial Fellow. J. Bargman reports Consultancy: Davita Healthcare Partners; Glaxo Smith Kline; Bayer,Otsuka; Honoraria: Baxter Healthcare, Davita Healthcare Partners, Glaxo Smith Kline; Advisory or Leadership Role: Editorial Boards: <i>Journal of the American Society of Nephrology</i>, <i>Peritoneal Dialysis International</i>, <i>Clinical Journal of the American Society of Nephrology</i>; Associate Editor for JASN; and Speakers Bureau: DaVita Healthcare Partners, Baxter Canada, Baxter Global, Glaxo Smith Kline.",
216,"B.A. Grimes reports Ownership Interest: Cisco, Mattel, and Oracle. L. Inker reports Consultancy: Diamtrix; Research Funding: funding to institute for research and contracts with the Chinnocks, National Institutes of Health, National Kidney Foundation, Omeros and Reata Pharmaceuticals; consulting agreements with Tricida Inc.; Advisory or Leadership Role: Alport Foundation—Medical Advisory Council, NKF—Scientific Advisory Board; and Other Interests or Relationships: American Society of Nephrology member, National Kidney Foundation member. E. Ku reports Ownership Interest: Edison Company; Research Funding: CareDX, Natera, NIH; and Advisory or Leadership Role: American Kidney Fund Health Equity Coalition, AJKD Associate Editor. G. Remuzzi reports Consultancy: Alexion Pharmaceuticals, AstraZeneca, Menarini Ricerche Spa, Otsuka, Silence Therapeutics; and Advisory or Leadership Role: member of numerous Editorial Boards of Scientific Medical Journals. M.J. Sarnak reports spouse works for Eli Lilly; Consultancy: Akebia (Steering Committee of a trial, Funds paid to Tufts Medical Center, Cardurian Consultant; and Research Funding: NIH). F. Schaefer reports Consultancy: Akebia, Amgen, Alexion, Alnylam, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius Medical Care, GSK, Otsuka, Purespring, Relypsa, Roche; Research Funding: Fresenius Medical Care, Novartis, Roche; Honoraria: Amgen, Kyowa Kirin, Otsuka, Roche; Patents or Royalties: Springer (textbook royalties); and Advisory or Leadership Role: Scientific Advisory Board activities for Alexion, Otsuka. E. Wühl reports Advisory or Leadership Role: Editorial Board Member: Pediatric Nephrology, Journal of Hypertension, Executive Board Member German Hypertension League (Deutsche Hochdruckliga, DHL), Vize-Chair COST Action HyperChildNET (EU Program Horizon 2020); Advisory Board activities: Alnylam Pharmaceuticals (Advisory Board member), Desitin and, Hartmann. All remaining authors have nothing to disclose.",
217,"S. Anand reports consultancy agreements with GLG group and Vera Therapeutics, honoraria from St. Rose Hospital (CME activity), and advisory or leadership roles for i3C (ISN) & ANIO, unpaid. S. Anand reports that Ascend Clinical Laboratory funded sample assays for S. Anand's COVID-19 seroepidemiology work. S. Anand is supported by National Institute for Diabetes and Digestive and Kidney Health grant #K23 DK101826. P. Deshpande's husband is an allergist and has been a consultant for Sanofi; P. Deshpande's husband has been involved in industry and federally funded research; P. Deshpande's husband received honoraria from the NY Allergy Society; and P. Deshpande's husband participated in an advisory board for Sanofi. M. Vijayan reports ownership interest in Amazon, American Express, AT&T, Cleveland Cliffs Steel, Plug Power, and Warner Bros. M. Vijayan's spouse reports employment with Hennes & Mauritz. The remaining author has nothing to disclose.",
218,"I. Bajema reports Consultancy: Aurinia, Boehringer Ingelheim, CatBio, GSK, Hansa, Novartis, Otsuka, Toleranzia, Vera, and Vifor; Advisory or Leadership Role: C3 Glomerulopathy review board (Novartis, The Netherlands) and Glomerular Disease Council (Vifor Pharma); and Other Interests or Relationships: Director of Bajema Institute of Pathology, Past President of Renal Pathology Society, and Vice-President of European Vasculitis Society (EUVAS). S. Bate reports Employer: IQVIA and Manchester University NHS Foundation Trust. B. Brilland reports Honoraria: CSL Vifor and Sanofi. S.R. Brix reports Honoraria: Vifor; Advisory or Leadership Role: Vifor; and Speakers Bureau: Vifor. N. Brown reports Honoraria: Vifor; and Other Interests or Relationships: Chair of Education Committee, United Kingdom and Ireland Vasculitis Society. N. Dhaun reports Consultancy: Travere Pharmaceutical; Research Funding: Pfizer and Travere Pharma; and Advisory or Leadership Role: Travere. A. Dhaygude reports Honoraria: Speaker fees for AstraZenica and Advisory or Leadership Role: Vifor Pharma. G. Duruvu reports Consultancy: Amgen, Aurinia, Calliditas, ChemoCentryx, GSK, and Otsuka. D. Ilyas reports Research Funding: PhD Research Projects funded by Invizius Limited. D.R.W. Jayne reports Consultancy: AstraZeneca, Boehringer-Ingelheim, Chemocentryx, Chinook, GSK, Novartis, Otsuka, Roche/Genentech, Takeda, and Vifor; Ownership Interest: Aurinia; Research Funding: GSK, Roche/Genentech, and Vifor; Honoraria: GSK, Otsuka, and Vifor; Advisory or Leadership Role: Aurinia; and Speakers Bureau: GSK and Vifor. J.C. Jennette reports Employer: Sangamo Therapeutics, Inc. R.B. Jones reports Research Funding: GSK and Roche; Honoraria: Roche; and Advisory or Leadership Role: Advisory boards for CSL Vifor and GSK. J.S. Lees reports Honoraria: AstraZeneca. M.A. Little reports Research Funding: CSL Vifor; Patents or Royalties: Euroimmun; and Speakers Bureau: CSL Vifor. S.P. McAdoo reports Consultancy: CSL Vifor and GSK; Research Funding: AstraZeneca and Therini Bio; Honoraria: Celltrion, Rigel Pharmaceuticals, and ThermoFisher Scientific; and Advisory or Leadership Role: Co-chair United Kingdom and Ireland Vasculitis Society (unpaid). J.M. Mejía-Vilet reports Honoraria: AstraZeneca, Boehringer-Ingelheim, Novartis, and Roche. E. Nic an Riogh reports Research Funding: Health Research Board Ireland and Wellcome (203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland supports the Irish Clinical Academic Training (ICAT) Program, of which Dr. E. Nic an Riogh is a Wellcome-HRB Irish Clinical Academic Training (ICAT) Fellow. C.D. Pusey reports Consultancy: Alentis and Vifor; Honoraria: Amgen and Med Update Europe; and Advisory or Leadership Role: <i>CJASN</i>. K.I. Stevens reports Consultancy: Bayer, Boehringer Ingelheim, and Vifor; and Advisory or Leadership Role: ERAEUROCONGRESS Ltd. Company Director (no remuneration). V. Tesar reports Consultancy: AstraZeneca, Bayer, Boehringer-Ingelheim, Calliditas, Eli Lilly, Fresenius Medical Care, GSK, Novartis, Omeros, Otsuka, Swixx BioPharma, and Travere; Honoraria: AstraZeneca, Bayer, Boehringer-Ingelheim, Calliditas, Eli Lilly, Fresenius Medical Care, Novartis, Omeros, Swixx Biopharma, and Travere; and Advisory or Leadership Role: member of the scientific advisory board of B. Braun, Fresenius Medical Care and member of the steering committee of clinical trials sponsored by Calliditas, Novartis, Omeros, Otsuka, and Travere. T. Wiech reports Honoraria: Alexion, Bayer, Eleva, GlaxoSmithKline GmbH, and Novartis; and Advisory or Leadership Role: Eleva and Novartis. All remaining authors have nothing to disclose.",
219,"G. Abbadessa also reports Patents or Royalties: Sanofi; and Advisory or Leadership Role: Biond Biologics and HiFi Bio. G. Abbadessa, M. Dudek, H. Lee, L. Lépine, J.-A. Paul, D. Semiond, and N. Ternes are Sanofi employees and may hold stock/stock options in the company. N. Ali reports institutional funding for the present study; and Research Funding: Regeneron and Sanofi—clinical trials, PI. O. Bestard reports a grant from Sanofi for the memory B-cell experiments; and Patents or Royalties: Oxford Immunotec. J.M. Cruzado reports consulting fees: Diaverum; payment or honoraria: Chiesi and Vifor; participation on a Data Safety Monitoring Board or Advisory Board: Astra Zeneca, Chiesi, MSD, Sanofi, and Vifor; he serves as an Associate Editor for the <i>American Journal of Transplantation</i> and <i>Clinical Kidney Journal</i>. A.O. Gaber reports support for the present manuscript by Sanofi; Grants or contracts: Hansa Pharma, Novartis, and Veloxis; he serves on the American Society of Transplant Surgeons Council to which Sanofi provides meeting and educational support. A.O. Gaber also reports Ownership Interest: adaptive immune therapy, Eli Lilly, Novonordisk, oil companies and financials, and Technology; Research Funding: Amplyx Therapeutics, Angion, CareDx, Hansa Biopharma, Medior Therapeutics, Novartis, Sanofi, and Veloxis; Honoraria: Europhins, Optum Health, Sanofi, and Veloxis; Patents or Royalties: Research patent pending, developed in my lab; and Other Interests or Relationships: Chairman of BOD for Nora's Gift Foundation. R.A. Montgomery reports Consultancy: CareDx, Genzyme, Hansa Medical, Indyairone, Sanofi-Aventis, and Veloxis Pharmaceuticals; Research Funding: Hansa Biopharma and United Therapeutics; Honoraria: CareDx, Genzyme, Hansa Medical, Indyairone, Sanofi-Aventis, and Veloxis Pharmaceuticals; and Advisory or Leadership Role: CareDx, Hansa Biopharma, Genzyme, and Sanofi-Aventis US. J.-A. Paul also reports Ownership Interest: Amazon, Apple, Pfizer, and Tesla. D. Semiond reports Employer: Sanofi; Ownership Interest: Sanofi; and Patents or Royalties: Sanofi. D. Seron reports Sanofi support for this clinical trial, including medical writing support. M. Stegall reports consulting fees from Sanofi. M. Stegall reports Consultancy: Aiosyn, eGenesis, Hansa, and Novartis; Research Funding: Janssen, Talaris, and Veloxis; and Advisory or Leadership Role: Aisosyn and eGenesis. A.R. Tambur reports consulting fees from Sanofi; Honoraria: Thermo Fisher/One Lambda; Advisory or Leadership Role: Sanofi, and was also the central laboratory for this clinical trial; and Speakers Bureau: Thermo-Fisher. A. Torija reports a grant from Sanofi for the memory B-cell experiments. F. Vincenti reports grants or contracts from Sanofi. F. Vincenti also reports Research Funding: Angion, Astellas, CSL Behring, Merck, Novartis, Pfizer, and Viela Bio; and Honoraria: Sanofi and Veloxis. All remaining authors have nothing to disclose.",
220,"J.O.R. received consultancy fees from Takeda, Merck, and Co. C.N.K. received consultancy fees from Takeda, Merck, Oxford Immunotec, Qiagen, and Biotest. L.C.P. received consultancy fees from AstraZeneca and Biotest and travel grant from Takeda. The other authors declare no conflicts of interest.",
221,P.S.M. has received “in kind” support from Transmedics and XVIVO through provision of research modules for preclinical research on donor heart preservation. The other authors declare no conflicts of interest.,
222,"W.J.W. Bos reports Research Funding: Dutch Kidney Foundation, Leading the Change, St. Antonius Research Fund, and ZonMW; and Advisory or Leadership Role: Chair ICHOM Working Group CKD, various committees on Value Based Healthcare of the Association of Dutch University Hospitals (NFU), Various committees of the Dutch Nephrology Quality Initiative “Nefrovisie,”, Linnean Initiative. F.W. Dekker reports Research Funding: Astellas, Chiesi, and Vifor. J.I. Rotmans reports Consultancy: Xeltis BV; Advisory or Leadership Role: Advisory Board Nextkidney and President Vascular Access Society; and Other Interests or Relationships: Chair Thematic Working Group Vascular Tissue Engineering at TERMIS, Member Guideline Committee Dutch Society of Nephrology, and President-Elect Vascular Access Society. M. van Diepen reports Employer: Leiden University Medical Center; spouse: ING Bank. All remaining authors have nothing to disclose.",
223,"D.A. is employed by Revivicor, Inc., a subsidiary of United Therapeutics. United Therapeutics was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. The other authors declare no conflicts of interest.",
224,"K.W. Chan reports employment with the University of Hong Kong and consultancy for Chinese Medicine Development Committee for Hong Kong Government and for Chinese Medicine Hospital Project Committee for Hong Kong Government. B.J. Cowling, Y. Feng, and W.H. Yiu report employment with The University of Hong Kong. T.P. Ip reports research funding from Amgen and Boehringer-Ingelheim. A.S.K. Kwong reports employment with Hospital Authority. S.L. Lui reports employment with Tung Wah Hospital; ownership interest in Hang Seng Bank (Hong Kong), Bank of China (Hong Kong), and Tracker Fund (Hong Kong); and research funding from Bayer Healthcare Pharmaceutical Inc. and Otsuka Pharmaceutical Development & Commercialization Inc. K.C.B. Tan reports employment with University of Hong Kong and speakers bureau for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, and Sanofi. S.C.W. Tang reports employment with the University of Hong Kong; consultancy for Eledon Pharmaceuticals and Travere Therapeutics, Inc.; honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Novartis; advisory or leadership roles as Theme and Subspecialties Editor of <i>Nephrology Dialysis Transplantation</i>, Associate Editor of <i>Glomerular Diseases</i>, and member of KDIGO Executive Committee; role as member of the Editorial Boards of <i>American Journal of Nephrology</i>, <i>CJASN</i>, <i>Journal of Nephrology, Kidney Diseases</i>, and <i>Kidney International</i>; speakers bureau for AstraZeneca; and other interests or relationships as President of Asian Pacific Society of Nephrology. All remaining authors have nothing to disclose.",
225,"J.P. Grande reports an advisory or leadership role as a member of the editorial board for <i>Biochemistry and Molecular Biology Education Journal</i>. A. Kukla reports research funding as a site subinvestigator on the multicenter international study A Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW) sponsored by Novo Nordisk and honoraria from UpToDate. A.D. Rule reports an advisory or leadership role with <i>Journal of the American Society of Nephrology</i> as an associate editor, <i>Mayo Clinic Proceedings</i> as a section editor, and the National Institute of Diabetes and Digestive and Kidney Diseases—Urological Diseases of America Contract Management Board and other interests or relationships with UpToDate. Because A.D. Rule is an associate editor of Journal of the American Society of Nephrology, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript. C.A. Schinstock reports research funding from CSL Bering, Sanofi, and Veloxis; Honoraria from CSL Bering and Veloxis; an advisory or leadership role with Veloxis; and an upcoming advisory board meeting with CSL Bering. M.D. Stegall reports consultancy agreements with eGenesis, Hansa, and Novartis and research funding from Janssen, Talaris, and Veloxis. All remaining authors have nothing to disclose.",
226,"M.A. Cadnapaphornchai reports consultancy agreements with Otsuka Pharmaceutical, honoraria from Otsuka, and an advisory or leadership role for Otsuka Tolvaptan pediatric steering committee. A. Dandurand reports employment with Cerevel Therapeutics and was an employee of Otsuka at the time of the study. A. Dandurand's spouse reports employment with Cerberus Sentinel. L.A. Greenbaum reports consultancy agreements with Advicenne, Alexion, Arrowhead Pharmaceuticals, Aurinia, Cara Therapeutics, Handok, Natera, Novartis, Otsuka, and Roche; research funding from AbbVie, Advicenne, Alexion, Apellis, Aurinia, Reata Pharmaceuticals, Roche, and Vertex; honoraria from Alexion and Otsuka; advisory or leadership role for Alexion; and DSMB payments for Akebia, Alnylam, Reata, Relypsa, Travere, and UCSD. L.M. Guay-Woodford serves a consultant for and receives honoraria from Natera, Inc. and Otsuka Pharmaceutical. M. Litwin reports consultancy agreements with Alnylam, Bayer, Otsuka, and Travere; honoraria from Alnylam, Bayer, Otsuka, and Travere; and advisory or leadership roles for Bayer and Otsuka. D. Mekahli reports consultancy for Otsuka Pharmaceuticals and Reata as a representative of the University Hospital of Leuven and the KU Leuven University; educational grants from Otsuka Pharmaceuticals and Galapagos paid to the University Hospital of Leuven—all outside the submitted work; serves on an advisory board of Galapagos, Otsuka Pharmaceuticals, Reata, and Sanofi Genzyme as a representative of the University Hospital of Leuven and KU Leuven; is a member of the European Reference Network for Rare Kidney Diseases (ERKNet); and is supported by the clinical research fund of UZ Leuven (Belgium) and the Research Foundation Flanders (FWO; G0C8920N; 1804123N). F. Schaefer reports consultancy agreements with Akebia, Alexion, Alnylam, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius Medical Care, GSK, Otsuka, Purespring, Relypsa, and Roche; research funding from Fresenius Medical Care; honoraria from Amgen, Kyowa Kirin, Otsuka, and Roche; textbook royalties from Springer; Scientific Advisory Board activities for Alexion and Otsuka; and is a member of ERKNet. T. Seeman reports consultancy agreements with Otsuka Pharmaceutical. L. Shi, S.E. Shoaf, and K. Sikes are employees of Otsuka Pharmaceutical.",
227,"M. Kurella Tamura reports employment with VA Palo Alto Health Care System, honoraria from American Federation for Aging Research, role as an Associate Editor of <i>CJASN</i>, and advisory or leadership roles for Beeson External Advisory Committee and Clin-Star Advisory Board. L. Tian reports employment with Gilead Inc., consultancy for Athersys Inc. and Biogen Inc., and ownership interest in Gilead Inc. All remaining authors have nothing to disclose.",
228,"B.G. Jaar reports honoraria from the American Board of Internal Medicine—Nephrology; royalties from UpToDate; and advisory or leadership roles for the American Board of Internal Medicine, <i>BMC Medicine</i>, <i>BMC Nephrology</i>, <i>CJASN</i>, and the National Kidney Foundation. The remaining author has nothing to disclose.",
229,"R.A. Fenton reports advisory or leadership roles as an Associate Editor for <i>American Journal of Physiology-Renal Physiology</i>, Editorial board member of <i>JASN</i>, and Chair of APS Renal section. R.T. Gansevoort reports consultancy for AstraZeneca, Bayer, Galapagos, Mironid, and Sanofi-Genzyme; research funding from Abbvie, AstraZeneca, Bayer, Galapagos, Otsuka Pharmaceuticals, Roche, and Sanofi-Genzyme; and role on the Editorial Boards of <i>American Journal of Kidney Diseases</i>, <i>CJASN</i>, <i>Journal of Nephrology</i>, <i>Kidney360</i>, <i>Nephrology Dialysis Transplantation</i>, and <i>Nephron Clinical Practice</i>. F. Geurts reports research funding from Novo Nordisk Foundation (NNF18OC0031686). E.J. Hoorn reports research funding from Aurinia; honoraria from UpToDate; role on Editorial Boards of <i>American Journal of Physiology-Renal Physiology</i>, <i>JASN</i>, and <i>Journal of Nephrology</i>; and role as a Board Member of ERA Working Group Genes & Kidney and as a Board Member of Dutch Federation of Nephrology. E. Meijer reports research funding from Dutch Kidney Foundation, Ipsen, Otsuka Pharmaceuticals, and Sanofi (all money was paid directly to the institution) and other interests or relationships with Dutch Kidney Foundation, Health Holland, Nieren.nl, NvN, and werkgroep erfelijke nierziekten. M. Salih reports an advisory or leadership role for NedMed.nl Scientific advisory board. All remaining authors have nothing to disclose.",
230,Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Ken-ichiro Seino reports financial support was provided by MEXT. Ken-ichiro Seino has patent pending to Licensee. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.,
231,"E.F. Barreto reports Consultancy: Wolters Kluwer; Research Funding: AHRQ and NIAID; and Honoraria: Vifor Pharma. K. Koo reports Other Interests or Relationships: UpToDate. J.C. Lieske reports Consultancy: Allena, Alnylam, American Board of Internal Medicine, BioMarin, Chinook, Dicerna, Federation Bio, Intellia, Mirium, Novobiome, NovoNordisc, Orfan, Oxidien, OxThera, Siemens, and Synlogic; Research Funding: Allena, Alnylam, Dicerna, Novobiome, OxThera, Retrophin, Siemens, and Synlogic; Honoraria: American Board of Internal Medicine and Up to Date; and Advisory or Leadership Role: ABIM and Kidney International. A.D. Rule reports Patents or Royalties: UpToDate; and Advisory or Leadership Role: <i>JASN</i>—Associate Editor, <i>Mayo Clinic Proceedings</i>—Section Editor, and NIDDK—Urological Diseases of America Contract Management Board. All remaining authors have nothing to disclose.",
232,The authors declare no conflict of interest.,No
233,"J. Barratt reports receiving consulting and speaker fees from Alnyam, Argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, Galapagos, Novartis, Omeros, Otsuka, Travere Therapeutics, Vera Therapeutics, and Visterra; grant support from Argenx, Calliditas, Chinook, Galapagos, GSK, Novartis, Omeros, Travere Therapeutics, and Visterra; consultancy for Alebund, Alnylam, Alpine, Argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, HiBio, Kira, Novartis, Omeros, Otsuka, Q32 Bio, Roche, Sanofi, Takeda, Travere Therapeutics, Vera Therapeutics, Vifor, and Visterra; research funding from Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Travere Therapeutics, and Visterra; reports serving as scientific/medical advisor to Alnylam, Astellas, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Roche, Travere Therapeutics, UCB, and Visterra, Inc.; is a member of the Editorial Boards of <i>CJASN</i>, <i>Clinical Science</i>, <i>Glomerular Diseases</i>, and <i>Kidney International</i> is a member of Kidney Health Initiative; is Treasurer of International IgA Nephropathy Network; and has lectured, chaired, or participated in symposia/panel discussions for Calliditas, Omeros, and Travere Therapeutics. K. Carroll reports employment with KJC Statistics Limited; consultancy fees from Cerium Pharmaceuticals Inc., Chinook Therapeutics Inc., Dimerix, GSK, Omeros Corp, Reata Pharmaceuticals, Sanifit Therapeutics, and Travere Therapeutics Inc., as a part of KJC Statistics Limited with ownership interests; ownership interest in KJC Statistics Limited; and advisory or leadership roles for Omeros Academic Advisory Board and GSK Steering Committee. C.K. Cheung reports receiving consulting and speaker fees from Alpine Immune Sciences, Calliditas, Chinook, CSL Vifor, George Clinical, Novartis, Otsuka, Roche, Stada, Travere Therapeutics, Vera Therapeutics; receiving grant support from GlaxoSmithKline and Travere Therapeutics; being on a data monitoring committee for Roche; and being on the speakers bureau for Stada Pharma. R.A. Lafayette reports receiving personal fees and grants from Alexion, Aurinia, Calliditas, GlaxoSmithKline, HI-Bio, Novartis, Omeros, Otsuka, Pfizer, Roche, Travere Therapeutics, and Vera Therapeutics; consultancy for Alexion, Inc., Aurinia, Calliditas, Inc., Chinook, Inc., Novartis, Omeros, Inc., Otsuka, Inc., Travere, Inc., Vera, Inc., and Visterra, Inc.; research funding from Apellis, Calliditas, Chemocentryx, Chinook, NIH, Omeros, Otsuka, Pfizer, Roche, Travere, and Vera; and being on a data monitoring committee for Alkahest and Equillium. A. Liew reports employment with The Kidney & Transplant Practice Pte Ltd; consultancy for DaVita Inc; Alnylam Pharmaceuticals, Baxter Healthcare, Bayer, Boehringer-Ingelheim, Chinook Therapeutics, Eledon Pharmaceuticals, George Clinical, Kira Pharmaceuticals, Otsuka Pharmaceuticals, and ProKidney; honoraria from Alnylam Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer, Boehringer-Ingelheim, Chinook Therapeutics, and Otsuka Pharmaceuticals; advisory or leadership roles for <i>Kidney and Blood Pressure Research</i> (Editorial Board), <i>Kidney International</i> (Editorial Board), <i>Kidney Research and Clinical Practice</i> (Editorial Board), <i>Nephrology</i> (Associate Editor), and <i>Peritoneal Dialysis International</i> (Editorial Board); other interests or relationships as Secretary and Executive of ISPD, Chair of ISN Renal Disaster Preparedness Working Group, Working Group Member of KDIGO Guideline on Diabetes Management in CKD, Working Group Member of KDIGO Guideline Update on Glomerular Diseases, and Chair of Asian-Pacific Society of Nephrology Guideline on Diabetic Kidney Disease; has served as a consultant and member of advisory boards for Alnylam Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer-Ingelheim, Chinook Therapeutics, Dimerix Limited, Eledon Pharmaceuticals, George Clinical, GlaxoSmithKline, Kira Pharmaceuticals, Otsuka Pharmaceuticals, Prokidney, Visterra Inc., and Zai Lab Co. Ltd; has received speaker's honorarium from AstraZeneca, Baxter Healthcare, Boehringer-Ingelheim, Chinook Therapeutics, and Otsuka Pharmaceuticals; and has served as a member of Data Safety and Monitoring Committee for Dimerix Limited and Zai Lab Co. Ltd. V. Perkovic is employed by UNSW Sydney and the Royal North Shore Hospital and serves as a Board Director for St. Vincents Health Australia, George Clinical, and several Medical Research Institutes. V. Perkovic has led or served on the Steering Committees of trials funded by AbbVie, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Janssen, Novartis, Novo Nordisk, Otsuka, Pfizer, Travere Therapeutics, and Tricida. V. Perkovic also reports having received honoraria for scientific presentations and/or advisory board attendance from AbbVie, Amgen, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, Chinook, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Pfizer, Pharmalink, Reata, Relypsa, Roche, Sanofi, and Servier; consultancy for AbbVie, Astellas, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chinoo, Dimerix, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Merck, Metavant, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, PharmaLink, Relypsa, Retrophin, Roche, Sanofi, Servier, Travere, Tricida, UpToDate, and Vitae; ownership interest in George Clinical; research support from the Australian National Health and Medical Research Council (Senior Research Fellowship and Program Grant); honoraria from AbbVie, Astellas, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Dimerix, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Merck, Metavant, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Pfizer, PharmaLink, Relypsa, Retrophin, Roche, Sanofi, Servier, Travere, Tricida, UpToDate, and Vitae; advisory or leadership roles for Steering committees for AbbVie, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Novartis, Pfizer, Travere; and role on Board Director for St. Vincents Health Australia, George Clinical. D.V. Rizk reports research funding from Calliditas Therapeutics (Pharmalinks), Chinook Pharmaceuticals, Otsuka Pharmaceuticals (Visterra), Pfizer Pharmaceuticals, Reata Pharmaceuticals, Travere Therapeutics, Vera Therapeutics, and Vertex Pharmaceuticals; consulting fees from Calliditas Therapeutics (Pharmalinks), Chinook Pharmaceuticals, Eledon Pharmaceuticals, George Clinical, GSK, Novartis, Otsuka Pharmaceuticals (Visterra), and Roche-Group; ownership in Reliant Glycosciences LLC; and advisory or leadership roles for Visterra Inc. Scientific Advisory Board, Calliditas advisory board, Eledon Pharmaceuticals Steering Committee, George Clinical National Leader, Novartis pharmaceuticals Steering Committee, Otsuka Steering Committee, and Vera Therapeutics Executive Advisory Committee. Y. Suzuki reports research funding from Argenx, Astellas Pharma Inc., AstraZeneca, Aurinia Pharmaceuticals, Baxter Limited, Bayer, Boeringer, Chinook, Chugai, Daiichi Sankyo Company, Limited, Eisai, Kissei, Kyowa Kirin, Mochida, Moderna, Ono Pharmaceutical Co., Ltd., Otsuka US, Pfizer, Retrophin, Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical, Tanabe Mitsubishi, Teijin Pharma, Torii Pharmaceutical Co., Ltd, Travere Therapeutics, and Visterra; consulting fees from Argenx, Chinook, Novartis, Otsuka, Takeda, Travere Therapeutics, and Visterra; speaker fees from Astellas, AstraZeneca, Bayer Yakuhin, Daiichi Sankyo Co., Kissei Pharmaceutical Co., Kowa Company, Kyowa Kirin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Novartis, and Otsuka; honoraria from Astellas, AstraZeneca, Bayer, Daiichi Sankyo, Kyowa Kirin, Novartis, Sumitomo Dainippon, Takeda, and Tanabe Mitsubishi Pharmaceutical company; and advisory or leadership roles for ARGENX Inc., Chinook Therapeutics, Kyowa Kirin Co., Ltd, Morphosys Inc., Novartis Pharma Co. Ltd, Travere/Retrophin Inc., and Visterra/Otsuka Inc. V. Tesař reports consultancy fees from AstraZeneca, Bayer, Boehringer-Ingelheim, Calliditas, Eli Lilly, Fresenius Medical Care, GSK, Novartis, Omeros, Otsuka, Swixx BioPharma, and Travere; advisory or leadership role as a member of the scientific advisory board of B.Braun and Fresenius Medical Care; and member of the steering committee of clinical trials sponsored by Calliditas, Novartis, Omeros, Otsuka, and Travere. H. Trimarchi is a consultant in nephrology to George Clinical and is on the Advisory Board and is a Steering Committee member of glomerular disease trials funded by Calliditas, Chinook, Dimerix, Novartis, Omeros, Otsuka, Travere Therapeutics, Vera Therapeutics, and Visterra; reports receiving honoraria from AstraZeneca, Genzyme-Sanofi, and GlaxoSmithKline; consultancy for Alexion, AstraZeneca, Bayer, Biocryst, Calliditas, Chinook, Dimerix, Gador, George Clinical, GlaxoSmithKline, Novartis, Raffo, Roche, Sanofi-Genzyme, Travere, Vera, and Visterra-Otsuka; honoraria from AstraZeneca, Bayer, Biocryst, Calliditas, Chinook, Dimerix, Gador, George Clinical, GlaxoSmithKline, Novartis, Raffo, Roche, Sanofi-Genzyme, Travere, Vera, and Visterra-Otsuka; and advisory or leadership roles for AstraZeneca, Bayer, Biocryst, Calliditas, Chinook, Dimerix, Gador, George Clinical, GlaxoSmithKline, Novartis, Raffo, Roche, Sanofi-Genzyme, Travere, Vera, and Visterra-Otsuka. M.G. Wong reports consultancy for Chinook, Eledon, CSL Behring, Dimerix Ltd, George Clinical, Otuska, and Travere Therapeutic; honoraria from Alpine, Amgen, AstraZeneca, Baxter, Borringher, Chinook, CSL Behring, Dimerix, Eledon, George Clinical, Horizon, Otsuka, and Travere Therapeutics for scientific presentation; and advisory or leadership roles for Chinook, CSL Behring, Dimerix Ltd, Eledon, Horizon, Otuska, and Travere Therapeutic. H. Zhang is employed by Peking University First Hospital and reports receiving consultancy fees for being a Steering Committee member from Calliditas, Chinook, Novartis, Omeros, and Otsuka. H. Zhang also reports having participated in symposia or panel discussions and received honoraria for scientific presentations from Novartis and Omeros.",
234,"M.L., B.R., E.W., A.S., P.B., and J.-M.A. are founders of XTransplant GmbH. U.B. and A.S. are shareholders of XL-protein GmbH. D.A. is chief executive officer and chief scientific officer of Revivicor, Inc. XTransplant, XL-Protein, and Revivicor were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. The other authors declare no conflicts of interest.",
235,"Disclosure The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. J. Ge receives research support from Merck and Co, and consults for Astellas Pharmaceuticals.",
236,"S. Breitenstein reports employment with, and patents or royalties from, Bayer AG. B.P. Dixon reports consultancy agreements with Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Novartis Pharmaceuticals; honoraria from Alexion Pharmaceuticals, Apellis Pharmaceuticals, and Novartis Pharmaceuticals; and an advisory or leadership role for aHUS Action Network (unpaid). T. Eissing reports employment with and ownership interest in Bayer AG. M.R. Denburg reports employment with The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania; research funding from Mallinckrodt; patents or royalties from InBore LLC; advisory or leadership role on the Editorial Board of <i>Kidney International Reports</i> and the NKF Delaware Valley Medical Advisory Board; and other interests or relationships with American Society of Pediatric Nephrology Research and Program Committees. M.R. Denburg's spouse reports consultancy agreements with Trisalus Life Sciences, ownership interest in Precision Guided Interventions LLC and In-Bore LLC, research funding from Instylla, and an advisory or leadership role for Trisalus Life Sciences Scientific Advisory Board. V.R. Dharnidharka reports consultancy agreements with Atara Biotherapeutics and Medincell; research funding from CareDx; honoraria from CareDx and Sanofi; advisory or leadership roles for North American Pediatric Renal Trials and Collaborative Studies (unpaid) and the Council for American Society of Pediatric Nephrology (unpaid); and other interests or relationships with Independent Data Safety Monitoring Committee, Akebia/MedPace. J.T. Flynn reports serving as Editor-in-Chief of <i>Pediatric Nephrology</i>; serving as an Editorial Board member of <i>Blood Pressure Monitoring, Hypertension</i>, and <i>Journal of Pediatrics</i>; serving as a Board Member of Renal Physicians Association; and reports other interests or relationships with American Society of Pediatric Nephrology, International Pediatric Nephrology Association, and Renal Physicians Association. C.B. Forrest reports employment with Children's Hospital of Philadelphia and patents or royalties from Johns Hopkins University; C.B. Forrest does not receive any personal funding, but the Children's Hospital of Philadelphia receives funding that C.B. Forrest oversees from UCB, Bayer, Lily, and Sanofi. S.L. Furth, A. Goodwin Davies, M. Maltenfort, and J.R. Mcdonald report employment with Children's Hospital of Philadelphia. C.A. Gluck reports employment with Nemours Children's Health, honoraria from Travere, and an advisory or leadership role for Travere. C.A. Hovinga reports employment with Critical Path Institute and an advisory or leadership role for the FDA. A. Kaiser reports employment with, ownership interest in, and patents or royalties with Bayer AG and reports other interests or relationships with EFSPI SIG “Small populations.” M. Mitsnefes reports consultancy agreements with KBP BIOSCIENCES. A. Neu reports employment with Johns Hopkins University School of Medicine; consultancy agreements with Akebia; research funding from Alexion, AstraZeneca, Bayer, Bayer, BMS, CareDx, Covis (AMAG), Horizon, Leadiant, Otsuka, Reata, Relypsa, and Retrophin; honoraria from American Board of Pediatrics; advisory or leadership roles as President of the Board of Directors of The North American Pediatric Renal Trials and Collaborative Studies, a member of the Project Committee of ASN's NTDS, and Co-Medical Editor of American Board of Pediatrics Nephrology Subboard; and other interests or relationships as faculty member for the Children's Hospital Association's Standardizing Care to Improve Outcomes Collaborative. Johns Hopkins has a joint venture with Fresenius Medical Care, which funds the medical director position for the pediatric dialysis unit. A.L. Skversky reports employment with and ownership interest in Bayer Pharmaceuticals. W.E. Smoyer reports consultancy agreements with Visterra, Otsuka, and Vertex; ownership interest in NephKey Therapeutics; research funding from Aurinia; honoraria from USC for CTSA External Advisory Committee and from UCLA for CTSA External Advisory Committee; royalties from UpToDate; and advisory or leadership roles as member of the Board of Directors of Pediatric Nephrology Research Consortium (PNRC), member of the Board of Directors of NephCure Kidney International (NKI), and a member of the Coordinating Committee of the Institute for the Advancement of Clinical Trials in Children (I-ACT). M.J. Somers reports consultancy agreements with Alnylam, Dicerna, Horizon, Orfan Biotech, and Precision Biosciences; research funding from BioPorto and Dicerna; and advisory or leadership role for NAPRTCS Board of Directors and as ASPN Past President.",
237,"A. D'Alessandro reports Consultancy: Hemanext Inc., Macopharma Inc.; and Ownership Interest: Omix Technologies Inc. All remaining authors have nothing to disclose.",
238,"C. Brusq reports Consultancy: Medtronic France SAS; Honoraria: Laboratoires Grünenthal SAS, Lundbeck SAS, and Medtronic France SAS; and Speakers Bureau: Laboratoires Grünenthal SAS, Lundbeck SAS, and Medtronic France SAS. M. Fila reports Consultancy: Alexion and Roche; and Honoraria: Alexion. V. Frémeaux-Bacchi reports Consultancy: Alexion Pharmaceuticals, Apellis, BioCryps, Novartis, Roche, Sobi, and UCB; Research Funding: Alexion Pharmaceuticals; Honoraria: Alexion Pharmaceuticals, Apellis, BioCryps, Novartis, Roche, Sobi, and UCB; and Advisory or Leadership Role: Alexion Pharmaceuticals, Apellis, BioCryps, Novartis, and Sobi. V. Guigonis reports Research Funding: INRESA. J. Harambat reports Consultancy: Alnylam; Research Funding: Alnylam, Bayer, and GSK; Honoraria: Alnylam; Advisory or Leadership Role: ESPN Council Member, ESPN/ERA-EDTA Chairman, and <i>Pediatric Nephrology</i> Editorial Board; and Other Interests or Relationships: EDTA member, ESPN member, and IPNA member. A.-L. Sellier-Leclercq reports Consultancy: Alexion and Alnylam; Honoraria: Alexion and Alnylam; and Advisory or Leadership Role: Alexion, Alnylam, and Novartis. T. Ulinski reports Consultancy: Alfasigma; Honoraria: Alfasigma; and Advisory or Leadership Role: Alfasigma. All remaining authors have nothing to disclose.",
239,"O. Carlsson and C. De Leon report employment with Triomed AB. J. Hegbrant reports employment with JBA Medical AB; consultancy for Triomed AB; ownership interest in Diaverum AB, LundaTec AB, NorrDia AB, Redsense Medical AB, and Triomed AB; and advisory or leadership roles for Board of Directors of NorrDia AB and Redsense Medical AB. O. Heimbürger reports research funding from AstraZeneca, Baxter, and Triomed; honoraria from AstraZeneca, Baxter Healthcare, Fresenius Medical Care, and Vifor for presentations at company-organized courses; speakers bureau for AstraZeneca; and other interests or relationships as Secretary of Swedish Society of Renal Medicine (2021); and role on Editorial Boards of <i>Blood Purification</i>, <i>Clinical Nephrology</i>, <i>Peritoneal Dialysis International</i>, and <i>Turkish Journal of Nephrology</i>. G. Martus reports research funding from The Swedish Kidney Foundation to Lunds University and from The Swedish Foundation for Kidney Disease to Lunds University and other interests or relationships from Triomed AB (Lund, Sweden) as a clinical study principal investigator. M. Wilkie reports consultancy for Triomed, research funding from Baxter, honoraria from Baxter and Fresenius, speakers bureau for Baxter, and other interests or relationships with International Society for Peritoneal Dialysis. All remaining authors have nothing to disclose.",
240,"S.D. Anker reports consultancy for Actimed, Amgen, AstraZeneca, Bayer, Bioventrix, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Novartis, Occlutech, Pfizer, Repairon, Sensible Medical, Servier, V-Wave, and Vectorious; research funding from Abbott Vascular and Vifor Pharma; advisory or leadership roles for Actimed, Amgen, AstraZeneca, Bayer, Bioventrix, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Novartis, Occlutech, Pfizer, Repairon, Sensible Medical, Servier, V-Wave, and Vectorious; trial/registry steering committee work & consultancy: Actimed, Amgen, AstraZeneca, Bayer, Bioventrix, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Novartis, Occlutech, Pfizer, Repairon, Sensible Medical, Servier, V-Wave, and Vectorious; research grants and personal fees from Abbott Vascular and Vifor (IIT/trial steering committee work); and personal fees from Bayer, Boehringer Ingelheim and Impulse Dynamics (Trial steering committee work), Cardiac Dimensions and Occlutech (Advisory committee work), Novartis, and Servier (Registry Steering Committee). S.D. Anker is named as a coinventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but S.D. Anker does not benefit personally from the related issued patents. J. Butler reports employment with Baylor Scott and White; consulting fees from Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Cardior, CVRx, Foundry, G3 Pharma, Imbria, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, Sequana Medical, V-Wave Ltd., and Vifor; advisory or leadership roles for clinical trials with BI, Cardior, CVRx, Foundry, G3 Pharma, Imbria, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, Sequana Medical, V-Wave Ltd., and Vifor; and speakers bureaus for AstraZeneca, BI/Lilly, Novartis, and Vifor. G. Filippatos reports consultancy for Amgen, Bayer, Boehringer Ingelheim, Impulse Dynamics, Medtronic, Novartis, Servier, and Vifor; research funding from European Union; honoraria from Bayer and BI; advisory or leadership role for EJHF President of Hellenic Heart failure Society, JACC HF; speakers bureau for Bayer and Boehringer Ingelheim; and personal fees from Boehringer Ingelheim (Lecture and Trial Committee member), Novartis (lecture fees and Trial/Registry Committee member), and Servier (Lecture and Registry Committee member). U.-M. Göhring received personal fees from Vifor Pharma as a Vifor Pharma employee. E.A. Jankowska reports consultancy for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiac Dimensions, Pfizer, Pharmacosmos, Respicardia, Servier, Vifor Pharma, and Zoll; honoraria from Abbott, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Cardiac Dimensions, Gedeon Richter, Novartis, Pfizer, Pharmacosmos, Respicardia, Sanofi, Servier, Swixx Biopharma, Takeda, Vifor Pharma, and Zoll; research grants and personal fees from Vifor Pharma (co-PI of the AFFIRM trial); personal fees from Abbott, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Cardiac Dimensions, Fresenius, Gedeon Richter, Novartis, Pfizer, and Servier; advisory or leadership role as 2020–2022 member of the Executive Committee of the Heart Failure Association of European Society of Cardiology (voluntary activity); and speakers bureau for Abbott, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Cardiac Dimensions, Gedeon Richter, Novartis, Pfizer, Pharmacosmos, Sanofi, Servier, Swixx Biopharma, Takeda, and Vifor Pharma. B.-A. Kirwan reports employment with SOCAR Research SA. V. Kumpeson reports employment with CSL Vifor and ownership interest in CSL Vifor and Genentech. I.C. Macdougall reports consultancy for GlaxoSmithKline and Vifor Pharma, research funding from Vifor Pharma, honoraria from GlaxoSmithKline and Vifor Pharma, and role as a steering committee member for GlaxoSmithKline trials. M. Metra reports personal fees from Abbott vascular, AstraZeneca, Bayer, Boheringer Ingelheim, and Roche diagnostics as a member of Trials Committees or advisory boards; personal fees from AstraZeneca, Abbott vascular, Bayer, Edwards Therapeutics, Livanova, Vifor pharma, and WindTree Therapeutics as a member of Trials Committees or for speeches at sponsored meetings; personal fees from AstraZeneca, Bayer, Boheringer Ingelheim, and Vifor pharma as member of Trials Committees or advisory boards; personal fees from Abbott vascular, Edwards Therapeutics, and Novartis for speakers bureau; and personal fees from Abbott Vascular, Actelion (DMC Member), Amgen (Executive Committee member and National PI), AstraZeneca, Bayer (participation in advisory boards), Edwards Therapeutics (speeches at sponsored symposia), LivaNova (Executive Committee member), Servier (participation in advisory boards and speeches at sponsored symposia), Vifor Pharma (Executive Committee member), and Windtree Therapeutics (Executive Committee member and advisory board). P. Ponikowski reports consultancy for Amgen, AstraZeneca, Bayer, Berlin Chemie, BMS, Boehringer Ingelheim, Impulse Dynamics, MSD, Novartis, Pfizer, Respicardia, Servier, and Vifor Pharma; research funding from Vifor Pharma; honoraria from Amgen, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Impulse Dynamics, MSD, Novartis, Pfizer, Respicardia, Servier, and Vifor Pharma; speakers bureau for Amgen, AstraZeneca, Bayer, Berlin Chemie, BMS, Boehringer Ingelheim, Impulse Dynamics, MSD, Novartis, Pfizer, Respicardia, Servier, and Vifor Pharma; research grants and personal fees from Vifor Pharma (PI of AFFIRM-AHF; participation in clinical trials); and personal fees from Abbott Vascular, Amgen, AstraZeneca, Bayer, Berlin Chemie, BMS, Boehringer Ingelheim, Cibiem, Impulse Dynamics (participation in clinical trials), Novartis, Pfizer, and Servier. F. Ruschitzka has not received personal payments by pharmaceutical companies or device manufacturers in the last 3 years. Remuneration for the time spent in following consulting activities were made directly to the University of Zurich and do not impact on F. Ruschitzka's personal remuneration: AstraZeneca (IMC), Bayer, Boehringer Ingelheim, Citi Research, Klub Class, Novo Nordisk, Radcliffe Group, Stiftung Pfizer Forschungspreis, and Vifor. The Department of Cardiology (USZ/UZH) reports grants from Abbott, Amgen, AstraZeneca, Bayer, Berlin Heart, B.Braun, Biosense, Biosensors, Biotronik, BMS, Boehringer, Boston Scientific, Bracco, Cardinal Health, Corteria, Daiichi, Diatools, Edwards, Fresenius, Guidant, Hamilton, Kaneka, Kantar, Labormed.Zentrum, Medtronic, MSD, Mundipharma, Novartis, Novo Nordisk, Orion, Pfizer, Quintiles, Sahajanand, Sanofi, Sarstedt, Servier, SIS, SNF, SSS, Terumo, Trama Solutions, VWave, Vascular Medical, Vifor, Wissens Plus, and ZOLL; remuneration for following lectures were made directly to the UZH: Abbott, Amgen, AstraZeneca (A+ Science), Bayer (At the Limits), Boehringer, Boston Scientific (CCEServices), Brigham & Women's Hospital Boston, C.T.I, Charité Berlin (Medical Education Global Solutions), Hong Kong Heart Failure Society, HUG(GECORE), Inselspital, LUKS, Medscape(WebMD), Medtronic, Medworld, Novartis, ÖGK, Roche, Romanian Society of Card, Ruwag, Sanofi-Aventis, Servier, Swiss Heart Failure Academy, Trama Solutions; remuneration for following Advisory Boards were made directly to the University of Zurich and do not impact on F. Ruschitzka's personal remuneration: Bayer: HF Expert Summit, Advisory Board Meeting; Roche: Advisory Board Meeting; IMC/AstraZeneca: Advisory Board Meeting; and Amgen: Advisory Board Meeting. A.G. Stack reports consultancy for AstraZeneca and Vifor Pharma; educational grant from Vifor Pharma and research funding from AstraZeneca; honoraria from AstraZeneca and Vifor; role on the Editorial Board of <i>BMC Nephrology;</i> and in speakers bureau for Vifor. P. van der Meer reports consultancy from AstraZeneca, Novartis, Pfizer, Pharmacosmos, Pharmanord, Novo Nordisk, and Vifor Pharma—all fees paid to the institute; research funding from AstraZeneca, Pfizer, Pharmanord, and Vifor Pharma; and research grants and personal fees from Vifor Pharma (Executive Committee, speaker), research grants from AstraZeneca, Corvidia, Ionis, and Pfizer, and personal fees from Novartis and Servier (advisory board). S. Wächter reports employment with Vifor Pharma Ltd and CSL stock. D.C. Wheeler reports fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eledon, Galderma, George Clinical, Gilead, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, Pfizer, ProKidney, Tricida, Vifor, and Zydus for talks, advisory boards, trial committees, and consultancy; honoraria from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelhiem, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, Mundipharma, Napp, Pharmacosmos, Reata, and Vifor Fresenius; advisory or leadership role for AstraZeneca; speakers bureau for Amgen, AstraZeneca, Astellas, Janssen, Merck Sharp and Dohme, Mundipharma, Napp, and Vifor Fresenius; and personal fees and nonfinancial support from AstraZeneca, as well as personal fees from Astellas, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Mundipharma, Napp, Reata, Tricida, and Vifor Fresenius. The remaining author has nothing to disclose.",
241,"G. Bakris is supported by T32 NIH grant DK07011 and is a consultant to Alnylam, AstraZeneca, Bayer, Glaxo Smith Kline, InREGEN, Ionis, Janssen, KBP Biosciences, and Novo Nordisk. M. Brinker reports ownership interest: Bayer AG. M. Brinker, R. Nkulikiyinka, P. Schloemer, and C. Tasto are Bayer employees. S.B. Gasparyan, M. Karpefors, D.J. Little, and J. Rossert are AstraZeneca employees. H.L. Heerspink is consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli-Lilly, Gilead, Janssen, Merck, Novo Nordisk, ProKidney, Travere Therapeutics, and Vifor Fresenius. He has received research support from AstraZeneca, Boehringer Ingelheim, Janssen, and Novo Nordisk; honoraria: lecture fees from AstraZeneca and NovoNordisk; and speakers bureau: AstraZeneca. N. Jongs reports travel grants from AstraZeneca. D.J. Little reports ownership interest: AstraZeneca and other interests or relationships: volunteer as a nephrologist at Walter Reed National Military Medical Center. V. Perkovic serves as a Board Director for St. Vincents Health Australia, George Clinical, and several Medical Research Institutes. He has received honoraria for Steering Committee roles and scientific presentations and/or advisory board attendance from Abbvie, Amgen, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Chinook, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, Pharmalink, Reata, Relypsa, Roche, Sanofi, Servier, Travere, and Tricida. J. Rossert reports ownership interest: Amgen, AstraZeneca, and Vertex. C. Tasto reports ownership interest: Bayer AG. D.C. Wheeler has received honoraria and/or consultancy fees from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bayer, Eledon, Galderma, George Clinical, Gilead, GlaxoSmithKline, Janssen, Medscape, Merck Sharp and Dohme, Mundipharma, Napp, Pfizer, Pharmacosmos, ProKidney, Reata, Takeda, Tricida, Vifor Fresenius, and Zydus and advisory or leadership role: AstraZeneca; and speakers bureau: Amgen, Astellas, AstraZeneca, Janssen, Merck Sharp and Dohme, Mundipharma, Napp, and Vifor Fresenius. R. Nkulikiyinka reports Employer: Bayer AG; and Ownership Interest: Bayer AG. G. Bakris reports Consultancy: Janssen, Bayer, KBP Biosciences, Novo Nordisk, Astra-Zeneca, Ionis, Alnylam, Medscape; Honoraria: Merck, Novo Nordisk, Astra Zeneca, Ionis, Alnylam, KBP Biosciences, and Bayer; Advisory or Leadership Role: KBP Biosciences, American J Nephrology, Editor, Diabetes Care, Assoc. Ed.,; American Heart Assoc.; UpToDate-Nephrology; and Other Interests or Relationships: American Diabetes Association, American Heart Association, Blood Pressure Council. V. Perkovic reports Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Travere, Tricida, UptoDate; Ownership Interest: George Clinical; Research Funding: AstraZeneca, Bayer, Chinook, Gilead, GlaxoSmithKline, Janssen, Novartis, Novo Nordisk, Otsuka, Travere, Tricida,; Honoraria: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Travere, Tricida, UptoDate; and Advisory or Leadership Role: Steering committees for Bayer, Chinook, GlaxoSmithKline, Janssen, Novartis, Novo Nordisk, Otsuka, Pfizer, Travere; Board Director for St Vincents Health Australia, George Clinical.",
242,"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alexander G Bick reports a relationship with TenSixteen Bio that includes: consulting or advisory. Javid Moslehi reports a relationship with Bristol Myers Squibb, AstraZeneca, Myovant, Cytokinetics, Takeda, BeiGene, Kiniksa, Kurome Therapeutics, and Pfizer that includes: consulting or advisory.",
243,S.D.G. consults for Sanofi and Novartis—activities unrelated to the current work. The other authors declare no conflicts of interest. The BAASIS is copyright the University of Basel (Switzerland) but is freely available for academic and clinical purposes after registration on the BAASIS website ( https://baasis.nursing.unibas.ch/ ).,
244,"N.C. is member of the Governing Council of the Agencia Española de Medicamentos y Productos Sanitarios (Spanish Medicine and Medical Device Agency), pro bono appointment (as expert of recognized prestige in the field of Health Sciences, not representing any institution). The other authors declare no conflicts of interest.",
245,"A.K. Agarwal reports employment with VA Central California Health Care System; consultancy for Akebia; honoraria from Amgen; advisory or leadership roles for ASDIN, <i>Clinical Nephrology</i>, <i>Frontiers in Nephrology</i>, <i>International Journal of Nephrology</i>, ISN, <i>Journal of Vascular Access</i>, KSAP, NKF, and <i>The Open Urology & Nephrology Journal</i> (all unpaid); advisor role to AstraZeneca and Otsuka; research support from Akebia Pharmaceuticals; and other interests or relationships with ASDIN, ASN, ISN, and NKF. E. Hurlburt reports employment with CorMedix, Inc. P. Mounts reports employment with, ownership interest in, and advisory or leadership role for CorMedix Inc. A. Pfaffle reports employment with, ownership interest in, and advisory or leadership roles for CorMedix Inc. A. Pfaffle has served as the Chief Scientific Officer and Head of Patient Advocacy and Special Projects at CorMedix. E.C. Poggio is the founder and owner of Biostatistical Consulting Inc. (BCI), which provided statistical design and analysis services to CorMedix Inc. BCI provides biostatistical consulting to numerous pharmaceutical, biotech, and medical device companies for which it is paid. E.C. Poggio reports ownership interest in AstraZeneca, Acurx, and Biostatistical Consulting Inc. E.C. Poggio's wife reports employment with AstraZeneca. P. Roy-Chaudhury reports employment with VAMC Salisbury, NC; consultancy for Akebia, Alexion (AstraZeneca Rare Diseases), AstraZeneca, Bayer, Becton Dickinson, CorMedix, Humacyte, Medtronic, Target RWE, and WL Gore; ownership interest as Chief Scientific Officer and Founder of Inovasc LLC; NIH Small Business Grants as MPI or site PI with Adgero, Cylerus, Eko, and Inovasc; honoraria from Akebia, Alexion (AstraZeneca Rare Diseases), AstraZeneca, Bayer, Becton Dickinson, Cormedix, Humacyte, Medtronic, N9, and WL Gore; research funding from Bayer; and advisory or leadership roles for Akebia, Alexion (AstraZeneca Rare Diseases), ASN, AstraZeneca, Bayer, Becton Dickinson, BioMed Innovations, Cormedix, Editorial Board of <i>Journal of Vascular Access</i>, Humacyte, Medtronic, N9, Vascular Access Society of the Americas, and WL Gore.",
246,Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.,No
247,"J.R. Sedor reports employment with Cleveland Clinic; consultancy for Boehringer Ingelheim; research funding from Calliditas, Chinook, Travere, and Vertex for clinical trials; grants from NIAID and NIDDK; honoraria from Boehringer Ingelheim; patents or royalties for APOL1 transgenic mice licensed to Sanofi Genzyme and patent issued for machine learning analysis of kidney biopsies; advisory or leadership role for Kidney Foundation of Ohio—kidney patient organization for direct aid-Board of Directors, NephCure Kidney International, and Chair of Kidney X Steering Committee; role on Editorial Boards of <i>American Journal of Nephrology</i>, <i>Glomerular Diseases</i>, <i>JASN</i>, and <i>Seminars in</i>
<i>Nephrology</i>; and role as a member of ISN.",
248,"J.R. Sedor reports consultancy: Boehringer Ingelheim; Research Funding: Calliditas, Goldfinch Bio, Novartis, and Travere for clinical trials; Honoraria: Boehringer Ingelheim; Patents or Royalties: APOL1 transgenic mice licensed to Sanofi Genzyme; Invention disclosure for machine learning analysis of kidney biopsies; Advisory or Leadership Role: Kidney Foundation of Ohio—kidney patient organization for direct aid—Board of Directors, NephCure Kidney International, Chair Kidney X Steering Committee; and Other Interests or Relationships: Editorial Boards—Seminars in <i>Nephrology</i>, <i>Journal of the American Society of Nephrology</i>, <i>American Journal of Nephrology</i>, <i>Glomerular Diseases</i>, ISN—Member.",
249,"M.H. Abramson reports employment with Icahn School of Medicine at Mount Sinai. B.O. Adegbite reports employment with Mount Sinai. E.U. Azeloglu reports employment with Icahn School of Medicine at Mount Sinai, consultancy for Ikena Oncology, ownership interest in Novartis, research funding from Aurinia Pharmaceuticals and Renalytix AI, patents or royalties from Mount Sinai Health System, and role on <i>Kidney International</i> Editorial Board. K.N. Campbell reports employment with Icahn School of Medicine at Mount Sinai; consultancy for Calliditas, Chinook, Sanofi, and Travere; research funding from Aurinia; and Board memberships (unpaid) for National Kidney Foundation and Nephcure Foundation. L. Chan reports employment with Icahn School of Medicine at Mount Sinai, consultancy for CSL Vifor Pharma, INC, research funding from NIH, and honoraria from Fresenius. K. Chauhan reports employment with Icahn School of Medicine at Mount Sinai. S.G. Coca reports employment with Icahn School of Medicine at Mount Sinai—Mount Sinai owns part of Renalytix; consultancy for 3ive, Axon, Bayer, Boehringer-Ingelheim, Nuwellis, Renalytix, Reprieve Cardiovascular, Takeda, and Vifor; ownership interest in pulseData and Renalytix; research funding from ProKidney, Renal Research Institute, Renalytix, and XORTX; patents or royalties from Renalytix; and role as an Associate Editor for <i>Kidney360</i> and role on the Editorial Boards of <i>CJASN</i>, <i>JASN</i>, and <i>Kidney International</i>. S. El Ghaity-Beckley reports employment with Mount Sinai Health System. V. Gutgarts reports employment with Memorial Sloan Kettering Cancer Center. E.A. Jaimes reports employment with Memorial Sloan Kettering Cancer Center and honoraria from Natera and UpToDate. M. Kremyanskaya reports consultancy for AbbVie, CTI, Incyte, Morphosys, and Protagonist and honoraria from AbbVie, CTI, Incyte, Morphosys, and Protagonist. B. Marcellino reports employment with Mount Sinai Health System. J.O. Mascarenhas reports employment with Icahn School of Medicine at Mount Sinai; consultancy for Abbvie, BMS, Celgene, CTI Bio, Geron, GSK, Incyte, Kartos, Karyopharm, MorphoSys, Novartis, Pfizer, and Roche; research funding from Abbvie, BMS, CTI Bio, Geron, Incyte, Kartos, Novartis, and PharmaEssentia; honoraria from Abbvie, BMS, Celgene, CTI Bio, Geron, GSK, Incyte, Kartos, Karyopharm, MorphoSys, Novartis, Pfizer, and Roche; and advisory or leadership roles for BMS, CTI Bio, Geron, and Incyte. K.A. Meliambro reports employment with Icahn School of Medicine at Mount Sinai. F.M. Musteata reports employment with Regeneron. S.P. Salvatore reports ownership interest in AAPL, CCNE, COIN, DIS, DKNG, Fundrise, IBM, KD, LCID, MJ, RIVN, and VZ. All remaining authors have nothing to disclose.",
250,"H.K. Choi reports Consultancy: Allena, Ani, Horizon, LG, Ono, and Protalix; Research Funding: Horizon; Honoraria: Allena, Ani, Horizon, LG, Ono, and Protalix; and Advisory or Leadership Role: Allena, Ani, Horizon, LG, Ono, and Protalix. T. Merriman reports Research Funding: VariantBio. D. Mount reports Consultancy: Allena Pharmaceuticals, Alnylam Pharmaceuticals, ANI Pharmaceuticals, and Horizon Pharma; and Honoraria: McGraw Hill and UpToDate. All remaining authors have nothing to disclose.",
251,"J. Barratt reports consultancy for Alnylam Pharmaceuticals, Argenx, Astellas, BioCryst, Calliditas, Chinook Therapeutics, Dimerix, Galapagos, GSK, Novartis, Omeros, Travere Therapeutics, UCB, Vera Therapeutics, and Visterra; research funding from Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Travere Therapeutics, and Visterra; and advisory or leadership roles on the Editorial Boards of <i>CJASN, Clinical Science, Glomerular Diseases,</i> and <i>Kidney International</i>. F. Braddon reports employment with UK Kidney Association and UK Renal Registry. D.P. Gale reports consultancy for Alexion, Britannia, Calliditas, Judo Bio, Novartis, Reata Inc, and Travere Therapeutics, Inc.; research funding from Novartis, Pfizer, Sanofi, and Travere; and other interests or relationships as Trustee for AlportUK and Chair of UK Kidney Association Rare Diseases Committee. B. Hendry reports employment with Travere Therapeutics, stock in Travere Therapeutics, an advisory or leadership role for South West Thames Institute for Renal Research (Board Chair), and other interests or relationships as Emeritus Professor, King's College London. A. Mercer reports employment with JAMCO Pharma Consulting AB and consultancy for Travere Therapeutics, Inc and Vera Therapeutics, Inc. K. Osmaston reports employment with UK Kidney Association. D. Pitcher reports employment with UK Kidney Association and current ongoing work as part of employment with UK Kidney Association to analyze data held in the UK National Registry of Rare Kidney Diseases (RaDaR) with Travere Therapeutics, Pfizer, and Sanofi. M.A. Saleem reports employment with University of Bristol; consultancy for Confo Therapeutics, Mission Therapeutics, Pfizer, Purespring Therapeutics, Retrophin, and Travere Therapeutics, Inc.; ownership interest in Purespring Therapeutics; research funding from Evotec, Retrophin, and UCB; honoraria from Purespring Therapeutics as Director and Chief Scientific Officer; patents or royalties from Purespring Therapeutics and University of Bristol; and advisory or leadership role as Director, Purespring Therapeutics. R. Steenkamp reports employment with UK Kidney Association, UK Renal Registry. A.N. Turner reports consultancy for Purespring 2021–current, Enyo Pharma from 2022, and Calliditas Therapeutics from 2023; advisory board/speaker for Shire-Takeda (2017–20) and Sanofi-Genzyme (2019–current); speakers bureau for staff education, Chiesi 2022; and other interests or relationships as Trustee and supporter of the patient-led charity Alport UK. K. Wang reports employment with and stock in Travere. K. Wong reports employment with UK Kidney Association.",
252,Disclosure The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.,No
253,"P.F.H. holds shares in Transcriptome Sciences Inc (TSI), a University of Alberta research company dedicated to developing molecular diagnostics, and is supported in part by a licensing agreement between TSI and Thermo Fisher and by a research grant from Natera. P.F.H. is a consultant to Natera. The other authors declare no conflicts of interest.",
254,"P.F.H. reports having shares in Transcriptome Sciences Inc, a University of Alberta research company with an interest in molecular diagnostics, and is a consultant to Natera, Inc. K.S.M-T. is an employee of Transcriptome Sciences Inc. A.P., Z.D., P.G., and P.B. are all employees of Natera Inc., with stocks or options to buy stocks in the company. C.L. and D.L. are employees of One Lambda Inc. L.G.H. is a consultant for AdaptImmune Therapeutics. All remaining authors declare no conflicts of interest and have nothing to disclose.",
255,"R. Inanaga reports honoraria from Astellas Pharma, Inc., Novartis Pharma K.K., and Otsuka Pharmaceuticals. Y. Kanakubo reports ownership interest in Takeda Pharmaceuticals. Y. Kanakubo is a member of the committee on diversity promotion in Japan Primary Care Association (JPCA), the committee on sexual health in JPCA, and the Gender Equality Promotion Committee in Chiba Medical Association. Y. Kanakubo serves as a member of the board of Nijiiro Doctors, an organization to promote awareness and education within the medical community regarding LGBTQ issues. As a member of Nijiro Doctors, Y. Kanakubo works with Novartis Pharma K.K. on projects but does not receive personal board compensation. N. Kurita has acted as a consultant to GlaxoSmithKline K.K.; has received honoraria from the following for-profit companies: Selista Corporation and UCB Japan K.K.; has received grants from the Japan Society for the Promotion of Science; and has received payments for speaking and educational events from Eisai Co. Ltd., Selista Corporation, Taisho Pharmaceutical Co. Ltd., and UCB Japan K.K. M. Matsunami reports payments for speaking and educational events from Astellas Pharma Inc. and Baxter Co., Ltd. T. Suzuki reports serving on speakers bureaus for Astellas Pharma Inc., AstraZeneca K.K, Baxter Co., Ltd., Bayer Yakuhin., Ltd., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., CureApp, Inc., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K, Kaneka Medix Corp, Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kyowa Kirin Co., Ltd, Mochida Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd, Novartis Pharma K.K., Novo Nordisk Pharma., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical, Terumo Corp, Torii Pharmaceutical Co., Ltd. T. Toida reports consultancy for Astellas Pharma Inc. and speakers bureau for AstraZeneca K.K., Kyowa Kirin Co., Ltd., Nobelpharma Co., Ltd, Ono Pharmaceutical Co., Ltd., and Torii Pharmaceutical Co., Ltd. T. Toishi reports serving on a speakers bureau for Otsuka Pharmaceuticals. All remaining authors have nothing to disclose.",
256,<b>Financial Disclosure:</b> Dr. Workeneh is a consultant for AstraZeneca and Otsuka Pharmaceutical. Dr. Rondon-Berrios reports serving as an associate editor for Frontiers in Medicine/Nephrology and serving as an editorial board member for the Clinical Journal of the American Society of Nephrology. Dr. Chowdhury and Dr. Turcotte declare that they have no relevant financial interests.,
257,"A.G. Gharavi reports receiving research grants from the National Institutes of Health and the Renal Research Institute. A.G. Gharavi also reports consultancy: AstraZeneca Center for genomics research, Goldfinch Bio: Actio biosciences, Novartis: Travere; ownership interest: Actio; research funding: Natera; honoraria: Sanofi, Alnylam; and advisory or leadership role: Editorial board: <i>JASN</i> and <i>Journal of Nephrology</i>. G. Povysil is an employee of and has ownership interest in Waypoint Bio. E. Cocchi reports research funding: <i>American Society of Nephrology</i>. H. Milo Rasouly reports research funding: Natera. K. Kiryluk reports consultancy: Calvariate, HiBio; and research funding: AstraZeneca, Vanda, Bioporto, Aevi Genomics, and Visterra. Because A.G. Gharavi is an Associate Editor of the <i>JASN</i>, he was not involved in the peer review process for this manuscript. A guest editor oversaw the peer review and decision-making process for this manuscript.",
258,"Competing interests. J.L.K., T.T., and S.G.T. have a financial interest related to this research. Patents on senolytic drugs are held by Mayo Clinic and Brigham and Women’s Hospital. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. No conflicts of interest, financial or otherwise, are declared by the other authors. Declaration of interests. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Stefan G. Tullius has patent Methods And Materials For Improving Transplant Outcomes licensed to Stefan G. Tullius. James L. Kirkland has patent Methods And Materials For Improving Transplant Outcomes licensed to Stefan G. Tullius. Tamar Tchkonia has patent Methods And Materials For Improving Transplant Outcomes licensed to Stefan G. Tullius.",
259,"A.R. Chang reports employment with Geisinger Health System; consultancy for Amgen, Medscape, Novartis, and Reata; research funding from Bayer, Novartis, and Novo Nordisk; advisory or leadership roles for Amgen and Reata; and grant support from National Kidney Foundation. D.M. Charytan reports consultancy for Allena Pharmaceuticals (DSMB), Amgen, AstraZeneca, CSL Behring, Eli Lilly/Boehringer Ingelheim, Fresenius, Gilead, GSK, Medtronic, Merck, Novo Nordisk, Renalytix, and Zogenix; research funding from Medtronic-clinical trial support, Amgen, Gilead, and Novo Nordisk; royalties from UpToDate for authorship/edits on reviews; advisory or leadership role as an Associate Editor of <i>CJASN</i>; and expert witness fees related to proton pump inhibitors. M.E. Grams reports advisory or leadership roles for <i>American Journal of Kidney Diseases</i>, <i>CJASN</i>, <i>JASN</i> Editorial Fellowship Committee, NKF Scientific Advisory Board, KDIGO Executive Committee (co-chair elect), USRDS Scientific Advisory Board, and ASN Publication Committee; grant funding from NKF, which receives funding from multiple pharmaceutical companies; grant funding from NIH; payment from academic institutions for grand rounds; payment from NephSAP; and travel reimbursement from KDIGO and the Korean Society of Nephrology. J.-I. Shin reports research funding from NIH and Merck. All remaining authors have nothing to disclose.",
260,Disclosure. The authors of this manuscript have no conflicts of interest to disclose as described by the <i>American Journal of Transplantation</i>.,No
261,"I. Ayoub reports consultancy agreement with Aurinia Advisory Board, honoraria from Aurinia, and advisory or leadership roles for Lupus Foundation of America (not paid) and Aurinia (paid). B. Blazius reports ownership interest in Apple, Bank of America, Cisco, Delta, Deere, Disney, Ford, JP Morgan, Netflix, Pfizer, Qualcom, and Viatris. P. Canetta reports consultancy agreements with Chinook, Novartis, Otsuka, and Travere and research funding from Calliditas, Novartis, and Travere. D. Chen is part of Kidney Health Initiative APOL1 Group and reports research funding from Vertex Pharmaceuticals. A. Chishti reports ownership interest in Apple, Google, Microsoft, and Tesla. V. D'Agati reports serving on the Editorial Board of <i>Kidney International</i>. R. Falk reports research funding from Vertex Pharmaceutica and honoraria from other universities for presentations and from ASN for presentations at Board Review Course. R. Gbadegesin reports research funding from AstraZeneca, Goldfinch Biotech, Reata, and Travere and an advisory or leadership role for Alport Syndrome Foundation Advisory Board. A. Gharavi reports consultancy agreements with AstraZeneca Center for genomics research, Actio Biosciences, Goldfinch Bio, Novartis, and Travere; ownership interest in Actio; research funding from Natera and Renal Research Institute; honoraria from Alnylam and Sanofi; and serving on the Editorial Boards of <i>JASN</i> and <i>Journal of Nephrology</i>. D. Gipson reports research funding from Travere (to University of Michigan), Boehringer-Ingelheim, Goldfinch Bio, Novartis, and Reata; advisory boards/steering committees for AstraZeneca, Goldfinch Bio, Roche/Genentech, and Vertex; and other interests or relationships with Nephrotic Syndrome Patient Reported Outcome Consortium (public-private partnership, with Pfizer, GSK, Goldfinch Bio, NephCure Kidney International) and as Co-chair for National Kidney Foundation Improving Vaccinations in Kidney Disease Workshop. D. Gipson reports consultancy between University of Michigan and Vertex, AstraZeneca, Boehringer-Ingelheim, Goldfinch Bio, Roche, and Genentech; no individual consultancy agreements. L.A. Greenbaum reports consultancy agreements with Alexion, Arrowhead Pharmaceuticals, Aurinia, Cara Therapeutics, Natera, Novartis, Otsuka, and Roche; research funding from Abbvie, Advicenne, Alexion, Apellis, Aurinia, Otsuka, Reata Pharmaceuticals, Roche, and Vertex; an advisory or leadership role for Alexion; and DSMB payments from Alnylam, Akebia, Reata, Relypsa, Travere, and UCSD. M. Helmuth and A. Smith report employment with Arbor Research Collaborative for Health. S. Hogan reports honoraria from NIH/NIDDK (grant reviewer) and serving as a VA grant reviewer. L. Holzman reports employment with University of Pennsylvania, Department of Veterans Affairs; consultancy agreements with Arnold & Porter Kaye Scholer LLP; honoraria from NIH/NIDDK; patents or royalties from University of Michigan; advisory or leadership roles for <i>Journal of Clinical Investigation</i>, NephCure Kidney International, ASN, and <i>JASN</i>; and other interests or relationships with NephCure Kidney International. M. Kallash reports research funding from Duplex - Retrophin- PI. J.M. Kidd reports stock in multiple companies including Amazon, Apple, CVS, Delta Airlines, Dominion power, Ford, PNC, and Tesla as well as diversified mutual funds; Virginia Catalyst grant funding; honoraria from Boca Raton Regional Hospital; and serving as a member of American Society of Nephrology and National Kidney Foundation. J. Kopp reports an NIH patent. M. Kretzler reports sponsored research project as PI at U Michigan: NIH, JDRF, Chan Zuckerberg Initiative, amfAR, Angion, AstraZeneca, Boehringer-Ingelheim, Certa, Chinook, Elpidera, Gilead, Goldfinch, Ionis, Jansen, Lilly, Maze, Novo Nordisk, RenalytixAI, Regeneron, and Travere. M. Kretzler reports advisory or leadership roles for Council of NIH-National Center for Advancing Translational Sciences (NCATS), Advisory Board of Nephcure Kidney International, and Editorial Boards of <i>JASN</i>, <i>Kidney Disease</i>, and <i>Kidney International</i>. M. Kretzler reports consultancy as an employee of U Michigan for: Astellas, Boehringer Ingelheim, Certa, Janssen, Novo Nordisk, and Poxel. A.K. Mottl reports consultancy agreements with Bayer and Chinook; research funding from Alexion, Aurinia, Bayer, Calliditas, Duke Clinical Research Institute, Pfizer, and University of Pennsylvania; honoraria from UpToDate; and advisory or leadership roles for Bayer and Chinook. K. Mucha reports Patent No.: US 11029314 B2 (Mucha <i>et al.</i>) and serving as a <i>Archivum Immunologiae et Therapiae Experimentalis</i> Editorial Board member (2020–2022) and a Polish Society of Internal Medicine National Board Member 2016–2022. C. Nester reports honoriaria for serving on advisory boards for Alexion, Apellis, Biocryst, and Novartis; research funding from Retrophin - Pediatric Recruiting Site for the Duet Trial, Achillion—Site PI—C3G Trial, Alexion, Avacopan—Site PI—C3G Trial, Novartis—Site PI—C3G Trial, and Apellis—Site PI—C3G Trial. R.S. Parekh reports ownership interest in Synaptive-stock, Coramed-stock, and SpineFx; research funding from Canadian Institute of Health Research (CIHR), NIH, and Ontario Ministry; patents or royalties from IZI and SpineFx; serving as an Associate Editor of <i>CJASN</i>, a Board Member of Bishop Strachan School, and a Board Member of Conference of Independent Schools of Ontario; and an advisory or leadership role for ISN Council. R.S. Parekh's spouse reports patents or royalties from Coramed and serving as an officer of Coramed and SpineFx. Y. Peleg reports consultancy agreements with Aurinia Pharmaceuticals and KOL Insights at VMLY&R Health, honoraria from Aurinia Pharmaceuticals and KOL Insights at VMLY&R Health, and an advisory or leadership role for Aurinia Pharmaceuticals. K. Reidy reports research funding from Advicienne and Travere; advisory or leadership roles for AAP Executive committee, Neonatal Kidney Collaborative, and Frontiers; and other interests or relationships with Ruth Gottscho Kidney Foundation, NIH funding, and Preeclampsia Foundation funding. B. Robinson was an employee of Arbor Research Collaborative for Health, which administers the DOPPS Program, during the manuscript production period. Global support for the ongoing DOPPS Program is provided without restriction on publications by a variety of private industry, professional society, and public funders. For details see https://www.dopps.org/AboutUs/Support.aspx. B. Robinson has received consultancy fees or travel reimbursement in the last 3 years from AstraZeneca and Monogram Health, paid directly to his institution of employment, and from GlaxoSmithKline. B. Robinson reports serving on the Editorial Board of <i>American Journal of Kidney Diseases</i> and the Board of Directors of Kidney Health Initiative. V. Royal reports consultancy agreements with Vertex Pharmaceuticals and honoraria from Janssen. D. Selewski reports research funding from Travere Therapeutics, Inc. W.E. Smoyer reports consultancy agreements with Otsuka, Vertex, and Visterra; ownership interest in NephKey Therapeutics; research funding from Aurinia; honoraria from USC for CTSA External Advisory Committee and from UCLA for CTSA External Advisory Committee; royalties from UpToDate; and advisory or leadership roles as member of the Board of Directors of Pediatric Nephrology Research Consortium (PNRC), member of the Board of Directors of NephCure Kidney International (NKI), and a member of the Coordinating Committee of the Institute for the Advancement of Clinical Trials in Children (I-ACT). J. Sperati reports consultancy agreements with Alnylam Pharmaceuticals and Q32 Bio; research funding from Achillion Pharmaceuticals, Alnylam Pharmaceuticals, National Institutes of Health, and Novartis Pharmaceuticals; honoraria from Alexion Pharmaceuticals and Alnylam Pharmaceuticals; and advisory or leadership roles for <i>Advances in Chronic Kidney Disease</i> (Editorial Board), <i>Current Hypertension Reports</i> (Section Editor), American Board of Internal Medicine Nephrology Longitudinal Assessment Committee, and National Kidney Foundation Education Committee. T. Srivastava reports research funding from Apellis Pharmaceuticals, Bristol-Myer-Squib, Roche, and Travere; honoraria from Alnylam; an advisory or leadership role for <i>Case Reports in Pediatrics</i>; and other interests or relationships with UpToDate. J. Steinke reports serving on the Gift of Life Advisory Board. H. Trachtman reports employment with RenalStrategies LLC; consultancy agreements with Aclipse, Akebia, Alexion (inactive), Angion, Astellas (inactive), Bristol Meyers Squibb (inactive), Chemocentryx (DMSB), Complexa (inactive), Goldfinch Bio, Kaneka (inactive), Natera (RenaSight), Otsuka (DSMB Chair), Travere Therapeutics, and Walden; support for trial design from Travere Therapeutics and Goldfinch and Walden; support for clinical work from Alexion; honoraria for attendance at glomerular disease panels organized by Reata and Astellas; patents or royalties for design of EPPIK trial conducted by Travere Therapeutics, planned submission; advisory or leadership roles for DSMB RIVUR Trial (completed), DSMB bumetanide-seizure trial (completed), Chair of DSMB Otsuka trials of tolvaptan in children; DSMB for ANCA vasculitis for Chemocentryx (completed), Steering Committee for Abatacept Trial for BMS (completed), Steering Committee for DUPRO (DUPLEX and PROTECT trials for Travere Therapeutics, Steering Committee for Goldfinch Bio (Steering Committee), and MEDCAC committee member for KHI Board of Directors; serving on Editorial Boards for <i>Glomerular Disease</i>, <i>Kidney360</i>, and <i>Pediatric Nephrology</i>; and serves as a partner with NephCure Kidney International in efforts to promote pediatric participation in clinical trials for glomerular disease. K. Twombley reports consultancy agreements with Horizon; research funding from AHRQ, Kaneka, and NIDDK; and honoraria from American Academy of Pediatrics and American Board of Pediatrics. All remaining authors have nothing to disclose.",
262,"M. Naesens is involved in a clinical study with CareDx (Brisbane, CA), involving the use of donor-derived cell-free DNA in kidney transplant recipients. M. Naesens also reports Consultancy: Agomab, Aiosyn, Argenx, and Hansa; Research Funding: CareDx; Honoraria: Argenx and Hansa; and Patents or Royalties: M. Naesens is inventor of two patents related to the FWO-SBO application—EP19152365.3: mRNA-based biomarkers for antibody-mediated transplant rejection. This biomarker was licensed in September 2020 to CareDx, a precision medicine solutions company focused on solutions for transplant patients—PCT/EP2018/097044: Biomarkers for typing allograft recipients (patent application submitted in December 2018). E. Van Loon reports Patents or Royalties: Shared inventorship of European patent mRNA-based biomarker for antibody-mediated transplant rejection, filed on January 17, 2019. The remaining author has nothing to disclose.",
263,"M. Brinker reports Employer: Bayer AG; and Ownership Interest: Bayer AG. P. Schloemer is a Bayer employee. L. Frison reports Employer: AstraZeneca. L. Frison, S.B. Gasparyan, M. Karpefors, D.J. Little, and J. Rossert are AstraZeneca employees. H.L. Heerspink is consultant for AstraZeneca, Bayer, Behring, Boehringer Ingelheim, Chinook, CSL Dimerix, Eli-Lilly, Gilead, Janssen, Merck, Novo Nordisk, ProKidney, Travere Therapeutics, and Vifor Fresenius. He has received research support from AstraZeneca, Boehringer Ingelheim, Janssen, and Novo Nordisk. H.L. Heerspink also reports Honoraria: Lecture fees from AstraZeneca and NovoNordisk. N. Jongs reports travel grants from AstraZeneca. N. Jongs reports Speakers Bureau: AstraZeneca. D.J. Little reports Ownership Interest: AstraZeneca; and Other Interests or Relationships: volunteer as a nephrologist at Walter Reed National Military Medical Center. R. Nkulikiyinka reports Employer: Bayer AG; and Ownership Interest: Bayer AG. N. Rethemeier reports Employer: Bayer AG; and Ownership Interest: Bayer AG. J. Rossert reports Ownership Interest: Amgen, AstraZeneca, and Vertex. C. Tasto Employer: Bayer AG; and reports Ownership Interest: Bayer AG.",
264,"J. Coresh reports ownership interest in Healthy.io; consultancy for Healthy.io and SomaLogic; research funding from National Institute of Health and National Kidney Foundation; and an advisory or leadership role for SomaLogic. D.K. Farrington reports employment with Kidney Care Bermuda and Bermuda Home Dialysis Services Ltd. and MedStar Emergency Medicine Physicians. M.E. Grams reports advisory or leadership roles for ASN Publication Committee, <i>JASN</i> Editorial Fellowship Committee, KDIGO Executive Committee (co-chair elect), NKF Scientific Advisory Board, and USRDS Scientific Advisory Board; role on the Editorial Boards of <i>American Journal of Kidney Diseases</i> and <i>CJASN</i>; grant funding from NKF, which receives funding from multiple pharmaceutical companies; grant funding from NIH; payment from academic institutions for grand rounds; payment from NephSAP; and travel reimbursement from KDIGO and the Korean Society of Nephrology. K. Matsushita reports consultancy for Akebia and Kyowa Hakko Kirin; honoraria from Fukuda Denshi and Kowa Company Ltd.; and advisory or leadership roles for <i>American Journal of Kidney Disease</i>, <i>Circulation Reports</i>, and <i>Kidney International</i>. All remaining authors have nothing to disclose.",
265,"P Berg reports Patents or Royalties inventor in two patent applications filed by Aarhus University, Denmark One describes the use of urinary bicarbonate excretion as a biomarker in cystic fibrosis, the second describes the use of urinary acid–base markers as a prognostic marker and companion diagnostic in patients with CKD J Leipziger reports the following: Ownership Interest Osram Siemens, and Siemens Energy All remaining authors have nothing to disclose S Svendsen reports Patents or Royalties Patent on employing a urine acid base score as guideline for base supplementation in chronic kidney disease (5% ownership) J Holst reports Consultancy: JJH Novo Nordisk, Merck/MSD Spouse Mette M Rosenkilde (MMR) Alphasights Eli Lilly Shouti/Structure TX Zealand Pharma Alcimed Novo Nordisk Ownership Interest: JJH/MMR Bainan Biotech Antag Therapeutics Research Funding Scohia Honoraria Novo Nordisk Merck/MSD Advisory or Leadership Role JJH Novo Nordisk Eli Lilly Zealand pharma Speakers Bureau Novo Nordisk Novo Nordisk Pharma Novo Nordisk Scandinavia AB and Mayo Clinic and Other Interests or Relationships JJH Member of the Incretin EASD Study Group.",
266,"J. Butler reports Consultancy: Consulting fees from 3ivelabs, Abbott, American Regent, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element, Faraday, G3 Pharmaceutical, Imbria, Impulse Dynamics, Innolife, Inventiva, Ionis, Janssen, LivaNova, Lexicon, Medtronic, Merck, Novartis, Novo Nordisk, Otsuka, Occlutech, PharmaCosmos, Roche, Sanofi, Secretome, Sequana, Tricog, and Vifor; Honoraria: As above consultancy; Advisory or Leadership Role: As above consultancy; and Speakers Bureau: AstraZeneca, Boehringer Ingelheim-Lilly, Impulse Dynamics, and Novartis. L. Bellumkonda reports Consultancy: CareDx; Research Funding: Natera; Honoraria: CareDx; and Advisory or Leadership Role: CareDx. S.P. Collins reports Consultancy: Abbott, Boehringer Ingelheim, and Reprieve Cardiovascular; and Research Funding: Beckman Coulter. Z.L. Cox reports grants from AstraZeneca; and Consultancy with Roche and Translational Catalyst. D.H. Ellison reports Consultancy: Boehringer Ingelheim; Honoraria: Boston University School of Medicine and Renaissance School of Medicine; Patents or Royalties: Author, UpToDate; and Advisory or Leadership Role: Consulting Editor, <i>Hypertension</i> and Editorial Board, <i>American Journal of Physiology-Renal Physiology</i> and <i>JASN</i>. M.P. Field reports Employer: Elemental Scientific. S.E. Inzucchi has served on clinical trial committees or as a consultant to Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Lexicon, Merck, Novo Nordisk, Pfizer, and vTv Therapeutics; and has delivered lectures sponsored by AstraZeneca and Boehringer Ingelheim. S.E. Inzucchi reports Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novo Nordisk, and Pfizer; Honoraria: AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novo Nordisk, and Pfizer; Advisory or Leadership Role: Editor-in-Chief, Diabetes Channel, PracticeUpdate website (honoraria received from Elsevier); and Speakers Bureau: Not on any speaker's bureaus/rosters but gave lectures supported by AstraZeneca and Boehringer Ingelheim in the past. J.B. Ivey-Miranda reports personal fees from AstraZeneca, Boehringer Inglheim, Merck, Moksha8, Novartis, and Translational Catalyst. J.B. Ivey-Miranda reports Research Funding: AstraZeneca and Sequana; and Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Merck, Moksha8, and Novartis. C. Maulion reports Consultancy: Sequana Medical. V.S. Rao has a patent for Treatment of diuretic resistance US20200079846A1 issued to Corvidia Therapeutics Inc. and Yale with royalties paid to Yale University, V.S. Rao and J.M. Testani and a patent Methods for measuring renalase WO2019133665A2 issued to Yale. V.S. Rao reports personal fees from Translational Catalyst. V.S. Rao reports Consultancy: Translational Catalyst; and Patents or Royalties: Corvidia Therapeutics. J.M. Testani reports Consultancy: 3ive labs, AstraZeneca, Bayer, BD, Boehringer Ingelheim, Bristol Myers Squibb, Cardionomic, Cytokinetics, Edwards Life Sciences, FIRE1, Lexicon Pharmaceuticals, Lilly, MagentaMed, Merck, Novartis, Otsuka, Precardia, Regeneron, Relypsa, Reprieve, Inc., Sanofi, Sequana Medical, Windtree Therapeutics, and W.L. Gore; Ownership Interest: Reprive, Inc. and Sequana Medical; Research Funding: 3ive labs, Abbott, Boehringer Ingelheim, Bristol Myers Squibb, FIRE1, Lexicon Pharmaceuticals, Merck, Otsuka, Reprieve, Inc., Sanofi, and Sequana Medical; Honoraria: 3ive labs, AstraZeneca, Bayer, BD, Boehringer Ingelheim, Bristol Myers Squibb, Cardionomic, Cytokineitcs, Edwards Life Sciences, FIRE1, Lexicon Pharmaceuticals, Lilly, MagentaMed, Merck, Novartis, Otsuka, Precardia, Regeneron, Relypsa, Reprieve, Inc., Sanofi, Sequana Medical, Windtree Therapeutics, and W.L. Gore; and Patents or Royalties: Corvidia, Reprieve, Inc., Sequana Medical, and Yale University. J.M. Turner reports grants and/or personal fees from 3ive labs, Abbott, AstraZeneca, Bayer, BD, Bristol Myers Squibb, Cardionomic, Edwards Life Sciences, FIRE1, Lexicon Pharmaceuticals, Lilly, MagentaMed, Merck, Novartis, Otsuka, Precardia, Regeneron, Relypsa, Reprieve, Inc., Sanofi, Sequana Medical, Windtree Therapeutics, and W.L. Gore. In addition, J.M. Turner has a patent for Treatment of diuretic resistance issued to Corvidia Therapeutics Inc. and Yale, a patent methods for measuring renalase issued to Yale, and a patent Treatment of diuretic resistance pending with Reprieve, Inc. J.M. Turner reports Consultancy: Sequana Medical; and Research Funding: Bayer, Boehringer Ingelheim, and Sequana Medical. D.R. Wiederin is the President of Elemental Scientific. D.R. Wiederin reports Employer: Elemental Scientific; Consultancy: Elemental Scientific; Ownership Interest: Elemental Scientific; Research Funding: Elemental Scientific; Patents or Royalties: Elemental Scientific; Advisory or Leadership Role: Elemental Scientific; and Speakers Bureau: Elemental Scientific. C.S. Wilcox reports Consultancy: AstraZeneca, Bayer, Bristol Myers Squibb, Relypsa, Sarfez Inc., Sequana, and Vifor; Ownership interest: Sarfez Inc.; Honoraria: Sequana; and Advisory or Leadership Role: Sarfez Inc., scientific advisor and Sequane, Data monitoring and safety committee for SAHARA and MOJAVE trials. F.P. Wilson reports Ownership Interest: Owner of Efference, LLC; Research Funding: Amgen, Boeringher-Ingelheim, Vifor, and Whoop; Advisory or Leadership Role: Editorial Board—<i>American Journal of Kidney Disease</i> and <i>CJASN</i>; and Other Interests or Relationships: Medical Columnist—Medscape. All remaining authors have nothing to disclose.",
267,"V. Birardi, L.S. Hodge, and H. Leher are employees and stockholders of Aurinia Pharmaceuticals Inc. H. Menn-Josephy is a consultant for Aurinia Pharmaceutical Inc., a consultant and on the Medical Education Board for GlaxoSmithKline, and a Co-Principal Investigator in clinical trials carried out by AstraZeneca, Biogen, Human Genome Sciences, Merck Pharmaceuticals, and Pfizer. H. Menn-Josephy reports honoraria from Aurinia Pharmaceuticals and GlaxoSmithKline (GSK) Pharmaceutical, advisory or leadership roles for Aurinia Pharmaceuticals and GlaxoSmithKline (GSK) Pharmaceutical, and speaker bureau for Aurinia Pharmaceuticals for voclosporin.",
268,DISCLOSURES. The authors of this manuscript have no conflicts of interest to disclose as described by the <i>American Journal of Transplantation</i>. Declaration of interests. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.,No
269,C.J.E.W. has received consulting fees from Jazz pharmaceuticals and Nefro Health and speaker honoraria from OrganOx Ltd. The other authors declare no conflicts of interest.,
270,"S.S. Farouk reports serving on the Editorial Boards of <i>American Journal of Kidney Diseases, Clinical Transplantation</i>, and <i>Journal of Nephrology</i>. K.L. Gibson reports employment with The UNC Kidney Center; consultancy for Aurinia Inc. and Travere Inc. (formally Retrophin); research funding from Aurinia Inc., Genentech Inc., and Travere, Inc.; an advisory or leadership role for Travere Inc.; other interests or relationships with KDIGO Writing Group (nonpaid) and IPNA Writing Group (nonpaid); and role of current ASN Treasurer. B.D. Humphreys reports consultancy for Chinook Therapeutics, Janssen, and Pfizer; ownership interest in Chinook Therapeutics; research funding from Janssen and Pfizer; honoraria from Novartis; patents or royalties from Evotec, AG; and serving on the Editorial Boards of <i>American Journal of Physiology Renal Physiology</i>, <i>JCI Insight</i>, <i>Kidney International</i>, and <i>Seminars in Nephrology</i>; advisory or leadership roles for advisory board of RegMed XB, Regenerative Medicine Crossing Borders and Chinook Therapeutics; is President-elect of ASCI; and is on the Board of Scientific Advisors of NIDDK. T. Ibrahim reports employment with American Society of Nephrology, ownership interest in Thompson Italian (restaurant), and an advisory or leadership role as Past President of the Council of Medical Specialty Societies. J.M. Orlowski reports employment with Association of American Medical College; ownership interest in Amazon, Apple, and Google; and advisory or leadership roles for Creighton University Board of Trustees, Marquette University Board of Trustees, Medical College of Wisconsin Board of Trustees, and Montini Catholic High School Board of Trustees. J.M. Orlowski's husband has consulted with Greenlee. M.E. Rosenberg reports honoraria from Wolter Kluwer Health as an UpToDate author and reports other interests or relationships as co-editor of the textbook <i>Chronic Renal Disease</i> with Paul Kimmel. S.M. Udani reports employment with Nephrology Associates of Northern Illinois; consultancy for Abbott, AstraZeneca, Aurinia, Bayer, Boehringer-Ingelheim, Calliditas, Dimerix, Goldfinch Bio, Natera, Talaris, and Travere; ownership interest in Strive Health; research funding from AstraZeneca, Bayer, Calliditas, CareDx, Chinook, Dimerix, Goldfinch Bio, Goldfinch Bio, Mallinckrodt, Novartis, and Travere; honoraria from Abbott, Alexion, AstraZeneca, Boehringer-Ingelheim, Calliditas, Goldfinch Bio, Mallinckrodt, Natera, and Travere; advisory or leadership roles for National Kidney Foundation of Illinois and Nephcure Kidney Network; speakers bureau for Abbott, AstraZeneca, Aurinia, Boehringer-Ingelheim, and Natera; and other interests or relationships with National Kidney Foundation and Nephcure. J.S. Waitzman reports consultancy for Tome Biosciences. J.S. Waitzman's spouse reports employment with Takeda Pharmaceuticals. M. West reports employment with American Society of Nephrology. All remaining authors have nothing to disclose.",
271,T.W. received speaker’s honoraria from eGenesis and Mallinckrodt/Therakos and is a DSMB member for Quell Therapeutics. The other author declares no conflicts of interest.,
272,"F.T. Chebib reports employment with Mayo Clinic, research support from Natera Inc. and Otsuka Pharmaceuticals, educational fellowship grant from Otsuka Pharmaceuticals, Patent no US20200368191A1, and advisory or leadership role for PKD Foundation—Chair of Education Advisory Panel. M.B. Chonchol reports consultancy for Otsuka; research funding from DOD, NIH, OTSUKA, and PKD Foundation; honoraria from Otsuka; and advisory or leadership role as a Deputy Editor for <i>CJASN</i>. N.K. Dahl reports employment with Mayo Clinic, consultancy for Otsuka Pharmaceuticals, research funding as a PI for clinical trials sponsored by Reata and Vertex, honoraria from Natera and Otsuka Pharmaceutical, advisory or leadership role for Natera Scientific Advisory Board and PKD Foundation, role on the unbranded speakers bureau for Otsuka until December 2022, and other interests or relationships with Medical Advisory Board and NKF NE Chapter. A. Ghanem reports employment with Mayo Clinic. M. Mrug reports employment with Department of Veterans Affairs Medical Center, Birmingham, AL; consultancy for Caraway Therapeutics, Chinook, Goldilocks Therapeutics, Natera, Otsuka Corporation, Reata, and Sanofi; research funding from Chinook, Goldilocks Therapeutics, Otsuka Corporation, Palladio, and Sanofi; honoraria from Chinook, Natera, Otsuka Corporation, Reata, and Sanofi; and advisory or leadership roles for PKD Foundation and STAGED-PKD steering committee (Sanofi), and Advisory Board (Carraway Therapeutics, Goldilocks Therapeutics, Sanofi, and Santa Barbara Nutrients). K.L. Nowak reports consultancy for Otsuka Pharmaceutical Development & Commercialization, Inc.; research funding from Otsuka Pharmaceutical Development & Commercialization, Inc. (data analysis); other interests or relationships with the PKD Foundation; and a scientific presentation by the National Kidney Foundation. K.L. Nowak reports an advisory or leadership role for NephU: Improving Awareness and Patient Outcomes. NephU is supported by Otsuka America Pharmaceutical, Inc. (OAPI) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). F.F. Rahbari-Oskoui reports consultancy for Otsuka and UpToDate; research funding from Duke University, Kadmon, NIH, Reata, and Sanofi/Genzyme; honoraria from Otsuka; author royalties from UpToDate; advisory or leadership roles for <i>BMC Nephrology</i> (Associate Editor), <i>Journal of Cardiology and Vascular Medicine</i> (Editorial board Member), and PKD Foundation (Scientific Advisory Panel member); and role on unbranded speaker bureau for Otsuka (only raising disease awareness in ADPKD without any reference to commercial products). The remaining author has nothing to disclose.",
273,"C.J. Diamantidis reports consultancy for Optum Labs/UnitedHealth Group; stock in Roblox; research funding from NIDDK and PCORI; and advisory or leadership roles for DSMB for NIDDK COPE-AKI Study, Editorial Board for <i>Contemporary Clinical Trials</i>, Scientific Advisory Board for National Kidney Foundation, and Steering Committee for National Kidney Foundation Patient Network. A.S. Go reports employment with Kaiser Permanente Northern California and research funding from Amarin Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Janssen Research and Development, Novartis, and Pfizer. E.J. Horwitz reports other interests or relationships as medical director for in-patient dialysis services at MetroHealth Medical Center contracted with Fresenius Kidney Care and reports serving as a member of American Society of Nephrology (ASN) and member of the International Society of Peritoneal Dialysis (ISPD). C.-y. Hsu consulted for legal cases involving acute or CKD (Lewis Brisbois and McMasters Keith Butler), reports consulting on an <i>ad hoc</i> basis for companies regarding kidney disease (Aria Pharma and Triangle Insights Group), reports being paid for serving as a Steering Committee member on an industry-funded trial (LG Chem), and reports research funding from Satellite Healthcare and royalties from UpToDate. J.Y. Hsu reports advisory or leadership roles as an <i>American Journal of Kidney Diseases</i> Statistics/Epidemiology Editor, American Medical Association Statistical Reviewer, and member of <i>PLOS One</i> Statistical Advisory Board. J.P. Lash reports an advisory or leadership role for <i>Kidney360</i>. K.D. Liu reports consultancy for AM Pharma, Biomerieux, BOA Medical, Neumora, and Seastar Medical; stock in Amgen; and other interests or relationships from UpToDate. I.E. McCoy reports ownership interest in Google and Meta and research funding from Satellite Healthcare Inc. (nonprofit). A. Srivastava reports consultancy for CVS Caremark and Tate & Latham (Medicolegal consulting) and honoraria from AstraZeneca, Bayer, FNIH, and Horizon Therapeutics PLC. J. Taliercio reports consultancy for AstraZeneca, Merck & Co, Inc., and Otsuka and speakers bureau for Merck & Co, Inc. M.R. Weir reports consultancy for Akebia, AstraZeneca, Bayer, Boehringer-Ingelheim, CareDx, Janssen, Merck, Novo Nordisk, and Vifor Pharma—all are modest (less than $10,000); honoraria from above for <i>ad hoc</i> advisory board meetings; and advisory or leadership roles for above for <i>ad hoc</i> advisory board. All remaining authors have nothing to disclose.",
274,"D.M. Charytan reports consultancy for Allena Pharmaceuticals (DSMB), Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Fresenius, Gilead, GSK, Medtronic, Merck, Novo Nordisk, Renalytix, and Zogenix; research funding from Amgen, Gilead, Medtronic-clinical trial support, and Novo Nordisk; royalties from UpToDate for authorship/edits on reviews; role as an Associate Editor of <i>CJASN</i>; and expert witness fees related to proton pump inhibitors. F.R. Mc Causland reports consultancy for GlaxoSmithKline and Zydus Therapeutics Inc., and research funding paid to institution from Advanced Medical, Fifth Eye, NIH, and Satellite Healthcare.",
275,"M.J. Casey reports consultancy agreements with CareDx, Inc. and research funding from Dialysis Clinic, Inc. D. DuBay is a board member of the Island Peer Review Organization End-stage renal disease Network of the South Atlantic (nonprofit). T. Fülöp reports employment with the US Veterans Administration; editorship stipends from Taylor and Francis Online and Springer Nature; serving as an editor for <i>Journal of Medical Case Reports</i> and <i>Renal Failure</i>; serving as a subspecialty editor for <i>American Journal of Medical Sciences</i>; and serving on the editorial boards for <i>ASAIO Journal</i>, <i>BMC Nephrology</i>, <i>Clinical Nephrology</i>, <i>International Journal of Clinical Pharmacology and Therapeutics</i>, <i>Journal of Clinical Hypertension</i>, <i>Journal of Nephropharmacology</i>, <i>Therapeutic Dialysis and Apheresis</i>, and <i>World Journal of Translational Medicine</i>. All remaining authors have nothing to disclose.",
276,"Outside the submitted work, S.D. Navaneethan reported receiving personal fees from ACI clinical (event adjudication committee), AstraZeneca (Data safety monitoring board), Bayer, Boehringer Ingelheim/Eli Lilly, GlaxoSmithKline, Intercept (event adjudication committee), Vertex (event adjudication committee), and Vifor; and Advisory or Leadership Role: AJKD, <i>American Journal of Nephrology</i>, Cardiorenal Medicine, <i>CJASN</i>, <i>Current Opinion in Nephrology and Hypertension</i>, and KDIGO: Guideline writing committee member. W.E. Mitch reports Other Interests/Relationships (unpaid): <i>National Kidney Foundation</i>; <i>International Society of Nephrology</i>; <i>American Heart Association</i>; <i>American Society of Nephrology</i>; <i>American Diabetes Association</i>.",
277,<b>Financial Disclosure:</b> The authors declare that they have no relevant financial interests.,No
278,"M. Allon is the Editor-in-Chief of <i>Kidney360</i>. G.R. Cutter reports consultancy for AI therapeutics, AMO, AstraZeneca, Avexis, Bristol Meyers Squibb/Celgene, CSL Behring, DSMBs: Applied Therapeutics, Horizon, Immunic, Karuna, Kezar, Mapi, Merck, Mitsubishis, NHLBI (Protocol Review Committee), Novartis, Opko Biologics, Prothena, Reata, Regeneron, Sanofi-Aventis, Teva, University of Pennsylvania, University of Texas Southwestern, and Visioneering Technologies, Inc.; ownership interest in Pythagoras, Inc., a private consulting company; advisory or leadership role as a <i>JASN</i> Statistical editor; role on <i>Multiple Sclerosis Journal</i> Editorial Board and <i>Multiple Sclerosis and Related Diseases</i> Editorial Board; and Consulting or Advisory Boards for Alexion, Antisense Therapeutics, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Entelexo Biotherapeutics, Inc., Genentech, Genzyme, GW Pharmaceuticals, Hoya Corporation, Immunic, Immunosis Pty Ltd, Klein-Buendel Incorporated, Linical, Merck/Serono, Novartis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Roche, and SAB Biotherapeutics. The remaining author has nothing to disclose.",
279,"B. Smyth has received honoraria for speaking/consulting from CSL Vifor paid to his institution. B. Smyth is supported by a Research Establishment Fellowship from the Royal Australasian College of Physicians. R. Krishnasamy is supported by the Queensland Advancing Clinical Research Fellowship. M. Jardine is supported by a National Health and Medical Research Council Investigator Grant. M. Jardine is responsible for research projects that have received funding from Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro, and MSD; has received fees for Advisory, Steering Committee and/or Scientific Presentations from Akebia, Amgen, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Cesas Medical, Chinook, CSL, Janssen, Medcon International PACE CME (Physician’s Academy for Cardiovascular Education), Medscape, MSD, Occurx, Roche and Vifor; with any consultancy, honoraria or travel support paid to her institution. All remaining author have nothing to disclose.",
280,"A.H.J. Danser reports research funding from Alnylam Pharmaceuticals. M.H. De Borst reports consultancy for Astellas, AstraZeneca, Kyowa Kirin, Pharmacosmos, Sanofi Genzyme, and Vifor Pharma; research funding from Sanofi Genzyme and Vifor Pharma; and role as an Associate Editor of <i>Nephrology Dialysis Transplantation</i>. E.J. Hoorn reports research funding from Aurinia; honoraria from UpToDate; role on the Editorial Boards of <i>American Journal of Physiology-Renal Physiology, JASN, and Journal of Nephrology</i>; and role as a Board Member of ERA Working Group on Inherited Kidney Diseases and as a Board Member of Dutch Federation of Nephrology. L. Vogt reports consultancy for AstraZeneca, Netherlands, Bayer BV Netherlands, and Vifor Pharma, Netherlands; research funding from Dutch Kidney Foundation and Health Holland; and role as an Associate Editor of <i>BMC Nephrology</i>. E.H.A. Michels reports funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 847786 (FAIR). The funding is unrelated to the current manuscript. J.I. Rotmans reports consultancy for Xeltis BV; advisory or leadership role for Advisory Board of Nextkidney; and other interests or relationships as Chair of Thematic Working Group Vascular Tissue Engineering at TERMIS, president-elect of Vascular Access Society, and member of Guideline Committee for Dutch Society of Nephrology. All remaining authors have nothing to disclose.",
281,"K.J.L. serves on the Medtronic DT-PAS/APOGEE trial advisory board and receives funding and unrelated sponsored research agreements from Amgen, Novartis, Implicit, and Kiniksa Biosciences. The other authors declare no conflicts of interest.",
282,"N. Aslam reports employment with Mayo Clinic; ownership interest in Doximity; research funding from AstraZeneca, Baxter, Idorsia, Novartis, and Otsuka; and advisory or leadership roles for FSN Board of Directors and Travere Therapeutics Advisory Board. D. Roth reports consultancy agreements with Erofins and ownership interest in AbbVie, Amgen, Becton Dickenson, CareDx, Johnson and Johnson, Merck, Regeneron, Teladoc, Vertex, and Walgreens. A.D. Sastry reports consultancy agreements with Travetere; joint venture partners with DaVita and US Renal; stocks in Amgen, Johnson and Johnson, Pfizer, and Vertex; honoraria from Travetere; and serving as President of the FSN. M.S. Segal reports employment with Malcom Randall VA Medical Center and research funding for a clinical trial with Alexion and a clinical trial with RegenMed.",
283,"C.J.E.W. has received speaker fees from OrganOx Ltd, and his department has received fees from Nefro Health and Jazz Pharmaceuticals for his presence on advisory boards. A.J.B. has a share in the patent for the circuit design used in the OrganOx metra device. The other authors declare no conflicts of interest.",
284,"S. Davies reports consultancy for Ellen Medical; research funding from Baxter Healthcare and collaborative research with Fresenius MC; honoraria for Advisory Board Membership for Baxter Healthcare Inc., Ellen Medical, and Fresenius Medical Care; and advisory or leadership roles for International Society of Nephrology (Kidney Failure Strategy), International Society of Peritoneal Dialysis (Member, co-chair PDOPPS Committee), President EuroPD, and Trustee Kidney Research UK. M. Lambie reports honoraria from Baxter Healthcare, Fresenius Medical Care, and NxStage and a research grant from Baxter Healthcare (unrelated to this work). J. Morelle reports consultancy for Alexion Pharmaceuticals, AstraZeneca, Bayer, GlaxoSmithKline, and Sanofi-Genzyme; research funding from Alexion Pharmaceuticals, AstraZeneca, and Baxter Healthcare; advisory or leadership roles for Alexion Pharmaceuticals, AstraZeneca, Bayer, Sanofi-Genzyme, and Versantis; speaker honoraria from AstraZeneca, Baxter Healthcare, and Fresenius Medical Care; funding from the Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG, Brussels, Belgium), the National Fund for Scientific Research (FRS-FNRS, Brussels, Belgium), and the Saint-Luc Foundation (Brussels, Belgium); and travel grant from Sanofi-Genzyme and Vifor Pharma. C.M. Öberg reports consultancy for Baxter Healthcare, research funding from Baxter Healthcare and Fresenius Medical Care, honoraria from Baxter Healthcare, and role on <i>Peritoneal Dialysis International</i> Editorial Board. C.M. Öberg is the inventor pending patents filed by Gambro Lundia AB (Baxter) (unrelated to this work).",
285,"P.G. Blake serves as a contracted employee of Ontario Renal Network and reports honoraria from Baxter Global and Otsuka Australia, advisory or leadership role as Medical Director of Ontario Renal Network (a paid role), and role on the Editorial Board of the <i>American Journal of Nephrology</i>. C.R. Butler is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number K23DK129777. R. Mehrotra reports consultancy for Light Line Medical; role on the Editorial Boards for the <i>Journal of Renal Nutrition</i> and <i>Peritoneal Dialysis International</i>; advisory or leadership roles as Editor-in-Chief of <i>CJASN</i>, President-Elect of the International Society for Peritoneal Dialysis, and Chair of Nephrology Longitudinal Assessment Approval Committee of the American Board of Internal Medicine; and other interests or relationships as Chair of Board of Trustees, Northwest Kidney Centers. M. Mendu serves as Associate Chief Medical Officer at the Brigham and Women’s Hospital and on the advisory board for New England Life Care. G. Roberts is the Director of External Relations and Patient Engagement at the Kidney Research Institute and Center for Dialysis Innovation in the Division of Nephrology at the University of WA and reports ownership interest in Options Unlimited International (50%), honoraria from ProKidney, and University of Washington patent titled “Water-Conserving Kidney Dialysis System Incorporating Urea Phot-Oxidation”; advisory or leadership roles for KHI Board of Directors, LifeCenter NW Advisory Board, Center for Innovations in Cancer & Transplants chair of Community Engagement (Eng.) Committee (Comm.) (CEC), KRI Patient Advisory Comm., CDI Patient Advisory Board, Kidney Precision Medicine Project CEC, C-Path Patient Eng. Comm. & DIKI Project, Expert Patient Panel for CRIC study, and University of Minnesota's Office of Discovery and Translation: Reduce Medication-Related Disparities in African American Patients with Chronic Kidney Disease; speakers bureau for the American Association of Kidney Patients; and other interests or relationships with ASN COVID-19 Response Team & Transplant Subcommittee; HDU Advisory Comm, APOLLO CAB, ASN NTSD QAIE WG, APOLLO, International Nephrology Society (ISN) Patient Group, Can-SOLVE CIRAC, KHI APOL1 Steering Comm., American Association of Kidney Patients, KDIGO CKD & Complications in Dialysis WGs, NKF Ambassador, KAC Diversity WG & Patient Education Series, CPATH BmDR Charter/Governance BioMarkers WG, and NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. G. Roberts's spouse reports consultancy for Vorsitz. S.L. Tummalapalli is supported by K08HS028684 from the Agency for Healthcare Research and Quality and received research funding (paid to employer) from Scanwell Health, Inc. and travel support (paid to the International Society of Nephrology) from Abbott Pharmaceuticals. S. Watnick serves as the Chief Medical Officer at Northwest Kidney Centers and reports employment with Puget Sound VA Medical Center; stock options in Interwell; honoraria from the <i>American Society of Nephrology</i>—BRCU, Policy (KCP Co-Chair); roles on <i>CJASN</i> Editorial Board, ASN Quality Committee, ASN Home Dialysis Task Force, ASN Policy and Advocacy Committee (unpaid), and as ASN Co-representative for KCP (paid); and other interests or relationships with CMO of Northwest Kidney Centers, a not-for-profit organization, plan to join Quanta Advisory Board. D.E. Weiner is the Medical Director of Clinical Research for Dialysis Clinic, Inc., with support paid to his institution; reports research funding from Bayer (site PI), Cara (site PI), and Vertex (site PI), with all compensation paid to Tufts MC; and reports and other interests or relationships as a member of the Safety and Clinical Events Committee for “A Prospective, Multi-Center, Open-Label Assessment of Efficacy and Safety of Quanta SC+ for Home Hemodialysis” Trial (Avania CRO) and a member of the Adjudications Committee for ProKidney REACT Trial (George Institute CRO). D.E. Weiner reports advisory or leadership roles as Co Editor-in-Chief, <i>NKF Primer on Kidney Diseases, 8th Edition;</i> Editor-in-Chief, <i>Kidney Medicine;</i> Medical Director of Clinical Research, Dialysis Clinic Inc.; Member, ASN Quality and Policy Committees and ASN representative to KCP; and Member, Scientific Advisory Board, National Kidney Foundation.",
286,"F. Hildebrandt is a cofounder and S.A.B. member of Goldfinch Biopharma Inc. F. Hildebrandt also reports Research Funding: NIH; Honoraria: Sanofi; Patents or Royalties: NPHP1; and Advisory or Leadership Role: Goldfinch-Bio. K.M. Kirschner reports Ownership Interest: Bio-Techne. E. Banne reports Consultancy: Pronto Diagnostics, Israel; and Research Funding: Rhythm Pharmaceuticals. R.P. Lifton reports Advisory or Leadership Role: Roche Board of Directors, and Genentech Board of Directors. A.J. Majmundar reports Consultancy: Judo Bio, Inc. C.-H.W. Wu reports Advisory or Leadership Role: GENE (journal), and The Association of Chinese Geneticists in America (ACGA). All remaining authors have nothing to disclose.",
287,"R. Calderon-Margalit's husband is an employee of AEYE Health, which has patents pending on the use of ML in ophthalmology. Y. Frishberg reports consultancy agreements with Alnylam Pharmaceuticals and advisory or leadership roles for Alnylam Pharmaceuticals Safety Review Committee. D. Magen reports research funding from Alnylam Pharmaceuticals. L.C. Regev-Epstein reports research funding from Nierstichting Nederland. All remaining authors have nothing to disclose.",
288,"R.J.M. Bindels reports serving on the scientific board of the Dutch Kidney Foundation, and serving in an advisory or leadership role for RegMed XB (Regenerative Medicine Crossing Borders). J.H.F. de Baaij reports receiving research funding from the Dutch Diabetes Research Foundation and Dutch Kidney Foundation. M. Konrad reports having consultancy agreements with Otsuka. M. Kwint reports having ownership interest in Pacific Biosciences. R. Vargas-Poussou reports serving in an advisory or leadership role for Advicenne. All remaining authors have nothing to disclose.",
289,"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This study was supported by funding from The Hospital for Sick Children Transplant and Regenerative Medicine Centre (TRMC). PPPR has been co-investigator on an investigator-led project funded by Pfizer that is unrelated to this study. JU reports being a past investigator for Sanofi/Regeneron, fees from Pfizer and AstraZeneca, all unrelated to vaccines. SKM has received honoraria for lectures from GlaxoSmithKline, was a member of ad hoc advisory boards for Pfizer, Sanofi Pasteur, and Merck and is a co-investigator on an investigator-led grant from Pfizer, all unrelated to this study. All authors have no conflict of interest relevant to this publication to declare. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.",
290,"A.S. Kliger reports employment with Metabolism Associates, New Haven; consultancy for ASN; multiple equity positions managed by UBS; advisory or leadership roles as American Society of Nephrology Chair of NTDS, Chair of EPC Advisory Committee, and Co-Chair of COVID-19 Response Team; and other interests or relationships with the American Society of Nephrology and Renal Physicians Association. V. Kumar reports research funding from NIH CTOT studies—subinvestigator, United Therapeutics/Revivicor—XenoTransplantation—subinvestigator (starting January 2022 with funds paid to the institution and not directly to V. Kumar); honoraria from the American Society of Nephrology for the early course for ASN kidney week invited lecture, ASN/AST—speaker, American Society of Nephrology/American Society of Transplantation for combined TNCC invited video lecture—honoraria, ASN: COVID 19 effort—honoraria, NKF talks—travel and hotel but no honoraria, AREP for an educational webinar, Medscape for a podcast, Elsevier for a book chapter, WebMD for a webinar, and Nephronet—honoraria for a lecture; advisory or leadership role for the American Society of Transplantation—Elected Councilor AST BOARD (no payment), Veloxis—member of Delphi group examining the effectiveness of Envarsus in Kidney Transplant Recipients in an evidence-based fashion with the ultimate goal of publication (honorarium deferred), exam item writer for ABIM (no honorarium), Region 3 UNOS living donor physician representation on the UNOS Living Donor Committee (no honorarium), ASN Transplant Workforce Member, and ASN CET Workgroup; other interests or relationships with American Society of Transplantation (AST): Board Liaison to the Living Donor Community of Practice, AST Transplant Community and Community Education Committee, Incoming Chair of Planning Committee for AST Cutting Edge in Transplantation Planning Committee (CeOT) 2022, Member of AST Community Education Committee, UNOS Region 3 Representative to OPTN Living Donor Community, and Schwartz Center Rounds for compassionate Rounds—facilitator. J. Silberzweig reports employment with The Rogosin Institute; consultancy work for Alkahest, Bayer, Honeywell, Kaneka, and St. Gobain; holds stock in AT&T, American Express, IBM, and Wells Fargo; is the national principal investigator for two clinical trials sponsored by Kaneka: one is using their Lixelle device for treatment of <i>β</i>-2-microglobulin amyloidosis in patients with kidney failure and the other is using lipid apheresis for the treatment of focal glomerulosclerosis; research funding from Kaneka; and advisory or leadership roles for American Society of Nephrology: Nephrologists Transforming Dialysis Safety COVID-19 and Other Current and Emerging Threats workgroup, COVID-19 Response team, and Emergency Partnership Initiative. J. Silberzweig's wife is an employee of Elevance Health, is an employee and stock holder of Anthem, and holds stock in American Express, AT&T, Elevance Health, IBM, and Wells Fargo. S. Stark reports employment with the American Society of Nephrology. S. Stark's husband reports consultancy for Akebia, AstraZeneca, CSL Behring (all inactive as of August 1, 2023), Disc Medicine, Fibrogen, GlaxoSmithKline (active), Otsuka, and Rockwell Medical; honoraria from Akebia, AstraZeneca, CSL Behring, Disc Medicine, Fibrogen, GlaxoSmithKline, Otsuka, and Rockwell Medical; speakers bureau for Akebia and AstraZeneca; and other interests or relationships with DaVita (Medical Director Agreement). D. White reports employment with the American Society of Nephrology.",
291,I. Kurtz reports having a consultancy agreement with Medibeacon Inc.; reports receiving research funding from the National Institutes of Health (NIH) and the Smidt Family Foundation; reports receiving honoraria from PHC Holdings Corporation; and reports having an advisory or leadership role as a US Kidney Research Corporation Board member. G.J. Schwartz reports receiving research funding from the National Institute of Diabetes and and Digestive and Kidney Diseases.,
292,"A.M.J.S. is supported through a Canada Research Chair (Tier 1) in Regenerative Medicine and Transplant Surgery, and through grant support from the Juvenile Diabetes Research Foundation, Diabetes Canada, the Canadian Donation and Transplant Research Program, the Diabetes Research Institute Foundation of Canada, the Alberta Diabetes Foundation, and the Canadian Stem Cell Network. B.A.M.-G. is supported by the Patronato del Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ), the Fundacion para la Salud y la Educacion Dr. Salvador Zubirán (FunSaEd), and the CHRISTUS Excellence and Innovation Center. A.M.J.S. serves as a consultant to ViaCyte Inc. The other authors declare no conflicts of interest.",
293,"S. Agarwal, M.A. Aponte, and M. Bucovsky report the employment with Columbia University. M.R. Allen reports employment with Roudebush Veterans Administration; research funding from MBX Biosciences; and role on the Editorial Boards for <i>Bone</i>, <i>Calcified Tissue International</i>, and <i>Osteoporosis International</i>. M. Fusaro reports consultancy for Vifor-Pharma and honoraria from Abiogen and Amgen. P. Khairallah reports role on the Editorial Board of <i>American Journal of Kidney Diseases</i>. D. McMahon provides statistical consulting services to Hospital for Special Surgery and New York University, both located in New York City. T.L. Nickolas reports employment with Columbia University; consultancy for Alnylam and Pharmacosmos; research funding from Amgen; honoraria from Alnylam and Pharmacosmos; and advisory or leadership roles for Amgen and Pharmacosmos. Columbia University has licensed patents on NGAL to Abbott Diagnostics and Alere. J. Silberzweig reports consultancy work for Honeywell, Kaneka, and St. Gobain; stock in A&T, American Express, IBM, and Wells Fargo; research funding as the national principal investigator for two clinical trials sponsored by Kaneka: one is using their Lixelle device for treatment of Beta-2-microglobulin amyloidosis in patients with ESKD and the other is using lipid apheresis for the treatment of focal glomerulosclerosis; and advisory or leadership roles for American Society of Nephrology: Nephrologists Transforming Dialysis Safety COVID-19 and Other Current and Emerging Threats workgroup, COVID-19 Response team, and Emergency Partnership Initiative. J. Silberzweig's wife is an employee of Anthem and holds stock in the company. J. Sung reports ownership interest in Alphabet, Amazon, Bank of America, Citigroup, Intel, and Meta. J. Wallace reports employment with Boardable and roles on the Editorial Boards for <i>Advances in Computed Tomography</i>, <i>Bone</i>, <i>Bone Reports</i>, <i>Current Osteoporosis Reports</i>, <i>Journal of Biomechanical Engineering</i>, <i>PLOS One</i>, and <i>Scientific Reports</i>. All remaining authors have nothing to disclose.",